

ALERE INC.  
Form 10-K/A  
April 29, 2011

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-K/A**  
(Amendment No. 1)

**ANNUAL REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF  
1934**  
**For the fiscal year ended December 31, 2010.**

**Commission file number 000-16789**

**ALERE INC.**  
(Exact Name of Registrant as Specified in Its Charter)

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>04-3565120</b> (I.R.S. Employer Identification No.)
<b>51 Sawyer Road, Suite 200, Waltham, Massachusetts</b> (Address of principal executive offices)	<b>02453</b> (Zip Code)
<b>(781) 647-3900</b> (Registrant's telephone number, including area code)	

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 (the Exchange Act):

<b>Title of Each Class</b>	<b>Name of Each Exchange on Which Registered</b>
Common Stock, \$0.001 per share par value	New York Stock Exchange
Series B Convertible Perpetual Preferred Stock, \$0.001 per share par value	New York Stock Exchange
9.00% Senior Subordinated Notes Due 2016, \$0.001 per share par value	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Exchange Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act of 1933. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The aggregate market value of the voting common stock held by non-affiliates of the registrant based on the closing price of the registrant's stock on the New York Stock Exchange on June 30, 2010 (the last business day of the registrant's most recently completed second fiscal quarter) was \$1,901,649,455.

As of April 20, 2011, the registrant had 85,485,171 shares of common stock, par value \$0.001 per share, outstanding.

---

**ALERE INC.**

**FORM 10-K**

**For The Fiscal Year Ended December 31, 2010**

	<b>Page</b>
<b><u>PART I</u></b>	
<u>ITEM 1.</u> <u>Business</u>	3
<u>ITEM 1A.</u> <u>Risk Factors</u>	14
<u>ITEM 1B.</u> <u>Unresolved Staff Comments</u>	30
<u>ITEM 2.</u> <u>Properties</u>	30
<u>ITEM 3.</u> <u>Legal Proceedings</u>	30
<u>ITEM 4.</u> <u>Removed and Reserved</u>	30
<b><u>PART II</u></b>	
<u>ITEM 5.</u> <u>Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u>	31
<u>ITEM 6.</u> <u>Selected Consolidated Financial Data</u>	33
<u>ITEM 7.</u> <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	35
<u>ITEM 7A.</u> <u>Quantitative and Qualitative Disclosures About Market Risk</u>	56
<u>ITEM 8.</u> <u>Financial Statements and Supplementary Data</u>	58
<u>ITEM 9.</u> <u>Changes In and Disagreements With Accountants On Accounting and Financial Disclosure</u>	60
<u>ITEM 9A.</u> <u>Controls and Procedures</u>	60
<u>ITEM 9B.</u> <u>Other Information</u>	61
<b><u>PART III</u></b>	
<u>ITEM 10.</u> <u>Directors, Executive Officers and Corporate Governance</u>	62
<u>ITEM 11.</u> <u>Executive Compensation</u>	67
<u>ITEM 12.</u> <u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>	79
<u>ITEM 13.</u> <u>Certain Relationships and Related Transactions, and Director Independence</u>	82
<u>ITEM 14.</u> <u>Principal Accounting Fees and Services</u>	83
<b><u>PART IV</u></b>	
<u>ITEM 15.</u> <u>Exhibits and Financial Statement Schedules</u>	84
<u>Signatures</u>	90
<u>EX-10.30</u>	
<u>EX-23.1</u>	
<u>EX-23.2</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-101 INSTANCE DOCUMENT</u>	
<u>EX-101 SCHEMA DOCUMENT</u>	
<u>EX-101 CALCULATION LINKBASE DOCUMENT</u>	
<u>EX-101 LABELS LINKBASE DOCUMENT</u>	

[EX-101 PRESENTATION LINKBASE DOCUMENT](#)

[EX-101 DEFINITION LINKBASE DOCUMENT](#)

---

**Table of Contents**

**EXPLANATORY NOTE**

The primary purpose of this Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 (the Original Report ) is to amend Part III, Items 10 through 14 of the Original Report, which was filed with the U.S. Securities and Exchange Commission on March 1, 2011, to include information previously omitted from the Original Report in reliance on General Instruction G to Form 10-K, which provides that registrants may incorporate by reference certain information from a definitive proxy statement filed with the SEC within 120 days after the end of the fiscal year.

We are also amending Part IV, Item 15 of the Original Report to include certain exhibits required to be filed with this Amendment No. 1 and to file one other exhibit.

We have made no other significant changes to the Original Report. In order to preserve the nature and character of the disclosures set forth in the Original Report, this report speaks as of the date of the filing of the Original Report, March 1, 2011, and we have not updated the disclosures in this report to speak as of a later date.

**Table of Contents**

**PART I**

*This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as may, could, should, would, intend, will, expect, anticipate, believe, estimate, continue or similar words. Readers should carefully review statements that contain these words because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other forward-looking information. We caution investors that all such forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from any projected results or expectations that we discuss in this report. You should therefore carefully review the risk factors and uncertainties discussed in Item 1A entitled Risk Factors, which begins on page 13 of this report, as well as those factors identified from time to time in our periodic filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements.*

*Unless the context requires otherwise, references in this Annual Report on Form 10-K to we, us, our, or our company refer to Alere Inc. and its subsidiaries.*

**ITEM 1. BUSINESS**

**GENERAL**

Alere Inc. enables individuals to take charge of improving their health and quality of life at home, under medical supervision, by developing new capabilities in near-patient diagnosis, monitoring and health management. Our global leading products and services, as well as our new product development efforts, focus on cardiology, women's health, infectious disease, oncology and toxicology. We are confident that our ability to offer rapid diagnostic tools combined with value-added healthcare services will improve care for patients, lower costs to payers and help healthcare providers become more effective.

Our company, then known as Inverness Medical Innovations, Inc., was formed to acquire the women's health and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. Since that time, we have grown our businesses through strategic acquisitions, tactical use of our intellectual property portfolio and through organic growth. In July 2010, our company changed its name from Inverness Medical Innovations, Inc. to Alere Inc. Our common stock is listed on the New York Stock Exchange under the symbol ALR.

Our principal executive offices are located at 51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453 and our telephone number is (781) 647-3900. Our website is [www.alere.com](http://www.alere.com), and we make available through the investor center of this site, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the Securities and Exchange Commission, or the SEC. We also make our code of ethics and certain other governance documents and policies available through our website. We intend to make required disclosures of amendments to our code of ethics, or waivers of a provision of our code of ethics, on the Corporate Governance page of our website's investor center.

**Segments**

Our major reportable operating segments are professional diagnostics, health management and consumer diagnostics. Financial information about our reportable segments is provided in Note 17 of the Notes to Consolidated Financial Statements which are included elsewhere in this report. As discussed in Note 23 of the Notes to Consolidated Financial Statements, in January 2010, we completed the divestiture of our entire vitamins and nutritional supplements business segment and the results of this former business segment are classified as discontinued operations.



## **Table of Contents**

### **Products and Services**

*Professional Diagnostics.* Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which we define as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. Within professional diagnostics, we focus on point-of-care, rapid diagnostic testing and health monitoring and the developing patient self-testing market. We distinguish the point-of-care and patient self-testing markets from clinical diagnostic markets consisting of large, centralized laboratories offering a wide range of highly-automated laboratory services in hospital or related settings. The point-of-care market for rapid diagnostic products consists primarily of small and medium size laboratories and testing locations, such as physician office laboratories, specialized mobile clinics, emergency rooms and some rapid-response laboratories in larger medical centers.

In the market for rapid diagnostic products, the ability to deliver faster, accurate results at reasonable prices generally drives demand. This means that, while there is certainly demand for faster, more efficient automated equipment from large hospitals and major reference testing laboratories, there is also growing demand by point-of-care facilities and smaller laboratories for fast, high-quality, less expensive, self-contained diagnostic kits. As the speed and accuracy of such products improve, we believe that these products will play an increasingly important role in achieving early diagnosis, timely intervention and therapy monitoring outside of acute medicine environments, especially where supplemented by the support and management services that we also provide.

Our current professional diagnostic products include point-of-care and laboratory tests sold within our focus areas of cardiology, women's health, infectious disease, oncology and toxicology. While we currently sell these products under numerous brands, as discussed below, we have begun a process of consolidating many of our brands under the Alere name.

*Cardiology.* Cardiovascular disease encompasses a spectrum of conditions and illnesses, including high blood pressure, high cholesterol, metabolic syndrome, coronary artery disease, heart attack, heart failure and stroke. It is estimated that 80 million Americans alone have one or more types of cardiovascular disease. The worldwide cardiology diagnostic market, including the markets for heart failure diagnostics, coronary artery disease risk assessment, coagulation testing and acute coronary syndrome, exceeds \$1.5 billion. Our Triage, Cholestech LDX and INRatio products, all acquired through acquisitions in 2007, have established us as a leader in this market. The Triage system consists of a portable fluorometer that interprets consumable test devices for cardiovascular conditions, as well as the detection of certain drugs of abuse. The Triage cardiovascular tests include the following:

*Triage BNP Test.* An immunoassay that measures B-type Natriuretic Peptide (BNP) in whole blood or plasma, used as an aid in the diagnosis and assessment of severity of heart failure. The test is also used for the risk stratification of patients with acute coronary syndrome and heart failure. We also offer a version of the Triage BNP Test for use on Beckman Coulter lab analyzers.

*Triage Cardiac Panel.* An immunoassay for the quantitative determination of creatine kinase-MB (CK-MB), myoglobin and troponin I in whole blood or plasma, used as an aid in the diagnosis of acute myocardial infarction.

*Triage CardioProfilER Panel.* An immunoassay for use as an aid in the diagnosis of acute myocardial infarction, the diagnosis and assessment of severity of congestive heart failure, risk stratification of patients with acute coronary syndromes and risk stratification of patients with heart failure. This panel combines

troponin I, CK-MB, myoglobin and BNP to provide rapid, accurate results in whole blood and plasma.

*Triage Profiler Shortness of Breath (S.O.B.) Panel.* An immunoassay for use as an aid in the diagnosis of myocardial infarction, the diagnosis and assessment of severity of congestive heart failure, the

## **Table of Contents**

assessment and evaluation of patients suspected of having disseminated intravascular coagulation and thromboembolic events, including pulmonary embolism and deep vein thrombosis, and the risk stratification of patients with acute coronary syndromes. This panel combines troponin I, CK-MB, myoglobin, BNP and d-dimer to provide rapid, accurate results in whole blood and plasma.

*Triage D-Dimer Test.* An immunoassay for use as an aid in the assessment and evaluation of patients suspected of having disseminated intravascular coagulation or thromboembolic events, including pulmonary embolism and deep vein thrombosis.

*Triage NGAL.* An immunoassay for use in the rapid, quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in anticoagulated whole blood or plasma specimens. Studies have shown a link between elevated NGAL levels and the later occurrence of elevated creatinine indicative of prior acute kidney injury. Triage NGAL is not available for sale in the United States.

Our Cholestech LDX System is a point-of-care monitor of blood cholesterol and related lipids which is used to test patients at risk of, or suffering from, heart disease and related conditions. The Cholestech LDX System makes it possible to provide a complete lipid profile with tests for total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides, and glucose, as well as tests for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (for liver enzyme monitoring), and high sensitivity C-reactive protein, or hs-CRP. The system can also provide coronary heart disease risk assessment from the patient's results as measured on the lipid profile cassette. The Cholestech LDX System provides results in five minutes per test cassette (seven minutes for hs-CRP) and is CLIA-waived, meaning the United States Food and Drug Administration, or FDA, has waived the more stringent requirements for laboratory testing applicable to moderate or high complexity laboratories based on the Cholestech LDX System's ease of use and accuracy. This waiver allows the Cholestech LDX System to be marketed to physician offices, rather than hospitals or larger laboratories.

Our Alere INRatio System is an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly prescribed medication used to prevent blood clots. The Alere INRatio System measures PT/INR, which is the patient's blood clotting time reported pursuant to an internationally normalized ratio, to help ensure that patients at risk of blood clot formation are maintained within the therapeutic range with the proper dosage of oral anticoagulant therapy. The Alere INRatio System is 510(k) cleared by the FDA for use by healthcare professionals, as well as for patient self-testing, and is also CE marked in Europe. The system is targeted to both the professional, or point-of-care market, as well as the patient self-testing market. Today we sell an improved version of the system, the Alere INRatio2 System, which targets the patient self-testing market through enhanced ease of use. Patient self-testing has gained significant momentum since March 2008 when Centers for Medicare & Medicaid Services expanded coverage of home INR monitoring to include chronic atrial fibrillation and venous thromboembolism patients on warfarin.

We also distribute the epoc<sup>®</sup> Blood Analysis System for blood gas and electrolyte testing pursuant to an agreement with Epocal, Inc., or Epocal. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides wireless bedside blood gas and electrolyte measurement testing solutions and complements our Triage products in cardiology and emergency room settings. Utilizing easy to use, low-cost disposable Smart-Cards<sup>™</sup>, the epoc System produces laboratory quality results in critical and acute care settings in about 30 seconds. The epoc System received FDA 510(k) clearance in 2006 for marketing in the U.S. and is also CE marked in Europe.

During 2010, we launched the Alere Heart Check System in Europe. The Alere Heart Check provides a quantitative reading of BNP in 10 minutes using a fingerstick sample (12 microliters) with substantially equivalent performance to lab instruments. Initially being marketed as a point-of-care device, the Alere Heart Check System is ultimately designed for home use and is intended to enable doctors to remotely monitor BNP levels of congestive heart failure

patients and adjust their therapy accordingly.

## **Table of Contents**

We also sell disposable, lateral flow rapid diagnostic tests for d-dimer and troponin I under our Clearview brand. These tests offer efficiency, as well as ease of use and accuracy, to clinics, hospitals and laboratories around the world.

Women's Health. Since women's health and general sexual health issues are a global health concern, this area remains a priority for us. In the professional marketplace, we are a global leader in pregnancy fertility/ovulation testing and bone therapy (osteoporosis) monitoring. Our professional pregnancy tests are generally urine-based, CLIA-waived rapid tests in dipstick or cassette format.

Our professional women's health products also target diseases or conditions, such as pre-eclampsia, rubella, pre-term labor and premature rupture of membrane, which pose unique threats to mothers or their unborn or newborn babies. We also market a portfolio of tests for sexually-transmitted diseases. Our women's health products are currently sold under our Aceava, Clearview, Sure-Step, Inverness Medical TestPack and Osteomark brands.

Infectious Disease. We believe that the demand for infectious disease diagnostic products is growing faster than many other segments of the immunoassay market due to the increasing incidence and awareness of certain diseases or groups of diseases, including viral hepatitis, respiratory syncytial virus (RSV), influenza, pneumonia, tuberculosis, human immunodeficiency virus (HIV) / acquired immunodeficiency syndrome (AIDS), enteric disease, herpes and other sexually-transmitted diseases. To meet this demand, we have continued to expand our product offerings and now offer one of the world's largest infectious disease test menus. We develop and market a wide variety of point-of-care tests for influenza A/B, strep throat, HIV, herpes simplex virus (HSV-2), hepatitis C (HCV), malaria, pneumonia, C.difficile, infectious mononucleosis, lyme disease, chlamydia, H.pylori, RSV, rubella and other infectious diseases. Our tests for infectious disease are currently sold under brand names which include Aceava, Alere, BinaxNOW, Clearview, Determine, TestPack, DoubleCheckGold, Panbio, Standard Diagnostics and TECHLAB. We have also started commercializing the Alere CD4 Analyzer in several countries in Africa. The Alere CD4 Analyzer is the first point-of-care platform which measures absolute CD4 counts in HIV patients with results in 20 minutes, using single-use, disposable fingerstick cartridges.

In addition to point-of-care products, we also offer a line of indirect fluorescent antibody, or IFA, assays for over 20 viral, bacterial and autoimmune diseases, a full line of serology diagnostic products covering a broad range of disease categories and over 70 enzyme-linked immunosorbent assays, or ELISA tests, for a wide variety of infectious and autoimmune diseases, as well as a full line of automated instrumentation for processing ELISA tests. We are the exclusive U.S. distributor of the AtheNA Multi-Lyte® Test System, a multiplexed, fluorescent bead-based system designed to simultaneously perform multiple assays from a single sample using just one well. It offers a simple and streamlined alternative to IFA and ELISA testing, providing improved clinical sensitivity and comparable clinical specificity in a labor-saving, automation-friendly format. Our IFA, serology and ELISA products, which generally serve the clinical diagnostics laboratory markets, are generally marketed under our Wampole brand.

Demand for certain infectious disease tests, such as influenza A/B, or flu, is significantly affected by the seasonal nature of the cold and flu season. As a result, we typically experience higher sales of our flu tests in the first and fourth quarters. Sales of our flu products also vary widely from year to year based in large part on the severity, duration and timing of the onset of the cold and flu season. While we believe that these factors will continue to impact sales of certain of our infectious disease products, there can be no assurance that our future sales of these products will necessarily follow historical patterns.

Oncology. Among chronic disease categories, we are focused on oncology diagnostics as an area of significant future opportunity. The Matritech NMP22 BladderChek Test is the only in-office test approved by the FDA as an aid in the diagnosis of bladder cancer. The NMP22 BladderChek Test is a non-invasive assay, performed on a single urine sample that detects elevated levels of NMP22 protein. The test can be performed in a physician's office with results

delivered during the patient visit, allowing a rapid, accurate and cost-effective means of aiding the detection of bladder cancer in patients at risk, when used in conjunction with standard diagnostic procedures. We also offer the NMP22 Test Kit, a quantitative ELISA also designed to detect elevated levels of NMP22 protein.

## **Table of Contents**

Our Clearview FOB and Ultra FOB rapid tests aid in the early detection of colorectal cancer, the third most common type of cancer in men and women. Also, as a result of our November 2010 acquisition of AdnaGen AG, or AdnaGen, a German company specializing in the development of cancer diagnostics through the detection and analysis of circulating tumor cells, we now sell the AdnaTest ColonCancer and AdnaTest BreastCancer products, which are CE-certified for the detection of circulating tumor cells.

***Toxicology.*** Drug abuse is a major global health problem, as well as a social and economic burden. In addition to being a primary cause of lost workforce productivity, family conflict and drug-related crime, drug abuse is linked globally to the spread of HIV/AIDS through contaminated needles. Drug abuse is one of the most costly health problems in the United States, and increasingly abroad. As a result, employers, law enforcement officials, healthcare professionals and others expend considerable effort to ensure their employees, patients and other constituents are free of substance abuse and misuse. This critical need creates a significant market for simple and reliable laboratory, point-of-care and rapid toxicology tests to detect both the most commonly abused substances and an ever-evolving set of esoteric and regional toxins. Additionally, physicians are increasingly utilizing drug testing to identify and address signs of prescription drug misuse. Urine and oral-based screening and confirmation tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of immunoassays have made them the most widely-accepted method for toxicology screening.

We offer one of the most comprehensive lines of drugs of abuse tests, reagent systems and laboratory testing options available today. Our products include tests to detect alcohol, as well as various device platforms for the detection of the following illicit and prescription drugs of abuse: amphetamines/methamphetamines, cocaine, opiates, phencyclidine, tetrahydrocannabinol, acetaminophen, barbiturates, benzodiazepines, methadone, propoxyphene and tricyclic antidepressants, using urine and, for some applications, saliva, hair and other body fluids.

Our rapid toxicology tests are sold primarily under the brands Triage, iScreen, Concateno and SureStep. The TOX Drug Screen panel sold for use with our Triage MeterPro system detects the presence of many of the illicit and prescription drugs listed above at the point of care in approximately 15 minutes. It is widely used in hospital and clinical testing as a laboratory instrument to aid in the detection of drug abuse. Our Drug Detection System, or DDS, is an enhanced, on-site saliva drug detection system utilized in roadside testing which displays results for the presence of up to six different drugs in under five minutes and two drugs in under 90 seconds.

We also offer comprehensive laboratory-based testing services throughout Europe under the name Concateno and in the United States under the names Alere Toxicology Services, or Alere Toxicology, and Redwood Laboratories, or Redwood. Alere Toxicology's laboratories are certified by the U.S. Substance Abuse and Mental Health Services Administration, or SAMHSA. Through Redwood, we offer comprehensive, low-cost laboratory testing services to multiple domestic clients, including law enforcement agencies, penal systems, insurers and employers in the United States. In addition, we are expanding our offerings in the growing market for pain management services, or the monitoring and documentation of adherence to prescription drug treatment plans through diagnostic testing.

***Health Management.*** Our health management business strives to empower participants of our programs and physicians so they can work together towards better health. We believe that by utilizing existing professional diagnostic devices and new devices under development to enhance the delivery of health management and by improving the quality of medical data available to healthcare providers, we can further facilitate cost containment and outcome-driven decision making. We also provide services supporting home INR testing. Currently, our health management business is principally conducted in the United States, but we have plans to expand further internationally.

Our expert-designed health management programs:

embrace the entire lifespan, from pre-cradle to end-of-life, and targeted health states, from wellness to prevention to total health management of the individual for those having various chronic illnesses;



**Table of Contents**

target high-cost chronic conditions with programs designed to improve outcomes and reduce expenditures;

provide health coaches who engage and motivate participants during teachable moments;

help participants improve their health by supporting their individual health goals;

help payers, physicians and patients connect more efficiently through the exchange of health information;

bring greater clarity to healthcare with empowering technologies that lead to better outcomes; and

offer the expertise of more than 1,800 healthcare professionals who share a passion for patient and customer care.

Our key health management programs are:

Care. The Alere Disease Management (Chronic Care) Program provides technology-enabled, evidence-based solutions for managing chronic and high-cost conditions, improving clinical outcomes and reducing healthcare costs. The Alere Disease Management Program assists individuals with chronic diseases or conditions to better manage their care by increasing their knowledge about their illnesses, potential complications and the importance of medication and treatment plan compliance. Our highly-trained clinicians proactively contact participants to monitor their progress and ensure they are following the plan of care set by their physician. They work with participants to identify potential gaps in care, which occur when individuals are not treated in accordance with national standards of care, or best practices, or when an individual fails to comply with his or her treatment plan.

We offer a personal health support model of care. This model differs from providers of traditional, total population health models in several ways, including how individuals are selected, as well as a more disciplined approach to defining who can benefit from what kinds of touches and how these specific interactions are best accomplished. A second key differentiator is the use of the Alere DayLink Monitor for persons participating in higher risk health management programs. The DayLink Monitor records a participant's weight and/or blood glucose, as well as answers to questions regarding their symptoms. This information is gathered daily and sent to our clinicians for review. The Alere Disease Management Program currently assists individuals with the following chronic diseases or conditions: asthma, coronary artery disease, chronic obstructive pulmonary disease, diabetes, heart failure, pain, weight management and depression. In addition, we also offer Complex Care Management for participants who require more attention and care than a traditional disease management program provides. What distinguishes our two programs is that Complex Care provides on-site care, and the Disease Management (Chronic Care) Program involves telephone contact with Alere clinicians.

Patient Self-Testing Services. We also offer services designed to support anticoagulation management for patients at risk for stroke and other clotting disorders who can benefit from home INR monitoring. As mentioned above, home INR monitoring has grown increasingly popular since the Centers for Medicare & Medicaid Services expanded coverage to include home INR monitoring of chronic atrial fibrillation and venous thromboembolism patients on warfarin. Our Alere Home Monitoring business assists patients in acquiring home INR monitors, including our Alere INRatio2 monitors, and seeking Medicare reimbursement and insurance coverage, while providing physicians with a comprehensive solution for incorporating home INR monitoring into their practice. Our CoagNow program includes our Face-2-Face patient training model, which utilizes experienced nurse educators, patient scheduling, collection and reporting of home testing results to the physician and CoagClinic, our sophisticated web-based application that provides healthcare professionals with real-time access to patient information.

Women's & Children's Health. Our Women's and Children's Health division delivers a wide spectrum of obstetrical care services, ranging from a risk assessment to identify women at risk for pregnancy complications to a neonatal program for early infant care management. In between, are first and second trimester genetic testing, as well as home-based obstetrical programs to manage and monitor pregnant women who have medical or pregnancy-related problems that could harm the health of the mother or baby. We deliver

## **Table of Contents**

telephonic and home-based nursing services that support physician and patient goals. We have developed and refined these services over the years to accommodate physician plans of care. We focus on assessment of patient data and providing education. Our high-risk pregnancy management program revenues tend to be seasonal. Revenues tend to decrease with the onset of the holiday season starting with Thanksgiving in the United States. As a result, first and fourth quarter revenues each year tend to be lower than second and third quarter revenues.

*Oncology.* The Alere Oncology Program is the longest-running cancer management program (since 1994) in the U.S. The Alere Oncology Program manages adults diagnosed with any cancer that requires treatment beyond a single surgery. Since the program's inception, we have managed more than 65,000 participants. Cancer continues to challenge employers and health plans as they search for tools to compassionately manage this condition among their population in the most cost-effective manner. By incorporating best of breed practices and coordinating with physicians and participants, we provide an integrated solution to proactively manage this expensive and debilitating disease.

*Wellness.* Wellness Solutions is a suite of integrated wellness programs and resources designed to help organizations reduce health risks and improve the health and productivity of their employees and health plan members, while reducing healthcare-related costs. Wellness programs include screening for risk factors associated with diabetes, cardiovascular heart disease, hypertension and obesity; screening for high-risk pregnancies; assessments of health risks for broad populations; programs that promote better health by encouraging sustainable changes in behavior and health coaching. Our Free & Clear business specializes in web-based learning and phone-based cognitive behavioral coaching to help employers, health plans and state governments improve the overall health and productivity of their covered populations. Free & Clear's evidence-based programs address the four key modifiable health risks that contribute to chronic disease: tobacco use, poor nutrition, physical inactivity and stress.

*Technology Solutions.* Our technology solutions provide employers and health plans with a powerful portal or front door to our continuum of healthcare services and allow individuals to create a confidential on-line record of their personal healthcare data that is compliant with the requirements of the Health Insurance Portability and Accountability Act and its regulations, or HIPAA. Our Apollo technology platform, which was launched in January 2010, provides the framework and supporting infrastructure for a series of significant enhancements to Alere's services, including a dynamic, interactive and personalized experience for employees via an enhanced health portal, and was designed to provide us with the ability to integrate data from a variety of sources, including health plans, pharmacy benefit managers, self-reported data and point-of-care devices.

Apollo serves as the hub for participants to access their medical information, personal health record and appropriate health programs and offers the following key enhancements:

- personalized platform that acts as a virtual coach, presenting content based on data collected on the participant and delivering personal health support in a way that is designed to feel satisfying to the participant when they need it the most;

- a meaningful, engaging experience with content and activities presented based on the participant's preferences, activities and personal health data; and

- a deep, rich library of multi-media resources designed to address individual learning styles that can be generated dynamically by the system or located through a search by the participant.

Providing access to the broad-based resources of the Apollo portal demonstrates a commitment to the enhanced health of an organization's population.

*Consumer Diagnostics.* In 2007, we and affiliates of The Procter & Gamble Company, or P&G, commenced a 50/50 joint venture for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. As part of this arrangement, we transferred essentially all of the assets of our consumer diagnostics business, other than our manufacturing and core intellectual property assets, to the joint venture, and P&G acquired its interest in the joint venture. Accordingly, substantially all of the consumer diagnostics business conducted by us prior to

## **Table of Contents**

the joint venture, including all of our products targeting the worldwide over-the-counter pregnancy and fertility/ovulation test market, are now sold by the joint venture, which is an unconsolidated entity operating primarily under the name SPD Swiss Precision Diagnostics GmbH, or SPD.

As part of the SPD joint venture, we entered into a finished product purchase agreement, pursuant to which we currently manufacture and sell to SPD substantially all of the consumer diagnostic products which it sells. We also entered into certain transition and long-term services agreements with SPD, pursuant to which we provide certain operational support services to the joint venture. Our consumer diagnostics segment recognizes the revenue and costs arising from these arrangements.

Our other current consumer diagnostic products consist of our market-leading First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring and colon cancer screening. Taking advantage of our leadership in the field of women's health, we also sell Balance Activ Vaginal Gel directly to consumers and health care professionals for the effective treatment of bacterial vaginosis without antibiotics.

## **Methods of Distribution and Customers**

In the United States, Canada, the United Kingdom, Ireland, Germany, Italy, Spain, Switzerland, the Netherlands, Belgium, France, Austria, India, Japan, China, South Korea, Taiwan, Australia, New Zealand, South Africa, Brazil, Argentina and Colombia, we distribute our professional diagnostic products to hospitals, reference laboratories, physician offices and other point-of-care settings through our own sales forces and distribution networks. In these countries, as well as in all other major world markets, we also utilize third-party distributors to sell our products. Our Alere Home Monitoring business facilitates the distribution of our Alere INRatio PT/INR coagulation monitors by contacting targeted customers and facilitating the Medicare reimbursement process for physicians and for patients monitoring at home.

We market our health management programs primarily to health plans (both commercial and governmental) and self-insured employers and, to a lesser extent, to pharmaceutical companies and physicians, through our employee sales force and channel partners.

We market and sell our First Check consumer drug testing products in the United States through retail drug stores, drug wholesalers, groceries and mass merchandisers. These products compete intensively with other brand name drug testing products based on price, performance and brand awareness.

## **Manufacturing**

Our primary manufacturing facilities are located San Diego, California; Scarborough, Maine; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. We also manufacture products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom.

Our primary manufacturing facilities are ISO certified and registered with the FDA. We manufacture substantially all of our consumable diagnostic products at these facilities. We also manufacture the consumable diagnostic devices containing the diagnostic chemistry or other proprietary diagnostic technology, which are used in conjunction with our diagnostic or monitoring systems, including our Triage system, our Cholestech LDX monitoring devices, our Alere INRatio monitoring devices and the digital pregnancy and ovulation prediction tests and fertility monitors that we supply to the SPD joint venture. We contract with third parties to supply the electronic reader portion of these diagnostic or monitoring systems and to supply various other products that we sell, including our Triage BNP Test for use on Beckman Coulter systems, a majority of our IFA tests and our TECHLAB products.

**Research and Development**

Our primary research and development centers are in San Diego, California; Scarborough, Maine; Jena, Germany and Stirling, Scotland. We also conduct research and development at various of our other facilities, including facilities in the United States, Australia, China, Germany, Israel, South Korea, and the United

## **Table of Contents**

Kingdom. Our research and development programs currently focus on the development of cardiology, women's health, infectious disease, oncology and toxicology products and on health management programs.

## **Global Operations**

We are a global company with major manufacturing facilities in the United States, China, Japan, Korea and significant research and development operations in the United States, Germany and the United Kingdom. Our distribution network supporting our professional diagnostics business includes offices in the United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia France, Germany, Hong Kong, India, Israel, Italy, Japan, the Netherlands, New Zealand, South Africa, South Korea, Spain, Switzerland, Taiwan and the United Kingdom.

Our professional diagnostic products are sold throughout the world. Our health management programs are offered almost exclusively in the United States. During 2010 and 2009, respectively, approximately 64% and 69% of our net revenue was generated from the United States, approximately 17% and 17% of our net revenue was generated from Europe, and approximately 19% and 14% of our net revenue was generated from customers located elsewhere.

## **Competition**

*Professional Diagnostics.* Our professional diagnostics products are primarily point-of-care rapid diagnostic testing products focused within the areas of cardiology, women's health, infectious disease, oncology and toxicology. Competition for rapid diagnostic products is intense and is primarily based on price, quality, breadth of product line and distribution capabilities. Some competitors in the market for professional rapid diagnostic products, such as Becton Dickinson, are large companies with substantial resources, while numerous smaller, yet aggressive companies also compete with us. No competitor, small or large, offers a portfolio of professional rapid diagnostic products as broad as ours and, as a result, our competitors differ significantly within each of our areas of focus. Some automated immunoassay systems may also be considered to compete with our products when labor shortages force laboratories to automate or when the costs of such systems are lower. Such systems are provided by Abbott, Siemens, Beckman Coulter, Johnson & Johnson, Roche and other large diagnostic companies.

In cardiology, the majority of diagnostic immunoassays utilized by physicians and other healthcare providers are performed by independent clinical reference laboratories and hospital-based laboratories using automated analyzers for batch testing. As a result, the primary competitors for our Triage and Cholestech LDX point-of-care testing systems, which consist of rapid diagnostic devices interpreted by portable electronic readers, are the large diagnostic companies identified above who produce automated immunoassay systems. We expect these large companies to continue to compete vigorously to maintain their dominance of the cardiology testing market. Although we offer our Triage BNP test for use on Beckman Coulter Immunoassay Systems, our other primary cardiology products are not currently designed for automated batch testing. Our Triage products face strong competition from Abbott's i-Stat hand-held system and our Cholestech LDX system also faces direct competition from Abaxis Medical Diagnostics, which markets its point-of-care blood laboratory systems to physician office laboratories. The primary competitors for our Alere INRatio PT/INR monitoring system are Roche and International Technidyne Corporation, which recently merged with Nexus Dx, who together currently account for approximately 75% of the domestic sales of PT/INR point-of-care and patient self-testing devices.

Becton Dickinson, Quidel and Meridian Bioscience, are the largest competitors for our rapid diagnostic tests targeted at women's health and infectious disease. Our HIV products, in particular, also compete with tests offered by Orasure Technologies. Newer technologies utilizing amplification techniques for analyzing molecular DNA gene sequences, from companies such as Abbott, Becton Dickinson, Roche, Cepheid and Gen-Probe, are making in-roads into the infectious disease market.

In oncology, our NMP-22 diagnostic products aid in diagnosing and monitoring bladder cancer patients, in conjunction with standard diagnostic procedures, and are based on our proprietary nuclear matrix protein technology. Our NMP-22 BladderChek Test is currently the only in-office test approved by the FDA as an aid



## **Table of Contents**

in the diagnosis of bladder cancer. However, competition in the development and marketing of cancer diagnostics and therapeutics, using a variety of other technologies, is intense. Competing diagnostic products based on other technologies may be introduced by other companies and could adversely affect our competitive position. In a larger sense, our tests also compete with more invasive or expensive procedures, such as surgery, bone scans, magnetic resonance imaging and other in vivo imaging techniques. In the market for urine-based diagnostic tests, our NMP-22 tests also compete with existing cellular-based tests, such as the microscopic examination of suspicious cells, and UroVysion, which is a fluorescent in-situ hybridization test.

In toxicology, the competitors for our drugs of abuse tests include many of the large diagnostics companies named above, which manufacture instrumented drug tests, reagents or instruments sold in a variety of formats to customers in the worldwide employment, transportation, government and clinical sectors. Additionally, in many markets in which the barriers to entry are low due to less stringent regulations, we compete with dozens of privately-held, boutique manufacturers of lateral flow point-of-care drug tests. Our worldwide drug testing laboratory services compete with hundreds of multi-national and regional clinical, toxicology and forensic laboratories.

We also sell ELISA and multiplex immunoassay diagnostic testing products, as well as serology, IFA and microbiology tests, all primarily targeted at infectious and autoimmune disease. Our ELISA tests compete against the large diagnostics companies named above, which manufacture state-of-the-art automated immunoassay systems and a wide array of diagnostic products designed for processing on those systems. Other competitors, including INOVA Diagnostics, DiaSorin and Diamedx, are smaller companies that compete based on quality and service. In the United States and Canada, we focus on matching the instrumentation and product testing requirements of our customers by offering a wide selection of diagnostic products and test equipment. The markets for our serology, IFA and microbiology products are mature and competition is based primarily on price and customer service. Our main competitors in serology and microbiology testing include Remel and Biokit. Our main competitors in IFA testing are Bio-Rad Laboratories, INOVA Diagnostics, Immuno Concepts, Trinity Biotech, Meridian Biosciences and DiaSorin. However, products in these categories also compete to a large extent against rapid membrane and ELISA products, which are often easier to perform and read and can be more precise.

Generally, our professional diagnostic products competitive positions may be based on, among other things, being first to market with a novel product, product performance, accuracy, convenience, cost-effectiveness, the strength of our intellectual property and price, as well as on the effectiveness of our sales force and our marketing and distribution partners. Where we face competition from large diagnostic companies, these competitors have greater resources than we do. In addition, certain competitors may have more favorable competitive positions than we do in markets outside of the United States.

We believe that our dedication to research and development and our strong intellectual property portfolio, coupled with our manufacturing expertise, diversified product positioning, global market presence and established distribution networks, provide us with a competitive advantage in the point-of-care markets in which we compete.

*Health Management.* Competition in the health management market is intense because barriers to entry are low. Other health management service providers include Health Dialog, Healthways and numerous smaller service providers. Our competitors and potential competitors also include health plans, self-insured employers, healthcare providers, pharmaceutical companies, pharmacy benefit management companies, case management companies and other organizations that provide services to health plans, state governments and self-insured employers. Some of these entities, health plans and self-insured employers in particular, may be customers or potential customers and may own, acquire or establish health management service providers or capabilities for the purpose of providing health management services in-house. Many of these competitors are considerably larger than we are and have access to greater resources. We believe however that our ability to improve clinical and financial outcomes and our technology platforms, most notably our new Apollo system, will enable us to compete effectively.

*Consumer Diagnostics.* Our First Check tests compete against over-the-counter diagnostic tests sold primarily by Phamatech, but also by other smaller competitors. Essentially, all of our remaining consumer

## **Table of Contents**

diagnostic product sales are to SPD, our joint venture. These products are sold by SPD in retail markets where competition is intense and based primarily on brand recognition and price. Our revenues, as well as our share of the profits from the sale of these products by SPD, are dependent upon SPD's ability to effectively compete in these markets.

## **Patents and Proprietary Technology; Trademarks**

We have built a strong intellectual property portfolio consisting of an increasing number of patents, patent applications and licensed patents which are intended to protect our vision of the technologies, products and services of the future. Our intellectual property portfolio consists of patents that we own and, in some cases, patents or other proprietary rights that we license from third parties, which may be limited in terms of field of use or transferability and may require royalty payments.

The medical products industry, including the diagnostic testing industry, historically has been characterized by extensive litigation regarding patents, licenses and other intellectual property rights. Litigation relating to intellectual property rights is also a risk in the health management industry.

We believe that our history of successfully enforcing our intellectual property rights in the United States and abroad demonstrates our resolve in enforcing our intellectual property rights, the strength of our intellectual property portfolio and the competitive advantage that we have in this area. We have incurred substantial costs, both in asserting infringement claims against others and in defending ourselves against patent infringement claims and we expect to incur substantial litigation costs as we continue to aggressively protect our technology and defend our proprietary rights.

Finally, we believe that certain of our trademarks are valuable assets that are important to the marketing of both our products and services. Many of these trademarks have been registered with the United States Patent and Trademark Office or internationally, as appropriate.

The medical products industry, including the diagnostic testing industry, and the health management industry place considerable importance on obtaining and enforcing patent and trade secret protection for new technologies, products, services and processes. Trademark protection is an important factor in the success of certain of our product lines and health management programs. Our success therefore depends, in part, on our abilities to obtain and enforce the patents and trademark registrations necessary to protect our products, to preserve our trade secrets and to avoid or neutralize threats to our proprietary rights from third parties. We cannot, however, guarantee our success in enforcing or maintaining our patent rights; in obtaining future patents or licensed patents in a timely manner or at all; or as to the breadth or degree of protection that our patents or trademark registrations or other intellectual property rights might afford us. For more information regarding the risks associated with our reliance on intellectual property rights see the discussion in Item 1A entitled "Risk Factors" on pages 13 through 28 of this report.

## **Government Regulation**

Our businesses are subject to extensive and frequently changing federal, state, local and foreign laws and regulations. Changes in applicable laws or any failure to comply with existing or future laws, regulations or standards could have a material adverse effect on our results of operations, financial condition, business and prospects. We believe our current arrangements and practices are in material compliance with applicable laws and regulations. There can be no assurance that we are in compliance with all applicable laws and regulations or that we will be able to comply with new laws or regulations.

Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most notably, all of our products sold in the United States are subject to the Federal Food, Drug and Cosmetic Act, or the FDCA, as implemented and enforced by the FDA. All of our diagnostic products sold in the United States require either FDA clearance to market under Section 510(k) of the FDCA, or Pre-market Approval, or PMA, which may require pre-clinical and clinical trials. Foreign countries may require similar or more onerous approvals to manufacture or market these products. The marketing of our consumer diagnostic products is also subject to

## **Table of Contents**

regulation by the U.S. Federal Trade Commission, or the FTC. In addition, we are required to meet regulatory requirements in countries outside the United States, which can change rapidly with relatively short notice. We must also demonstrate to the FDA that our diagnostic tests intended for home use or for use by laboratories holding a Certificate of Waiver under the Clinical Laboratory Improvement Act of 1967 and the Clinical Laboratory Amendments of 1988, or CLIA, including most physician office laboratories, are simple with a low risk of error. Foreign countries may require similar or more onerous approvals to manufacture or market our products.

CLIA extends federal oversight to many clinical laboratories, including certain of our drug testing laboratories in the United States, by requiring that they be certified to meet quality assurance, quality control and personnel standards. Laboratories also must undergo proficiency testing and are subject to inspections. Certain of our drug testing laboratories perform drug testing on employees of federal government contractors and certain other entities and are therefore regulated by the Substance Abuse and Mental Health Services Administration, or SAMHSA, which has established detailed performance and quality standards that laboratories must meet to be approved to perform drug testing on employees of federal government contractors and certain other entities.

Certain of the clinicians, such as nurses, must comply with individual licensing requirements. All of our clinicians who are subject to licensing requirements are licensed in the state in which they are physically present, such as the location of the call center from which they operate and, if applicable, states in which they visit or interact with patients, to the extent such licensure is required. In the future, multiple state licensing requirements for healthcare professionals who provide services telephonically over state lines may require us to license more of our clinicians in more than one state. New judicial decisions, agency interpretations or federal or state laws or regulations could increase the requirement for multi-state licensing of a greater number of our clinical staff, which would increase our administrative costs.

Certain aspects of our health management business are subject to unique licensing or permit requirements by state and local health agencies. In addition, our health management business is subject to HIPAA and the Health Information Technology for Economic and Clinical Health, or HITECH, Act. We are also required to obtain certification to participate in certain governmental payment programs, such as various state or federal Medicare/Medicaid programs. Some states have established Certificate of Need/Determination of Need, or CON/DON, programs regulating the expansion of healthcare operations. The failure to obtain, renew or maintain any of the required licenses, certifications or CON/DONs could adversely affect our business.

For more information about the governmental regulations to which our business is subject and the risk associated with non-compliance with those regulations, see the risk factors discussed in Item 1A entitled **Risk Factors** on pages 13 through 28 of this report.

## **Employees**

As of January 31, 2011, we had approximately 11,900 employees, including temporary and contract employees, of which approximately 6,500 employees are located in the United States. In addition, we utilize consultants specializing in areas such as research and development, risk management, regulatory compliance and marketing.

## **ITEM 1A. RISK FACTORS**

*The risks described below may materially impact your investment in our company or may in the future, and, in some cases already do, materially affect us and our business, financial condition and results of operations. You should carefully consider these factors with respect to your investment in our securities.*

**We face intense competition, and our failure to compete effectively may negatively affect sales of our products and services.**

The industries in which we operate, including the medical diagnostic products industry and the healthcare industry, are rapidly evolving, and developments are expected to continue at a rapid pace. Competition in these industries is intense and expected to increase as new products, services and technologies become

## **Table of Contents**

available and new competitors enter the market. Our competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. Many of our existing or potential competitors have substantially greater research and development capabilities, clinical, manufacturing, regulatory and marketing experience and financial and managerial resources than we do. Our sales and results of operations may be adversely affected by:

customers' perceptions of the comparative quality of our competitors' products or services;

the ability of our competitors to develop products, services and technologies that are more effective than ours or that render ours obsolete;

our competitors' ability to obtain patent protection or other intellectual property rights that would prevent us from offering competing products or services;

the ability of our competitors to obtain regulatory approval for the commercialization of products or services more rapidly or effectively than we do; and

competitive pricing by our competitors.

In addition, as markets for our novel products become saturated with competing products, such as for our meter-based Triage BNP test, the growth rates of sales unit volume and average selling prices for those products may decline, which may adversely impact our product sales, gross margins and overall financial results. This may occur even if we are able to successfully introduce new products in these markets, and achieve market acceptance of those products, in a timely manner.

### **We may experience difficulties that may delay or prevent our development, introduction or marketing of new or enhanced products or services.**

Our success depends on our ability to effectively introduce new and competitive products and services. The development of new or enhanced products or services is a complex, costly and uncertain process. Furthermore, developing and manufacturing new products and services requires us to anticipate customers' and patients' needs and emerging technology trends accurately. We may experience research and development, manufacturing, marketing and other difficulties that could delay or prevent our introduction of new or enhanced products and services. The research and development process in the healthcare industry generally takes a significant amount of time from design stage to product launch. This process is conducted in various stages, and each stage presents the risk that we will not achieve our goals. We may have to abandon a product in which we have invested substantial resources. We cannot be certain that:

any of our products or services under development will prove to be safe and effective in clinical trials;

we will be able to obtain, in a timely manner or at all, necessary regulatory approvals;

the products and services we develop can be manufactured or provided at acceptable cost and with appropriate quality; or

these products and services, if and when approved, can be successfully marketed.

These factors, as well as manufacturing or distribution problems or other factors beyond our control, could delay the launch of new products or services. Any delay in the development, production, marketing or distribution of a new product or service could materially and adversely affect our competitive position, our branding and our results of operations.

**Our financial condition and results of operations may be adversely affected by international business risks.**

We generate a significant percentage of our net revenue from outside the United States, and a significant number of our employees, including manufacturing, sales, support, and research and development personnel,



**Table of Contents**

are located in foreign countries, including Australia, China, England, Germany, India, Israel, Japan and South Korea. Conducting business outside the United States subjects us to numerous risks, including:

decreased liquidity resulting from longer accounts receivable collection cycles typical of foreign countries;

lower productivity resulting from difficulties we encounter in staffing and managing sales, support, and research and development operations across many countries;

lost revenues or unexpected expenses resulting from difficulties associated with enforcing agreements and collecting receivables through foreign legal systems;

lost revenues or unexpected expenses resulting from disputes with third-party distributors of our products or from third parties claiming distribution rights to our products under foreign laws or legal systems;

lost revenues or unexpected expenses resulting from the imposition by foreign governments of trade barriers such as tariffs, quotas and import restrictions;

higher cost of sales resulting from import or export licensing requirements;

lost revenues or other adverse effects resulting from acts of war, terrorism, theft or other lawless conduct or otherwise resulting from economic, social or political instability in or affecting foreign countries in which we sell our products or operate;

adverse effects resulting from changes in foreign regulatory or other laws affecting sales of our products or our foreign operations;

greater tax liability resulting from international tax laws, including U.S. taxes on foreign subsidiaries;

increased financial accounting and reporting burdens and complexities;

increased costs to comply with changes in legislative or regulatory requirements;

lost revenues or increased expenses resulting from the failure of laws to protect our intellectual property rights; and

lost revenues resulting from delays in obtaining import or export licenses, transportation difficulties and delays resulting from inadequate local infrastructure.

Our international operations subject us to varied and complex domestic, foreign and international laws and regulations. Compliance with these laws and regulations often involves significant costs or requires changes in our business practices that may reduce revenues and profitability. We could incur additional legal compliance costs associated with our global operations and could become subject to legal penalties if we do not comply with certain regulations. For example, we are subject to the United States Foreign Corrupt Practices Act which, among other restrictions, prohibits U.S. companies and their intermediaries from making payments to foreign officials for the purpose of obtaining or retaining business or otherwise obtaining favorable treatment, as well as anti-bribery and corruption laws of other jurisdictions. Our training and compliance program and our other internal control policies and procedures may not always protect us from acts committed by our employees or agents.

**Because our business relies heavily on foreign operations and revenues, changes in foreign currency exchange rates and our need to convert currencies may negatively affect our financial condition and results of operations.**

Our business relies heavily on our foreign operations. Four of our six largest manufacturing operations are conducted outside the United States in China, Japan and South Korea and we also have manufacturing operations in Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. We also have significant research and development operations in Germany and the United Kingdom, and we also conduct research and development activities outside of the United States in Australia, China, Israel and South Korea. In addition, for the year ended December 31, 2010, approximately 36% of our net revenue was derived from

## **Table of Contents**

sales outside the United States. Because of the scope of our foreign operations and foreign sales, we face significant exposure to movements in foreign currency exchange rates. Our primary exposures are related to the operations of our European and Asia Pacific subsidiaries and our manufacturing facilities in China, Japan and South Korea. These exposures may change over time as our business practices evolve and could result in increased costs or reduced revenue and could affect our actual cash flow. Changes in the relative values of currencies occur regularly and, in some instances, may have a significant impact on our operating results. We cannot predict with any certainty changes in foreign currency exchange rates or the degree to which we can cost-effectively mitigate these risks.

### **Healthcare reform legislation could adversely affect our revenue and financial condition.**

The Patient Protection and Affordable Care Act of 2010 (as amended by the Health Care and Education Reconciliation Act of 2010), or the PPACA, makes comprehensive reforms at the federal and state level affecting the coverage and payment for healthcare services in the United States. In particular, the PPACA significantly alters Medicare Advantage reimbursements by setting the federal benchmark payment closer to the payments in the traditional fee-for-service Medicare program. This change could reduce our revenues from the Medicare Advantage plans for which we perform services, although the precise effect on any particular plan, much less the impact on us, is impossible to predict. Effective January 1, 2013, the PPACA includes a 2.3% excise tax on the sale of certain medical devices. Legislative provisions impose federal reporting requirements regarding payments or relationships between manufacturers of covered drugs, devices or biological, or medical supplies, and physicians, among others.

Additionally, the PPACA requires that providers of health insurance plans maintain specified minimum medical loss ratios. If our health management services are not classified as quality improving activities under the PPACA, as implemented in regulations issued at the end of 2010, health insurance providers will not be permitted to count expenditures on those services toward the calculation of their medical loss ratios, which may adversely impact demand for our health management services and the results of operations of our health management business.

Legislative and regulatory bodies are likely to continue to pursue healthcare reform initiatives and may continue to reduce the funding of the Medicare and Medicaid programs, including Medicare Advantage, in an effort to reduce overall healthcare spending. The ultimate impact of all of the reforms in the PPACA, and its impact on us, is impossible to predict. If all of the reforms in the legislation are implemented, or if other reforms in the United States or elsewhere are adopted, those reforms may have an adverse effect on our financial condition and results of operations.

### **If the results of clinical studies required to gain regulatory approval to sell our products are not available when expected, or do not demonstrate the safety and effectiveness of those products, we may be unable to sell those products.**

Before we can sell certain of our products, we must conduct clinical studies intended to demonstrate that those products are safe and effective and perform as expected. The results of these clinical studies are used to obtain regulatory approval from government authorities such as the FDA. Clinical studies are experiments involving human patients having the diseases or medical conditions that the product is trying to evaluate or diagnose. Conducting clinical studies is a complex, time-consuming and expensive process. In some cases, we may spend several years completing the necessary clinical studies.

If we fail to adequately manage our clinical studies, those clinical studies and corresponding regulatory approvals may be delayed or we may fail to gain approval for our products altogether. Even if we successfully manage our clinical studies, we may not obtain favorable results and may not obtain regulatory approval. If we are unable to market and sell our new products or are unable to obtain approvals in the timeframe needed to execute our product strategies, our business and results of operations would be materially and adversely affected.



**Table of Contents**

**If we are unable to obtain required clearances or approvals for the commercialization of our products in the United States, we would not be able to sell those products in the United States.**

Our future performance depends on, among other matters, the timely receipt of necessary regulatory approvals for new products. Regulatory approval can be a lengthy, expensive and uncertain process. In addition, regulatory processes are subject to change, and new or changed regulations can result in increased costs and unanticipated delays.

In the United States, clearance or approval to commercially distribute new medical devices is received from the FDA through clearance of a Premarket Notification, or 510(k), or through approval of a PMA. The FDA may deny 510(k) clearance because, among other reasons, it determines that our product is not substantially equivalent to another U.S. legally marketed device. The FDA may deny a PMA because, among other reasons, it determines that our product is not sufficiently safe or effective. As part of the clearance or approval process, if we intend to sell certain diagnostic tests for home use or for use by laboratories holding a CLIA Certificate of Waiver, including most physician office laboratories, we must generally provide data demonstrating to the FDA's satisfaction that our tests are simple with a low risk of error. Failure to obtain FDA clearance or approval would preclude commercialization in the United States, and failure to obtain CLIA-waived status for any product would preclude us from selling that product for home use or to CLIA-waived laboratories, which could materially and adversely affect our future results of operations.

Modifications or enhancements that could significantly affect safety or effectiveness, or that constitute a major change in the intended use of the device, require new 510(k) or PMA submissions. We have made modifications to some of our products since receipt of initial 510(k) clearance or PMA. With respect to several of these modifications, we filed new 510(k)s describing the modifications and received FDA 510(k) clearance. We have made other modifications to some of our products that we believe do not require the submission of new 510(k)s or PMAs. The FDA may not agree with any of our determinations not to submit a new 510(k) or PMA for any of these modifications made to our products. If the FDA requires us to submit a new 510(k) or PMA for any device modification, we may be prohibited from marketing the modified products until the new submission is cleared or approved by the FDA.

The FDA has proposed changes to the 510(k) process. If the changes to the 510(k) process are adopted as proposed, the time and cost to obtain a 510(k) clearance or PMA could increase significantly.

**We are subject to regulatory approval requirements of the foreign countries in which we sell our products, and these requirements may prevent or delay us from marketing our products in those countries.**

We are subject to the regulatory approval requirements for each foreign country in which we sell our products. The process for complying with these approval requirements can be lengthy and expensive. Any changes in foreign approval requirements and processes may cause us to incur additional costs or lengthen review times of our products. We may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations.

**Our business is subject to substantial regulatory oversight and our failure to comply with applicable regulations may result in significant costs or, in certain circumstances, the suspension or withdrawal of previously obtained clearances or approvals.**

Our businesses are extensively regulated by the FDA and other federal, state and foreign regulatory agencies. These regulations impact many aspects of our operations, including development, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping.

The FDA and foreign regulatory agencies may require post-market testing and surveillance to monitor the performance of approved products or may place conditions on any product approvals that could restrict the commercial applications of those products. The discovery of problems with a product may result in restrictions on the product, including withdrawal of the product from the market. In addition, in some cases we may sell

## **Table of Contents**

products or provide services which are reliant on the use or commercial availability of products of third parties, including medical devices, equipment or pharmaceuticals, and regulatory restrictions placed upon any such third party products could have a material adverse impact on the sales or commercial viability of our related products or services.

We are subject to routine inspection by the FDA and other agencies for compliance with the Quality System Regulation and Medical Device Reporting requirements in the United States and other applicable regulations worldwide. Our manufacturing facilities and those of our suppliers and distributors also are, or can be, subject to periodic regulatory inspections.

Under CLIA, some of our drug testing laboratories in the United States are required to be certified to meet quality assurance, quality control and personnel standards. Laboratories also must undergo proficiency testing and are subject to inspections. Our laboratories that perform drug testing on employees of federal government contractors and some other entities are regulated by the United States SAMHSA, which has established detailed performance and quality standards that laboratories must meet in order to perform this work.

Portions of our health management business are subject to unique licensing or permit requirements. For example, we may be required to obtain certification to participate in governmental payment programs, such as state or federal Medicaid/Medicare programs. We may need an operating license in some states, and some states have established Certificate of Need programs regulating the expansion of healthcare operations. In addition, we believe that some of our health management services are educational in nature, do not constitute the practice of medicine or provision of healthcare and, thus, do not require that we maintain federal or state licenses to provide these services. However, it is possible that federal or state laws regarding the provision of virtual or telephonic medicine could be revised or interpreted to include our services, or that other laws may be enacted which require licensure or otherwise relate to our health management services. In that event, we may incur significant costs to comply with such laws and regulations.

We are also subject to laws relating to matters such as privacy, safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with these laws and regulations. If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products or injunctions against our distribution of products, termination of our service agreements by our customers, disgorgement of money, operating restrictions and criminal prosecution.

New laws may be enacted, or regulatory agencies may impose new or enhanced standards, that would increase our costs, as well as expose us to risks associated with non-compliance.

### **We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future.**

We are subject to laws regulating fraud and abuse in the healthcare industry, including anti-kickback and false claims laws. The Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Many states have also adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for health care items or services reimbursed by any payer, not only the Medicare, Medicaid and Veterans Administration programs. These laws constrain the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with hospitals, physicians, laboratories and other potential purchasers of medical devices and related services.

Other laws generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or are for items or services that were not provided as claimed. These laws may also be triggered by failure to return identified overpayments to a payer. Anti-kickback and false claims laws prescribe civil



## **Table of Contents**

and/or criminal penalties for noncompliance that can be substantial including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs. Furthermore, since we are reimbursed directly by federal healthcare programs for certain goods and services and, given that many of our customers rely on reimbursement from Medicare, Medicaid and other governmental programs to cover a substantial portion of their expenditures, our exclusion from such programs as a result of a violation of these laws could have a material adverse effect on our business, results of operations, financial condition and cash flows. The interpretation and enforcement of these laws and regulations are uncertain and subject to rapid change.

**Billing and payment for healthcare services are highly regulated, and the failure to comply with applicable laws and regulations can result in civil or criminal sanctions, including exclusion from federal and state healthcare programs.**

A portion of our healthcare products and services are paid for by private and governmental third-party payers, such as Medicare and Medicaid. These third-party payers typically have different and complex billing and documentation requirements that we must satisfy in order to receive payment, and they carefully audit and monitor our compliance with these requirements. We must also comply with numerous other laws applicable to billing and payment for healthcare services, including privacy laws. Failure to comply with these requirements may result in non-payment, refunds, exclusion from government healthcare programs, and civil or criminal liabilities, any of which may have a material adverse effect on our revenues and earnings.

**The health management business is a relatively new component of the overall healthcare industry, making its future uncertain.**

The health management services that we provide are relatively new components of the overall healthcare industry. Accordingly, our health management customers have not had significant experience in purchasing, evaluating or monitoring such services, which can result in a lengthy sales cycle. The success of our health management business depends on a number of factors. These factors include:

our ability to differentiate our health management services from those of competitors;

the extent and timing of the acceptance of our services as a replacement for, or supplement to, traditional managed-care offerings;

the effectiveness of our sales and marketing efforts with customers and their health plan participants;

our ability to devise new and additional services beneficial to health plans and employers and their respective participants or employees;

our ability to obtain and retain all necessary licenses, permits and regulatory clearances and approvals related to our services and any products used as part of our services, and to deliver effective, reliable and safe services to our customers and their participants;

our ability to achieve, measure and effectively communicate cost savings for health plans and employers through the use of our services; and

our ability to obtain, retain and renew contracts with health maintenance organizations, preferred provider organizations and other managed-care plans as competition increases and to the extent that health plan customers attempt to provide health management services themselves.

Since the health management business is continually evolving, we may not be able to anticipate and adapt to the developing market. Moreover, we cannot predict with certainty the future growth rate or the ultimate size of the market.

**Increasing health insurance premiums and co-payments may cause individuals to forgo health insurance and avoid medical attention, either of which may reduce demand for our products and services.**

Health insurance premiums and co-payments have generally increased in recent years. These increases may cause individuals to forgo health insurance, as well as medical attention. This behavior may reduce

## **Table of Contents**

demand for our point-of-care diagnostic products and also reduce the number of lives managed by our health management programs. Increased co-payments may cause insured individuals to forgo medical attention, thereby reducing demand for our professional diagnostic tests, as well as revenues under certain health management programs.

### **Rising unemployment may negatively impact the collectability of uninsured accounts and patient due accounts and/or reduce total health plan populations.**

Some of our health management contracts provide reimbursement to us based on total relevant populations managed by health plans. If unemployment rates rise, our revenues under these contracts may be reduced as managed lives may decrease. One of the primary collection risks of our health management business accounts receivable relates to uninsured patient accounts and patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable insurance policy, but patient responsibility amounts (deductibles and co-payments) remain outstanding. If unemployment rates rise, these uninsured and patient due accounts could increase as a percentage of the health management business accounts receivable. Deterioration in the collectability of these accounts could adversely affect the health management business collection of accounts receivable, cash flows and results of operations. These financial pressures could have an adverse impact on our business.

### **A portion of our health management fees are contingent upon performance.**

Some of our existing health management agreements contain savings or other guarantees, which provide that our revenues, or a portion of them, are contingent upon projected cost savings or other quality performance measures related to our health management programs. There is no guarantee that we will accurately forecast cost savings and clinical outcome improvements under our health management agreements or meet the performance criteria necessary to recognize potential revenues under the agreements. Additionally, untimely, incomplete or inaccurate data from our customers, or flawed analysis of such data, could have a material adverse impact on our ability to recognize revenues.

### **If our costs of providing health management services increase, we may not be able to pass these cost increases on to our customers.**

Many of our health management services are provided pursuant to long-term contracts that we may not be able to re-negotiate. If our costs increase, we may not be able to increase our prices, which would adversely affect our overall profit margin and net income.

### **Demands of third-party payers, cost reduction pressures among our customers and restrictive reimbursement practices may adversely affect our revenues.**

Our ability to negotiate favorable contracts with non-governmental payers, including managed-care plans, significantly affects the revenues and operating results of our health management business. Our customers continue to face cost reduction pressures that may cause them to curtail their use of, or reimbursement for, health management services, to negotiate reduced fees or other concessions or to delay payment. Furthermore, the increasing leverage of organized buying groups among non-governmental payers may reduce market prices for our products and services, thereby reducing our profitability. Reductions in price increases or the amounts received from managed-care, commercial insurance or other payers could have a material adverse effect on the financial position, cash flows and results of operations of our health management business.

In addition, the ability of our customers to obtain appropriate reimbursement for products and services from third-party payers is critical to the success of our business because it affects which products customers purchase and the prices they are willing to pay. If we develop a new product but the product is not approved for reimbursement by private and governmental third-party payers, the product may not be successful. Domestic and foreign healthcare

reforms may further reduce reimbursement levels and adversely affect demand for and profitability of our products and services. These reforms, along with other cost-containment initiatives, could have a material adverse effect on our business, results of operations and financing condition.

## **Table of Contents**

### **Our data management and information technology systems are critical to maintaining and growing our business.**

Our business, particularly our health management business, is dependent on the effective use of information technology and, consequently, technology failure or obsolescence may negatively impact our business. In addition, data acquisition, data quality control, data security and data analysis, which are a cornerstone of our health management programs, are intense and complex processes subject to error. Untimely, incomplete or inaccurate data, flawed analysis of data or our inability to properly integrate, implement and update systems could have a material adverse impact on our business and results of operations. In particular, we are relying on our recently launched healthcare portal, Apollo, to provide the framework and supporting infrastructure for significantly enhanced future health management programs and to provide a competitive advantage. Apollo is a relatively new system and may not provide these expected benefits or meet our needs or the needs of our customers or program participants.

We expect that we will need to continue to improve and further integrate our information technology systems by training and educating our employees with respect to system improvements and integrations on an ongoing basis in order to effectively run our business. If we fail to successfully manage our information technology systems, including Apollo, our business and operating results could be adversely affected.

### **Poor economic conditions may negatively impact our toxicology business.**

The high rates of unemployment currently affecting the United States and other countries negatively impact the demand for pre-employment drug testing. Additionally, reduced government funding for drug screening programs negatively impacts the market for our toxicology tests. If these trends continue or accelerate, they may have a material adverse impact on the results of operations of our toxicology business.

### **If we deliver products with defects, we may be subject to product recalls or negative publicity, our credibility may be harmed, market acceptance of our products may decrease and we may be exposed to liability.**

The manufacturing and marketing of professional and consumer diagnostics involve an inherent risk of product liability claims. For example, a defect in one of our diagnostic products could lead to a false positive or false negative result, affecting the eventual diagnosis. Our product development and production are extremely complex and could expose our products to defects. Manufacturing and design defects could lead to recalls (either voluntary or required by the FDA or other government authorities) and could result in the removal of a product from the market. Defects in our products could also harm our reputation, lead to negative publicity and decrease sales of our products.

In addition, our marketing of monitoring services may cause us to be subjected to various product liability or other claims, including, among others, claims that inaccurate monitoring results lead to injury or death. Any product liability or other claim brought against us, regardless of merit, could be costly to defend and could result in an increase to our insurance premiums. If we are held liable for a claim, that claim could materially damage our business and financial condition.

### **We may experience manufacturing problems or delays due to, among other reasons, our volume and specialized processes, which could result in decreased revenue or increased costs.**

The global supply of our products depends on the uninterrupted efficient operation of our manufacturing facilities. Many of our manufacturing processes are complex and involve sensitive scientific processes, including unique and often proprietary antibodies which cannot be replicated or acquired through alternative sources without undue delay or expense. Other processes present difficult technical challenges to obtain the manufacturing yields necessary to operate profitably. In addition, our manufacturing processes may require complex and specialized equipment which can be

expensive to repair or replace with required lead times of up to a year.

The manufacturing of certain of our products is concentrated in one or more of our plants, with limited alternate facilities. Any event that negatively impacts our manufacturing facilities, our manufacturing systems or equipment, or our contract manufacturers or suppliers could delay or suspend shipments of products or the

## **Table of Contents**

release of new products or could result in the delivery of inferior products. Our revenues from the affected products would decline and we could incur losses until such time as we or our contract manufacturers are able to restore our or their production processes or we are able to put in place alternative contract manufacturers or suppliers.

### **We rely on suppliers for raw materials and other products and services, and fluctuations in the availability and price of such products and services may adversely affect our business or results of operations.**

We rely on numerous third parties to supply raw materials and other components for our manufacturing processes. In some cases, these raw materials and components are available only from a sole supplier. We also rely on a number of significant third-party manufacturers to produce some of our professional diagnostics products. Stringent requirements of the FDA and other regulatory authorities regarding the manufacture of our products may prevent us from quickly establishing additional or replacement sources for the raw materials, components or manufacturing services that we use or from doing so without excessive cost. As a result, a reduction or interruption in supply or an inability to secure alternative sources of raw materials, components or manufacturing services could have a material adverse effect on our business, result of operations, financial condition and cash flows.

### **We may not realize the intended benefits of the relocation of some of our manufacturing facilities to China.**

In recent years we have shifted production of several of our products to our manufacturing facilities in China and closed less efficient and more expensive facilities elsewhere. We may shift production of additional products to China and other lower cost facilities. Moving production is difficult and involves significant risk. We may experience delays, inefficiencies and unanticipated costs as a result of problems establishing relationships with local materials suppliers; acquiring new facilities or adapting existing facilities and equipment to the production of new products; hiring, training and retaining personnel; and establishing and maintaining compliance with governmental regulations and industry standards. Any of these factors could have a material negative impact on our financial performance.

### **We could suffer monetary damages, incur substantial costs or be prevented from using technologies important to our products as a result of pending legal proceedings.**

We are involved in various legal proceedings arising out of our business. Because of the nature of our business, we may be subject at any particular time to commercial disputes, product liability claims, negligence claims or various other lawsuits arising in the ordinary course of our business, including infringement, distributor disputes, employment matters or investor matters. The lawsuits we face generally seek damages, sometimes in substantial amounts, for commercial or personal injuries allegedly suffered and can include claims for punitive or other special damages. An adverse ruling or rulings in one or more such lawsuits could, individually or in the aggregate, substantially harm our sales, operations or financial performance.

### **The rights we rely upon to protect the intellectual property underlying our products may not be adequate to prevent third parties from using our technology, which would reduce a competitive advantage provided by our patents.**

Our success depends in part on our ability to develop or acquire commercially valuable intellectual property rights and to enforce those rights. The degree of present and future protection for our intellectual property is uncertain and may change. The risks and uncertainties that we face with respect to our patents and other proprietary rights include the following:

pending patent applications we have filed, or to which we have exclusive rights, may not result in issued patents or may take longer than we expect to result in issued patents;

patents licensed or issued to us or our customers may not provide a competitive advantage;

other parties may challenge patents or patent applications licensed or issued to us or our customers;

other companies may design around technologies we have patented, licensed or developed; and



## **Table of Contents**

all patents have a limited life, meaning at some point valuable patents will expire and we will lose the competitive advantage they provide.

In addition to patents, we rely on a combination of trade secrets, non-disclosure agreements and other contractual provisions and technical measures to protect our intellectual property rights. Nevertheless, these measures may not be adequate to safeguard the technology underlying our products. If these measures do not protect our rights, third parties could access our technology and our competitive advantage in the market would be reduced. In addition, employees, consultants and others who participate in the development of our products may breach their agreements with us regarding our intellectual property, and we may not have adequate remedies for the breach. We also may not be able to effectively protect our intellectual property rights in some foreign countries. For a variety of reasons, we may decide not to file for patent, copyright or trademark protection or prosecute potential infringements of our patents. Our trade secrets may also become known through other means not currently foreseen by us. Despite our efforts to protect our intellectual property, our competitors or customers may independently develop similar or alternative technologies or products that are equal or superior to our technology and products without infringing any of our intellectual property rights, or design around our proprietary technologies.

### **Claims by others that our products infringe their proprietary rights could adversely affect our ability to sell our products and services and could increase our costs.**

Substantial litigation over intellectual property rights exists in the professional and consumer diagnostics industries and in the health management industry. We expect that our products and services could be increasingly subject to third-party infringement claims as the number and functionality of our products grows and as we enter new and different industries and markets. Third parties may have or obtain patents which our products and services or technology may actually or allegedly infringe. Any of these third parties might assert infringement claims against us. Any litigation could result in the expenditure of significant financial resources and the diversion of management's time and resources. In addition, litigation in which we are accused of infringement may result in negative publicity, have an impact on prospective customers, cause product delays, or require us to develop alternative technology, make substantial payments to third parties or enter into royalty or license agreements, which may not be available on acceptable terms, or at all. If a successful claim of infringement were made against us and we could not develop non-infringing technology or license rights to the infringed or similar technology on a timely and cost-effective basis, we may be forced to stop selling current products or abandon new products under development and we could be exposed to legal actions by our customers.

### **We may need to initiate lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could cause us to lose some of our intellectual property rights, which would reduce our ability to compete.**

In order to protect or enforce our patent rights, we may initiate litigation or other proceedings against, or enter into negotiations or settlement discussions with, third parties. Litigation may be necessary to:

- assert claims of infringement;
- enforce licensing terms and conditions;
- protect our trade secrets or know-how; or
- determine the enforceability, scope and validity of the proprietary rights of ourselves or others.

We have initiated a number of lawsuits against competitors whom we believe to be selling products that infringe our proprietary rights. These lawsuits and any other lawsuits that we initiate in the future could be expensive, take significant time and divert management's attention from other business concerns. Litigation also puts our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing. Additionally, we may provoke third parties to assert claims against us.

Patent law relating to the scope of claims in the technology fields in which we operate is still evolving and, consequently, patent positions in our industry are subject to change and often uncertain. We may not

## **Table of Contents**

prevail in any of these suits, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of these suits, there may be public announcements of the results of hearings, motions and other interim proceedings or developments in the litigation. If securities analysts or investors perceive any of these results to be negative, the trading prices of our securities may decline.

### **Our future business prospects may be limited if our acquisition strategy is not successful.**

As part of our business strategy, we seek to acquire or invest in businesses that offer complementary products, services or technologies to ours. If we are unable to identify and consummate acquisition opportunities, we may not achieve our growth targets. We may lose acquisition opportunities to competitors who offer a higher purchase price or who reach agreement with the target company earlier than we do. We may fail to complete acquisitions for many reasons, including failure to obtain antitrust or other regulatory clearances, failure to obtain requisite shareholder approval and failure to obtain necessary financing, and we may incur significant expenses, including potentially the expense of litigation, pursuing acquisitions, whether or not consummated.

### **Our business could be materially adversely affected as a result of the risks associated with our acquisition strategy.**

Since our inception, we have acquired numerous businesses, including Standard Diagnostics, Inc. in 2010; certain assets of ACON Laboratories, Inc. and certain related entities, or the ACON Second Territory Business, in 2009; and Alere San Diego, Inc., formerly Biosite Incorporated, or Biosite, in 2007. The ultimate success of our acquisitions depends, in part, on our ability to realize the anticipated synergies, cost savings and growth opportunities from integrating newly-acquired businesses or assets into our existing businesses. However, the acquisition and successful integration of independent businesses or assets is a complex, costly and time-consuming process, and the benefits we realize may not exceed the costs of the acquisition. The risk and difficulties associated with acquiring and integrating companies and other assets include, among others:

the impact of the acquisition on our financial and strategic position and reputation;

consolidating manufacturing, research and development operations and health management information technology platforms, where appropriate;

integrating newly-acquired businesses or product lines into a uniform financial reporting system;

coordinating sales, distribution and marketing functions and strategies, including the integration of our current health management products and services;

establishing or expanding manufacturing, sales, distribution and marketing functions in order to accommodate newly-acquired businesses or product lines or rationalizing these functions to take advantage of synergies;

preserving the important licensing, research and development, manufacturing and supply, distribution, marketing, customer and other relationships of acquired businesses;

minimizing the diversion of management's attention from ongoing business concerns;

the potential loss of key employees of the acquired business;

coordinating geographically separate operations; and

regulatory and legal issues relating to the integration of legacy and newly-acquired businesses.

These factors could have a material adverse effect on our business, results of operations or financial condition, and managing multiple acquisitions or investments at the same time could exacerbate these risks. To the extent that we issue equity securities in connection with any future acquisition or investment, existing shareholders may experience dilution. Additionally, regardless of the form of consideration we pay, acquisitions and investments could negatively impact our net income and earnings per share.

**Table of Contents**

**If goodwill or other intangible assets that we have recorded in connection with our acquisitions of other businesses become impaired, we could have to take significant charges against earnings.**

As a result of our acquisitions, we have recorded, and may continue to record, a significant amount of goodwill and other intangible assets. Under current accounting guidelines, we must assess, at least annually and potentially more frequently, whether the value of goodwill and other intangible assets has been impaired. For example, during the fourth quarter of 2010, we determined that our goodwill related to our health management business was impaired, resulting in a non-cash impairment charge in the amount of \$1.0 billion. Any further reduction or impairment of the value of goodwill or other intangible assets will result in additional charges against earnings, which could materially reduce our reported results of operations in future periods.

**We do not have complete control over the operations of SPD, our 50/50 joint venture with P&G, and we may be required to repurchase P&G's interest in SPD at fair market value.**

Because SPD is a 50/50 joint venture, we do not have complete control over its operations, including business decisions, which may impact SPD's profitability.

Additionally, P&G retains an option to require us to purchase P&G's interest in SPD at fair market value during the 60-day period beginning on May 17, 2011. The exercise of this option could strain our financial resources. Certain subsidiaries of P&G also have the right, at any time upon certain material breaches by us or our subsidiaries of our obligations under the joint venture documents, to acquire all of our interest in SPD at fair market value less any applicable damages.

**Our business has substantial indebtedness.**

We currently have, and will likely continue to have, a substantial amount of indebtedness. Our indebtedness could, among other things, make it more difficult for us to satisfy our debt obligations, require us to use a large portion of our cash flow from operations to repay and service our debt or otherwise create liquidity problems, limit our flexibility to adjust to market conditions, place us at a competitive disadvantage and expose us to interest rate fluctuations. As of December 31, 2010, we had total debt outstanding of approximately \$2.4 billion, which included approximately \$941.3 million in aggregate principal amount of indebtedness outstanding under our senior secured credit facility, \$250.0 million in aggregate principal amount of indebtedness outstanding under our junior secured credit facility, to which we refer, together with the senior secured credit facility, as our secured credit facilities. Our secured credit facilities mature in stages during the period beginning in 2013, 2014 or and continuing through 2015. At December 31, 2010, we also had an aggregate of \$1.0 billion in aggregate principal amount of indebtedness outstanding under our senior and senior subordinated notes, all of which matures in 2016 or 2018, as well as \$150.0 million in aggregate principal amount of indebtedness outstanding under our 2007 senior subordinated convertible notes, which matures in 2016.

We expect to obtain the money to pay our expenses and to pay the principal and interest on our indebtedness from cash flow from our operations and potentially from other debt or equity offerings. Accordingly, our ability to meet our obligations depends on our future performance and capital raising activities, which will be affected by financial, business, economic and other factors, many of which are beyond our control. If our cash flow and capital resources prove inadequate to allow us to pay principal and interest on our debt and meet our other obligations, we could face substantial liquidity problems and might be required to dispose of material assets or operations, restructure or refinance our debt and forego attractive business opportunities. We may be unable to do so on acceptable terms. In addition, the terms of our existing or future debt agreements may restrict us from pursuing any of these alternatives.

**The agreements governing our indebtedness subject us to various restrictions that may limit our ability to pursue business opportunities.**

The agreements governing our indebtedness subject us to various restrictions on our ability to engage in certain activities, including, among other things, our ability to:

acquire other businesses;

**Table of Contents**

raise additional capital;

incur additional debt;

pay dividends or make distributions or repurchase or redeem our stock or subordinated debt;

prepay indebtedness; and

consolidate, merge or sell all or substantially all of our assets.

These restrictions may limit or restrict our cash flow and our ability to pursue business opportunities or strategies that we would otherwise consider to be in our best interests.

**Our secured credit facilities contain certain financial and other restrictive covenants that we may not satisfy, and that, if not satisfied, could result in the acceleration of the amounts due under our secured credit facilities and the limitation of our ability to borrow additional funds in the future.**

The agreements governing our secured credit facilities subject us to various financial and other restrictive covenants with which we must comply on an ongoing or periodic basis. These include covenants pertaining to maximum consolidated leverage ratios, minimum consolidated interest coverage ratios and limits on capital expenditures. If we violate any of these covenants, we may suffer a material adverse effect. Most notably, our outstanding debt under our secured credit facilities could become immediately due and payable, our lenders could proceed against any collateral securing such indebtedness, and our ability to borrow additional funds in the future may be limited or terminated. Alternatively, we could be forced to refinance or renegotiate the terms and conditions of our secured credit facilities, including the interest rates, financial and restrictive covenants and security requirements of the secured credit facilities, on terms that may be significantly less favorable to us.

**A default under any of the agreements governing our indebtedness could result in a default and acceleration of indebtedness under other agreements.**

The agreements governing our indebtedness contain cross-default provisions whereby a default under one agreement could result in a default and acceleration of our repayment obligations under other agreements. If a cross-default were to occur, we may not be able to pay our debts or borrow sufficient funds to refinance them. Even if new financing were available, it may not be available on acceptable terms. If some or all of our indebtedness is in default for any reason, our business, financial condition and results of operations could be materially and adversely affected.

**We may not be able to satisfy our debt obligations upon a change of control or fundamental change, which could limit our opportunity to enter into a change of control or fundamental change transaction.**

If we undergo a change of control, as provided in our secured credit facilities, the senior notes or the senior subordinated notes, or a fundamental change or termination of trading, as provided in the 2007 senior subordinated convertible notes, we may be required to repay or repurchase some or all of such indebtedness. We may not have sufficient financial resources to satisfy all of our repayment and repurchase obligations. Our failure to purchase notes as required under the senior or senior subordinated notes or the 2007 senior subordinated convertible notes would constitute a default under the relevant indentures and under our secured credit facilities and could have material adverse consequences for us and our stakeholders.

**Non-competition obligations and other restrictions will limit our ability to take full advantage of our management team, the technology we own or license and our research and development capabilities.**

Members of our management team have had significant experience in the diabetes field. In addition, technology we own or license may have potential applications to this field and our research and development capabilities could be applied to this field. However, in conjunction with our split-off from Inverness Medical Technology, Inc., or IMT, we agreed not to compete with IMT and Johnson & Johnson in the field of diabetes through November 21, 2011. In addition, our license agreement with IMT prevents us from using any of the licensed technology in the field of diabetes. As a result of these restrictions, we are limited in our ability to pursue opportunities in the field of diabetes.



## **Table of Contents**

### **Our operating results may fluctuate for various reasons and, as a result, period-to-period comparisons of our results of operations will not necessarily be meaningful.**

Many factors relating to our business, such as those described elsewhere in this section, make our future operating results uncertain and may cause them to fluctuate from period to period. Because our revenue and operating results are difficult to predict, we believe that period-to-period comparisons of our results of operations are not a good indicator of our future performance. If revenue declines in a quarter, our results of operations will be harmed because many of our expenses are relatively fixed. In particular, research and development, sales and marketing and general and administrative expenses are not significantly affected by variations in revenue. If our quarterly operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price could drop suddenly and significantly.

### **Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.**

We are subject to income taxes in both the United States and various foreign jurisdictions, and we may take certain income tax positions on our tax returns that tax authorities may disagree with. We provide reserves for potential payments of tax to various tax authorities related to uncertain tax positions. However, the calculation of our tax liabilities involves the application of complex tax regulations to our global operations in many jurisdictions. Therefore, any dispute with any tax authority may result in a payment that is materially different from our current estimate of the tax liabilities associated with our returns.

Changes in tax laws or tax rulings could materially impact our effective tax rate. There are several proposals to reform U.S. tax rules being considered by U.S. law makers, including proposals that may reduce or eliminate the deferral of U.S. income tax on our unrepatriated earnings, potentially requiring those earnings to be taxed at the U.S. federal income tax rate, reduce or eliminate our ability to claim foreign tax credits, and eliminate various tax deductions until foreign earnings are repatriated to the U.S. Our future reported financial results may be adversely affected by tax rule changes which restrict or eliminate our ability to claim foreign tax credits or deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.

### **We may incur losses in excess of our insurance coverage.**

Our insurance coverage includes product liability, property, fire, terrorism and business interruption policies. Our insurance coverage contains policy limits, specifications and exclusions. We believe that our insurance coverage is consistent with general practices within our industry. Nonetheless, we may incur losses of a type for which we are not covered by insurance or which exceed the limits of liability of our insurance policies. In that event, we could experience a significant loss which could have a material negative impact on our financial condition.

### **Our future success depends on our ability to recruit and retain key personnel.**

Our future success depends on our continued ability to attract, hire and retain highly qualified personnel, including our executive officers and scientific, technical, sales and marketing employees, and their ability to manage growth successfully. Experienced personnel in our industry are in high demand and competition for their talents is intense. If we are unable to attract and retain key personnel, our business may be harmed. In addition, the loss of any of our key personnel, particularly key research and development personnel, could harm our business and prospects and could impede the achievement of our research and development, operation or strategic objectives.

### **Future sales of our common stock issuable upon conversion of our Series B Convertible Perpetual Preferred Stock, or Series B Preferred Stock, or our senior subordinated convertible notes may adversely affect the**

**market price of our common stock.**

Sales of a substantial number of shares of our common stock or other equity securities in the public market could depress the price of our common stock and impair our ability to raise capital through the sale of additional equity securities. The price of our common stock could be affected by possible sales of the substantial number of shares of our common stock potentially issuable upon conversion of our Series B

## **Table of Contents**

Preferred Stock or our senior subordinated convertible notes and by other hedging or arbitrage trading activity that may develop involving our common stock. If the conditions applicable to the conversion of our Series B Preferred Stock were satisfied, then subject to adjustment, each of the approximately 2.1 million shares of Series B Preferred Stock outstanding as of December 31, 2010 could convert into 5.7703 shares of our common stock, or approximately 12.1 million shares of our common stock. Upon certain extraordinary transactions, depending on the market price of our common stock at that time, the conversion rate could increase such that significantly more shares of common stock could be issued. Our \$150.0 million in aggregate principal amount of senior subordinated convertible notes is convertible into shares of our common stock at a conversion price of approximately \$43.98 per share, or approximately 3.4 million shares.

### **The holders of our Series B Preferred Stock are entitled to receive liquidation payments in preference to the holders of our common stock.**

As of December 31, 2010, the outstanding shares of our Series B Preferred Stock had an aggregate stated liquidation preference of approximately \$836.2 million. Dividends accrue on the shares of Series B Preferred Stock at a rate of 3% per annum, and we have the option to pay these dividends in shares of common stock or additional shares of Series B Preferred Stock and in either case must satisfy the dividend obligation by issuing the requisite number of shares based upon market prices. Upon a liquidation of our company, the holders of shares of Series B Preferred Stock will be entitled to receive a liquidation payment prior to the payment of any amount with respect to the shares of our common stock. The amount of this preferential liquidation payment is the aggregate stated liquidation preference, plus any accrued and unpaid dividends. Because of the substantial liquidation preference to which the holders of the Series B Preferred Stock are entitled, the amount available to be distributed to the holders of our common stock upon a liquidation of our company could be substantially limited or reduced to zero.

### **The terms of the Series B Preferred Stock may limit our ability to raise additional capital through subsequent issuances of preferred stock.**

For so long as any shares of Series B Preferred Stock remain outstanding, we are not permitted, without the affirmative vote or written consent of the holders of at least two-thirds of the Series B Preferred Stock then outstanding, to authorize or designate any class or series of capital stock having rights on liquidation or as to distributions (including dividends) senior to the Series B Preferred Stock. This restriction could limit our ability to plan for or react to market conditions or meet extraordinary capital needs, which could have a material adverse impact on our business.

### **Anti-takeover provisions in our organizational documents and Delaware law may limit the ability of our stockholders to control our policies and effect a change of control of our company and may prevent attempts by our stockholders to replace or remove our current management, which may not be in your best interests.**

Provisions of our certificate of incorporation and bylaws may discourage a third party from making a proposal to acquire us, even if some of our stockholders might consider the proposal to be in their best interests, and may prevent attempts by our stockholders to replace or remove our current management. These provisions include the following:

our certificate of incorporation provides for three classes of directors with the term of office of one class expiring each year, commonly referred to as a staggered board. By preventing stockholders from voting on the election of more than one class of directors at any annual meeting of stockholders, this provision may have the effect of keeping the current members of our board of directors in control for a longer period of time than stockholders may desire;

our certificate of incorporation authorizes our board of directors to issue shares of preferred stock without stockholder approval and to establish the preferences and rights of any preferred stock issued, which would allow the board to issue one or more classes or series of preferred stock that could discourage or delay a tender offer or change in control;

## **Table of Contents**

In addition, our board of directors may in the future adopt other protective measures, such as a stockholder rights plan, which could delay, deter or prevent a change in control.

### **ITEM 1B. UNRESOLVED STAFF COMMENTS**

None.

### **ITEM 2. PROPERTIES**

Our principal corporate administrative office, together with the administrative office for most of our United States consumer operations, is located at 51 Sawyer Road, Waltham, Massachusetts. Our health management business is headquartered in Atlanta, Georgia. We also operate a shared service center in Orlando, Florida, which houses certain critical back-office and sales operations supporting our U.S. professional diagnostics operations. These key administrative facilities are leased from third parties.

We own approximately 32.6 acres of land in San Diego, California which houses one of our six primary manufacturing operations, as well as significant administrative and research and development operations for our professional diagnostics business. Our buildings on this property total 336,000 square feet and include 167,000 square feet of manufacturing space for professional diagnostic products.

Our other primary manufacturing operations are in Hangzhou and Shanghai, China; Matsudo, Japan; Yongin, South Korea and Scarborough, Maine. We manufacture some of our consumer and professional diagnostics products in a manufacturing facility of approximately 410,000 square feet in Hangzhou, China, which we own. The majority of our consumer diagnostic products are manufactured in a facility of approximately 54,000 square feet in Shanghai, China, which we lease. We manufacture our Determine products in a leased space of approximately 35,000 square feet in Matsudo, Japan. We will also continue to rent 16,000 square feet of space in Matsudo from Abbott Laboratories through March 2011. Standard Diagnostics manufactures most of its professional diagnostic products in a 63,000 square foot facility, which it owns, in Yongin, South Korea. We manufacture certain professional diagnostic products in a 64,000 square foot facility that we lease in Scarborough, Maine.

We rely increasingly on toxicology laboratories to provide reliable drugs of abuse testing results to customers. We own two SAMHSA certified laboratories located in Gretna, Louisiana and Richmond, Virginia. We also operate laboratories in Santa Rosa, California; Austin, Texas and Abingdon, England.

We also have leases or other arrangements for other facilities in various locations worldwide, including smaller manufacturing operations and laboratories, as well as research and developments operations, administrative or sales offices, call centers and warehouses. We believe that adequate space for our manufacturing, testing and other operations will be available as needed.

### **ITEM 3. LEGAL PROCEEDINGS**

We are not a party to any pending legal proceedings that we currently believe could have a material adverse impact on our sales, operations or financial performance. However, because of the nature of our business, we may be subject at any particular time to lawsuits or other claims arising in the ordinary course of our business, and we expect that this will continue to be the case in the future.

### **ITEM 4. REMOVED AND RESERVED**



**Table of Contents****PART II****ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES****Unregistered Sales of Equity Securities and Use of Proceeds**

On December 17, 2010, we issued 400 shares of our common stock upon the exercise of warrants for cash, resulting in aggregate proceeds to us of \$5,416. These shares were offered and sold, in one transaction, pursuant to an exemption afforded by Section 4(2) of the Securities Act of 1933, as amended.

**Market Information**

Our common stock trades on the New York Stock Exchange (NYSE) under the symbol ALR. The following table sets forth the high and low sales prices of our common stock for each quarter during fiscal 2010 and 2009.

	<b>High</b>	<b>Low</b>
<b>Fiscal 2010</b>		
Fourth Quarter	\$ 36.81	\$ 26.61
Third Quarter	\$ 31.60	\$ 25.36
Second Quarter	\$ 40.32	\$ 26.06
First Quarter	\$ 44.87	\$ 38.30
<b>Fiscal 2009</b>		
Fourth Quarter	\$ 44.01	\$ 37.02
Third Quarter	\$ 41.86	\$ 30.27
Second Quarter	\$ 35.99	\$ 25.80
First Quarter	\$ 28.93	\$ 18.59

On February 23, 2011, there were 2,029 holders of record of our common stock.

**Dividend Policy**

We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings to support our growth strategy and do not anticipate paying cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs and plans for expansion. In addition, restrictive covenants under our secured credit facilities and the indentures governing the terms of our senior notes and our senior subordinated notes currently prohibit or limit the payment of cash or stock dividends.

**Table of Contents****Stock Performance Graph**

The following line graph compares the cumulative total stockholder return on our common stock from December 31, 2005 through December 31, 2010 with the cumulative total return of a broad equity market index and a published industry index. This graph assumes an investment of \$100.00 on December 30, 2005 in our common stock, and compares its performance with the NYSE Composite Index and the Dow Jones U.S. Healthcare Index (the Current Indices ). We paid no dividends on our common stock during the period covered by the graph. The Current Indices reflect a cumulative total return based upon the reinvestment of dividends of the stocks included in those indices. Measurement points are December 30, 2005 and the last trading day of each subsequent year end through December 31, 2010.

The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.

**Current Indices**

<b>Date</b>	<b>ALR</b>	<b>NYSE Composite Index</b>	<b>Dow Jones U.S. Healthcare Index</b>
12/30/05	\$ 100.00	\$ 100.00	\$ 100.00
12/29/06	\$ 163.22	\$ 117.86	\$ 105.20
12/31/07	\$ 236.95	\$ 125.62	\$ 112.10
12/31/08	\$ 79.76	\$ 74.25	\$ 85.17
12/31/09	\$ 175.07	\$ 92.66	\$ 101.24
12/31/10	\$ 154.37	\$ 102.71	\$ 103.70

The performance graph above shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (or the Exchange Act), or otherwise subject to the liabilities of that section. This graph will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.



**Table of Contents****ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA**

The following tables set forth selected consolidated financial data of our company as of and for each of the years in the five-year period ended December 31, 2010 and should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K.

On January 15, 2010, we completed the sale of our vitamins and nutritional supplements business. The sale included our entire private label and branded nutritional businesses and represents the complete divestiture of our entire vitamins and nutritional supplements business segment. The results of the vitamins and nutritional supplements business are included in income (loss) from discontinued operations, net of tax, for all periods presented in the statement of operations data below. The assets and liabilities associated with the vitamins and nutritional supplements business have been reclassified to current classifications as assets held for sale and liabilities related to assets held for sale and, as such, have impacted working capital amounts, which are reflected in the balance sheet data section below, for all balance sheet dates presented.

For a discussion of certain factors that materially affect the comparability of the selected consolidated financial data or cause the data reflected herein not to be indicative of our future results of operations or financial condition, see Item 1A Risk Factors, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operation and Notes 2(r) and 4 of our consolidated financial statements included elsewhere in this report.

	<b>2010</b>	<b>For the Year Ended December 31,</b>			<b>2006</b>
		<b>2009</b>	<b>2008</b>	<b>2007</b>	
		<b>(in thousands, except per share data)</b>			
<b>Statement of Operations Data:</b>					
Net product sales	\$ 1,472,403	\$ 1,365,079	\$ 1,151,265	\$ 728,091	\$ 470,079
Services revenue	662,185	528,487	405,462	16,646	
Net product sales and services revenue	2,134,588	1,893,566	1,556,727	744,737	470,079
License and royalty revenue	20,759	29,075	25,826	21,979	17,324
Net revenue	2,155,347	1,922,641	1,582,553	766,716	487,403
Cost of net product sales	688,325	619,503	543,317	365,545	257,785
Cost of services revenue	325,286	240,026	177,098	5,261	
Cost of license and royalty revenue	7,149	8,890	8,620	9,149	5,432
Cost of net revenue	1,020,760	868,419	729,035	379,955	263,217
Gross profit	1,134,587	1,054,222	853,518	386,761	224,186
Operating expenses:					
Research and development	133,278	112,848	111,828	69,547	48,706
Purchase of in-process research and development				173,825	4,960
Sales and marketing	499,124	441,646	381,939	163,028	89,700
General and administrative	446,917	357,033	295,059	155,153	67,938

Edgar Filing: ALERE INC. - Form 10-K/A

Goodwill impairment charge	1,006,357				
(Gain) loss on dispositions, net		(3,355)			3,498
Operating income (loss)	(951,089)	146,050	64,692	(174,792)	9,384
Interest expense and other expenses, net, including amortization of original issue discounts and write-off of deferred financing costs	(116,697)	(105,802)	(102,939)	(73,563)	(17,595)
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,067,786)	40,248	(38,247)	(248,355)	(8,211)
Provision (benefit) for income taxes	(29,931)	15,627	(16,644)	(1,049)	5,712

**Table of Contents**

	<b>2010</b>	<b>For the Year Ended December 31,</b>			<b>2006</b>
		<b>2009</b>	<b>2008</b>	<b>2007</b>	
		<b>(in thousands, except per share data)</b>			
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(1,037,855)	24,621	(21,603)	(247,306)	(13,923)
Equity earnings of unconsolidated entities, net of tax	10,566	7,626	1,050	4,372	336
Income (loss) from continuing operations	(1,027,289)	32,247	(20,553)	(242,934)	(13,587)
Income (loss) from discontinued operations, net of tax	11,397	1,934	(1,048)	(418)	(3,255)
Net income (loss)	(1,015,892)	34,181	(21,601)	(243,352)	(16,842)
Less: Net income attributable to non-controlling interests	1,418	465	167	1,401	
Net income (loss) attributable to Alere Inc. and Subsidiaries	(1,017,310)	33,716	(21,768)	(244,753)	(16,842)
Preferred stock dividends	(24,235)	(22,972)	(13,989)		
Net income (loss) available to common stockholders(1)	\$ (1,041,545)	\$ 10,744	\$ (35,757)	\$ (244,753)	\$ (16,842)
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries:					
Net income (loss) per common share from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)	\$ (4.74)	\$ (0.39)
Net income (loss) per common share from discontinued operations	\$ 0.14	\$ 0.02	\$ (0.01)	\$ (0.01)	\$ (0.10)
Net income (loss) per common share(1)	\$ (12.33)	\$ 0.13	\$ (0.46)	\$ (4.75)	\$ (0.49)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries:					
Net income (loss) per common share from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)	\$ (4.74)	\$ (0.39)
Net income (loss) per common share from discontinued operations	\$ 0.14	\$ 0.02	\$ (0.01)	\$ (0.01)	\$ (0.10)
Net income (loss) per common share(1)	\$ (12.33)	\$ 0.13	\$ (0.46)	\$ (4.75)	\$ (0.49)

	2010	2009	December 31, 2008 (In thousands)	2007	2006
<b>Balance Sheet Data:</b>					
Cash and cash equivalents	\$ 401,306	\$ 492,773	\$ 141,324	\$ 414,732	\$ 71,104
Working capital	\$ 411,399	\$ 828,944	\$ 470,349	\$ 674,048	\$ 133,297
Total assets	\$ 6,330,374	\$ 6,943,992	\$ 5,955,360	\$ 4,880,759	\$ 1,085,771
Total debt	\$ 2,398,985	\$ 2,149,324	\$ 1,520,534	\$ 1,387,849	\$ 202,976
Total stockholders equity	\$ 2,575,038	\$ 3,527,555	\$ 3,278,838	\$ 2,586,667	\$ 714,138

(1) Net income (loss) available to common stockholders and basic and diluted net income (loss) per common share are computed consistent with annual per share calculations described in Notes 2(n) and 12 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

**Table of Contents**

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward-Looking Statements**

*This Annual Report on Form 10-K, including this Item 7, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by forward-looking words such as may, could, should, would, intend, will, expect, anticipate, believe, estimate, continue or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other forward-looking information.*

*Forward-looking statements in this Item 7 include, without limitation, statements regarding anticipated expansion and growth in certain of our product and service offerings, the impact of our research and development activities, potential new product and technology achievements, the potential for selective acquisitions, including acquisitions of health management businesses outside the United States, our ability to improve our working capital and operating margins, our expectations with respect to Apollo, our integrated health management technology platform, our ability to improve care and lower healthcare costs for both providers and patients, and our funding plans for our future working capital needs and commitments. Actual results or developments could differ materially from those projected in such statements as a result of numerous factors, including, without limitation, those risks and uncertainties set forth in Item 1A entitled Risk Factors, which begins on page 13 of this report, as well as those factors identified from time to time in our periodic filings with the Securities and Exchange Commission. We do not undertake any obligation to update any forward-looking statements. This report and, in particular, the following discussion and analysis of our financial condition and results of operations, should be read in light of those risks and uncertainties and in conjunction with our accompanying consolidated financial statements and notes thereto.*

**Overview**

We enable individuals to take charge of improving their health and quality of life at home, under medical supervision, by developing new capabilities in near-patient diagnosis, monitoring and health management. Our global, leading products and services, as well as our new product development efforts, currently focus on cardiology, women's health, infectious disease, oncology and toxicology. We are continuing to expand our product and service offerings in all of these categories.

As a global, leading supplier of near-patient monitoring tools, as well as value-added healthcare services, we are uniquely positioned to improve care and lower healthcare costs for both providers and patients. Our rapidly growing home coagulation monitoring business, which supports doctors' and patients' efforts to monitor warfarin therapy using our INRatio blood coagulation monitoring system, continues to represent an early example of this. We have also continued to introduce our new integrated health management technology platform, called Apollo, to our customers since its launch on January 1, 2010. Using a sophisticated data engine for acquiring and analyzing information, combined with a state of the art touch engine for communicating with individuals and their health partners, we expect Apollo to benefit healthcare providers, health insurers and patients alike by enabling more efficient and effective health management programs.

We have continued to grow through strategic acquisitions. Our February 2010 acquisition of Kroll Laboratory Specialists, Inc., now renamed Alere Toxicology, as well as other small acquisitions during the year, expanded the range of toxicology testing products and services that we can offer government agencies, employers, health plans and healthcare professionals. Our 2010 acquisition of Standard Diagnostics brought us a comprehensive range of rapid diagnostic products, with particular strength in the infectious disease category. This acquisition builds on our already significant presence in Asia-Pacific through its distribution capabilities in South Korea and India, and additionally

provides us with a strong management team and established manufacturing facilities in each of those countries. We also acquired a small health management provider in Australia and expect to continue to expand our health management business outside the U.S. through selective acquisitions.

## **Table of Contents**

During 2010, we completed several technology-based acquisitions that we hope will aid us in bringing future products or diagnostic platforms to market. Through the acquisition of two privately-owned research and development operations, we have enhanced our capabilities in the area of rapid molecular diagnostic testing. Additionally, in November 2010, we acquired AdnaGen, a small German company specializing in the development of cancer diagnostics through the detection and analysis of circulating tumor cells in order to determine the correct course of therapy for individual cancer patients. We hope that this acquisition will assist us in developing a rapid molecular testing platform focused on oncology, allowing for truly personalized cancer care.

We continued to lay the groundwork during 2010 for future revenue and earnings growth by focusing our efforts on new product development and introductions. We introduced our Alere Heart Check System in Europe and, while the European launch is in very early stages, early indicators are positive. The Alere Heart Check System provides a quantitative reading of BNP in 10 minutes using a fingerstick sample with substantially equivalent performance to lab instruments. The Alere Heart Check System, while launched as a point-of-care device, is ultimately designed for home use and is intended to enable doctors to remotely monitor BNP levels of congestive heart failure patients and adjust their therapy accordingly. Additionally, during 2010, we introduced our Alere CD4 Analyzer in additional countries in Africa and Asia-Pacific. The Alere CD4 Analyzer is the first point-of-care platform which measures absolute CD4 counts in HIV patients with results in 20 minutes, through single-use, disposable fingerstick cartridges. We also made headway during 2010 in sales of the epoc platform, and expect this trend to continue as we make progress in securing contracts through the relatively long sales process associated with integrated networks and large hospital systems. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides wireless bedside blood gas and electrolyte measurement testing solutions and complements our Triage products in cardiology and emergency room settings. Utilizing easy to use, low-cost disposable Smart-Cards<sup>tm</sup>, the epoc System produces laboratory-quality results in critical and acute care settings in about 30 seconds.

We continue to build momentum for two novel biomarkers, NGAL and placental growth factor (PIGF). In 2009, we introduced the Triage NGAL test outside the U.S., as the world's first point-of-care test for acute kidney injury (AKI) and we expect U.S. FDA clearance for this product in 2012. In January 2010, we launched Triage PIGF in Europe. PIGF is a novel biomarker that aids in the early diagnosis of pre-eclampsia (PE), which is the leading cause of maternal and perinatal mortality. Our efforts have focused on building awareness and acceptance of this marker outside of the U.S., while key clinical studies needed to gain regulatory clearance in the U.S. and Japan are expected to commence in 2011.

## **2010 Financial Highlights**

Net revenue increased by \$232.7 million, or 12%, to \$2.2 billion in 2010, from \$1.9 billion in 2009.

Gross profit increased by \$80.4 million, or 8%, to \$1.13 billion in 2010, from \$1.05 billion in 2009.

For the year ended December 31, 2010, we generated a net loss of \$1.0 billion, or \$12.33 per basic and diluted common share after preferred stock dividends, based on a net loss available to common stockholders of \$1.0 billion. For the year ended December 31, 2009, we generated net income of \$33.7 million, or \$0.13 per basic and diluted common share after preferred stock dividends, based on net income available to common stockholders of \$10.7 million. The 2010 net loss included a \$1.0 billion non-cash charge associated with the impairment of goodwill in our health management business segment and reporting unit.

## **Results of Operations**

The following discussions of our results of continuing operations exclude the results related to the vitamins and nutritional supplements business segment, which was previously presented as a separate operating segment prior to its

divestiture in January 2010. The vitamins and nutritional supplements business segment has been segregated from continuing operations and reflected as discontinued operations for all periods presented. See Discontinued Operations below. Results excluding the impact of currency translation are calculated on the basis of local currency results, using foreign currency exchange rates applicable to the



**Table of Contents**

earlier comparative period. We believe presenting information using the same foreign currency exchange rates helps investors isolate the impact of changes in those rates from other trends. Our results of operations were as follows:

*Year Ended December 31, 2010 Compared to Year Ended December 31, 2009*

**Net Product Sales and Services Revenue.** Net product sales and services revenue increased by \$241.0 million, or 13%, to \$2.1 billion in 2010 from \$1.9 billion in 2009. Net product sales and services revenue increased primarily as a result of our health management and professional diagnostics-related acquisitions which contributed \$338.0 million of the increase. Excluding the impact of currency translation, net product sales and services revenue in 2010 grew by approximately \$237.6 million, or 13%, over 2009. Offsetting the increased net product sales and services revenue contributed by acquisitions was a decrease in North American flu-related net product sales during 2010, as compared to 2009. Net product sales from our North American flu sales declined approximately \$82.3 million, comparing 2010 to 2009, from \$101.1 million in 2009 to \$18.8 million in 2010, as a result of a weaker than normal flu season in 2010 and unusually strong flu sales during 2009 caused by the H1N1 flu outbreak. In addition, worldwide respiratory sales, excluding North American flu sales discussed above, declined approximately \$19.4 million, comparing 2010 to 2009. Net product sales and services revenue in our health management segment, excluding the impact of acquisitions, was adversely impacted by the increasingly competitive environment, particularly in the less differentiated services, such as disease management and case management.

**Net Product Sales and Services Revenue by Business Segment.** Net product sales and services revenue by business segment for 2010 and 2009 are as follows (in thousands):

	2010	2009	% Increase (Decrease)
Professional diagnostics	\$ 1,440,718	\$ 1,238,251	16%
Health management	598,819	521,695	15%
Consumer diagnostics	95,051	133,620	(29)%
Net product sales and services revenue	\$ 2,134,588	\$ 1,893,566	13%

*Professional Diagnostics*

The increase in net product sales and services revenue from our professional diagnostics business segment was \$202.5 million, or 16%, resulting in \$1.4 billion of net product sales and services revenue in 2010. Net product sales and services revenue increased primarily as a result of our acquisitions of: (i) the ACON Second Territory Business, in April 2009, which contributed \$15.2 million of net product sales and services revenue in excess of those earned in the prior year's comparative period, (ii) Concateno, in August 2009, which contributed \$48.8 million of net product sales and services revenue in excess of those earned in the prior year's comparative period, (iii) Standard Diagnostics, in February 2010, which contributed \$78.9 million of net product sales and services revenue, (iv) Alere Toxicology, in February 2010, which contributed \$31.3 million of net product sales and services revenue and (v) various less significant acquisitions, which contributed an aggregate of \$41.8 million of such increase. Offsetting the increased net product sales and services revenue contributed by acquisitions was a decrease in North American flu-related net product sales during 2010 compared to 2009. Net product sales from our North American flu sales declined approximately \$82.3 million, comparing 2010 to 2009, as a result of a weaker than normal flu season in 2010 and unusually strong flu sales during 2009 caused by the H1N1 flu outbreak. In addition, worldwide respiratory sales, excluding North American flu sales discussed above, declined approximately \$19.4 million, comparing 2010 to 2009.

Excluding the impact of currency translation, net product sales and services revenue from our professional diagnostics business segment increased by \$198.7 million, or 16%, comparing 2010 to 2009. Excluding the impact of currency translation and the decrease in flu-related sales during the comparable periods, organic growth for our professional diagnostics net product sales and services revenue was 6%.

**Table of Contents***Health Management*

Our health management net product sales and services revenue increased \$77.1 million, or 15%, to \$598.8 million in 2010 from \$521.7 million in 2009. Of the increase, net product sales and services revenue increased primarily as a result of our acquisitions of: (i) Free & Clear, Inc., or Free & Clear, in September 2009, which contributed \$55.5 million of net products sales and services revenue in excess of those earned in the prior year's comparative period, (ii) Tapestry Medical, Inc., or Tapestry, in November 2009, which contributed \$45.3 million of net product sales and services revenue (which includes revenue transferred to Tapestry from our QAS subsidiary) in excess of those earned in the prior year's comparative period, (iii) CVS Caremark's common disease management program, or Accordant, in September 2009, which contributed \$15.3 million of net product sales and services revenue in excess of those earned in the prior year's comparative period and (iv) various less significant acquisitions, which contributed an aggregate of \$5.9 million of such increase. Net product sales and services revenue in our health management segment, excluding the impact of these acquisitions, was adversely impacted by the increasingly competitive environment, particularly in the less differentiated services, such as disease management and case management.

*Consumer Diagnostics*

Our consumer diagnostics net product sales and services revenue decreased by \$38.6 million, or 29%, to \$95.1 million in 2010 from \$133.6 million in 2009. The decrease during 2010, as compared to 2009, was primarily driven by a decrease of approximately \$35.0 million of manufacturing revenue associated with our manufacturing agreement with our 50/50 joint venture with P&G, or SPD, whereby we manufacture and sell consumer diagnostic products to SPD. Our manufacturing revenue is generated on a cost-plus basis. Manufacturing revenue has been adversely impacted as a result of transitioning the manufacturing of our consumer diagnostic-related products to some of our lower cost facilities and to certain third party facilities. Net product sales by SPD were \$193.8 million and \$184.6 million during 2010 and 2009, respectively. The transition of the manufacturing of our consumer diagnostic-related products to the lower cost facilities has been substantially completed at the end of 2010.

**Net Product Sales and Services Revenue by Geographic Location.** Net product sales and services revenue by geographic location for 2010 and 2009 are as follows (in thousands):

	<b>2010</b>	<b>2009</b>	<b>% Increase</b>
United States	\$ 1,363,145	\$ 1,302,376	5%
Europe	358,865	315,130	14%
Elsewhere	412,578	276,060	49%
Net product sales and services revenue	\$ 2,134,588	\$ 1,893,566	13%

Net product sales and services revenue of \$1.4 billion and \$1.3 billion generated in the United States were approximately 64% and 69%, respectively, of total net product sales and services revenue for the year ended December 31, 2010 and 2009, respectively. The growth in net product sales and services revenue in all geographic regions resulted primarily from the various acquisitions and organic growth, both discussed above. The increase in net product sales and services revenue outside the U.S. and Europe was primarily a result of our acquisition of Standard Diagnostics located in South Korea.

**License and Royalty Revenue.** License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue decreased by \$8.3 million, or 29%, to

\$20.8 million in 2010, from \$29.1 million in 2009. The decrease in license and royalty revenue during 2010, as compared to 2009, was largely attributed to a decrease in royalty payments received from Quidel under existing licensing agreements and a \$5.0 million royalty payment received during 2009 in connection with a license arrangement in the field of animal health diagnostics. The decrease in royalties received from Quidel during 2010, compared to 2009, is a result of a decrease in flu-related product sales.

**Table of Contents**

**Gross Profit and Margin.** Gross profit increased by \$80.4 million, or 8%, to \$1.13 billion in 2010, from \$1.05 billion in 2009. The increase in gross profit during 2010, compared to 2009, was largely attributed to the increase in net product sales and services revenue resulting from acquisitions and organic growth from our professional diagnostics business segment. Cost of net revenue during 2010 included amortization of \$6.6 million relating to the write-up of inventory to fair value in connection with certain acquisitions. Cost of net revenue during 2009 included amortization of \$2.0 million relating to the write-up of inventory to fair value in connection with the acquisition of Concateno during the third quarter of 2009. Reducing gross profit for 2010 and 2009 was \$3.9 million and \$9.5 million in restructuring charges, respectively.

Cost of net revenue included amortization expense of \$63.0 million and \$42.1 million for 2010 and 2009, respectively.

Overall gross margin was 53% in 2010, compared to 55% in 2009.

**Gross Profit from Net Product Sales and Services Revenue by Business Segment.** Gross profit from net product sales and services revenue increased by \$86.9 million to \$1.1 billion in 2010, from \$1.0 billion in 2009. Gross profit from net product sales and services revenue by business segment for 2010 and 2009 is as follows (in thousands):

	2010	2009	% Increase (Decrease)
Professional diagnostics	\$ 801,745	\$ 733,640	9%
Health management	297,085	280,547	6%
Consumer diagnostics	22,147	19,850	12%
Gross profit from net product sales and services revenue	\$ 1,120,977	\$ 1,034,037	8%

*Professional Diagnostics*

Gross profit from our professional diagnostics net product sales and services revenue increased by \$68.1 million, or 9%, to \$801.7 million during 2010, compared to \$733.6 million during 2009, principally as a result of gross profit earned on revenue from acquired businesses, as discussed above. Reducing gross profit for 2010 was amortization of \$6.6 million relating to the write-up of inventory to fair value in connection with various acquisitions. Reducing gross profit for 2009 was amortization of \$2.0 million relating to the write-up of inventory to fair value in connection with the acquisition of Concateno during the third quarter of 2009. Start up costs incurred during 2010 associated with our production of CD4 disposable tests also contributed to reduced gross profit during 2010, as compared to 2009. Reducing gross profit for 2010 and 2009 was \$3.3 million and \$8.6 million in restructuring charges, respectively.

As a percentage of our professional diagnostics net product sales and services revenue, gross profit from our professional diagnostics business was 56% in 2010, compared to 59% in 2009. The inventory write-ups noted above, coupled with higher revenue from our recently acquired toxicology businesses, which contribute lower than segment average gross margins, and a decrease in North American flu-related net product sales, which contribute higher than segment average gross margin, contributed to the decrease in gross margin percentage for 2010, compared to 2009.

*Health Management*

Gross profit from our health management net product sales and services revenue increased by \$16.5 million, or 6%, to \$297.1 million during 2010, compared to \$280.5 million during 2009. The increase in gross profit was largely

attributed to gross profit earned on revenues from recent acquisitions, as discussed above. Reducing gross profit for both 2010 and 2009 was \$0.6 million in restructuring charges.

As a percentage of our health management net product sales and services revenue, gross profit from our health management business was 50% in 2010, compared to 54% in 2009. The lower margin percentage earned during 2010, as compared to 2009, is a result of the increasingly competitive environment for the

## Table of Contents

health management segment, particularly in the less differentiated services, such as disease management and case management. In addition, reserves totaling approximately \$3.0 million were established during the fourth quarter of 2010 for the potential return of unused test strips distributed in connection with our home monitoring portion of the health management business.

### *Consumer Diagnostics*

Gross profit from our consumer diagnostics net product sales and services revenue increased \$2.3 million, or 12%, to \$22.1 million during 2010, compared to \$19.8 million during 2009. The increase in gross profit is primarily a result of changes in net product sales and services revenue mix during the year ended December 31, 2010, compared to the year ended December 31, 2009.

As a percentage of our consumer diagnostics net product sales and services revenue, gross profit from our consumer diagnostics business was 23% for 2010, compared to 15% in 2009.

**Research and Development Expense.** Research and development expense increased by \$20.4 million, or 18%, to \$133.3 million in 2010, from \$112.8 million in 2009. Included in research and development expense in 2010 is \$7.1 million of stock-based compensation expense, representing an increase of approximately \$1.9 million from 2009. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling \$0.5 million were included in research and development expense during 2010, representing a decrease of approximately \$0.6 million from 2009. Amortization expense of \$4.8 million and \$3.7 million was included in research and development expense for 2010 and 2009, respectively.

Research and development expense as a percentage of net revenue was 6% for both 2010 and 2009.

**Sales and Marketing Expense.** Sales and marketing expense increased by \$57.5 million, or 13%, to \$499.1 million in 2010, from \$441.6 million in 2009. Amortization expense of \$212.3 million and \$186.9 million was included in sales and marketing expense for 2010 and 2009, respectively. The remaining increase in sales and marketing expense primarily relates to additional spending related to newly-acquired businesses. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling \$1.5 million were included in sales and marketing expense during 2010, representing a decrease of approximately \$0.4 million from 2009.

Sales and marketing expense as a percentage of net revenue was 23% for both 2010 and 2009.

**General and Administrative Expense.** General and administrative expense increased by \$89.9 million, or 25%, to \$446.9 million in 2010, from \$357.0 million in 2009. The increase in general and administrative expense relates primarily to \$60.1 million of compensation expense recorded in connection with purchasing the remaining shares of a minority shareholder of Standard Diagnostics during the fourth quarter of 2010. Partially offsetting the increase was a decrease in legal spending of approximately \$7.1 million for 2010, as compared to 2009. Acquisition-related costs of \$8.2 million and \$15.9 million were included in general and administrative expense for 2010 and 2009, respectively. Amortization expense of \$18.4 million and \$22.9 million was included in general and administrative expense for 2010 and 2009, respectively.

General and administrative expense as a percentage of net revenue was 21% and 19% for 2010 and 2009, respectively.

**Impairment of Goodwill.** We conducted our annual goodwill impairment analysis during the fourth quarter of 2010. When conducting Step 1 of the impairment analysis, as prescribed by ASC 350, *Intangibles - Goodwill and Other*, or ASC 350, the analysis indicated that the carrying value of the net assets of our health management reporting unit exceeded the estimated fair value of the reporting unit. As a result, we were required to complete Step 2 of the

impairment analysis, as prescribed by ASC 350, to determine the amount of the goodwill impairment charge. The Step 2 portion of the analysis indicated that we needed to record a goodwill impairment charge of approximately \$1.0 billion, which was recorded during the fourth quarter of 2010. Any further reduction or impairment of the value of goodwill or other intangible assets will result in additional charges against earnings, which could materially reduce our reported results of operations



**Table of Contents**

in future periods. Further details of the goodwill impairment analysis are disclosed in Note 2 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

**Gain on Disposition.** In 2009, we disposed of our majority ownership interest in our Diamics Inc., or Diamics, operation, which was part of our professional diagnostics reporting unit and business segment. During the period from the date of acquisition of Diamics in July 2007 until its disposition in September 2009, under the principles of consolidation, we consolidated 100% of the operating results of the Diamics operations in our consolidated statement of operations. As a result of the disposition, we recorded a gain of \$3.4 million during the year ended December 31, 2009.

**Interest Expense.** Interest expense includes interest charges, and the amortization of deferred financing costs and original issue discounts associated with certain debt issuances. Interest expense increased by \$32.6 million, or 31%, to \$139.4 million for the year ended December 31, 2010, from \$106.8 million for the year ended December 31, 2009. The increase was principally due to additional interest expense incurred on our 9% subordinated notes, 7.875% senior notes and 8.625% subordinated notes, totaling \$69.5 million for the year ended December 31, 2010, compared to \$32.3 million for the year ended December 31, 2009.

**Other Income (Expense), Net.** Other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses and other income and expense. The components and the respective amounts of other income (expense), net are summarized as follows (in thousands):

	2010	2009	Change
Interest income	\$ 1,960	\$ 2,342	\$ (382)
Foreign exchange gains (losses), net	9,752	1,267	8,485
Other	11,026	(2,613)	13,639
Other income (expense), net	\$ 22,738	\$ 996	\$ 21,742

Other income (expense), net for 2010 includes a \$4.5 million gain on a sale of marketable securities, a net recovery of \$3.3 million related to certain restructuring activities, a \$3.1 million net gain associated with legal settlements related to previously disclosed intellectual property litigation relating to our health management businesses and approximately \$0.5 million of income associated with a settlement of prior years' royalties during 2010, which were partially offset by a charge related to an accounts receivable reserve for a prior year's sale.

Other income (expense), net for 2009 includes \$1.9 million of expense associated with fully-vested compensation-related costs for certain executives incurred in connection with the acquisition of Concateno during the third quarter of 2009, a \$2.9 million realized foreign currency gain associated with restricted cash established in connection with the acquisition of Concateno, and \$0.6 million of stamp duty tax incurred during 2009 in connection with an incremental investment made in one of our foreign subsidiaries.

**Provision (Benefit) for Income Taxes.** Provision (benefit) for income taxes decreased by \$45.6 million, to a \$29.9 million benefit in 2010, from a \$15.6 million provision in 2009. The effective tax rate in 2010 was 3%, compared to 39% in 2009. The decrease in the provision for income taxes from 2009 to 2010 is primarily related to the tax benefit associated with the goodwill impairment charge. The decrease in the effective tax rate between the two years primarily results from the inability to record a tax benefit on the majority of the goodwill impairment charge recorded during 2010.

The primary components of the 2010 provision for income taxes relate to U.S. federal and state income taxes, taxes on foreign income and the recognition of a tax benefit associated with the goodwill impairment charge recorded during 2010. The primary components of the 2009 benefit for income taxes relate to U.S. federal and state income taxes and taxes on foreign income.

**Equity Earnings in Unconsolidated Entities, Net of Tax.** Equity earnings in unconsolidated entities are reported net of tax and include our share of earnings in entities that we account for under the equity method of accounting. Equity earnings in unconsolidated entities, net of tax, for the year ended December 31, 2010 reflect the following: (i) earnings from our 50% interest in SPD in the amount of \$8.5 million,

**Table of Contents**

(ii) earnings from our 40% interest in Vedalab S.A., or Vedalab, in the amount of \$0.2 million and (iii) earnings from our 49% interest in TechLab, Inc., or TechLab, in the amount of \$1.9 million. Equity earnings in unconsolidated entities, net of tax, for the year ended December 31, 2009 reflect the following: (i) earnings from our 50% interest in SPD in the amount of \$5.7 million, (ii) earnings from our 40% interest in Vedalab in the amount of approximately \$0.5 million and (iii) earnings from our 49% interest in TechLab, in the amount of \$1.7 million.

**Income (Loss) from Discontinued Operations, Net of Tax.** The results of the vitamins and nutritional supplements business are included in income (loss) from discontinued operations, net of tax, for all periods presented. For the year ended December 31, 2010, the discontinued operations generated net income of approximately \$11.4 million, as compared to net income of \$1.9 million for the year ended December 31, 2009. The net income of \$11.4 million for the year ended December 31, 2010 includes a gain of \$18.7 million (\$11.6 million, net of tax) on the sale of the vitamins and nutritional supplements business.

**Net Income (Loss).** For the year ended December 31, 2010, we generated a net loss of \$1.0 billion, or \$12.33 per common share after preferred stock dividends, based on a net loss available to common stockholders of \$1.0 billion. For the year ended December 31, 2009, we generated net income of \$33.7 million, or \$0.13 per diluted common share after preferred stock dividends, based on net income available to common stockholders of \$10.7 million. The net income (loss) in 2010 and 2009 resulted from the various factors as discussed above. See Note 12 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for the calculation of net income (loss) per common share.

*Year Ended December 31, 2009 Compared to Year Ended December 31, 2008*

**Net Product Sales and Services Revenue.** Net product sales and services revenue increased by \$336.8 million, or 22%, to \$1.9 billion in 2009 from \$1.6 billion in 2008. Excluding the unfavorable impact of currency translation, net product sales and services revenue in 2009 grew by approximately \$363.8 million, or 23%, over 2008. Of the currency adjusted increase, revenue increased primarily as a result of our professional diagnostic-related acquisitions which contributed \$233.2 million of the increase. Additionally, as a result of the H1N1 flu outbreak, revenues from our North American flu sales increased by approximately \$66.5 million, or 192%, in 2009, from \$34.6 million in 2008.

**Net Product Sales and Services Revenue by Business Segment.** Net product sales and services revenue by business segment for 2009 and 2008 are as follows (in thousands):

	2009	2008	% Increase (Decrease)
Professional diagnostics	\$ 1,238,251	\$ 1,029,528	20%
Health management	521,695	392,399	33%
Consumer diagnostics	133,620	134,800	(1)%
Net product sales and services revenue	\$ 1,893,566	\$ 1,556,727	22%

*Professional Diagnostics*

The increase in net product sales and services revenue from our professional diagnostics business segment was \$208.7 million, or 20%, resulting in \$1.2 billion of net product and services revenue in 2009. As a result of the H1N1 flu outbreak, revenues from our North American flu sales increased approximately \$66.5 million comparing 2009 to

2008. Additionally, net product sales and services revenue increased as a result of our acquisitions of: (i) the ACON Second Territory Business, in April 2009, which contributed \$38.3 million of net product sales and services revenue, (ii) Concateno, in August 2009, which contributed \$33.3 million of net product sales and services revenue, (iii) Prodimol Biotecnologia S.A., or Prodimol, in October 2008, which contributed additional net product sales and services revenue of \$6.4 million in excess of those earned in the prior year's comparative period, (iv) Vision Biotech Pty Ltd, or Vision, in September 2008, which contributed additional net product sales and services revenue of \$6.3 million in excess of those earned in the prior year's

**Table of Contents**

comparative period and (v) various less significant acquisitions, which contributed an aggregate of \$11.2 million of such increase.

*Health Management*

Our health management net product sales and services revenue increased \$129.3 million, or 33%, to \$521.7 million in 2009 from \$392.4 million in 2008. Of the increase, net product sales and services revenue increased primarily as a result of our acquisitions of: (i) Matria Healthcare Inc., or Matria, in May 2008, which contributed additional net product sales and services revenue of \$103.0 million in excess of those earned in the prior year's comparative period, (ii) Free & Clear, in September 2009, which contributed \$14.3 million of net product sales and services revenue, (iii) Accordant, in September 2009, which contributed \$11.5 million of net product sales and services revenue and (iv) various less significant acquisitions, which contributed an aggregate of \$8.9 million of such increase.

*Consumer Diagnostics*

Our consumer diagnostics net product sales and services revenue decreased by \$1.2 million, or 1%, to \$133.6 million in 2009 from \$134.8 million in 2008. The decrease during the year ended December 31, 2009, as compared to the year ended December 31, 2008, was primarily driven by a decrease in net product sales and services revenue associated with our First Check at-home drug testing business.

**Net Product Sales and Services Revenue by Geographic Location.** Net product sales and services revenue by geographic location for 2009 and 2008 are as follows (in thousands):

	2009	2008	% Increase
United States	\$ 1,302,376	\$ 1,098,894	19%
Europe	315,130	283,552	11%
Elsewhere	276,060	174,281	58%
Net product sales and services revenue	\$ 1,893,566	\$ 1,556,727	22%

Net product sales and services revenue of \$1.3 billion and \$1.1 billion generated in the United States were approximately 69% and 71%, respectively, of total net product sales and services revenue for the year ended December 31, 2009 and 2008, respectively. The growth in net product sales and services revenue in all geographic regions resulted primarily from the various acquisitions and organic growth, both discussed above.

**License and Royalty Revenue.** License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue increased by \$3.2 million, or 13%, to \$29.1 million in 2009, from \$25.8 million in 2008. The increase in license and royalty revenue during 2009, as compared to 2008, was primarily attributed to an increase in royalty payments received from Quidel under existing licensing agreements and a \$5.0 million royalty payment received in connection with a license arrangement in the field of animal health diagnostics.

**Gross Profit and Margin.** Gross profit increased by \$200.7 million, or 24%, to \$1.1 billion in 2009, from \$853.5 million in 2008. The increase in gross profit for 2009, as compared to 2008, was largely attributed to the increase in net product sales and services revenue resulting from acquisitions, an increase in flu-related sales associated with the H1N1 flu outbreak, and organic growth from our professional diagnostics business segment.

Included in gross profit in 2009 were restructuring charges totaling \$9.5 million associated with the closure of various manufacturing and operating facilities and \$2.0 million of stock-based compensation expense. Included in gross profit in 2008 were restructuring charges totaling \$17.9 million associated with the closure of various manufacturing and operating facilities and \$1.5 million of stock-based compensation expense. Cost of net revenue included amortization expense of \$42.1 million and \$43.4 million in 2009 and 2008, respectively.

Overall gross margin was 55% in 2009, compared to 54% in 2008.

**Table of Contents**

**Gross Profit from Net Product Sales and Services Revenue by Business Segment.** Gross profit from net product sales and services revenue increased by \$197.7 million to \$1.0 billion in 2009, from \$836.3 million in 2008. Gross profit from net product sales and services revenue by business segment for 2009 and 2008 is as follows (in thousands):

	2009	2008	% Increase (Decrease)
Professional diagnostics	\$ 733,640	\$ 596,186	23%
Health management	280,547	214,356	31%
Consumer diagnostics	19,850	25,770	(23)%
Gross profit from net product sales and services revenue	\$ 1,034,037	\$ 836,312	24%

*Professional Diagnostics*

Gross profit from our professional diagnostics net product sales and services revenue increased by \$137.5 million, or 23%, to \$733.6 million during 2009, compared to \$596.2 million during 2008, principally as a result of gross profit earned on revenue from acquired businesses, as discussed above. Reducing gross profit for 2009 and 2008 was \$8.6 million and \$17.9 million in restructuring charges, respectively.

As a percentage of our professional diagnostics net product sales and services revenue, gross profit from our professional diagnostics business was 59% in 2009, compared to 58% in 2008.

*Health Management*

Gross profit from our health management net product sales and services revenue increased by \$66.2 million, or 31%, to \$280.5 million during 2009, compared to \$214.4 million during 2008. The increase in gross profit was largely attributed to gross margins earned on revenues from recent acquisitions, as discussed above. Reducing gross profit for 2009 was \$0.6 million in restructuring charges.

As a percentage of our health management net product sales and services revenue, gross profit from our health management business was 54% in 2009, compared to 55% in 2008.

*Consumer Diagnostics*

Gross profit from our consumer diagnostics net product sales and services revenue decreased \$5.9 million, or 23%, to \$19.8 million during 2009, compared to \$25.8 million during 2008. The decrease in gross profit is primarily a result of net product sales and services revenue mix during the year ended December 31, 2009, compared to the year ended December 31, 2008.

As a percentage of our consumer diagnostics net product sales and services revenue, gross profit from our consumer diagnostics business was 15% for 2009, compared to 19% in 2008.

**Research and Development Expense.** Research and development expense increased by \$1.0 million, or 1%, to \$112.8 million in 2009, from \$111.8 million in 2008. Included in research and development expense in 2009 is \$5.2 million of stock-based compensation expense, representing an increase of approximately \$0.6 million from 2008. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses

totaling \$1.1 million were included in research and development expense during 2009, representing a decrease of approximately \$6.2 million from 2008. Amortization expense of \$3.7 million was included in research and development expense for both 2009 and 2008.

Research and development expense as a percentage of net revenue decreased to 6% for 2009, from 7% for 2008.

**Sales and Marketing Expense.** Sales and marketing expense increased by \$59.7 million, or 16%, to \$441.6 million in 2009, from \$381.9 million in 2008. Amortization expense of \$186.9 million and \$148.6 million was included in sales and marketing expense for 2009 and 2008, respectively. The remaining



**Table of Contents**

increase in sales and marketing expense primarily relates to additional spending related to newly-acquired businesses. Also included in sales and marketing expense is \$4.2 million of stock-based compensation expense, representing a decrease of approximately \$0.1 million from 2008. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling \$1.9 million were included in sales and marketing expense during 2009, representing a decrease of approximately \$2.4 million from 2008.

Sales and marketing expense as a percentage of net revenue decreased to 23% for 2009, from 24% for 2008.

**General and Administrative Expense.** General and administrative expense increased by \$62.0 million, or 21%, to \$357.0 million in 2009, from \$295.1 million in 2008. The increase in general and administrative expense relates primarily to additional spending related to newly-acquired businesses. Contributing to the increase in general and administrative expense for 2009, as compared to 2008, was \$15.9 million for acquisition-related costs recorded in connection with our adoption of a new accounting standard for business combinations on January 1, 2009. Also included in general and administrative expense is \$16.7 million of stock-based compensation expense, representing an increase of approximately \$0.7 million from 2008. Amortization expense of \$22.9 million and \$18.2 million was included in general and administrative expense for 2009 and 2008, respectively.

General and administrative expense as a percentage of net revenue was 19% for both 2009 and 2008.

**Interest Expense.** Interest expense includes interest charges and the amortization of deferred financing costs. Interest expense in 2009 also includes the amortization of original issue discounts associated with certain debt issuances. Interest expense increased by \$5.7 million, or 6%, to \$106.8 million for the year ended December 31, 2009, from \$101.1 million for the year ended December 31, 2008. Such increase was principally due to additional interest expense incurred on our 9% subordinated notes and 7.875% senior notes, totaling \$32.3 million for the year ended December 31, 2009. Substantially offsetting this increase was lower interest expense incurred due to lower interest rates charged during the year ended December 31, 2009, compared to the year ended December 31, 2008.

**Other Income (Expense), Net.** Other income (expense), net, includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. The components and the respective amounts of other income (expense), net, are summarized as follows (in thousands):

	<b>2009</b>	<b>2008</b>	<b>Change</b>
Interest income	\$ 2,342	\$ 6,566	\$ (4,224)
Foreign exchange gains (losses), net	1,267	(457)	1,724
Other	(2,613)	(7,916)	5,303
Other income (expense), net	\$ 996	\$ (1,807)	\$ 2,803

Other income (expense), net for 2009 increased by \$2.8 million as compared to 2008, and included a decrease in interest income of \$4.2 million which resulted from lower interest earned on available cash balances, \$1.9 million of expense associated with fully-vested compensation-related costs for certain executives incurred in connection with the acquisition of Concateno during the third quarter of 2009, a \$2.9 million realized foreign currency gain associated with restricted cash established in connection with the acquisition of Concateno, and \$0.6 million of stamp duty tax incurred during 2009 in connection with an incremental investment made in one of our foreign subsidiaries. Other income (expense), net, for 2008 includes a \$12.5 million charge associated with an arbitration decision, a \$1.7 million realized foreign currency loss associated with restricted cash established in connection with the acquisition of BBI

partially offset by \$5.5 million of income associated with settlements of prior year's royalties during 2008.

**Provision (Benefit) for Income Taxes.** Provision (benefit) for income taxes increased by \$32.3 million, to a \$15.6 million provision in 2009, from a \$16.6 million benefit in 2008. The effective tax rate in 2009 was 39%, compared to 43% in 2008. The increase in the provision for income taxes from 2008 to 2009 is primarily related to increased income in foreign jurisdictions. The decrease in the effective tax rate between

## **Table of Contents**

the two years primarily results from the mix of tax jurisdictions, along with the impact of increased U.S. research and development credits.

The primary components of the 2009 provision for income taxes relates to U.S. federal and state income taxes and taxes on foreign income. The primary components of the 2008 benefit for income taxes relates to U.S. federal and state income taxes, taxes on foreign income and the recognition of benefit on German and United Kingdom losses.

**Discontinued Operations, Net of Tax.** The results of the vitamins and nutritional supplements business are included in income (loss) from discontinued operations, net of tax, for all periods presented. For the year ended December 31, 2009, the discontinued operations generated net income of \$1.9 million, as compared to a net loss of \$1.0 million for the year ended December 31, 2008.

**Net Income (Loss).** For the year ended December 31, 2009, we generated net income of \$33.7 million, or \$0.13 per basic and diluted common share after preferred stock dividends, based on net income available to common stockholders of \$10.7 million. For the year ended December 31, 2008, we generated a net loss of \$21.8 million, or \$0.46 per basic and diluted common share after preferred stock dividends, based on net loss available to common stockholders of \$35.8 million. The net income in 2009 and the net loss 2008 resulted from the various factors as discussed above. See Note 12 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for the calculation of net income (loss) per common share.

## **Liquidity and Capital Resources**

Based upon our current working capital position, current operating plans and expected business conditions, we currently expect to fund our short and long-term working capital needs primarily using existing cash and our operating cash flow, and we expect our working capital position to improve as we improve our future operating margins and grow our business through new product and service offerings and by continuing to leverage our strong intellectual property position. As of December 31, 2010, we have \$401.3 million of cash on our accompanying consolidated balance sheet.

In addition to our cash resources, we may also utilize the revolving credit line, under which we have \$150.0 million available for borrowing at December 31, 2010, or other sources of financing to fund a portion of our capital needs and other future commitments, including our contractual contingent consideration obligations and future acquisitions. Our ability to access the capital markets may be impacted by the amount of our outstanding debt and equity and the extent to which our assets are encumbered by our outstanding secured debt. The terms and conditions of our outstanding debt instruments also contain covenants which expressly restrict our ability to incur additional indebtedness and conduct other financings. As of December 31, 2010, we had \$2.4 billion in outstanding indebtedness comprised of \$400.0 million of 8.625% subordinated notes due 2018, \$244.8 million of 7.875% senior notes due 2016, \$389.7 million of 9% senior subordinated notes due 2016, \$941.3 million under our First Lien Credit Agreement, \$250.0 million under our Second Lien Credit Agreement and \$150.0 million of 3% senior subordinated convertible notes. The terms and conditions of our outstanding debt are disclosed in Note 6 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

If the capital and credit markets experience volatility or the availability of funds is limited, we may incur increased costs associated with issuing commercial paper and/or other debt instruments. In addition, it is possible that our ability to access the capital and credit markets could be limited by these or other factors at a time when we would like, or need, to do so, which could have an impact on our ability to refinance maturing debt and/or react to changing economic and business conditions.

Our funding plans for our working capital needs and other commitments may be adversely impacted by unexpected costs associated with integrating the operations of newly-acquired companies, executing our cost savings strategies and prosecuting and defending our existing lawsuits and/or unforeseen lawsuits against us. We also cannot be certain that our underlying assumed levels of revenues and expenses will be realized. In addition, we intend to continue to make significant investments in our research and development efforts related to the substantial intellectual property portfolio we own. We may also choose to further expand our research

**Table of Contents**

and development efforts and may pursue the acquisition of new products and technologies through licensing arrangements, business acquisitions, or otherwise. We may also choose to make significant investment to pursue legal remedies against potential infringers of our intellectual property. If we decide to engage in such activities, or if our operating results fail to meet our expectations, we could be required to seek additional funding through public or private financings or other arrangements. In such event, adequate funds may not be available when needed or may be available only on terms which could have a negative impact on our business and results of operations. In addition, if we raise additional funds by issuing equity or convertible securities, dilution to then existing stockholders may result.

After December 31, 2010, we repurchased in negotiated transactions 118,000 shares of our Series B preferred stock which were convertible into approximately 681,000 shares of our common stock, at a cost of \$31.4 million, which we paid in cash. Following these repurchases, we have approximately \$18.6 million remaining from the initial \$50.0 million repurchase program authorized by our Board of Directors in December 2010.

In connection with the formation of SPD in May 2007, we entered into an option agreement with P&G, pursuant to which P&G has the right, for a period of 60 days commencing on May 17, 2011, to require us to acquire all of P&G's interest in SPD at fair market value, and P&G has the right, upon certain material breaches by us of our obligations to SPD, to acquire all of our interest in SPD at fair market value.

*Summary of Changes in Cash Position*

As of December 31, 2010, we had cash and cash equivalents of \$401.3 million, a \$91.5 million decrease from December 31, 2009. Our primary sources of cash during the year ended December 31, 2010 included \$275.4 million generated by our operating activities, \$400.0 million of proceeds from the issuance of our 8.625% subordinated notes, \$62.6 million of net proceeds received from the sale of our vitamins and nutritional supplements business, an \$8.8 million return of capital from SPD, \$3.5 million in cash dividends received from certain equity method investments, \$3.2 million of proceeds from the sale of certain marketable securities, net of cash used to purchase marketable securities and \$19.0 million of proceeds from common stock issuances under employee stock option and stock purchase plans. Our primary uses of cash during the year ended December 31, 2010 related to \$523.5 million net cash paid for acquisitions and transactional costs, \$146.8 million related to net repayments under our revolving line of credit, \$95.4 million of capital expenditures, net of proceeds from the sale of equipment, \$52.9 million paid to acquire the remaining non-controlling interest in Standard Diagnostics, \$13.0 million paid for financing costs related to certain debt issuances, \$9.8 million related to repayments of long-term debt and a \$12.9 million increase in other assets, primarily relating to the purchase of licenses and other investments. Fluctuations in foreign currencies negatively impacted our cash balance by \$9.3 million during the year ended December 31, 2010.

*Operating Cash Flows*

Net cash provided by operating activities during the year ended December 31, 2010 was \$275.4 million, which resulted from net loss from continuing operations of \$1.0 billion, \$1.3 billion of non-cash items and \$38.2 million of cash used to meet net working capital requirements during the period. The \$1.3 billion of non-cash items included a \$1.0 billion goodwill impairment charge related to our health management reporting unit and business segment, \$372.8 million related to depreciation and amortization, \$29.9 million related to non-cash stock-based compensation expense and \$13.8 million of non-cash interest expense, including the amortization of deferred financing costs and original issue discounts, partially offset by a \$74.4 million decrease related to changes in our deferred tax assets and liabilities resulting from amortization of intangible assets partially offset by the utilization of tax loss carryforwards, \$10.6 million in equity earnings in unconsolidated entities and a \$4.5 million gain recognized on the sale of marketable securities.

*Investing Cash Flows*

Our investing activities during the year ended December 31, 2010 utilized \$553.7 million of cash, including \$523.5 million used for acquisitions and transaction-related costs, net of cash acquired,

## **Table of Contents**

\$95.4 million of capital expenditures, net of proceeds from the sale of equipment, a \$12.9 million increase in other assets, offset by \$62.6 million of net proceeds received from the sale of our vitamins and nutritional supplements business, an \$8.8 million return of capital from SPD, \$3.5 million in cash dividends received from certain equity method investments and \$3.2 million of proceeds from the sale of certain marketable securities, net of cash used to purchase marketable securities.

### *Financing Cash Flows*

Net cash provided by financing activities during the year ended December 31, 2010 was \$196.1 million. Financing activities during the year ended December 31, 2010 primarily included \$400.0 million of proceeds from the issuance of our 8.625% subordinated notes and \$19.0 million cash received from common stock issuances under employee stock option and stock purchase plans, offset by \$146.8 million related to net repayments under our revolving line of credit, \$52.9 million paid to acquire the remaining non-controlling interest of Standard Diagnostics, \$13.0 million paid for financing costs related to certain debt issuances and \$9.8 million related to repayments of long-term debt.

As of December 31, 2010, we had an aggregate of \$3.5 million in outstanding capital lease obligations which are payable through 2015.

### *Income Taxes*

As of December 31, 2010, we had approximately \$156.1 million of domestic NOL and capital loss carryforwards and \$60.3 million of foreign NOL and capital loss carryforwards, respectively, which either expire on various dates through 2030 or may be carried forward indefinitely. These losses are available to reduce federal, state and foreign taxable income, if any, in future years. These losses are also subject to review and possible adjustments by the applicable taxing authorities. In addition, the domestic NOL carryforward amount at December 31, 2010 included approximately \$102.2 million of pre-acquisition losses at Matria, QAS, ParadigmHealth, Biosite, Cholestech, Redwood, HemoSense, Ischemia, Inc. and Ostex International, Inc. Effective January 1, 2009, we adopted a new accounting standard for business combinations. Prior to adoption of this standard, the pre-acquisition losses were applied first to reduce to zero any goodwill and other non-current intangible assets related to the acquisitions, prior to reducing our income tax expense. Upon adoption of the new accounting standard, the reduction of a valuation allowance is generally recorded to reduce our income tax expense.

Furthermore, all domestic losses are subject to the Internal Revenue Service Code Section 382 limitation and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%. Section 382 imposes an annual limitation on the use of these losses to an amount equal to the value of the company at the time of the ownership change multiplied by the long-term tax exempt rate. We have recorded a valuation allowance against a portion of the deferred tax assets related to our NOLs and certain of our other deferred tax assets to reflect uncertainties that might affect the realization of such deferred tax assets, as these assets can only be realized via profitable operations.

### **Off-Balance Sheet Arrangements**

We had no material off-balance sheet arrangements as of December 31, 2010.

**Table of Contents****Contractual Obligations**

The following table summarizes our principal contractual obligations as of December 31, 2010 (in thousands):

Contractual Obligations	Total	Payments Due by Period			Thereafter
		2011	2012-2013	2014-2015	
Long-term debt obligations(1)	\$ 2,411,015	\$ 16,891	\$ 22,047	\$ 1,162,329	\$ 1,209,748
Capital lease obligations(2)	3,530	2,126	1,300	104	
Operating lease obligations(3)	185,115	33,772	57,770	41,485	52,088
Pension obligations	3,966	661	1,322	1,322	661
Minimum royalty obligations	40	40			
Acquisition-related obligations(4)	26,959	23,171	3,788		
Purchase obligations capital expenditure	11,787	11,763	24		
Purchase obligations other(5)	33,423	32,344	1,079		
Interest on debt(6)	611,901	96,540	190,846	190,846	133,669
<b>Total</b>	<b>\$ 3,287,736</b>	<b>\$ 217,308</b>	<b>\$ 278,176</b>	<b>\$ 1,396,086</b>	<b>\$ 1,396,166</b>

- (1) Includes original issue discounts associated with the 9% senior subordinated notes and 7.875% senior notes. See description of various financing arrangements in Note 6 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
- (2) See Note 8 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
- (3) See Note 11(a) of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
- (4) Includes \$14.5 million of deferred payments associated with the acquisition of the ACON Second Territory Business, \$10.5 million in deferred payments associated with the acquisition of Accordant, \$1.2 million in deferred payments associated with the acquisition of Biolinker S.A. and \$0.8 million in deferred payments associated with the acquisition of RMD Networks, Inc.
- (5) Other purchase obligations relate to inventory purchases and other operating expense commitments.
- (6) Includes our non-variable interest-bearing debt. See the description of various financing arrangements in Note 6 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

In addition to the contractual obligations detailed above, we have contractual contingent consideration arrangements related to the following acquisitions:

A privately-owned research and development business has a maximum earn-out of \$57.5 million that, if earned, is expected to be paid during 2012 through 2014.

A privately-owned U.K. research and development business has a maximum earn-out of up to \$125.0 million that, if earned, is expected to be paid during an eight-year period ending on the eighth anniversary of the



acquisition, but could extend thereafter.

Accordant has a maximum earn-out of \$6.0 million that, if earned, is expected to be paid in quarterly payments of \$1.5 million beginning in the fourth quarter of 2012.

AdnaGen has a maximum earn-out of \$63.0 million that, if earned, is expected to be paid during 2012 through 2016.

Capital Toxicology maximum earn-out of \$16.0 million that, if earned, is expected to be paid in annual amounts during 2012 through 2013.

**Table of Contents**

Free & Clear achieved its earn-out during 2010 resulting in an accrual of approximately \$11.0 million as of December 31, 2010. Payment of this earn-out is expected to be made during the second quarter of 2011.

Immunoanalysis has a maximum remaining earn-out potential of \$4.7 million that, if earned, is expected to be paid in annual amounts during 2012 through 2013.

JSM achieved a portion of its earn-out during 2010 resulting in an accrual of approximately \$0.6 million as of December 31, 2010. Payment of this portion of the earn-out is expected to be made during the second quarter of 2011. JSM has a maximum remaining earn-out potential of \$2.4 million that, if earned, is expected to be paid during 2012-2013.

Medlab has maximum earn-out of \$10.0 million that, if earned, is expected to be paid in annual amounts during 2012 through 2017.

Mologic Limited, or Mologic, achieved a portion of its earn-out during the fourth quarter of 2010 resulting in an accrual of approximately \$3.9 million as of December 31, 2010. Payment of this portion of the earn-out is expected to be made during the first quarter of 2011. Mologic has a maximum remaining earn-out potential of \$15.0 million that, if earned, is expected to be paid in shares of our common stock during 2012 and 2013.

Tapestry achieved its 2010 financial targets resulting in an accrual of approximately \$10.7 million as of December 31, 2010. Cash payment for this portion of the earn-out is expected to be made during the first quarter of 2011. Tapestry has a maximum remaining earn-out potential of \$14.3 million that, if earned, is expected to be paid during 2012.

Our privately-owned health management business acquired in 2008 achieved its final earn-out during 2010 resulting in an accrual of approximately \$31.8 million as of December 31, 2010. Payment of this earn-out is expected to be made during the first quarter of 2011.

For further information pertaining to our contractual contingent arrangements see Note 11 of our accompanying consolidated financial statements.

Further, we have additional contractual obligations as follows:

Agreements with Epocal

In November 2009, we entered into a distribution agreement with Epocal, Inc., or Epocal, to distribute the epoc<sup>®</sup> Blood Analysis System for blood gas and electrolyte testing for \$20.0 million, which is recorded on our accompanying consolidated balance sheet in other intangible assets, net. We also entered into a definitive agreement to acquire all of the issued and outstanding equity securities of Epocal for a total potential purchase price of up to \$255.0 million, including a base purchase price of up to \$172.5 million if Epocal achieves certain gross margin and other financial milestones on or prior to October 31, 2014, plus additional payments of up to \$82.5 million if Epocal achieves certain other milestones relating to its gross margin and product development efforts on or prior to this date. We also agreed that, if the acquisition is consummated, we will provide \$12.5 million in management incentive arrangements, 25% of which will vest over three years and 75% of which will be payable only upon the achievement of certain milestones. The acquisition will also be subject to other closing conditions, including the receipt of any required antitrust or other approvals.

Option agreement with P&G

In connection with the formation of SPD in May 2007, we entered into an option agreement with P&G, pursuant to which P&G has the right, for a period of 60 days commencing on May 17, 2011, to require us to acquire all of P&G's interest in SPD at fair market value, and P&G has the right, upon certain material breaches by us of our obligations to SPD, to acquire all of our interest in SPD at fair market value. No gain on the proceeds that we received from P&G through the formation of SPD will be recognized in our financial statements until P&G's option to require us to purchase its interest in SPD expires. If P&G chooses to exercise its option, the deferred gain carried on our books would be reversed in connection with the repurchase transaction. As of December 31, 2010, the deferred gain of \$288.4 million is presented as a current liability on

## **Table of Contents**

our accompanying consolidated balance sheet. As of December 31, 2009, the deferred gain of \$288.8 million is presented as a long-term liability.

### **Critical Accounting Policies**

The consolidated financial statements included elsewhere in this Annual Report on Form 10-K are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The accounting policies discussed below are considered by our management and our audit committee to be critical to an understanding of our financial statements because their application depends on management's judgment, with financial reporting results relying on estimates and assumptions about the effect of matters that are inherently uncertain. Specific risks for these critical accounting policies are described in the following paragraphs. For all of these policies, management cautions that future events rarely develop exactly as forecast and the best estimates routinely require adjustment. In addition, the notes to our audited consolidated financial statements for the year ended December 31, 2010, included elsewhere in this Annual Report on Form 10-K, include a comprehensive summary of the significant accounting policies and methods used in the preparation of our consolidated financial statements.

#### *Revenue Recognition*

We primarily recognize revenue when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed or determinable and (4) collection is reasonably assured.

The majority of our revenue is derived from product sales. We recognize revenue upon title transfer of the products to third-party customers, less a reserve for estimated product returns and allowances. Determination of the reserve for estimated product returns and allowances is based on our management's analyses and judgments regarding certain conditions. Should future changes in conditions prove management's conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be adversely affected.

Additionally, we generate services revenue in connection with contracts with health plans (both commercial and governmental) and self-insured employers, whereby we provide clinical expertise through fee-based arrangements. Revenue for fee-based arrangements is recognized over the period in which the services are provided. Some contracts provide that a portion of our fees are at risk if our customers do not achieve certain financial cost savings or we do not achieve certain other clinical and operational metrics, over a period of time, typically one year. Revenue subject to refund is not recognized if (i) sufficient information is not available to calculate performance measurements or (ii) interim performance measurements indicate that we are not meeting performance targets. If either of these two conditions exists, we record the amounts as other current liabilities in the consolidated balance sheet, deferring recognition of the revenue until we establish that we are meeting the performance criteria. If we do not meet the performance targets at the end of the contractual period we are obligated under the contract to refund some or all of the at risk fees. Our deferred revenue balance was \$25.9 million and \$24.0 million, as of December 31, 2010 and 2009, respectively.

We also receive license and royalty revenue from agreements with third-party licensees. Revenue from fixed-fee license and royalty agreements is recognized on a straight-line basis over the obligation period of the related license agreements. License and royalty fees that the licensees calculate based on their sales, which we have the right to audit under most of our agreements, are generally recognized upon receipt of the license or royalty payments, unless we are able to reasonably estimate the fees as they are earned. License and royalty fees that are determinable prior to the receipt thereof are recognized in the period they are earned.

#### *Use of Estimates for Sales Returns and Other Allowances and Allowance for Doubtful Accounts*

Certain sales arrangements require us to accept product returns. From time to time, we also enter into sales incentive arrangements with our retail customers, which generally reduce the sale prices of our products. As a result, we must establish allowances for potential future product returns and claims resulting from our sales incentive arrangements against product revenue recognized in any reporting period. Calculation of these

## **Table of Contents**

allowances requires significant judgments and estimates. When evaluating the adequacy of the sales returns and other allowances, our management analyzes historical returns, current economic trends and changes in customer and consumer demand and acceptance of our products. When such analysis is not available and a right of return exists, we record revenue when the right of return is no longer applicable. Material differences in the amount and timing of our product revenue for any reporting period may result if changes in conditions arise that would require management to make different judgments or utilize different estimates.

Our total provision for sales returns and other allowances related to sales incentive arrangements amounted to \$37.3 million, \$60.2 million and \$35.8 million, or 3%, 4% and 3%, respectively, of net product sales in 2010, 2009 and 2008, respectively, which have been recorded against product sales to derive our net product sales. Of these amounts, approximately \$14.0 million, \$9.3 million and \$9.3 million, for 2010, 2009 and 2008, respectively, represent allowances for future deductions which have been provided against our related accruals for such charges with the balance charged directly against net sales.

Similarly, our management must make estimates regarding uncollectible accounts receivable balances. When evaluating the adequacy of the allowance for doubtful accounts, management analyzes specific accounts receivable balances, historical bad debts, customer concentrations, customer credit-worthiness, current economic trends and changes in our customer payment terms and patterns. Our accounts receivable balance was \$397.1 million and \$354.5 million, net of allowances for doubtful accounts of \$20.4 million and \$12.5 million, as of December 31, 2010 and 2009, respectively.

### *Valuation of Inventories*

We state our inventories at the lower of the actual cost to purchase or manufacture the inventory or the estimated current market value of the inventory, less cost to sell. In addition, we periodically review the inventory quantities on hand and record a provision for excess and obsolete inventory. This provision reduces the carrying value of our inventory and is calculated based primarily upon factors such as forecasts of our customers' demands, shelf lives of our products in inventory, loss of customers and manufacturing lead times. Evaluating these factors, particularly forecasting our customers' demands, requires management to make assumptions and estimates. Actual product and services revenue may prove our forecasts to be inaccurate, in which case we may have underestimated or overestimated the provision required for excess and obsolete inventory. If, in future periods, our inventory is determined to be overvalued, we would be required to recognize the excess value as a charge to our cost of sales at the time of such determination. Likewise, if, in future periods, our inventory is determined to be undervalued, we would have over-reported our cost of sales, or understated our earnings, at the time we recorded the excess and obsolete provision. Our inventory balance was \$257.7 million and \$221.5 million, net of a reserve for excess and obsolete inventory of \$12.3 million and \$12.6 million, as of December 31, 2010 and 2009, respectively.

### *Valuation of Goodwill and Other Long-Lived and Intangible Assets*

Our long-lived assets include (1) property, plant and equipment, (2) goodwill and (3) other intangible assets. As of December 31, 2010, the balances of property, plant and equipment, goodwill and other intangible assets, net of accumulated depreciation and amortization, were \$390.5 million, \$2.8 billion and \$1.7 billion, respectively.

Goodwill and other intangible assets are initially created as a result of business combinations or acquisitions of intellectual property. The values we record for goodwill and other intangible assets represent fair values calculated by accepted valuation methods. Such valuations require us to provide significant estimates and assumptions which are derived from information obtained from the management of the acquired businesses and our business plans for the acquired businesses or intellectual property. Critical estimates and assumptions used in the initial valuation of goodwill and other intangible assets include, but are not limited to: (1) future expected cash flows from product sales,

customer contracts and acquired developed technologies and patents, (2) expected costs to complete any in-process research and development projects and commercialize viable products and estimated cash flows from sales of such products, (3) the acquired companies' brand awareness and market position, (4) assumptions about the period of time over which we will

**Table of Contents**

continue to use the acquired brand and (5) discount rates. These estimates and assumptions may be incomplete or inaccurate because unanticipated events and circumstances may occur. If estimates and assumptions used to initially value goodwill and intangible assets prove to be inaccurate, ongoing reviews of the carrying values of such goodwill and intangible assets, as discussed below, may indicate impairment, which will require us to record an impairment charge in the period in which we identify the impairment.

Where we believe that property, plant and equipment and intangible assets have finite lives, we depreciate and amortize those assets over their estimated useful lives. For purposes of determining whether there are any impairment losses, as further discussed below, our management has historically examined the carrying value of our identifiable long-lived tangible and intangible assets and goodwill, including their useful lives where we believe such assets have finite lives, when indicators of impairment are present. In addition, we conduct an impairment review on the carrying values of all goodwill on at least an annual basis. For all long-lived tangible and intangible assets and goodwill, if an impairment loss is identified based on the fair value of the asset, as compared to the carrying value of the asset, such loss would be charged to expense in the period we identify the impairment. Furthermore, if our review of the carrying values of the long-lived tangible and intangible assets with finite lives indicates impairment of such assets, we may determine that shorter estimated useful lives are more appropriate. In that event, we will be required to record higher depreciation and amortization in future periods, which will reduce our earnings.

*Valuation of Goodwill*

In accordance with ASC 350, we test goodwill at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator.

In performing the impairment test, we utilize the two-step approach prescribed under ASC 350. The first step requires a comparison of the carrying value of each reporting unit to its estimated fair value. To estimate the fair value of our reporting units for Step 1, we use a combination of the income approach and the market approach. The income approach is based on a discounted cash flow analysis, or DCF, and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value, using a risk-adjusted discount rate. Assumptions used in the DCF require the exercise of significant judgment, including judgment about appropriate discount rates and terminal values, growth rates and the amount and timing of expected future cash flows. The forecasted cash flows are based on our most recent budget and for years beyond the budget, our estimates are based on assumed growth rates. We believe our assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates, which are intended to reflect the risks inherent in future cash flow projections, used in the DCF are based on estimates of the weighted-average cost of capital, or WACC, of market participants relative to each respective reporting unit. The market approach considers comparable market data based on multiples of revenue or earnings before taxes, depreciation and amortization, or EBITDA.

If the carrying value of a reporting unit exceeds its estimated fair value, we are required to perform the second step of the goodwill impairment test to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of a reporting unit's goodwill to its carrying value. The implied fair value of goodwill is derived by performing a hypothetical purchase price allocation for the reporting unit as of the measurement date, allocating the reporting unit's estimated fair value to its assets and liabilities. The residual amount from performing this allocation represents the implied fair value of goodwill. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded.



We conducted our annual impairment test for our reporting units during the fourth quarter of 2010. Key assumptions (which vary by reporting unit) used in determining fair value under the discounted cash flow approach included discount rates ranging from 12.5% to 13.0%, projected compound average revenue growth

**Table of Contents**

rates of 6.0% to 10.0% and terminal value growth rates of 4.0%. In determining the appropriate discount rate, we considered the weighted-average cost of capital for each reporting unit, which among other factors considers the cost of common equity capital and the marginal cost of debt of market participants. Key assumptions (which again vary by reporting unit) used in determining fair value under the market approach were based on observed market multiples of enterprise value to revenue and EBITDA for both comparable publicly-traded companies and recent merger and acquisition transactions involving similar companies to estimate appropriate controlling basis multiples to apply to each of the reporting units. Based on the multiples implied by this market data, we selected multiples of revenue of 1.0 to 2.8 times and multiples of EBITDA of 7.5 to 10.0 times. In assessing the reasonableness of our estimated fair values of the reporting units, management compared the results of the valuation analyses against our then-current market capitalization to imply a control premium. Based on this analysis, the implied control premium was within the range of comparable industry transactions.

The Step 1 impairment analysis indicated that the carrying value of the net assets of our Health Management reporting unit exceeded the estimated fair value of the reporting unit. As a result, we were required to perform Step 2 of the goodwill impairment test to determine the amount, if any, of goodwill impairment charges for the Health Management reporting unit. We completed Step 2, consistent with the procedures described above, and determined that a goodwill impairment charge in the amount of approximately \$1.0 billion was required. The resulting goodwill impairment charge is reflected in operating income (loss) in our accompanying consolidated statements of operations.

The estimate of fair value requires significant judgment. We based our fair value estimates on assumptions that we believe to be reasonable but that are unpredictable and inherently uncertain, including estimates of future growth rates and operating margins and assumptions about the overall economic climate and the competitive environment for our business units. There can be no assurance that our estimates and assumptions made for purposes of our goodwill and identifiable intangible asset testing as of the time of testing will prove to be accurate predictions of the future. If our assumptions regarding business plans, competitive environments or anticipated growth rates are not correct, we may be required to record goodwill and/or intangible asset impairment charges in future periods, whether in connection with our next annual impairment testing or earlier, if an indicator of an impairment is present before our next annual evaluation.

Impairment charges related to goodwill have no impact on our cash balances or compliance with financial covenants under our Amended and Restated Credit Agreement.

*Valuation of Other Long-Lived Tangible and Intangible Assets*

Factors we generally consider important which could trigger an impairment review on the carrying value of other long-lived tangible and intangible assets include the following: (1) significant underperformance relative to expected historical or projected future operating results, (2) significant changes in the manner of our use of acquired assets or the strategy for our overall business, (3) underutilization of our tangible assets, (4) discontinuance of product lines by ourselves or our customers, (5) significant negative industry or economic trends, (6) significant decline in our stock price for a sustained period, (7) significant decline in our market capitalization relative to net book value and (8) goodwill impairment identified during an impairment review.

We conducted our annual goodwill impairment test for our reporting units during the fourth quarter of 2010. The impairment test indicated there was an impairment of goodwill associated with our health management reporting unit, and thus, a potential impairment of our long-lived tangible and intangible assets associated with the same reporting unit. We conducted an analysis as prescribed under ASC 360 *Property, Plant and Equipment*, utilizing an undiscounted cash flow model. The analysis indicated there was no impairment of the long-lived tangible or intangible assets associated with our health management reporting unit. Although we believe that the carrying value of our long-lived tangible and intangible assets was realizable as of December 31, 2010, future events could cause us to

conclude otherwise.

## **Table of Contents**

### *Stock-Based Compensation*

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. Determining the fair value of stock-based awards at the grant date requires judgment, including estimating our stock price volatility and employee stock option exercise behaviors. If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be materially impacted.

Our expected volatility is based upon the historical volatility of our stock. The expected term is based on the assumption that all outstanding options will be exercised at the midpoint of the vesting date and the full contractual term, including data on experience to date. As stock-based compensation expense is recognized in our consolidated statements of operations based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on historical experience. If factors change and we employ different assumptions, the compensation expense that we record in future periods may differ significantly from what we have recorded in the current period.

### *Accounting for Income Taxes*

As part of the process of preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure and assessing temporary differences resulting from differing treatment of items, such as reserves and accruals and lives assigned to long-lived and intangible assets, for tax and accounting purposes. These differences result in deferred tax assets and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered through future taxable income and, to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within our tax provision.

Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have recorded a valuation allowance of \$42.5 million as of December 31, 2010, due to uncertainties related to the future benefits, if any, from our deferred tax assets related primarily to our foreign businesses and certain U.S. net operating losses, or NOLs, and tax credits. Included in this valuation allowance is \$9.1 million for deferred tax assets of acquired companies, the future benefits of which will be generally applied to reduce our income tax expense. This is an increase of \$5.0 million from the valuation allowance of \$37.5 million as of December 31, 2009. The increase is primarily related to domestic state NOLs and domestic state credits. The valuation allowance is based on our estimates of taxable income by jurisdiction in which we operate and the period over which our deferred tax assets will be recoverable. In the event that actual results differ from these estimates or we adjust these estimates in future periods, we may need to establish an additional valuation allowance or reduce our current valuation allowance which could materially impact our tax provision.

We established reserves for tax uncertainties that reflect the use of the comprehensive model for the recognition and measurement of uncertain tax positions. We are currently undergoing routine tax examinations by U.S. federal, various state and foreign jurisdictions. Tax authorities periodically challenge certain transactions and deductions we reported on our income tax returns. We do not expect the outcome of these examinations, either individually or in the aggregate, to have a material adverse effect on our financial position, results of operations or cash flows.

### *Loss Contingencies*

In the section of this Annual Report on Form 10-K titled Part I, Item 3, Legal Proceedings, we have reported on material legal proceedings, if any. Because of the nature of our business, we may be subject at any particular time to lawsuits or other claims arising in the ordinary course of our business, and we expect that this will continue to be the case in the future.

## **Table of Contents**

We do not accrue for potential losses on legal proceedings where our company is the defendant when we are not able to reasonably estimate our potential liability, if any, due to uncertainty as to the nature, extent and validity of the claims against us, uncertainty as to the nature and extent of the damages or other relief sought by the plaintiff and the complexity of the issues involved. Our potential liability, if any, in a particular case may become reasonably estimable and probable as the case progresses, in which case we will begin accruing for the expected loss.

## **Recent Accounting Pronouncements**

See Note 2(r) in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, regarding the impact of certain recent accounting pronouncements on our consolidated financial statements.

## **ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The following discussion about our market risk disclosures involves forward-looking statements. Actual results could differ materially from those discussed in the forward-looking statements. We are exposed to market risk related to changes in interest rates and foreign currency exchange rates. We do not use derivative financial instruments for speculative or trading purposes.

### **Interest Rate Risk**

We are exposed to market risk from changes in interest rates primarily through our investing and financing activities. In addition, our ability to finance future acquisition transactions or fund working capital requirements may be impacted if we are not able to obtain appropriate financing at acceptable rates.

To manage our interest rate exposure, our strategy is to invest in short-term, highly-liquid investments. Our investment policy also requires investment in approved instruments with an initial maximum allowable maturity of eighteen months and an average maturity of our portfolio that should not exceed six months, with at least \$500,000 cash available at all times. Currently, our short-term investments are in money market funds with original maturities of 90 days or less. At December 31, 2010, our short-term investments approximated market value.

At December 31, 2010, we had term loans in the amount of \$941.3 million and a revolving line of credit available to us of up to \$150.0 million, of which there were no outstanding borrowings as of December 31, 2010, under our First Lien Credit Agreement. Interest on these term loans, as defined in the credit agreement, is as follows: (i) in the case of Base Rate Loans, at a rate per annum equal to the sum of the Base Rate and the Applicable Margin, each as in effect from time to time, (ii) in the case of Eurodollar Rate Loans, at a rate per annum equal to the sum of the Eurodollar Rate and the Applicable Margin, each as in effect for the applicable Interest Period, and (iii) in the case of other Obligations, at a rate per annum equal to the sum of the Base Rate and the Applicable Margin for Revolving Loans that are Base Rate Loans, each as in effect from time to time. The Base Rate is a floating rate which approximates the U.S. Prime rate and changes on a periodic basis. The Eurodollar Rate is equal to the LIBOR rate and is set for a period of one to three months at our election. Applicable margin with respect to Base Rate Loans is 1.00% and with respect to Eurodollar Rate Loans is 2.00%. Applicable margin ranges for our revolving line of credit with respect to Base Rate Loans is 0.75% to 1.25% and with respect to Eurodollar Rate Loans is 1.75% to 2.25% depending upon our consolidated leverage.

At December 31, 2010, we also had term loans in the amount of \$250.0 million under our Second Lien Credit Agreement. Interest on these term loans, as defined in the credit agreement, is as follows: (i) in the case of Base Rate Loans, at a rate per annum equal to the sum of the Base Rate and the Applicable Margin, each as in effect from time to time, (ii) in the case of Eurodollar Rate Loans, at a rate per annum equal to the sum of the Eurodollar Rate and the

Applicable Margin, each as in effect for the applicable Interest Period and (iii) in the case of other obligations, at a rate per annum equal to the sum of the Base Rate and the Applicable Margin for Base Rate Loans, as in effect from time to time. Applicable margin with respect to Base Rate Loans is 3.25% and with respect to Eurodollar Rate Loans is 4.25%.

**Table of Contents**

In August 2007, we entered into interest rate swap contracts, with an effective date of September 28, 2007, that had a total notional value of \$350.0 million and a maturity date of September 28, 2010. These interest rate swap contracts paid us variable interest at the three-month LIBOR rate, and we paid the counterparties a fixed rate of 4.85%. In March 2009, we extended our August 2007 interest rate hedge for an additional two-year period commencing in September 2010 at a one-month LIBOR rate of 2.54%. These interest rate swap contracts were entered into to convert \$350.0 million of the \$1.2 billion variable rate term loans under the secured credit facilities into fixed rate debt.

In January 2009, we entered into interest rate swap contracts, with an effective date of January 14, 2009, that had a total notional value of \$500.0 million and a maturity date of January 5, 2011. These interest rate swap contracts paid us variable interest at the one-month LIBOR rate, and we paid the counterparties a fixed rate of 1.195%. These interest rate swap contracts were entered into to convert \$500.0 million of the \$1.2 billion variable rate term loan under the secured credit facility into fixed rate debt. We did not extend the terms of this interest rate swap after January 5, 2011.

Assuming no changes in our leverage ratio and considering our interest rate swaps, including our interest rate swap that matured on January 5, 2011, which would affect the margin of the interest rates under the credit agreements, the effect of interest rate fluctuations on outstanding borrowings as of December 31, 2010 over the next twelve months is quantified and summarized as follows (in thousands):

	<b>Interest Expense Increase</b>
Interest rates increase by 100 basis points	\$ 8,413
Interest rates increase by 200 basis points	\$ 16,825

**Foreign Currency Risk**

We face exposure to movements in foreign currency exchange rates whenever we, or any of our subsidiaries, enter into transactions with third parties that are denominated in currencies other than our, or its, functional currency. Intercompany transactions between entities that use different functional currencies also expose us to foreign currency risk. During 2010, the net impact of foreign currency changes on transactions was a gain of \$9.8 million. Historically, we have not used derivative financial instruments or other financial instruments with original maturities in excess of three months to hedge such exposures.

Gross margins of products we manufacture at our foreign plants and sell in U.S. dollars or manufacture in our U.S. plants and sell in currencies other than the U.S. dollar are also affected by foreign currency exchange rate movements. Our gross margin on total net product sales was 53.3% in 2010. If the U.S. dollar had been stronger by 1%, 5% or 10%, compared to the actual rates during 2010, our gross margin on total net product sales would have been 53.3%, 53.6% and 53.9%, respectively.

In addition, because a substantial portion of our earnings is generated by our foreign subsidiaries, whose functional currencies are other than the U.S. dollar (in which we report our consolidated financial results), our earnings could be materially impacted by movements in foreign currency exchange rates upon the translation of the earnings of such subsidiaries into the U.S. dollar.

If the U.S. dollar had been uniformly stronger by 1%, 5% or 10%, compared to the actual average exchange rates used to translate the financial results of our foreign subsidiaries, our net product sales and net income would have been impacted by approximately the following amounts (in thousands):



	<b>Approximate (Decrease) in Net Revenue</b>	<b>Approximate Increase in Net Income</b>
<b>If, during 2010, the U.S. dollar was stronger by:</b>		
1%	\$ (6,050)	\$ 32
5%	\$ (30,251)	\$ 162
10%	\$ (60,502)	\$ 323

**Table of Contents****ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

The financial statements and supplementary data, except for selected quarterly financial data which are summarized below, are listed under Item 15(a) and have been filed as part of this Annual Report on Form 10-K on the pages indicated.

On January 15, 2010, we completed the sale of our vitamins and nutritional supplements business. The sale included our entire private label and branded nutritional businesses and represents the complete divestiture of our entire vitamins and nutritional supplements business segment. The results of the vitamins and nutritional supplements business are included in income (loss) from discontinued operations, net of tax, for all periods presented in the financial statements and supplementary data below.

The following table presents selected quarterly financial data for each of the quarters in the years ended December 31, 2010 and 2009 (in thousands, except per share data):

	<b>2010</b>			
	<b>First Quarter(2)</b>	<b>Second Quarter(3)</b>	<b>Third Quarter(4)</b>	<b>Fourth Quarter(5)</b>
Net revenue	\$ 515,254	\$ 522,960	\$ 538,679	\$ 578,454
Gross profit	\$ 273,957	\$ 271,998	\$ 285,546	\$ 303,086
Income (loss) from continuing operations	\$ 2,213	\$ (1,976)	\$ 4,825	\$ (1,032,351)
Income (loss) from discontinued operations, net of tax	\$ 11,946	\$ (35)	\$ 2	\$ (516)
Net income (loss) available to common stockholders(1)	\$ 8,968	\$ (8,347)	\$ (2,814)	\$ (1,039,352)
Basic Income (loss) per common share attributable to Alere Inc. and Subsidiaries:				
Income (loss) per common share from continuing operations	\$ (0.03)	\$ (0.10)	\$ (0.03)	\$ (12.23)
Income (loss) per common share from discontinued operations	\$ 0.14	\$	\$	\$ (0.01)
Net income (loss) per common share(1)	\$ 0.11	\$ (0.10)	\$ (0.03)	\$ (12.24)
Diluted Income (loss) per common share attributable to Alere Inc. and Subsidiaries:				
Income (loss) per common share from continuing operations	\$ (0.03)	\$ (0.10)	\$ (0.03)	\$ (12.23)
Income (loss) per common share from discontinued operations	\$ 0.14	\$	\$	\$ (0.01)
Net income (loss) per common share(1)	\$ 0.11	\$ (0.10)	\$ (0.03)	\$ (12.24)

**Table of Contents**

	<b>2009</b>			
	<b>First Quarter(6)</b>	<b>Second Quarter(7)</b>	<b>Third Quarter(8)</b>	<b>Fourth Quarter(9)</b>
Net revenue	\$ 425,153	\$ 438,652	\$ 512,665	\$ 546,171
Gross profit	\$ 234,450	\$ 237,896	\$ 280,297	\$ 301,579
Income (loss) from continuing operations	\$ 7,738	\$ 4,886	\$ 19,870	\$ (247)
Income (loss) from discontinued operations, net of tax	\$ (1,347)	\$ (166)	\$ 413	\$ 3,034
Net income (loss) available to common stockholders	\$ 771	\$ (1,197)	\$ 14,299	\$ (3,129)
Basic Income (loss) per common share attributable to Alere Inc. and subsidiaries:				
Income (loss) per common share from continuing operations(1)	\$ 0.03	\$ (0.02)	\$ 0.17	\$ (0.08)
Income (loss) per common share from discontinued operations	\$ (0.02)	\$	\$ 0.01	\$ 0.04
Net income (loss) per common share	\$ 0.01	\$ (0.02)	\$ 0.18	\$ (0.04)
Diluted Income (loss) per common share attributable to Alere Inc. and subsidiaries:				
Income (loss) per common share from continuing operations(1)	\$ 0.03	\$ (0.02)	\$ 0.17	\$ (0.08)
Income (loss) per common share from discontinued operations	\$ (0.02)	\$	\$	\$ 0.04
Net income (loss) per common share	\$ 0.01	\$ (0.02)	\$ 0.17	\$ (0.04)

- (1) Net income (loss) available to common stockholders and basic and diluted net income (loss) per common share are computed consistent with the annual per share calculations described in Notes 2(n) and 12 of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
- (2) Included in net income for the first quarter of 2010 is \$8.0 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$2.8 million relating to an inventory write-up recorded in connection with acquisitions, acquisition-related costs in the amount of \$4.0 recorded in connection with the adoption of a ASC 805, *Business Combinations*, on January 1, 2009, \$3.1 million of income recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, *Business Combinations*, expenses of \$0.3 million (\$0.2 million, net of tax) incurred in connection with the sale of our vitamins and nutritional supplements business and \$7.6 million of non-cash stock-based compensation expense.
- (3) Included in net loss for the second quarter of 2010 is \$7.1 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$2.8 million relating to an inventory write-up recorded in connection with acquisitions, acquisition-related costs in the amount of \$2.0 recorded in connection with the adoption of a ASC 805, *Business Combinations*, on January 1, 2009, \$3.8 million of income recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, *Business Combinations* and \$8.1 million of non-cash stock-based compensation expense.
- (4) Included in net loss for the third quarter of 2010 is a net recovery of \$1.6 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$1.3 million relating to inventory write-ups recorded in connection with acquisitions, acquisition-related costs in the amount of \$0.9

recorded in connection with the adoption of a ASC 805, *Business Combinations*, on January 1, 2009, \$4.6 million of expense recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, *Business Combinations* and \$7.3 million of non-cash stock-based compensation expense.

- (5) Included in net loss for the fourth quarter of 2010 is a goodwill impairment charge in the amount of \$1.0 billion related to our health management reporting unit and business segment, \$1.6 million related to restructuring charges associated with the decision to close various facilities, a net recovery of \$0.3 million relating to an inventory write-up recorded in connection with acquisitions, acquisition-related costs in the amount of \$1.4 million recorded in connection with the adoption of ASC 805, *Business Combinations*, on

**Table of Contents**

January 1, 2009, \$4.1 million of expense recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, *Business Combinations*, a \$0.7 million fair value write-down recorded in connection with an idle facility, a \$60.1 million compensation charge associated with our acquisition of minority shares of Standard Diagnostics, Inc. and \$6.9 million of non-cash stock-based compensation expense.

- (6) Included in net income for the first quarter of 2009 is \$5.4 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$4.7 million for acquisition-related costs recorded in connection with the adoption of a ASC 805, *Business Combinations*, on January 1, 2009 and \$5.9 million of non-cash stock-based compensation expense.
- (7) Included in net loss for the second quarter of 2009 is \$4.9 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$1.7 million for acquisition-related costs recorded in connection with the adoption of ASC 805, *Business Combinations*, on January 1, 2009 and \$6.6 million of non-cash stock-based compensation expense.
- (8) Included in net income for the third quarter of 2009 is \$6.2 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$0.7 million relating to an inventory write-up recorded in connection with the acquisitions, acquisition-related costs in the amount of \$5.1 million recorded in connection with the adoption of ASC 805, *Business Combinations*, on January 1, 2009, a \$3.4 million gain associated with management's decision to dispose of our Diamics, Inc. operations, a \$2.9 million net realized foreign currency gain associated with restricted cash established in connection with the acquisition of Concateno, a \$1.9 million compensation-related charge recorded in connection with the acquisition of Concateno, a \$0.3 million loss recorded in connection with the deferred payment of a portion of the ACON Second Territory Business purchase price consideration to be paid with our common stock and \$7.8 million of non-cash stock-based compensation expense.
- (9) Included in net loss for the fourth quarter of 2009 is \$6.9 million related to restructuring charges associated with the decision to close various facilities, a write-off in the amount of \$1.4 million relating to an inventory write-up recorded in connection with the acquisitions, acquisition-related costs in the amount of \$4.3 million recorded in connection with the adoption of ASC 805, *Business Combinations*, on January 1, 2009, \$1.8 million of expense recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, *Business Combinations*, a \$3.2 million fair value write-down recorded in connection with an idle facility, expenses of \$1.8 million (\$1.1 million, net of tax) incurred in connection with the sale of our vitamins and nutritional supplements business and \$7.9 million of non-cash stock-based compensation expense.

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

Not applicable.

**ITEM 9A. CONTROLS AND PROCEDURES**

*Management's Conclusions Regarding the Effectiveness of Our Disclosure Controls and Procedures*

Our management evaluated, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our management, including the CEO and CFO, concluded

that our disclosure controls and procedures were effective at that time. We and our management understand, nonetheless, that controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures. In reaching their conclusions stated above regarding the effectiveness of our disclosure controls and procedures, our CEO and CFO concluded that such disclosure controls and procedures were effective as of such date at the reasonable assurance level.

## **Table of Contents**

### *Management's Annual Report on Internal Control over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our company's internal control over financial reporting is a process designed under the supervision of the CEO and CFO to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

- (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
- (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of our management and directors; and
- (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

There are inherent limitations in the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding of controls. Accordingly, even effective internal controls can provide only reasonable assurances with respect to financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our company's internal control over financial reporting as of December 31, 2010. In making this assessment, management used the criteria established in *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on management's assessment and those criteria, management determined that the Company maintained effective internal control over financial reporting as of December 31, 2010.

In conducting management's evaluation of the effectiveness of our company's internal control over financial reporting, management excluded all entities acquired in purchase business combinations during 2010 from its assessment. The contribution from these acquisitions represented approximately 10% and 6% of total assets and net revenue, respectively, as of and for the year ended December 31, 2010. Refer to Note 4 of the accompanying consolidated financial statements for further discussion of our acquisitions and their impact on our consolidated financial statements.

The effectiveness of our internal control over financial reporting as of December 31, 2010 has been audited by PricewaterhouseCoopers LLP, our independent registered public accounting firm, as stated in their report which appears herein.

### *Changes in internal control over financial reporting*

There was no change in our internal control over financial reporting that occurred during our fourth fiscal quarter of 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **ITEM 9B. OTHER INFORMATION**

None.



**Table of Contents****PART III****ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE****Directors and Executive Officers**

The following biographical descriptions set forth certain information with respect to our directors and our executive officers who are not directors.

<b>Name</b>	<b>Age</b>	<b>Position</b>
Ron Zwanziger	57	Chairman of the Board, Chief Executive Officer and President
David Scott, Ph.D.	54	Director, Chief Scientific Officer
Jerry McAleer, Ph.D.	56	Director, Senior Vice President, Research & Development
John Bridgen, Ph.D.	64	Senior Vice President, Business Development
Gordon Norman, M.D.	62	Chief Innovation Officer
Hilde Eylenbosch, M.D.	47	Chief Commercial Officer
Robert Hargadon	54	Vice President, Global Culture and Performance
Tom Underwood	53	Chief Executive Officer, Alere Health, LLC
David Teitel	47	Chief Financial Officer, Vice President and Treasurer
Jon Russell	47	Vice President, Finance
Robert Di Tullio	58	Vice President, Global Regulatory and Clinical Affairs
Paul T. Hempel	62	Senior Vice President, Ethics/Compliance and Special Counsel, Assistant Secretary
Ellen Chiniara	52	Vice President, General Counsel and Secretary
Eli Y. Adashi, M.D.	66	Director
Carol R. Goldberg	80	Director
Robert P. Khederian	58	Director
John F. Levy	64	Director
John A. Quelch, D.B.A.	59	Director
James Roosevelt, Jr.	65	Director
Peter Townsend	76	Director

*Our Class I Directors Term Expiring 2011*

**John A. Quelch, D.B.A.** joined the Board on March 10, 2003. Since February 2011, Dr. Quelch has been Dean, Vice President and Distinguished Professor of International Management at the China Europe International Business School in Shanghai. From July 2001 through January 2011, he was Senior Associate Dean at the Harvard Business School. From July 1998 through June 2001, he was Dean of the London Business School. Dr. Quelch also serves as a director of WPP plc, the world's largest marketing and media services company. Dr. Quelch served as a director of Pepsi Bottling Group from 2005 to 2010 and of Gentiva Health Services, Inc. from 2006 to 2009. He is Chairperson of the Board's Nominating and Corporate Governance Committee. Through his general business experience and academic credentials, Dr. Quelch brings to our Board both industry and academic expertise in marketing and organizational management.

**John F. Levy** has served on the Board since May 30, 2001. Mr. Levy served as a director of Inverness Medical Technology from August 1996 through November 2001, when that company was acquired by Johnson & Johnson. Since 1993, he has been an independent consultant. Mr. Levy served as President and Chief Executive Officer of Waban, Inc., a warehouse merchandising company, from 1989 to 1993. Mr. Levy is Chairperson of the Board's Audit Committee and is a member of the Board's Nominating and Corporate Governance Committee. A former chief executive officer, Mr. Levy brings to our Board financial expertise, investment experience and a knowledge of distribution systems.

**Table of Contents**

**Jerry McAleer, Ph.D.** joined the Board on March 10, 2003. Dr. McAleer became Senior Vice President, Research & Development in July 2010. Prior to that, he served as our Vice President, Research and Development since our inception in May 2001 and as our Vice President, Cardiology since early 2006. Dr. McAleer served as Vice President of Research and Development of our predecessor company, Inverness Medical Technology, from 1999 through November 2001, when that company was acquired by Johnson & Johnson. From 1995 to 1999, Dr. McAleer served as Director of Development of Inverness Medical Limited, Inverness Medical Technology's primary research and development unit, where he headed the development of Inverness Medical Technology's electrochemical glucose strips. Prior to joining Inverness Medical Technology, Dr. McAleer held senior research and development positions at MediSense, a medical device company, and Ecossensors, Inc., an environmental research company. Dr. McAleer's scientific background in our industry provides our Board with valuable research and development expertise.

*Our Class II Directors Term Expiring 2012*

**Carol R. Goldberg** has served on the Board since May 30, 2001. Ms. Goldberg served as a director of our predecessor company, Inverness Medical Technology, from August 1992 through November 2001, when that company was acquired by Johnson & Johnson. Since December 1989, she has served as President of The AVCAR Group, Ltd., an investment and management consulting firm in Boston, Massachusetts. Ms. Goldberg is Chairperson of the Board's Compensation Committee. As the former President and Chief Operating Officer of Stop & Shop Companies, Inc., Ms. Goldberg brings a wealth of financial, marketing and consumer expertise to the Board.

**James Roosevelt, Jr.** joined the Board on February 6, 2009. Mr. Roosevelt has served as the President and Chief Executive Officer of Tufts Health Plan since 2005. From 1999 to 2005, Mr. Roosevelt was Senior Vice President and General Counsel of Tufts Health Plan. Mr. Roosevelt also serves as Co-Chair of the Rules and By-laws Committee of the Democratic National Committee, Co-Chair of the Board of Directors for the Tufts Health Care Institute, and member of the Board of Directors at American Health Insurance Plans, Emmanuel College and PointRight Inc., where he serves as a member of the Compensation Committee. Mr. Roosevelt is a member of the Board's Nominating and Corporate Governance Committee. Mr. Roosevelt brings to our Board extensive senior management, policy-making and financial experience within the health insurance industry, which includes important customers of the Company and is a driving force behind the demand for control of healthcare costs, which is reshaping the diagnostic and health management industries in which we operate.

**Ron Zwanziger** has served as our Chairman, Chief Executive Officer and President since our inception on May 11, 2001. Mr. Zwanziger served as Chairman, Chief Executive Officer and President of our predecessor company, Inverness Medical Technology, from its inception in 1992 through November 2001, when that company was acquired by Johnson & Johnson. From 1981 to 1991, he was Chairman and Chief Executive Officer of MediSense, a medical device company. Mr. Zwanziger also serves as a director and Chairperson of the Nominating and Corporate Governance Committee of AMAG Pharmaceuticals, Inc. As the Chief Executive Officer of the Company, as well as the founder and chief executive officer of two other successful medical diagnostic companies, Mr. Zwanziger brings strategic vision, leadership, extensive business and operating experience and an immense knowledge of the Company and the industry to the Board.

*Our Class III Directors Term Expiring 2013*

**Eli Y. Adashi, M.D., M.S., C.P.E., F.A.C.O.G.** joined the Board on April 1, 2009. The immediate past Dean of Medicine and Biological Sciences and the Frank L. Day Professor of Biology at Brown University, Dr. Adashi Harvard-educated in Health Care Management (M.S.; 2005; HSPH) has been a Professor of Medical Science at Brown University since 2004. A Physician-Scientist-Executive with over 25 years of experience in healthcare and in the life sciences, Dr. Adashi is a member of the Institute of Medicine of the National Academy of Sciences and of its Board on Health Sciences Policy, the Council on Foreign Relations, the Association of American Physicians, and the

American Association for the Advancement of Science. Dr. Adashi is a member of MEDCAC (Medicare Evidence Development & Coverage Advisory Committee) and an *ad hoc* member of the Reproductive Health Drugs Advisory Committee of the U.S. Food & Drug

## **Table of Contents**

Administration. Dr. Adashi is the author or co-author of over 250 peer-reviewed publications, over 120 book chapters/reviews, and 13 books focusing on ovarian biology, reproductive health and domestic health policy. Dr. Adashi is a member of the Board's Compensation Committee. Dr. Adashi brings to our Board senior management experience and immense knowledge and experience in medicine and science from the provider perspective.

**Robert P. Khederian** has served on the Board since July 31, 2001. Mr. Khederian is the Chairman of Belmont Capital, a venture capital firm he founded in 1996, and Provident Corporate Finance, an investment banking firm he founded in 1998. From 1984 through 1996, he was founder and Chairman of Medical Specialties Group, Inc., a nationwide distributor of medical products which was acquired by Bain Capital. Mr. Khederian served as the Chairman of the Board of Cambridge Heart, Inc. from August 2006 to August 2008. Mr. Khederian also served as the interim Chief Executive Officer of Cambridge Heart, Inc. from December 2006 to December 2007. Mr. Khederian is a member of the Board's Audit Committee and Compensation Committee. A former chief executive officer, Mr. Khederian has extensive knowledge of the capital markets and brings to the Board significant and valuable financial and investment expertise.

**David Scott, Ph.D.** has served on the Board since July 31, 2001 and has served as our Chief Scientific Officer since our inception in May 2001. Dr. Scott served as Chairman of Inverness Medical Limited, a subsidiary of our predecessor company, Inverness Medical Technology, from July 1999 through November 2001, when that company was acquired by Johnson & Johnson, and as a managing director of Inverness Medical Limited from July 1995 to July 1999. Dr. Scott's scientific and management background in our industry provides our Board with valuable general business and research and development expertise.

**Peter Townsend** has served on the Board since May 30, 2001. Mr. Townsend served as a director of our predecessor company, Inverness Medical Technology, from August 1996 through November 2001, when that company was acquired by Johnson & Johnson. From 1991 to 1995, when he retired, Mr. Townsend served as Chief Executive Officer and a director of Enviromed plc, a medical products company. Mr. Townsend is a member of the Board's Audit Committee. As a former chief executive officer of a medical products company, Mr. Townsend brings to the Board financial expertise, significant industry experience and an international business perspective.

### *Executive Officers Who Are Not Directors*

**John Bridgen, Ph.D.** has served as Senior Vice President, Business Development since July 2010, after serving as our Vice President, Business Development from June 2006 to July 2010. He served as our Vice President, Strategy from September 2005 to June 2006. Dr. Bridgen joined the Company in September 2002, upon our acquisition of Wampole Laboratories, LLC. Dr. Bridgen served as President of Wampole from August 1984 until September 2005. Prior to joining Wampole, Dr. Bridgen had global sales and marketing responsibility for the hematology and immunology business units of Ortho Diagnostic Systems Inc., a Johnson & Johnson company.

**Gordon Norman, M.D.** has served as our Chief Innovation Officer since February 2010. Since that time, Dr. Norman has also continued to serve as Executive Vice President and Chief Innovation Officer at our subsidiary, Alere Health, LLC, where he held the title of Executive Vice President, Science & Innovation from May 2008 to February 2010. From June 2007 to May 2008, Dr. Norman served as Executive Vice President, Chief Science Officer of Alere Medical, Inc., which we acquired in November 2007. From July 2005 to June 2007, Dr. Norman served Alere Medical as Executive Vice President and Chief Medical Officer. Prior to joining Alere Medical in July 2005, Dr. Norman served in a variety of executive medical management roles for PacifiCare Health Services beginning in July 1994.

**Hilde Eylenbosch, M.D.** has served as Chief Commercial Officer since November 2010, after having served as our Senior Vice President, Marketing from July 2010 to November 2010 and as our Vice President, Marketing from April 2009 to July 2010. Prior to April 2009, she served as Chief Executive Officer of SPD Swiss Precision Diagnostics

GmbH, our 50/50 joint venture with Procter & Gamble, since its inception on May 18, 2007. Dr. Eylembosch has also served as our President, Consumer Diagnostics since June 2006. Prior to assuming that title she served as Vice President, Consumer Diagnostics from July 2005 to June 2006, Vice

**Table of Contents**

President, Consumer Marketing from October 2004 to July 2005 and Vice President of International Women's Health from November 2001 to October 2004. Dr. Eylembosch served in the same capacity for our predecessor company, Inverness Medical Technology, from August 2001 until that company was acquired by Johnson & Johnson in November 2001. Prior to that, she held various positions at Inverness Medical Technology, including Director of U.S. Women's Health from September 1998 through October 2000. When she joined Inverness Medical Technology in January 1995, Dr. Eylembosch was responsible for marketing that company's women's health products in Europe. Before joining Inverness Medical Technology, Dr. Eylembosch was employed by Synthelabo, a French pharmaceutical company, where she held various marketing positions.

**Robert Hargadon** joined us as Vice President, Global Culture and Performance in October 2010. He has over 30 years of experience in human resources, leadership and organization development. Mr. Hargadon served as Vice President, Human Resources at drugstore.com from November 2006 through October 2010. Prior to that, Mr. Hargadon was General Manager, Corporate Learning and Development at Microsoft from September 2005 to April 2006 and held various human resources leadership positions at Boston Scientific Corporation from 1997 to 2005, including Vice President of International Human Resources and Vice President, Leadership Development from September 1997 to June 2005. Mr. Hargadon served as Vice President, Learning and Development at Fidelity Investments from 1993 to 1997. Mr. Hargadon also had 15 years of experience with the consulting firms Novations Group, Inc. and Harbridge House, which was acquired by PricewaterhouseCoopers LLP.

**Tom Underwood** has served as Chief Executive Officer of Alere Health, LLC since February 2010. Mr. Underwood served as President of the Technology Solutions Division of Alere from May 2008 and then as our Chief Information Officer from September 2009 to February 2010. Mr. Underwood served as President and Chief Operating Officer of Matria Healthcare from January 2008 until May 2008 when we acquired Matria. Prior to this role and since joining Matria Healthcare in June 2007, he served as Executive Vice President of Technology. Mr. Underwood came to Matria from First Consulting Group, or FCG, where he last served as President of Global Shared Services from May 2006 to June 2007. During his tenure with FCG, which began in February 2003, Mr. Underwood served in various executive leadership roles, including President of Global Shared Services, Executive Vice President of Healthcare, Executive Vice President of Government and Technology, and President of FCG Software Services. From January 2000 to February 2003, Mr. Underwood was Chief Executive Officer and President of Paragon Solutions, an offshore software development business that was acquired by FCG in February 2003. Prior to his employment with Paragon and FCG, from June 1995 to October 1998, Mr. Underwood was the technology executive for IMNET Systems, an electronic medical record solutions company, which was acquired by McKesson HBOC in October 1998. Earlier in his career, Mr. Underwood held numerous management and technology roles within Perceptics, a division of the Westinghouse Company, and AT&T Bell Laboratories.

**David Teitel** has served as our Chief Financial Officer, Vice President and Treasurer since December 2006. Mr. Teitel has over 20 years of public and private company finance experience, including nine years of audit experience at Arthur Andersen and senior financial positions with Thermo Electron Corp., which is now Thermo Fisher Scientific Inc. and Deknatel Snowden Pencer, Inc. Mr. Teitel joined the Company in December 2003 as Director of Finance Operations and assumed the title Vice President, Finance in December 2004.

**Jon Russell** has served as our Vice President, Finance since December 2006. In this role, Mr. Russell oversees financial systems management and integration and shares responsibility for external communications with the Chief Executive Officer. Previously, Mr. Russell was Chief Financial Officer of Wampole Laboratories, LLC from September 2005 to June 2006. He has more than 20 years of experience in finance and operations management, including senior operational finance positions in North America and Europe with Precision Castparts Corporation, Vertex Interactive, Inc. and Genicom Corporation. Mr. Russell began his career at Ernst & Young LLP.

**Robert Di Tullio** joined us as Vice President, Global Regulatory and Clinical Affairs in March 2010. He has over 37 years experience in the in vitro diagnostics industry, the last 26 of which have been in quality and regulatory management. Mr. Di Tullio served as Vice President, Regulatory Affairs and Quality at ProteoGenix, Inc., a custom antibody company, from July 2008 to March 2010. He held the position of Vice



## **Table of Contents**

President, Regulatory and Clinical Affairs and Quality at Sequenom, Inc., a genetic analysis company, from June 2007 to July 2008. From June 1992 to June 2007, Mr. Di Tullio served as Vice President, Regulatory Affairs and Quality Systems at Diagnostic Products Corporation, or DPC, an immuno-diagnostics company, and Siemens Medical Solutions Diagnostics, following its acquisition of DPC. Mr. Di Tullio has been co-chair of the AdvaMed Dx task force since 2007.

**Paul T. Hempel** served as our General Counsel and Secretary from our inception on May 11, 2001 until April 2006, when Mr. Hempel became Senior Vice President in charge of Leadership Development and Special Counsel, while retaining his role as Secretary, which he retained until May 2010. Mr. Hempel also retained oversight of our legal affairs until May 2007. In November 2010, Mr. Hempel became Senior Vice President, Ethics/Compliance and Special Counsel. Mr. Hempel served as General Counsel and Assistant Secretary of our predecessor company, Inverness Medical Technology, from October 2000 through November 2001, when that company was acquired by Johnson & Johnson. Prior to joining Inverness Medical Technology, he was a founding stockholder and Managing Partner of Erickson Schaffer Peterson Hempel & Israel PC from 1996 to 2000. Prior to 1996, Mr. Hempel was a partner and managed the business practice at Bowditch & Dewey LLP.

**Ellen Chiniara** serves as Vice President, General Counsel and Secretary and is responsible for managing legal matters for the Company. Ms. Chiniara joined us in October 2006 as General Counsel, Professional Diagnostics and became our Vice President and General Counsel in May 2007 and Secretary in May 2010. From 2002 to 2006, Ms. Chiniara was Associate General Counsel, Neurology of Serono, Inc., a biopharmaceutical company. Previously, she served as General Counsel to a healthcare venture capital fund and a healthcare management services organization, where she also was Chief Operating Officer of its clinical trial site management division. From 1994 to 1997, Ms. Chiniara was Assistant General Counsel at Value Health, a specialty managed healthcare company where she focused on disease management and healthcare IT. Prior to 1994, Ms. Chiniara was a partner with Hale and Dorr (now WilmerHale).

## **Corporate Governance**

### *The Audit Committee*

The Company has a standing Audit Committee consisting of Mr. Levy, its Chairperson, Mr. Khederian and Mr. Townsend. Among other things, the Audit Committee oversees our accounting and financial reporting processes, including the selection, retention and oversight of our independent registered public accounting firm and the pre-approval of all auditing and non-auditing services provided by the independent registered public accounting firm. The Board has determined that Mr. Levy is an audit committee financial expert, as defined by SEC rules adopted pursuant to the Sarbanes-Oxley Act.

### *Code of Ethics*

Our Board has adopted a code of ethics that applies to all of our employees and agents worldwide, including our chief executive officer, our chief financial officer, our controller, our other executive officers and the members of the Board. Known as the Alere Inc. Business Conduct Guidelines, the code of ethics is posted in its entirety on the Corporate Governance page of our website at [www.alere.com](http://www.alere.com). We intend to make required disclosures of amendments to our code of ethics, or waivers of a provision of our code of ethics, on the Corporate Governance page of our website.

## **Section 16(a) Beneficial Ownership Reporting Compliance**

Section 16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires our officers and directors and persons who beneficially own more than 10% of our outstanding shares of common stock or Series B preferred stock to file reports of ownership and changes in ownership with the Securities and Exchange Commission and the New York Stock Exchange. Such persons are required by applicable regulations to furnish us with copies of all reports filed pursuant to Section 16(a).

## **Table of Contents**

To our knowledge, based solely on a review of the copies of such reports received by us and certain written representations that no other reports were required, we believe that for the fiscal year ended December 31, 2010, all of our officers, directors and 10% beneficial owners complied with the requirements of Section 16(a).

## **ITEM 11. EXECUTIVE COMPENSATION**

### ***Compensation Discussion and Analysis***

This Compensation Discussion and Analysis discusses the compensation paid to our chief executive officer, or our CEO, our chief financial officer, or our CFO, and our three other most highly compensated executive officers. These officers are collectively referred to as the named executive officers for purposes of this discussion. We refer to Ron Zwanziger, our CEO; David Scott, Ph.D., our Chief Scientific Officer; and Jerry McAleer, Ph.D., our Senior Vice President, R&D, as our key executives.

### ***Philosophy and Objectives***

The objective of our executive compensation program for 2010 was to attract, retain and motivate the talented and dedicated executives who were critical to our goals of continued growth, innovation, increasing profitability and, ultimately, maximizing shareholder value. Specifically, we sought to attract and reward executives who displayed certain fundamental leadership characteristics for hiring and promotion that we had identified as consistent with our corporate goals and culture. We provided these executives with what we believed to be a competitive total compensation package consisting primarily of base salary, long-term equity incentive compensation and a broad-based benefits program. Our 2010 compensation program was designed to reward each executive's individual performance by considering generally their past and potential contribution to our achievement of key strategic goals, such as revenue generation, margin improvement and the establishment and maintenance of key strategic relationships. These performance factors were used primarily to determine the equity compensation awards granted to each executive. Our 2010 executive compensation program aimed to provide a risk-balanced compensation package which was competitive in our market sector and, more importantly, relevant to the individual executive.

Our policy for allocating between long-term and currently-paid compensation for 2010 was to ensure adequate base compensation to attract and retain personnel, while providing incentives to maximize long-term value for our company and our stockholders. For 2010, we provided (i) cash compensation in the form of base salary to meet competitive cash compensation norms and (ii) non-cash compensation in the form of stock-based awards to reward superior performance against long-term strategic goals. For 2011 and beyond, we have established a process pursuant to which we expect to provide participating executives with annual incentive compensation packages consisting of a combination of cash and stock-based awards. We expect that awards will be recommended to our Compensation Committee after year-end to the extent that applicable performance conditions have been satisfied and will be granted by the Compensation Committee, in its discretion, thereafter. The cash-based awards, if earned, are expected to vest in three equal installments over two years.

In 2010 we did not have a short-term, cash incentive compensation plan for our executive officers, and so we set the base salaries for our named executive officers at a level higher than the average base salaries for executives in similar positions with similar responsibilities at comparable companies. In general, we targeted our 2010 base salaries at the average of the range of annual total cash compensation (base salary plus annual non-equity incentive compensation) for competitive positions. Our Compensation Committee believed this compensation structure would focus our executives' attention primarily on long-term stock price appreciation, rather than short-term results, and yet would enable us to recruit and retain talented executives by ensuring that our annual cash compensation would be competitive with other companies.

***Executive Compensation Process***

The compensation of our named executive officers, as well as our other executive officers, has been reviewed by our Compensation Committee at least annually for consistency with the objectives described above. Our management, including our CEO, has participated in this review by making its own

**Table of Contents**

recommendations as to the compensation of our executive officers to the Compensation Committee. The Compensation Committee has considered the recommendations of management in assessing executive compensation, but from time to time it has also gathered and relied on other data and resources and has utilized the services of a compensation consultant in reviewing and determining executive compensation.

During 2009, the Compensation Committee engaged a compensation consultant, Aon Consulting's Radford Surveys + Consulting, or Radford, to assist the committee in assessing total compensation of our key executives. As part of its engagement, Radford assisted the Compensation Committee in selecting a new peer group to utilize in assessing the competitiveness of the compensation of our key executives. The peer group selected by the Compensation Committee for purposes of evaluating compensation of the key executives consisted of nineteen publicly traded companies in a similar industry space and with similar revenues and market capitalizations. Of the peer group companies, 26% were health management companies and 74% were diagnostics/medical equipment companies. Specifically, the peer group consisted of the following companies:

Beckman Coulter, Inc.

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Catalyst Health Solutions, Inc.

C.R. Bard, Inc.

Gen-Probe Incorporated

Healthways, Inc.

Hologic, Inc.

Hospira, Inc.

IDEXX Laboratories, Inc.

Kinetic Concepts, Inc.

Life Technologies Corporation

Lincare Holdings, Inc.

Magellan Health Services, Inc.

Myriad Genetics, Inc.

PerkinElmer, Inc.

RehabCare Group, Inc.

St. Jude Medical, Inc.

Varian Medical Systems, Inc.

In connection with its engagement, Radford provided a detailed report, the Radford Report, which included summary observations and considerations regarding our compensation philosophy and methodology, as well as detailed competitive assessments of the cash and equity compensation of the key executives. For 2010, the Compensation Committee did not engage Radford to update the Radford Report, but still considered the Radford Report in its assessment of the stock-based compensation of our key executives.

In determining each component of an executive's compensation, numerous factors particular to the executive were considered, including:

The individual's particular background, including prior relevant work experience;

The demand for individuals with the executive's specific expertise and experience;

## **Table of Contents**

The individual's role with us and the compensation paid to similar persons determined through benchmark studies, such as the Radford Report;

The individual's performance and contribution to our achievement of corporate goals and objectives; and

Comparison to our other executives.

### ***Elements of Compensation***

For 2010, executive compensation consisted of the following elements:

*Base Salary.* Base salary was established based on the factors discussed above. Our general compensation philosophy for 2010, as described above, was to offer a competitive base salary, plus long-term, equity-based incentive compensation. Because we did not offer short-term cash incentive compensation in 2010, we sought to ensure that the cash compensation of our executives would be competitive by targeting annual base salary for a particular individual near the average of the range of annual cash compensation (base salary plus annual non-equity incentive compensation) for executives in similar positions with similar responsibilities at comparable companies. Other elements of compensation, including past and present grants of stock-based awards, were also considered. The Compensation Committee believed that a competitive base salary was necessary to attract and retain a management team with the requested skills to lead our company. Despite this general philosophy, because our Compensation Committee decided in March 2010 to award discretionary, one-time cash bonuses to many of our executives as part of their 2009 compensation, no adjustment was made to the base salary of our named executives during 2010.

*Bonuses.* Cash bonuses and other non-equity incentive compensation have not historically been a regular or important element of our executive compensation strategy; instead, our Compensation Committee has focused on stock-based awards designed to reward long-term performance. Our Compensation Committee followed this strategy for 2010 and accordingly did not implement a cash bonus or other non-equity incentive compensation plan for 2010. While the Compensation Committee generally remains committed to this strategy, for 2011 and beyond, the Compensation Committee has established a process pursuant to which we expect to award certain executives and managers, upon satisfaction of applicable performance conditions and subject to future approval and grant by the Compensation Committee or the Board of Directors, option awards and cash awards on an annual basis. The cash awards, if earned, are expected to vest in three equal installments over two years.

On November 19, 2010, we paid Tom Underwood a bonus of \$462,666 pursuant to a retention and severance agreement with Mr. Underwood dated November 18, 2009, as amended. An identical bonus was paid to Mr. Underwood under this agreement in November 2009 and a third bonus in the same amount will be paid to Mr. Underwood in July 2011, subject to his continued employment. This agreement represents a restructuring of a change of control severance obligation under a 2007 agreement between Mr. Underwood and Matria Healthcare, Inc., a predecessor of Alere Health, LLC. The 2007 agreement predated our acquisition of Matria Healthcare and we viewed it as providing a potential disincentive to Mr. Underwood's continued employment.

*Stock Option and Stock-based Awards.* For 2010, our Compensation Committee believed that the use of stock options and other stock-based awards would continue to offer the best approach to achieving our long-term compensation goals. Consistent with this belief, our stockholder-approved stock option and incentive plans, or our Option Plans, were established to provide certain of our employees, including our executive officers, with incentives to help align those employees' interests with the interests of stockholders and with our long-term success. While our Option Plans allow our Compensation Committee to grant a number of different types of stock-based awards, other than one restricted stock grant made to Mr. Zwanziger in 2001, we have relied exclusively on stock options to provide equity

incentive compensation. Stock options granted to our executive officers have historically had an exercise price equal to the fair market value of our common stock on the grant date, except that the options granted in February 2010 to our key executives, discussed in more detail below, as well as certain options granted to the key executives in July 2008, have a premium



**Table of Contents**

exercise price of \$61.49. Our stock options have typically vested 25% per annum based upon continued employment over a four-year period, and generally have had terms expiring ten years after the date of grant. Stock option grants to our executive officers have been made in connection with the commencement of employment, in conjunction with an annual review of total compensation and, occasionally, following a significant change in job responsibilities or to meet other special retention or performance objectives. Proposals to grant stock options to our executive officers in 2010 were made by our CEO to the Compensation Committee. With respect to proposals for grants made to our executive officers in 2010, the Committee reviewed consultant reports, as discussed above, individual performance, the executive's existing compensation and other retention considerations. The Compensation Committee considered the estimated Black-Scholes valuation of each proposed stock option grant in determining the number of options subject to each grant in 2010. Generally, 2010 stock option grants for each named executive officer were based on the factors discussed above and were intended to be valued near the average of the range of the value of long-term incentive awards for executives in similar positions with similar responsibilities at comparable companies, although other elements of compensation, including salary, were also considered.

Generally, stock option grants to executive officers have been made in conjunction with meetings of the Board of Directors. In 2010, grants were made in accordance with the Board's previously adopted stock option granting policy, which includes the following elements:

Options to purchase shares of our common stock shall be granted effective as of the last calendar day of the following months: February, April, June, August, October and December (each such date a "Grant Date");

For each employee (or prospective employee) that is not (or, upon hire, will not be) subject to Section 16 of the Exchange Act, the CEO shall have the authority to grant, in his sole discretion, an option or options to purchase up to an aggregate of 5,000 shares of common stock (on an annual basis); provided, however, that total number of shares of common stock underlying such option grants shall not exceed 150,000 per calendar year.

The Compensation Committee must approve all other stock option grants. Grants by the Compensation Committee must be approved only at a meeting of the Compensation Committee with and in consultation with the other independent directors and not by written consent.

Grants of options to existing employees, shall be effective as of, and the grant date thereof shall for all purposes be deemed to be, the Grant Date following the date of approval (except that any grants subject to stockholder approval shall be effective as of the date of stockholder approval).

Options approved for new hires, including those hired through acquisitions, shall be effective as of, and the grant date thereof shall for all purposes be deemed to be, the Grant Date following the later of (i) the date of such approval or (ii) the date on which the new hire's employment commences.

We have not adopted stock ownership guidelines for our executive officers.

For 2010, our Compensation Committee considered the fact that the value of the CEO's total long-term incentive awards trailed the market at the 25th percentile and the value of the long-term incentive awards to our other key executives approximated the market at the 50th percentile. In February 2010, the Compensation Committee approved grants of stock options, or the February Grants, to purchase 250,000, 90,000 and 75,000 shares of common stock to Mr. Zwanziger, Dr. Scott and Dr. McAleer, respectively. While the closing price of our common stock on the date of grant was \$39.02, these options were granted with a premium exercise price of \$61.49, which was the offering price of a secondary offering of our common stock that we conducted in November 2007. Due to the premium exercise price and the fact that the price of our common stock would need to increase almost 65% in order for these option grants to be in the money, the Compensation Committee considered these grants to be stronger long-term incentives than

standard option grants and in the best interest of our stockholders.

In determining Mr. Zwanziger's February Grant, the Compensation Committee considered the analysis set forth in the Radford Report of the number of stock options required to deliver market competitive annual

**Table of Contents**

long-term incentives within the range of 2009 grants by our peer group. Taking that into consideration, coupled with the various factors described above, including Mr. Zwanziger's cash compensation, prior equity grants, significant history and role in leading the Company, his expertise and experience and his performance and contribution to our overall goals and objectives, as well as the fact that the exercise price of the grant would be at a significant premium to the then current trading price of our common stock, the Compensation Committee discussed and adopted the February Grant in an effort to meet our total compensation objectives. While background, expertise and experience, and individual performance and contribution to our overall goals and objectives are all subjective measures, and are not based on any stated quantifiable objectives, they played an important role in the Compensation Committee's overall decision-making process. These subjective factors were considered in the aggregate and, accordingly, no specific factor played a greater role in determining the grant.

In determining Dr. Scott's February Grant, the Compensation Committee considered the analysis set forth in the Radford Report of the number of stock options required to deliver market competitive annual long-term incentives within the range of 2009 grants by our peer group. Taking that into consideration, coupled with the various factors described above, including Dr. Scott's cash compensation, prior equity grants, significant history and role with the Company, his expertise and experience and his performance and contribution to our overall goals and objectives, as well as the fact that the exercise price of the grant would be at a significant premium to the then current trading price of our common stock, the Compensation Committee discussed and adopted the February Grant in an effort to meet our total compensation objectives. While background, expertise and experience, and individual performance and contribution to our overall goals and objectives are all subjective measures, and are not based on any stated quantifiable objectives, they played an important role in the Compensation Committee's overall decision-making process. These subjective factors were considered in the aggregate and, accordingly, no specific factor played a greater role in determining the grant.

In determining Dr. McAleer's February Grant, the Compensation Committee considered the analysis set forth in the Radford Report of the number of stock options required to deliver market competitive annual long-term incentives within the range of 2009 grants by our peer group. Taking that into consideration, coupled with the various factors described above, including Dr. McAleer's cash compensation, prior equity grants, significant history and role with the Company, his expertise and experience and his performance and contribution to our overall goals and objectives, as well as the fact that the exercise price of the grant would be at a significant premium to the then current trading price of our common stock, the Compensation Committee discussed and adopted the February Grant in an effort to meet our total compensation objectives. While background, expertise and experience, and individual performance and contribution to our overall goals and objectives are all subjective measures, and are not based on any stated quantifiable objectives, they played an important role in the Compensation Committee's overall decision-making process. These subjective factors were considered in the aggregate and, accordingly, no specific factor played a greater role in determining the grant.

As of June 30, 2010, Mr. Underwood was granted options to purchase 25,000 shares of common stock at an exercise price of \$26.66 per share. The Compensation Committee considered an analysis of total compensation for comparable executives and determined that Mr. Underwood's long-term incentive compensation remained below that of executives holding similar positions at comparable companies. In approving this grant, the Compensation Committee also considered the estimated Black-Scholes valuation of the proposed stock option grant, as well as Mr. Underwood's background, expertise and experience, and individual performance and significant contributions to our overall goals and objectives. While many of these factors are subjective measures, and are not based on any stated quantified objectives, they played an important role in the Compensation Committee's decision-making process. These subjective factors were considered in the aggregate and, accordingly, no specific factor played a greater role in determining the grants.

*Other Compensation.* Other than as discussed below, our named executive officers did not have employment or severance agreements in 2010. The named executive officers were not eligible to participate in, and did not have any accrued benefits under, any company-sponsored defined benefit pension plan in 2010. They were eligible to, and in some case did, participate in defined contributions plans, such as a 401(k) plan,

**Table of Contents**

on the same terms as other employees. The terms of these defined contribution plans varied depending on the jurisdiction of employment of the executive. In addition, consistent with our compensation philosophy, the Compensation Committee maintained in 2010 generally the same benefits and perquisites for our executive officers as in prior years. The Compensation Committee believes that these benefits and perquisites provided to our executive officers in 2010 were lower than median competitive levels for comparable companies. Finally, all of our executives were eligible to participate in our other employee benefit plans, including, medical, dental, life and disability insurance.

***Tax Implications***

Section 162(m) of the Internal Revenue Code of 1986, as amended, limits the deductibility on our tax return of compensation over \$1,000,000 to certain of the named executive officers unless, in general, the compensation is paid pursuant to a plan which is performance-related, non-discretionary and has been approved by our stockholders. We have periodically reviewed the potential consequences of Section 162(m) and on occasion have sought to structure the performance-based portion of our executive compensation to comply with the exemptions available under Section 162(m). We believe that options granted in 2010 under our Option Plans generally qualify as performance-based compensation under Section 162(m). However, we reserve the right to use our judgment to authorize compensation payments that do not comply with these exemptions when we believe that such payments are appropriate and in the best interest of the stockholders, after taking into consideration changing business conditions or the applicable officer's performance.

**Compensation Committee Report**

We, the Compensation Committee, have reviewed and discussed the Compensation and Discussion and Analysis beginning on page 67 of this annual report with management.

Based on this review and discussion, we recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this annual report.

**THE COMPENSATION COMMITTEE**

Carol R. Goldberg, Chairperson  
Eli Y. Adashi, Member  
Robert P. Khederian, Member

**Table of Contents****Compensation Committee Interlocks and Insider Participation**

During 2010, the members of the Compensation Committee were Ms. Goldberg (Chairperson), Dr. Adashi and Mr. Khederian. No member of the Compensation Committee has ever been an officer or employee of ours or any of our subsidiaries. None of our executive officers serves as a director or member of the compensation committee of another entity in a case where an executive officer of such other entity serves as a director of ours or a member of our Compensation Committee.

**Compensation of Executive Officers**

Set forth below is information regarding the compensation of our Chief Executive Officer, our Chief Financial Officer, and our three other most highly compensated executive officers for the fiscal year 2010. Such officers are collectively referred to as the named executive officers.

*Summary Compensation Table.* The following table sets forth information regarding the named executive officers compensation for the fiscal years 2010, 2009 and 2008. For our named executive officers, the amount of salary and bonus represented between 15% and 97% of the named executive officers total compensation for 2010.

**Summary Compensation Table**

<b>Name and Principal Position</b>	<b>Year</b>	<b>Salary (\$)</b>	<b>Bonus (\$)</b>	<b>Option Awards (\$)(1)</b>	<b>All Other Compensation (\$)(2)</b>	<b>Total (\$)</b>
Ron Zwanziger <i>Chairman, Chief Executive Officer and President</i>	2010	\$ 900,000		\$ 3,745,000	\$ 2,838	\$ 4,647,838
	2009	\$ 900,000	\$ 250,000		\$ 713	\$ 1,150,713
	2008	\$ 824,423		\$ 1,366,500	\$ 778	\$ 2,191,701
David Teitel <i>Chief Financial Officer</i>	2010	\$ 300,000			\$ 10,109	\$ 310,109
	2009	\$ 300,000	\$ 100,000	\$ 490,566	\$ 8,063	\$ 898,629
	2008	\$ 299,808			\$ 7,678	\$ 307,486
David Scott, Ph.D.(3) <i>Chief Scientific Officer</i>	2010	\$ 543,767		\$ 1,348,200		\$ 1,891,967
	2009	\$ 550,306	\$ 125,000			\$ 675,306
	2008	\$ 622,791		\$ 683,250		\$ 1,306,041
Jerry McAleer, Ph.D.(3) <i>Senior Vice President, Research &amp; Development</i>	2010	\$ 504,926		\$ 1,123,500		\$ 1,628,426
	2009	\$ 510,998	\$ 125,000			\$ 635,998
	2008	\$ 553,581		\$ 592,150		\$ 1,145,731
Tom Underwood(4) <i>Chief Executive Officer, Alere Health, LLC</i>	2010	\$ 439,600	\$ 462,666	\$ 261,868	\$ 10,092	\$ 1,174,226
	2009	\$ 439,600	\$ 587,666	\$ 752,000	\$ 7,569	\$ 1,786,835

(1) These amounts represent the aggregate grant date fair value of stock option awards made during 2010, 2009 and 2008, respectively, calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation – Stock Compensation (FASB ASC Topic 718), excluding estimated forfeitures. See Note 14 of the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of the relevant assumptions used in calculating these amounts.

- (2) The amounts in this column include for 2010: (a) matching contributions we made to our defined contribution plans in the amounts of \$9,081 on behalf of Mr. Teitel and \$9,379 on behalf of Mr. Underwood; and (b) life insurance premiums paid in the amounts of \$2,838 on behalf of Mr. Zwanziger, \$1,028 on behalf of Mr. Teitel and \$713 on behalf of Mr. Underwood.
- (3) Salary and other cash compensation for these named executive officers were paid in British pounds. British pounds were converted to U.S. dollars using the average exchange rate for the year reported.
- (4) Mr. Underwood was not a named executive officer in 2008.

**Table of Contents**

*Grants of Plan-Based Awards.* The following table sets forth certain information with respect to options granted to the named executive officers in 2010.

**Grants of Plan-Based Awards**

<b>Name</b>	<b>Grant Date(1)</b>	<b>Compensation Committee Approval Date(1)</b>	<b>All Other Option Awards: Number of Securities Underlying Options (#)(2)(3)</b>	<b>Exercise or Base Price of Option Awards (\$ / Sh)(4)</b>	<b>Grant Date Fair Value of Stock and Option Awards(5)</b>
Ron Zwanziger	2-28-2010	2-4-2010	250,000	\$ 61.49	\$ 3,745,000
David Teitel					
David Scott, Ph.D.	2-28-2010	2-4-2010	90,000	\$ 61.49	\$ 1,348,200
Jerry McAleer, Ph.D.	2-28-2010	2-4-2010	75,000	\$ 61.49	\$ 1,123,500
Tom Underwood	6-30-2010	5-20-2010	25,000	\$ 26.66	\$ 261,868

- (1) The grant dates of the options for the named executive officers are in accordance with our stock option granting policy, pursuant to which grants of options approved by the Compensation Committee for existing employees shall be effective as of the next Grant Date following the date of approval (except that any grants subject to stockholder approval shall be effective as of the date of stockholder approval). Under this policy, Grant Date means the last day of the following months: February, April, June, August, October and December.
- (2) All stock option awards were made under our 2001 Stock Option and Incentive Plan.
- (3) The terms of these options provide for vesting in four equal annual installments, commencing on the first anniversary of the date of grant and conditioned upon the recipient's continued employment with the Company on the applicable vesting date. The options will expire on the tenth anniversary of the grant date or, if earlier, 3 months after the recipient's employment terminates.
- (4) The exercise price of the stock option awards to the named executive officers is equal to, or at a premium to, the closing price of the common stock on the applicable Grant Date.
- (5) These amounts represent the aggregate grant date fair value of stock option awards made during 2010, calculated in accordance with FASB ASC Topic 718, excluding estimated forfeitures. See Note 14 of the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2010, for a discussion of the relevant assumptions used in calculating these amounts.



**Table of Contents**

*Outstanding Equity Awards at Fiscal Year-End.* The following table sets forth certain information with respect to unexercised options held by the named executive officers at the end of 2010.

**Outstanding Equity Awards at Fiscal Year-End**

Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Option Awards		
		Number of Securities Underlying Unexercised Options #(1) Unexercisable	Option Exercise Price (\$)	Option Expiration Date(2)
Ron Zwanziger	30,000(3)		\$ 14.92	2-12-2011
	65,000(4)		\$ 17.15	12-20-2011
	5,065		\$ 15.55	8-23-2012
	7,576		\$ 21.78	12-31-2013
	225,000	75,000	\$ 39.72	5-17-2017
	75,000	75,000	\$ 61.49	7-23-2018
		250,000	\$ 61.49	2-28-2020
David Teitel	10,000		\$ 21.38	12-11-2013
	10,000		\$ 24.25	12-17-2014
	5,000		\$ 34.40	10-4-2016
	20,000		\$ 38.10	12-15-2016
	15,000	5,000	\$ 48.14	8-31-2017
	5,896	17,685	\$ 35.58	6-30-2019
	2,500	7,500	\$ 38.01	10-30-2019
David Scott, Ph.D.	24,000(3)		\$ 14.92	2-12-2011
	199,691(5)		\$ 15.47	11-30-2011
	2,284		\$ 15.60	9-3-2012
	5,252		\$ 21.78	12-31-2013
	112,500	37,500	\$ 39.72	5-17-2017
	37,500	37,500	\$ 61.49	7-23-2018
		90,000	\$ 61.49	2-28-2020
Jerry McAleer, Ph.D.	16,000(3)		\$ 14.92	2-12-2011
	189,706(5)		\$ 15.47	11-30-2011
	129,413(6)		\$ 16.76	12-2-2011
	1,805		\$ 15.60	9-3-2012
	4,656		\$ 21.78	12-31-2013
	93,750	31,250	\$ 39.72	5-17-2017
	32,500	32,500	\$ 61.49	7-23-2018
		75,000	\$ 61.49	2-28-2020
Tom Underwood	12,500(7)	12,500(7)	\$ 33.17	6-30-2018
	500	500	\$ 18.91	12-31-2018
	3,000	9,000	\$ 35.58	6-30-2019
	10,000	30,000	\$ 35.60	8-31-2019

25,000

\$ 26.66

6-30-2020

- (1) Unless otherwise noted, options become exercisable in four equal annual installments beginning on the first anniversary of the date of grant.
- (2) Unless otherwise noted, the expiration date of each option occurs ten years after the date of grant of such option.
- (3) Options became fully exercisable on November 21, 2001.
- (4) Options became fully exercisable on December 20, 2001.

**Table of Contents**

- (5) Options became exercisable in equal monthly installments beginning on November 30, 2001 and ending on November 30, 2005.
- (6) Options became exercisable in equal monthly installments beginning on December 3, 2001 and ending on December 3, 2004.
- (7) Fifty percent of the stock option granted to Mr. Underwood on June 30, 2008 became exercisable on the second anniversary of the date of grant. An additional twenty-five percent of the stock option will become exercisable on each of the third and fourth anniversaries of the date of grant, in each case subject to Mr. Underwood's continued employment with the Company.

*Option Exercises and Stock Vested.* None of the named executive officers exercised any stock options during 2010, and no named executive officer held any stock awards that vested during 2010.

*Non-qualified Defined Contribution and Other Non-qualified Deferred Compensation Plans.* During 2010, our named executive officers did not participate in any non-qualified defined contribution or other deferred compensation plans.

*Pension Benefits.* During 2010, our named executive officers did not participate in any plan that provides for specified retirement benefits, or payments and benefits that will be provided primarily following retirement, other than defined contribution plans, such as our 401(k) savings plan.

*Employment Agreement and Potential Payments upon Termination or Change in Control.* On November 18, 2009, we entered into a retention and severance agreement with Tom Underwood in order to restructure change of control severance obligations existing under a 2007 agreement between Mr. Underwood and Matria Healthcare, Inc., a predecessor to Alere Health, LLC. On December 30, 2010, we entered into a letter agreement with Mr. Underwood amending a portion of the 2009 agreement. In addition to bonuses paid in 2009 and 2010, Mr. Underwood's retention and severance agreement provides that we will pay an additional stay bonus in the amount of \$462,666 to Mr. Underwood on July 1, 2011, as well as severance payable in a lump sum in the event of an involuntary termination without cause or a voluntary termination for good reason of Mr. Underwood's employment with the Company. As consideration for these severance benefits, Mr. Underwood agreed that (i) for one year after his employment terminates, if less than all of the stay bonuses has been paid, or (ii) for two years after his employment terminates, if the full amount of all of the stay bonuses has been paid, he will not compete with us within the United States. As part of the 2009 agreement, Mr. Underwood also entered into our standard non-solicitation agreement.

The table below sets forth the estimated payments and benefits that would be provided to the extent that payments under Mr. Underwood's agreement are triggered.

<b>Name and Position</b>	<b>Date of Termination</b>	<b>Severance Payments</b>	<b>Benefits</b>
Tom Underwood	On or before June 30, 2011	\$ 462,666(1)	\$ 25,892(3)
<i>Chief Executive Officer, Alere Health, LLC</i>	After June 30, 2011	\$ 439,600(2)	\$ 1,554(4)

- (1) Represents the stay bonus payable on July 1, 2011, which would be accelerated and would exceed the value of 12 months of Mr. Underwood's salary at December 31, 2010.

- (2) Represents 12 months of Mr. Underwood's salary at December 31, 2010.
- (3) Represents the cost at December 31, 2010 of continuation of all group benefits for which executives are eligible at the time of termination for two years, including cell phone and auto insurance, based on the assumptions used for financial reporting purposes under generally accepted accounting principles.
- (4) Represents the cost at December 31, 2010 of life insurance and disability insurance coverage for one year, based on the assumptions used for financial reporting purposes under generally accepted accounting principles.

Our named executive officers are employees-at-will and do not otherwise have employment or severance contracts with us. Other than provisions in our Option Plans that provide for all stock options to automatically become fully exercisable and any stock awards to become vested and non-forfeitable in the event of a change

**Table of Contents**

of control as defined in the plans, there are no other contracts, agreements, plans or arrangements that provide for payments to our named executive officers at, following, or in connection with any termination of employment, change in control of the Company or a change in a named executive officer's responsibilities. All of the outstanding stock options held by our named executive officers reported above under Outstanding Equity Awards at Fiscal Year-End were issued under our Option Plans and are subject to accelerated exercisability upon a change of control. The table below sets forth the value attributable to such an acceleration of exercisability.

<b>Name</b>	<b>Value Attributable to Acceleration of Exercisability of Stock Options upon a Change of Control(1)</b>
Ron Zwanziger	\$
David Teitel	\$ 18,039
David Scott, Ph.D.	\$
Jerry McAleer, Ph.D.	\$
Tom Underwood	\$ 339,400

- (1) Assumes the occurrence of a change of control of the Company on December 31, 2010. The value attributable to the acceleration of stock options equals the difference between the applicable option exercise prices and the closing sale price of our common stock as reported by the New York Stock Exchange on December 31, 2010, which was \$36.60, multiplied by the number of shares underlying the options.

**Risk Related to Compensation Policies**

Our compensation policies and practices for our employees, including our executive compensation program described in our Compensation Discussion and Analysis, aim to provide a risk-balanced compensation package which is competitive in our market sectors and relevant to the individual executive. Historically, we have provided cash compensation in the form of base salary to meet competitive cash compensation norms and non-cash compensation, primarily in the form of stock-based awards, to reward superior performance against long-term strategic goals. This focus on base salary supplemented by long-term, non-cash compensation discourages short-term risk taking and provides motivation for employees to pursue the same strategic goals, including increasing shareholder value. For 2011 and beyond, the Compensation Committee has established a process pursuant to which we expect to award to certain executives and managers, upon satisfaction of applicable performance conditions and subject to future approval and grant by the Compensation Committee, option and cash awards on an annual basis. Applicable performance criteria include, for example, earnings per share targets, free cash flow targets and organic growth targets. Because both the option and cash awards contemplated under this process would vest over several years, we believe that the process continues to discourage short-term risk taking and to align the interest of our executives and managers with those of our shareholders. We do not believe that risks arising from these practices, or our compensation policies and practices considered as a whole, are reasonably likely to have a material adverse effect on us.

**Table of Contents****Compensation of Directors**

The following table sets forth information regarding the compensation of our directors for 2010.

**Director Compensation**

Name(1)	Fees Earned or Paid in Cash \$(2)	Option Awards \$(3)	Total (\$)
Eli Adashi, M.D.	\$ 75,500	\$ 380,060	\$ 455,560
Carol R. Goldberg	\$ 14,333	\$ 380,060	\$ 394,393
Robert P. Khederian	\$ 15,000	\$ 380,060	\$ 395,060
John F. Levy	\$ 4,833	\$ 557,429	\$ 562,262
John A. Quelch, Ph.D.	\$ 7,500	\$ 468,750	\$ 476,250
James Roosevelt, Jr.	\$ 57,083	\$ 557,429	\$ 614,512
Peter Townsend	\$ 13,667	\$ 380,060	\$ 393,727

- (1) Ron Zwanziger, Jerry McAleer and David Scott are not included in this table as they are employees of the Company and receive no compensation for their services as directors. The compensation received by Mr. Zwanziger, Dr. McAleer and Dr. Scott as employees of the Company are shown in the Summary Compensation Table above.
- (2) Dr. Adashi received cash payments of \$18,750 each in April 2010, July 2010 and September 2010 and earned fees of \$19,250 as of December 31, 2010, which amount was paid in January 2011. Ms. Goldberg earned fees of \$14,333 as of December 31, 2010, which amount was paid in January 2011. Mr. Khederian earned fees of \$15,000 as of December 31, 2010, which amount was paid in January 2011. Mr. Levy earned fees of \$4,833 as of December 31, 2010, which amount was paid in January 2011. Mr. Quelch earned fees of \$7,500 as of December 31, 2010, which amount was paid in January 2011. Mr. Roosevelt received cash payments of \$18,750 each in April 2010 and July 2010 and \$12,500 in September 2010 and earned fees of \$7,083 as of December 31, 2010, which amount was paid in January 2011. Mr. Townsend earned fees of \$13,667 as of December 31, 2010, which amount was paid in January 2011. The cash compensation paid to directors is described in more detail below.
- (3) These amounts represent the aggregate grant date fair value of stock option awards made during 2010 calculated in accordance with FASB ASC Topic 718, excluding estimated forfeitures. All awards represent stock-based compensation for services rendered for the period October 31, 2010 through June 30, 2013. Each non-employee director received a stock option award during 2010 having a grant date fair value of \$380,060. In addition, based on their election to receive stock options in lieu of cash compensation, John F. Levy, John A. Quelch and James Roosevelt, Jr. each received a second option award during 2010 having a grant date fair value of \$177,369, \$88,690 and \$177,369, respectively. See Note 14 of the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of the relevant assumptions used in calculating these amounts. As of December 31, 2010, each director had the following number of options outstanding: Eli Adashi: 41,515; Carol R. Goldberg: 86,518; Robert P. Khederian: 59,999; John F. Levy: 126,006; John A. Quelch: 115,540; James Roosevelt, Jr.: 57,156; and Peter Townsend: 49,868.

Upon their election to the Board during 2009, Dr. Adashi and Mr. Roosevelt were each awarded compensation for the first year of their service as a director of \$75,000, payable quarterly in arrears, and an option to purchase 8,000 shares of our common stock. This package of cash compensation and stock options was intended to offer these new non-employee directors a level of total annual compensation similar to the annual compensation reflected in stock option grants made to our incumbent non-employee directors in October 2007, which vested over a three-year period. A portion of this cash compensation was paid in 2010.

During 2010, the Compensation Committee engaged Radford to assist the committee in assessing non-employee director compensation. The Compensation Committee considered, among other things, the merits of

**Table of Contents**

including a cash component in director compensation, the influence and preferences of RiskMetrics Group, and the demands placed upon the non-employee directors, given the acquisitive nature of the Company.

After reviewing the Radford data in May 2010, the Compensation Committee determined that the non-employee directors of the Company would receive a cash compensation of \$70,000 annually, plus additional cash compensation for committee service as described in the table below, payable quarterly in arrears beginning with the third calendar quarter of 2010 and subject to their continued service on the Board and any applicable committees. Each director was afforded a one-time right to receive, in lieu of all or part of her or his cash compensation for the period October 31, 2010 through June 30, 2013, stock options of equal value calculated as described below.

Chair (Total Additional Cash Compensation)	
Audit	\$ 24,000
Compensation	\$ 16,000
Nominating and Corporate Governance	\$ 10,000
Members other than the Chair (Total Additional Cash Compensation)	
Audit	\$ 12,000
Compensation	\$ 8,000
Nominating and Corporate Governance	\$ 5,000

In addition to the cash compensation described above, on October 31, 2010, each of the non-employee directors received stock options to purchase a number of shares of our common stock calculated using a Black-Scholes model based on (i) an assumed aggregate value on the grant date equal to the sum of (a) \$400,000, or \$150,000 annually for the period October 31, 2010 through June 30, 2013, and (b) the total amount of any cash compensation foregone for that period at the election of the director, as described above, (ii) \$29.55 per share, the closing price of our common stock on the New York Stock Exchange on the most recent trading day before the grant date and (iii) management estimates of other Black-Scholes variables, including estimated life and volatility. These options vest in three equal annual installments, beginning June 30, 2011.

Employee directors do not receive compensation for their services as directors.

## **ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

### **Security Ownership of Certain Beneficial Owners and Management**

The following table furnishes information as to shares of our common stock beneficially owned by:

- each person or entity known by us to beneficially own more than five percent of our common stock;
- each of our directors;
- each of our named executive officers (as defined in Compensation Discussion and Analysis on page 67); and
- all of our directors and executive officers as a group.

Unless otherwise stated, beneficial ownership is calculated as of April 20, 2011. For the purpose of this table, a person, group or entity is deemed to have beneficial ownership of any shares that such person, group or entity has the right to acquire within 60 days after such date through the exercise of options or warrants.





**Table of Contents**

<b>Name and Address of Beneficial Owner(1)</b>	<b>Common Stock</b>	
	<b>Amount and Nature of Beneficial Ownership(2)</b>	<b>Percent of Class(3)</b>
Capital Research Global Investors(4)	8,871,248	10.38%
Manning & Napier Advisors, Inc.(5)	7,965,058	9.32%
Thornburg Investment Management Inc.(6)	4,602,565	5.38%
ValueAct Capital(7)	4,563,782	5.34%
Ron Zwanziger(8)	3,973,343	4.62%
David Scott, Ph.D.(9)	857,442	1.00%
Jerry McAleer, Ph.D.(10)	758,944	*
John F. Levy(11)	207,543	*
Carol Goldberg(12)	127,648	*
John A. Quelch, D.B.A.(13)	79,204	*
Dave Teitel(14)	71,334	*
Robert P. Khederian(15)	46,484	*
Tom Underwood(16)	26,000	*
Peter Townsend(17)	16,353	*
Eli Adashi, M.D.(18)	6,184	*
James Roosevelt, Jr.(19)	5,334	*
All current executive officers and directors (20 persons)(20)	6,759,241	7.70%

\* Represents less than 1%

- (1) The address of each director or executive officer (and any related persons or entities) is c/o the Company at its principal office.
- (2) Unless otherwise indicated, the stockholders identified in this table have sole voting and investment power with respect to the shares beneficially owned by them.
- (3) The number of shares outstanding used in calculating the percentage for each person, group or entity listed includes the number of shares underlying options and warrants held by such person group, or entity that were exercisable within 60 days from April 20, 2011, but excludes shares of stock underlying options and warrants held by any other person, group or entity.
- (4) This information is based on information contained in a Schedule 13G/A filed with the SEC on February 11, 2011 by Capital Research Global Investors, a division of Capital Research and Management Company. The address provided therein for Capital Research Global Investors is 333 South Hope Street, Los Angeles, CA 90071.
- (5) This information is based on information contained in a Schedule 13G filed with the SEC on February 11, 2011 by Manning & Napier Advisors, Inc. Manning & Napier Advisors, Inc. reported that it has (i) sole voting power with respect to 5,480,598 shares and (ii) sole investment power with respect to 7,965,058 shares. The address provided therein for Manning & Napier Advisors, Inc. is 290 Woodcliff Drive, Fairport, NY 14450.

- (6) This information is based on information contained in a Schedule 13G filed with the SEC on January 24, 2011 by Thornburg Investment Management Inc. The address provided therein for Thornburg Investment Management Inc. is 2300 North Ridgetop Road, Santa Fe, New Mexico 87506.
- (7) This information is based on information contained in a Schedule 13D filed with the SEC on April 29, 2010 by ValueAct Capital Master Fund, L.P., VA Partners I, LLC, ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, ValueAct Holdings, L.P., and ValueAct Holdings GP, LLC, (collectively ValueAct Capital ). The address provided therein for ValueAct Capital is 435 Pacific Avenue, Fourth Floor, San Francisco, CA 94133.

**Table of Contents**

- (8) Consists of 3,421,408 shares of common stock, 36,794 shares of common stock issuable upon the exercise of warrants, and 515,141 shares of common stock underlying options exercisable within 60 days from April 20, 2011. Of the shares attributed to Mr. Zwanziger, 488,991 shares of common stock are owned by Ron Zwanziger as Trustee of the Zwanziger 2009 Annuity Trust, 224,276 shares of common stock are owned by Orit Goldstein as Trustee of the Zwanziger Family 2004 Irrevocable Trust and 1,652,476 shares of common stock and 36,794 shares of common stock issuable upon the exercise of warrants are owned by Zwanziger Family Ventures, LLC, a limited liability company managed by Mr. Zwanziger and his spouse. Of the other shares attributed to him, Mr. Zwanziger disclaims beneficial ownership of (i) 2,600 shares owned by his wife, Janet M. Zwanziger, (ii) 9,450 shares owned by the Zwanziger Goldstein Foundation, a charitable foundation for which Mr. Zwanziger and his spouse, along with three others, serve as directors, (iii) 273,500 shares owned by Ron Zwanziger as Trustee of the Zwanziger 2004 Revocable Trust, and (iv) 191,830 shares owned by Orit Goldstein as the Trustee of the Zwanziger Family Trust. Does not include 36,380 shares of common stock potentially acquirable by the Zwanziger Family Trust upon conversion of 3% senior subordinated notes at a conversion price of \$43.98 per share.
- (9) Consists of 440,215 shares of common stock and 417,227 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (10) Consists of 257,114 shares of common stock and 501,830 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (11) Consists of 126,693 shares of common stock, 4,000 shares of common stock issuable upon the exercise of warrants, and 76,850 shares of common stock underlying options exercisable within 60 days from April 20, 2011. Includes 1,007 shares of common stock owned by a charitable remainder unitrust of which Mr. Levy disclaims beneficial ownership.
- (12) Consists of 74,645 shares of common stock and 53,003 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (13) Consists of 5,000 shares of common stock and 74,204 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (14) Consists of 2,938 shares of common stock and 68,396 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (15) Consists of 20,000 shares of common stock and 26,484 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (16) Consists of 26,000 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (17) Consists of 16,353 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (18) Consists of 850 shares of common stock and 5,334 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (19) Consists of 5,334 shares of common stock underlying options exercisable within 60 days from April 20, 2011.
- (20)

Consists of 4,435,281 shares of common stock, 40,794 shares of common stock issuable upon the exercise of warrants and 2,283,166 shares of common stock underlying options exercisable within 60 days from April 20, 2011.

In addition, the Zwanziger Family Trust, a trust for the benefit of Mr. Zwanziger's children and the trustee of which is Mr. Zwanziger's sister, and Mr. Underwood own, respectively, 11,087 shares and 4,229 shares of our Series B preferred stock. The shares of Series B preferred stock owned by the Zwanziger Family Trust and Mr. Underwood represent, both individually and in the aggregate, less than 1% of the outstanding shares of the Series B preferred stock. Mr. Zwanziger disclaims beneficial ownership of the Series B preferred stock owned by the Zwanziger Family Trust. We are not aware that any of our directors or executive officers beneficially owns any other shares of Series B preferred stock.

**Table of Contents****Equity Compensation Plan Information**

The following table furnishes information with respect to compensation plans under which our equity securities are authorized for issuance as of December 31, 2010.

<b>Plan Category</b>	<b>Number of Securities</b>	<b>Weighted-Average</b>	<b>Number of Securities</b>
	<b>to be Issued Upon Exercise of Outstanding Options, Warrants and Rights(1)</b>		<b>Remaining Available for Future Issuance Under Equity Compensation Plans</b>
	<b>(a)</b>	<b>Exercise Price of Outstanding Options, Warrants and Rights</b>	<b>(Excluding Securities Reflected in Column (a)(2))</b>
		<b>(b)</b>	<b>(c)</b>
Equity compensation plans approved by security holders	8,349,165	\$ 35.81	1,685,882(3)
Equity compensation plans not approved by security holders	35,000(4)	\$ 35.60	
<b>Total</b>	<b>8,384,165</b>	<b>\$ 35.81</b>	<b>1,685,882(3)</b>

- (1) This table excludes an aggregate of 1,728,999 shares issuable upon exercise of outstanding options that we assumed in connection with various acquisition transactions. The weighted average exercise price of the excluded acquired options is \$34.67.
- (2) In addition to being available for future issuance upon exercise of options that may be granted after December 31, 2010, up to 905,505 shares under our 2010 Stock Option and Incentive Plan may instead be issued in the form of restricted stock, unrestricted stock, performance share awards or other equity-based awards.
- (3) Includes 780,377 shares issuable under our 2001 Employee Stock Purchase Plan.
- (4) Represents shares issuable upon exercise of outstanding options issued as inducement grants in connection with our acquisition of Concateno, plc. These options have terms which are substantially the same as options granted under our 2001 Stock Option and Incentive Plan.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE****Director Independence**

The Board of Directors has determined that the following directors are independent under the rules of the New York Stock Exchange: Dr. Adashi, Ms. Goldberg, Mr. Khederian, Mr. Levy, Dr. Quelch, Mr. Roosevelt and Mr. Townsend.

The Board has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each composed solely of directors who satisfy the applicable independence requirements of the New York Stock Exchange's listing standards.

#### **Policies and Procedures with Respect to Related Party Transactions**

Our Audit Committee Charter requires that the Audit Committee, which is composed solely of independent directors, conduct an appropriate review of, and be responsible for the oversight of, all related party transactions on an ongoing basis. We do not have written policies or procedures governing the Audit Committee's review of related party transactions but rely on the Audit Committee's exercise of business judgment in reviewing such transactions.

#### **Investments by the Zwanziger Family Trust**

In November 2008, the Zwanziger Family Trust, a trust established for the benefit of the children of Ron Zwanziger, our Chairman, Chief Executive Officer and President, and the trustee of which is Mr. Zwanziger's sister, purchased certain of our securities from third parties in market transactions. The purchase consisted of approximately \$1.0 million of each of the following securities: our common stock, our Series B preferred

## **Table of Contents**

stock, our 3% senior subordinated convertible notes, interests (\$1.0 million face amount) in our first lien credit agreement and interests (\$1.0 million face amount) in our second lien credit agreement. To the extent we make principal and interest payments under the convertible notes and the credit facilities in accordance with their terms, the Zwanziger Family Trust, as a holder of convertible notes and as a lender under the credit facilities, will receive its proportionate share. In connection with its purchases of interests under our first lien credit agreement and second lien credit agreement, the Trust agreed that, whenever the consent or vote of the lenders is required under the credit facilities, it will vote the outstanding principal amount of its holdings in the same proportion as the votes cast by the other lenders under these credit facilities.

### **ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES**

Our Audit Committee engaged PricewaterhouseCoopers LLP, or PwC, on June 18, 2010 to serve as our independent registered public accounting firm during the fiscal year ended December 31, 2010.

We expect representatives of PwC to be present at our 2011 annual meeting of stockholders, that they will have the opportunity to make a statement at such meeting if they so desire, and that they will be available to respond to appropriate questions from stockholders.

#### **Audit Fees**

Aggregate audit fees billed by PwC for 2010 were \$3,263,158. This includes \$630,000 billed for professional services rendered in connection with its audit of our internal control over financial reporting in connection with the 2010 audit. Audit fees also include fees billed in connection with PwC's review of our quarterly financial statements and audit services normally provided by the principal independent registered public accounting firm in connection with other statutory or regulatory filings. Aggregate audit fees billed by our prior independent registered public accounting firm, BDO USA, LLP, for 2009 were approximately \$3,384,737. In addition, prior to our change of principal auditors BDO USA billed us for audit fees for 2010 in the amount of \$488,800.

#### **Audit-related Fees**

Aggregate audit-related fees billed in 2010 by PwC and in 2009 by BDO USA were \$309,909 and \$484,650, respectively. Audit-related fees consist primarily of fees billed for professional services rendered by the firm for accounting consultations and services related to business acquisitions and financings.

#### **Tax Fees**

Aggregate tax fees billed in 2010 for 2010 tax-related services performed by PwC and BDO USA were \$981,821 and \$26,025, respectively. In addition, BDO USA billed us in 2010 for 2009 tax-related services in the amount of \$600,000. Tax fees include fees billed for professional services rendered by the firm for tax compliance, tax advice and tax planning.

#### **All Other Fees**

No other fees were billed by PwC or BDO USA, LLP for 2010 or 2009.

#### **Pre-approval Policies and Procedures**

The Audit Committee pre-approves all audit and non-audit services provided by the independent registered public accounting firm other than permitted non-audit services estimated in good faith by the independent registered public



accounting firm and management to entail fees payable of \$25,000 or less on a project-by-project basis and which would also qualify for exemption from the pre-approval requirements of the Securities Exchange Act of 1934, as amended. No services were provided for 2010 or 2009 in reliance on this exemption. The authority to pre-approve non-audit services may be delegated to one or more members of the Audit Committee, who shall present any services so pre-approved to the full Audit Committee at its next meeting.

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

(a) 1. Financial Statements.

The financial statements listed below have been filed as part of this report on the pages indicated:

Reports of Independent Registered Public Accounting Firms	F-2
Consolidated Statements of Operations for the Years Ended December 31, 2010, 2009 and 2008	F-4
Consolidated Balance Sheets as of December 31, 2010 and 2009	F-5
Consolidated Statements of Equity and Comprehensive Income (Loss) for the Years Ended December 31, 2010, 2009 and 2008	F-6
Consolidated Statements of Cash Flows for the Years Ended December 31, 2010, 2009 and 2008	F-9
Notes to Consolidated Financial Statements	F-10

2. Financial Statement Schedules.

All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission have been omitted because they are inapplicable or the required information is shown in the consolidated financial statements, or the notes, thereto, included herein.

3. Exhibits.

Some of the agreements filed as exhibits to this Annual Report Form 10-K contain representations and warranties that were made solely for the benefit of the parties to the agreement. These representations and warranties:

may have been qualified by disclosures that were made to the other party or parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements;

may apply standards of materiality that differ from those of investors; and

were made only as of specified dates contained in the agreements and are subject to subsequent developments and changed circumstances.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date that these representations and warranties were made or at any other time. Investors should not rely on them as statements of fact.

**Exhibit No. Description**

- 2.1 Acquisition Agreement by and among Inverness Medical Innovations, Inc., ACON Laboratories, Inc., Azure Institute, Inc., Oakville Hong Kong Co., Ltd., ACON Biotech (Hangzhou) Co., Ltd., and Karsson Overseas Ltd. dated March 16, 2009 (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K, event date April 30, 2009, filed on April 30, 2009)\*\*\*
- 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, for the quarter ended June 30, 2010)

- 3.2 Amended and Restated By-laws of the Company (incorporated by reference to Exhibit 3.3 to the Company's Annual Report on Form 10-K, as amended, for the year ended December 31, 2001)
- 4.1 Indenture, dated May 14, 2007, between the Company and U.S. Bank Trust National Association (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, event date May 9, 2007, filed on May 15, 2007)
- 4.2 Indenture dated as of May 12, 2009 between Inverness Medical Innovations, Inc., as issuer, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, event date May 12, 2009, filed on May 12, 2009)

**Table of Contents****Exhibit No. Description**

- 4.3 First Supplemental Indenture dated as of May 12, 2009 to Indenture dated as of May 12, 2009 among Inverness Medical Innovations, Inc., as issuer, the guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K, event date May 12, 2009, filed on May 12, 2009)
- 4.4 Second Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantee of Matria of New York Inc.) dated as of June 9, 2009 among Matria of New York Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.4 to Matria of New York Inc.'s Registration Statement on Form 8-A filed on June 9, 2009)
- 4.5 Third Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of GeneCare Medical Genetics Center, Inc. and Alere CDM LLC) dated as of August 4, 2009 among GeneCare Medical Genetics Center, Inc., as guarantor, Alere CDM LLC, as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.5 to GeneCare Medical Genetics Center, Inc. and Alere CDM LLC's Registration Statement on Form 8-A filed on August 4, 2009)
- 4.6 Fourth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantee of ZyCare, Inc.) dated as of September 22, 2009 among ZyCare, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.6 to ZyCare, Inc.'s Registration Statement on Form 8-A filed on September 24, 2009)
- 4.7 Fifth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Free & Clear, Inc. and Tapestry Medical, Inc.) dated as of November 25, 2009 among Free & Clear, Inc., as guarantor, Tapestry Medical, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.7 to Free & Clear, Inc. and Tapestry Medical, Inc.'s Registration Statement on Form 8-A, filed on November 25, 2009)
- 4.8 Sixth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantee of RMD Networks, Inc.) dated as of February 1, 2010 among RMD Networks, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.8 to RMD Networks, Inc.'s Registration Statement on Form 8-A, filed on February 1, 2010)
- 4.9 Seventh Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc. and Scientific Testing Laboratories, Inc.) dated as of March 1, 2010 among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc. and Scientific Testing Laboratories, Inc., as guarantors, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.9 to Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc. and Scientific Testing Laboratories, Inc.'s, Registration Statement on Form 8-A, filed on March 2, 2010)
- 4.10 Eighth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Alere NewCo, Inc., Alere NewCo II, Inc., New Binax, Inc. and New Biosite, Inc.) dated as of March 19, 2010 among Alere NewCo, Inc., Alere NewCo II, Inc., New Binax, Inc. and New Biosite, Inc., as guarantors, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.10 to Alere NewCo, Inc., Alere NewCo II, Inc., New Binax, Inc. and New Biosite, Inc.'s Registration Statement on Form 8-A, filed on March 19, 2010)
- 4.11

Ninth Supplemental Indenture dated September 21, 2010 to Indenture date as of May 12, 2009 among Alere Inc., as issuer, the subsidiary guarantors named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, event date September 15, 2010, filed with the SEC on September 21, 2010)

**Table of Contents****Exhibit No. Description**

- 4.12 Indenture dated as of August 11, 2009 between Inverness Medical Innovations, Inc., as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, event date August 11, 2009, filed on August 11, 2009)
- 4.13 First Supplemental Indenture dated as of August 11, 2009 among Inverness Medical Innovations, Inc., as issuer, the guarantor subsidiaries named therein, as guarantors, and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K, event date August 11, 2009, filed on August 11, 2009)
- 4.14 Second Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantee of ZyCare, Inc.), dated as of September 22, 2009, among ZyCare, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.4 to the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2009)
- 4.15 Fourth Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantees of Free & Clear, Inc. and Tapestry Medical, Inc.), dated as of November 25, 2009, among Free & Clear, Inc., as guarantor, Tapestry Medical, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.14 to the Company's Registration Statement on Form S-4 filed on February 12, 2010 (File 333-164897))
- 4.16 Sixth Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantee of RMD Networks, Inc.), dated as of February 1, 2010, among RMD Networks, Inc., as guarantor, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and the Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.16 to the Company's Registration Statement on Form S-4 filed on February 12, 2010 (File 333-164897))
- 4.17 Eighth Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantees of Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc. and Scientific Testing Laboratories, Inc.), dated as of March 1, 2010, among Laboratory Specialists of America, Inc., Kroll Laboratory Specialists, Inc. and Scientific Testing Laboratories, Inc., as guarantors, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and the Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.18 to the Company's Registration Statement on Form S-4/A filed on March 26, 2010 (File 333-164897))
- 4.18 Tenth Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantees of New Binax, Inc., New Biosite Incorporated, Alere NewCo, Inc., and Alere NewCo II, Inc.), dated as of March 19, 2010, among New Binax, Inc., New Biosite Incorporated, Alere NewCo, Inc., and Alere NewCo II, Inc., as guarantors, the Company, as issuer, the other guarantor subsidiaries named therein, as guarantors, and the Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.20 to the Company's Registration Statement on Form S-4/A filed on March 26, 2010 (File 333-164897))
- 4.19 Registration Rights Agreement dated as of September 28, 2009 among Inverness Medical Innovations, Inc., the Guarantors named therein, Jefferies & Company, Inc., Goldman Sachs & Co., and Wells Fargo Securities (incorporated by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K, event date September 28, 2009, filed on September 28, 2009)
- 4.20 Registration Rights Agreement dated September 21, 2010 among Alere Inc., the subsidiary guarantors named therein and Jefferies & Company, Inc., Goldman, Sachs & Co. and Citigroup Global Markets Inc., as Representatives of the Initial Purchasers (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K, event date September 15, 2010, filed September 21, 2010)

+10.1

BNP Assay Development, Manufacture and Supply Agreement between Biosite Incorporated and Beckman Coulter, Inc. effective June 24, 2003 (incorporated by reference to Exhibit 10.22 to Annual Report of Biosite Incorporated on Form 10-K, filed March 12, 2007)

- +10.2 Shareholder Agreement dated as of May 17, 2007 among Inverness Medical Switzerland GmbH, Procter & Gamble International Operations, SA and SPD Swiss Precision Diagnostics GmbH (incorporated by reference to Exhibit 10.12 to Company's Quarterly Report on Form 10-Q, for the period ended June 30, 2007)

**Table of Contents****Exhibit No. Description**

- 10.3 Option Agreement, dated as of May 17, 2007 among US CD LLC, SPD Swiss Precision Diagnostics GmbH, Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH, Procter & Gamble International Operations, SA and Procter & Gamble RHD, Inc. (incorporated by reference to Exhibit 10.13 to Company's Quarterly Report on Form 10-Q, for the period ended June 30, 2007)
- 10.4 Post-Closing Covenants Agreement, dated as of November 21, 2001, by and among Johnson & Johnson, IMT, the Company, certain subsidiaries of IMT and certain subsidiaries of the Company (incorporated by reference to Exhibit 10.1 to the Company's Annual Report on Form 10-K, as amended, for the year ended December 31, 2001)
- 10.5 Amended and Restated Investor Rights Agreement, effective as of April 30, 2009, by and among Inverness Medical Innovations, Inc., Ron Zwanziger, ACON Laboratories, Inc., AXURE Institute, Inc., LBI, Inc., Oakville Hong Kong Co., Ltd., ACON Biotech (Hangzhou) Co., Ltd., Karsson Overseas Ltd., Manfield Top Worldwide Ltd., Jixun Lin and Feng Lin (incorporated by reference to Exhibit 99.2 to the Company's Current Report on Form 8-K, event date April 30, 2009, filed on April 30, 2009)
- 10.6 Form of Warrant for the Purchase of Shares of Common Stock of the Company issued pursuant to the Note and Warrant Purchase Agreement dated as of December 14, 2001 (incorporated by reference to Exhibit 99.5 to the Company's Current Report on Form 8-K dated December 20, 2001)
- 10.7 Warrant for the Purchase of Shares of Common Stock of the Company, dated as of March 31, 2005, issued to Roger Piasio (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K, as amended, for the year ended December 30, 2006)
- 10.8 Form of Warrant Agreement issued pursuant to the Note and Warrant Purchase Agreement (incorporated by reference to Exhibit 99.3 to the Company's Current Report on Form 8-K dated January 4, 2002)
- 10.9 Inverness Medical Innovations, Inc. 2001 Stock Option and Incentive Plan, as amended (incorporated by reference to Appendix A to the Company's Proxy Statement filed on Schedule 14A as filed with the SEC on April 30, 2009)
- 10.10 Alere Inc. 2010 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2010)
- 10.11 Rules of Alere Inc. HM Revenue and Customs Approved Share Option Plan (2007), as amended (authorized for use under the Alere Inc. 2001 Stock Option and Incentive Plan and the Alere Inc. 2010 Stock Option and Incentive Plan) (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2010)
- \* 10.12 Summary of Terms of Stock Option Agreements under Alere Inc. Stock Option Plans
- 10.13 Summary of Non-Employee Director Compensation (incorporated by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2010)
- 10.14 Inverness Medical Innovations, Inc. 2001 Employee Stock Purchase Plan, as amended (incorporated by reference to Appendix B to the Company's Proxy Statement filed on Schedule 14A as filed with the SEC on April 30, 2009)
- 10.15 Underwriting Agreement dated as of May 7, 2009 among Inverness Medical Innovations, Inc., the subsidiary guarantors named therein, UBS Securities LLC, Goldman, Sachs & Co., and Banc of America Securities LLC, as representatives of the several underwriters named in the Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K, event date May 12, 2009, filed on May 12, 2009)
- 10.16 Underwriting Agreement dated as of August 5, 2009 among Inverness Medical Innovations, Inc., the subsidiary guarantors named therein, Jefferies & Company, Inc., Goldman, Sachs & Co., and Wells Fargo Securities, LLC as representatives of the several underwriters named in the Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K,





**Table of Contents****Exhibit No. Description**

- 10.17 Purchase Agreement dated as of September 23, 2009 among Inverness Medical Innovations, Inc., the Guarantors named therein, Jefferies & Company, Inc., Goldman, Sachs & Co., and Wells Fargo Securities, LLC (incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K, event date September 28, 2009, filed on September 28, 2009)
- 10.18 Purchase Agreement dated September 15, 2010 among Alere Inc., the subsidiary guarantors named therein and Jefferies & Company, Inc., Goldman, Sachs & Co. and Citigroup Global Markets Inc., as Representatives of the Initial Purchasers (incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K, event date September 15, 2010, filed with the SEC on September 21, 2010)
- 10.19 \$1,050,000,000 First Lien Credit Agreement dated as of June 26, 2007 among IM US HOLDINGS, LLC, as Borrower, Inverness Medical Innovations, Inc, as Guarantor, The Lenders and L/C Issuers Party Hereto General Electric Capital Corporation, as Administrative Agent, Citizens Bank of Massachusetts, Fifth Third Bank and Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services, Inc., as Co-Documentation Agents and UBS Securities LLC, as Joint Lead Arranger and Syndication Agent (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, event date June 26, 2007, filed on July 2, 2007)
- 10.20 First Amendment to First Lien Credit Agreement dated as of November 15, 2007 among IM US Holdings, LLC, as Borrower, Inverness Medical Innovations, Inc., as a Guarantor, the Lenders signatory hereto and General Electric Capital Corporation, as collateral agent and administrative agent for the Lenders (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated November 20, 2007)
- \*10.21 Second Amendment to First Lien Credit Agreement dated as of December 17, 2009 among IM US Holdings, LLC, as Borrower, Inverness Medical Innovations, Inc., as a Guarantor, the Lenders signatory hereto and General Electric Capital Corporation, as collateral agent and administrative agent for the Lenders
- \*10.22 Third Amendment to First Lien Credit Agreement dated as of December 7, 2010 among ALERE US HOLDINGS, LLC (f/k/a/ IM US Holdings, LLC), as Borrower, Alere Inc.(f/k/a/ Inverness Medical Innovations, Inc.), as a Guarantor, the Lenders signatory hereto and General Electric Capital Corporation, as collateral agent and administrative agent for the Lenders
- 10.23 \$250,000,000 Second Lien Credit Agreement dated as of June 26, 2007 among IM US HOLDINGS, LLC, as Borrower, Inverness Medical Innovations, Inc., as a Guarantor, The Lenders General Electric Capital Corporation, as Administrative Agent and UBS Securities LLC, as Syndication Agent, Joint Lead Arranger and Sole Bookrunner (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, event date June 26, 2007, filed on July 2, 2007)
- \*10.24 First Amendment to Second Lien Credit Agreement dated as of December 17, 2009 among IM US Holdings, LLC, as Borrower, Inverness Medical Innovations, Inc., as a Guarantor, the Lenders signatory hereto and General Electric Capital Corporation, as collateral agent and administrative agent for the Lenders
- \*10.25 Second Amendment to Second Lien Credit Agreement dated as of December 7, 2010 among ALERE US HOLDINGS, LLC (f/k/a IM US Holdings, LLC), as Borrower, Alere, Inc. (f/k/a/ Inverness Medical Innovations, Inc.), as a Guarantor, the Lenders signatory hereto and General Electric Capital Corporation, as collateral agent and administrative agent for the Lenders
- 10.26 First Lien Guaranty And Security Agreement dated as of June 26, 2007 among IM US HOLDINGS, LLC, as Borrower, and Each Grantor and General Electric Capital Corporation, as Administrative Agent (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K, event date June 26, 2007, filed on July 2, 2007)
- 10.27

Edgar Filing: ALERE INC. - Form 10-K/A

Second Lien Guaranty And Security Agreement dated as of June 26, 2007 among IM US HOLDINGS, LLC, as Borrower, and Each Grantor and General Electric Capital Corporation, as Administrative Agent (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K, event date June 26, 2007, filed on July 2, 2007)

88

---

**Table of Contents**

**Exhibit No. Description**

10.28	Retention and severance agreement, dated November 18, 2009 between Alere LLC and Thomas Underwood (incorporated by reference to Exhibit 10.32 to the Company's Annual Report on Form 10-K, as amended, for the year ended December 31, 2009)
* 10.29	Letter Agreement, dated December 30, 2010, between Alere Health, LLC and Thomas Underwood
** 10.30	Letter Agreement, dated May 14, 2010, between Alere Health, LLC and Gordon Norman
*21.1	List of Subsidiaries of the Company as of February 22, 2011
**23.1	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
**23.2	Consent of BDO USA, LLP, Independent Registered Public Accounting Firm
**31.1	Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
**31.2	Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
**32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act
**101	Interactive Data Files regarding (a) our Consolidated Statements of Operations for the Years Ended December 31, 2010, 2009 and 2008, (b) our Consolidated Balance Sheets as of December 31, 2010 and 2009, (c) our Consolidated Statements of Equity and Comprehensive Income (Loss) for the Years Ended December 31, 2010, 2009 and 2008, (d) our Consolidated Statements of Cash Flows for the Years Ended December 31, 2010, 2009 and 2010 and (e) the Notes to such Consolidated Financial Statements.

\* Previously filed

\*\* Filed herewith.

\*\*\* The Company agrees to furnish supplementally to the Securities and Exchange Commission ( the Commission ) a copy of any omitted schedule or exhibit to this agreement upon request by the Commission.

+ We have omitted portions of this exhibit which have been granted confidential treatment.

Management contract or compensatory plan or arrangement, or amendment thereto.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ALERE INC.

Date: April 29, 2011

By: */s/ Ron Zwanziger*  
Ron Zwanziger  
*Chairman, Chief Executive Officer and President*

90

---

**ALERE INC. AND SUBSIDIARIES**  
**CONSOLIDATED FINANCIAL STATEMENTS**

**Table of Contents**

	<b>Page</b>
<u>Reports of Independent Registered Public Accounting Firms</u>	F-2
<u>Consolidated Statements of Operations for the Years Ended December 31, 2010, 2009 and 2008</u>	F-4
<u>Consolidated Balance Sheets as of December 31, 2010 and 2009</u>	F-5
<u>Consolidated Statements of Equity and Comprehensive Income (Loss) for the Years Ended December 31, 2010, 2009 and 2008</u>	F-6
<u>Consolidated Statements of Cash Flows for the Years Ended December 31, 2010, 2009 and 2008</u>	F-9
<u>Notes to Consolidated Financial Statements</u>	F-10

F-1

---

**Table of Contents**

**Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Shareholders of Alere Inc. In our opinion, the accompanying consolidated balance sheet and the related consolidated statement of operations, statement of equity and comprehensive income (loss) and cash flows present fairly, in all material respects, the financial position of Alere Inc. and its subsidiaries at December 31, 2010, and the results of their operations and their cash flows for the year ended December 31, 2010 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2010, based on criteria established in *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A of Alere Inc.'s Annual Report on Form 10-K. Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audit. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As described in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A of Alere Inc.'s Annual Report on Form 10-K, management has excluded all entities acquired in purchase business combinations during 2010 from its assessment of internal control over financial reporting as of December 31, 2010. We have also excluded these entities acquired in purchase business combinations during 2010 from our audit of internal control over financial reporting. The total assets and net revenue of these entities represented approximately

10% and 6%, respectively, of the related consolidated financial statement amounts as of and for the year ended December 31, 2010.

**/s/ PricewaterhouseCoopers LLP**

Boston, Massachusetts

March 1, 2011

F-2

---



**Table of Contents**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The Board of Directors and Stockholders of  
Alere Inc.:

We have audited the accompanying consolidated balance sheet of Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (the Company) as of December 31, 2009, and the related consolidated statements of operations, equity and comprehensive income (loss), and cash flows for the years ended December 31, 2009 and 2008. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Alere Inc. at December 31, 2009, and the consolidated results of their operations and their cash flows for each of the years ended December 31, 2009 and 2008, in conformity with accounting principles generally accepted in the United States of America.

As described in Note 2 of the financial statements, the Company adopted the accounting standards related to Business Combinations, effective for business combinations entered into after January 1, 2009.

**/s/ BDO USA, LLP**

BDO USA, LLP (formerly known as BDO Seidman, LLP)  
Boston, Massachusetts  
February 26, 2010

F-3

---

Table of Contents

**ALERE INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

(in thousands, except per share amounts)

	<b>Year Ended December 31,</b>		
	<b>2010</b>	<b>2009</b>	<b>2008</b>
Net product sales	\$ 1,472,403	\$ 1,365,079	\$ 1,151,265
Services revenue	662,185	528,487	405,462
Net product sales and services revenue	2,134,588	1,893,566	1,556,727
License and royalty revenue	20,759	29,075	25,826
<b>Net revenue</b>	<b>2,155,347</b>	<b>1,922,641</b>	<b>1,582,553</b>
Cost of net product sales	688,325	619,503	543,317
Cost of services revenue	325,286	240,026	177,098
Cost of net product sales and services revenue	1,013,611	859,529	720,415
Cost of license and royalty revenue	7,149	8,890	8,620
<b>Cost of net revenue</b>	<b>1,020,760</b>	<b>868,419</b>	<b>729,035</b>
<b>Gross profit</b>	<b>1,134,587</b>	<b>1,054,222</b>	<b>853,518</b>
Operating expenses:			
Research and development	133,278	112,848	111,828
Sales and marketing	499,124	441,646	381,939
General and administrative	446,917	357,033	295,059
Goodwill impairment charge	1,006,357		
Gain on disposition		(3,355)	
<b>Operating income (loss)</b>	<b>(951,089)</b>	<b>146,050</b>	<b>64,692</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(139,435)	(106,798)	(101,132)
Other income (expense), net	22,738	996	(1,807)
<b>Income (loss) from continuing operations before provision (benefit) for income taxes</b>	<b>(1,067,786)</b>	<b>40,248</b>	<b>(38,247)</b>
Provision (benefit) for income taxes	(29,931)	15,627	(16,644)
<b>Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax</b>	<b>(1,037,855)</b>	<b>24,621</b>	<b>(21,603)</b>
Equity earnings of unconsolidated entities, net of tax	10,566	7,626	1,050
Income (loss) from continuing operations	(1,027,289)	32,247	(20,553)
Income (loss) from discontinued operations, net of tax	11,397	1,934	(1,048)

Edgar Filing: ALERE INC. - Form 10-K/A

<b>Net income (loss)</b>	(1,015,892)	34,181	(21,601)
Less: Net income attributable to non-controlling interests	1,418	465	167
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	(1,017,310)	33,716	(21,768)
Preferred stock dividends	(24,235)	(22,972)	(13,989)
<b>Net income (loss) available to common stockholders</b>	\$ (1,041,545)	\$ 10,744	\$ (35,757)
Basic net income (loss) per common share attributable to Alere Inc. and Subsidiaries:			
Income (loss) from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)
Income (loss) from discontinued operations	0.14	0.02	(0.01)
Net income (loss) per common share	\$ (12.33)	\$ 0.13	\$ (0.46)
Diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries:			
Income (loss) from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)
Income (loss) from discontinued operations	0.14	0.02	(0.01)
Net income (loss) per common share	\$ (12.33)	\$ 0.13	\$ (0.46)
<b>Weighted average shares-basic</b>	84,445	80,572	77,778
<b>Weighted average shares-diluted</b>	84,445	81,967	77,778

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****ALERE INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS****(in thousands, except par value amounts)**

	<b>As of December 31,</b>	
	<b>2010</b>	<b>2009</b>
<b>ASSETS</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 401,306	\$ 492,773
Restricted cash	2,581	2,424
Marketable securities	2,094	947
Accounts receivable, net of allowances of \$20,381 and \$12,462 at December 31, 2010 and December 31, 2009, respectively	397,148	354,453
Inventories, net	257,720	221,539
Deferred tax assets	57,111	66,492
Income tax receivable	1,383	1,107
Prepaid expenses and other current assets	74,914	73,075
Assets held for sale		54,148
<b>Total current assets</b>	<b>1,194,257</b>	<b>1,266,958</b>
Property, plant and equipment, net	390,510	324,388
Goodwill	2,831,300	3,463,358
Other intangible assets with indefinite lives	28,183	43,644
Finite-lived intangible assets, net	1,707,581	1,686,427
Deferred financing costs, net, and other non-current assets	81,401	72,762
Investments in unconsolidated entities	62,556	63,965
Marketable securities	9,404	1,503
Deferred tax assets	25,182	20,987
<b>Total assets</b>	<b>\$ 6,330,374</b>	<b>\$ 6,943,992</b>

**LIABILITIES AND EQUITY**

<b>Current liabilities:</b>		
Current portion of long-term debt	\$ 16,891	\$ 18,970
Current portion of capital lease obligations	2,126	899
Accounts payable	126,844	126,322
Accrued expenses and other current liabilities	345,832	279,732
Payable to joint venture, net	2,787	533
Deferred gain on joint venture	288,378	
Liabilities related to assets held for sale		11,558
<b>Total current liabilities</b>	<b>782,858</b>	<b>438,014</b>
<b>Long-term liabilities:</b>		

Long-term debt, net of current portion	2,378,566	2,128,515
Capital lease obligations, net of current portion	1,402	940
Deferred tax liabilities	420,166	442,049
Deferred gain on joint venture		288,767
Other long-term liabilities	169,656	116,818
<b>Total long-term liabilities</b>	<b>2,969,790</b>	<b>2,977,089</b>
<b>Commitments and contingencies</b> (Notes 8, 9 and 11)		
<b>Stockholders equity:</b>		
Series B preferred stock, \$0.001 par value (liquidation preference: \$836,222 at December 31, 2010 and \$793,696 at December 31, 2009); Authorized: 2,300 shares; Issued and outstanding: 2,091 shares at December 31, 2010 and 1,984 shares at December 31, 2009	718,554	694,427
Common stock, \$0.001 par value; Authorized: 200,000 shares; Issued and outstanding: 84,928 shares at December 31, 2010 and 83,567 at December 31, 2009	85	84
Additional paid-in capital	3,232,893	3,195,372
Accumulated deficit	(1,377,184)	(359,874)
Accumulated other comprehensive income (loss)	690	(2,454)
<b>Total stockholders equity</b>	<b>2,575,038</b>	<b>3,527,555</b>
Non-controlling interests	2,688	1,334
<b>Total equity</b>	<b>2,577,726</b>	<b>3,528,889</b>
<b>Total liabilities and equity</b>	<b>\$ 6,330,374</b>	<b>\$ 6,943,992</b>

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents**ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (LOSS)**

(in thousands, except par value amounts)

Preferred Stock Number of Shares	Amount	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Comprehensive Income (Loss)	Total Stockholders' Equity	Non-controlling Interest	Total Equity
		Number of Shares	Par Value						
	\$	76,789	\$ 77	\$ 2,937,143	\$ (371,822)	\$ 21,269	\$ 2,586,667	\$ 869	\$ 2,587,536
1,788	657,573						657,573		657,573
		580		20,945			20,945		20,945
		1,062	1	20,712			20,713		20,713
91	13,928			(14,026)			(98)		(98)
				20,973			20,973		20,973
				26,405			26,405		26,405

ck

y  
t

t

s

x  
s

ale  
of

n  
g

g

e

31,

17,542

17,542

17,542

(562)

(562)

(562)

(32,889)

(32,889)

(32,889)

(11,614)

(11,614)

(11,614)

(5,049)

(5,049)

(5,049)

167

167

(21,768)

(21,768)

(167)

(167)

(21,768)

1,879 \$ 671,501 78,431 \$ 78 \$ 3,029,694 \$ (393,590) \$ (28,845) \$ 3,278,838 \$ 869 \$ 3,279,707

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Table of Contents

## ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (LOSS)  
(Continued)

(in thousands, except par value amounts)

Preferred Stock Number of Shares	Preferred Stock Amount	Common Stock \$0.001		Additional Paid-in Capital	Accumulated Deficit	Accumulated Comprehensive Other (Loss)	Total Stockholders' Equity	Non-controlling Interest	Total Equity
		Number of Shares	Par Value						
1,879	\$ 671,501	78,431	\$ 78	\$ 3,029,694	\$ (393,590)	\$ (28,845)	\$ 3,278,838	\$ 869	\$ 3,279,707
		3,431	4	117,815			117,819		117,819
		1,705	2	30,013			30,015		30,015
105	22,926			(23,079)			(153)		(153)
				2,881			2,881		2,881
				28,220			28,220		28,220
				9,828			9,828		9,828
						(1,137)	(1,137)		(1,137)
						15,171	15,171		15,171



						11,389	11,389		11,389	
						968	968		968	
				33,716		33,716		465	465	
31,	1,984	\$ 694,427	83,567	\$ 84	\$ 3,195,372	\$ (359,874)	\$ (2,454)	\$ 3,527,555	\$ 1,334	\$ 3,528,889

The accompanying notes are an integral part of these consolidated financial statements.

F-7

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (LOSS)****(Continued)****(in thousands, except par value amounts)**

	Preferred Stock per Share	Amount	Common Stock Number of Shares	Par Value	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Stockholder Equity	Non-controlling Interest	Total Equity	Redeemable Non-co Int
2014		\$ 694,427	83,567	\$ 84	\$ 3,195,372	\$ (359,874)	\$ (2,454)	\$ 3,527,555	\$ 1,334	\$ 3,528,889	\$
			536		16,276			16,276		16,276	
			825	1	19,024			19,025		19,025	
2017		24,127			(24,279)			(152)		(152)	
					29,879			29,879		29,879	
					789			789		789	
							(113)	(113)		(113)	
							(210)	(210)		(210)	

						2,423	2,423		2,423	
						1,044	1,044		1,044	
			(4,168)				(4,168)	1,251	(2,917)	
								(1,315)	(1,315)	
				(1,017,310)		(1,017,310)	1,418		(1,015,892)	
91	\$ 718,554	84,928	\$ 85	\$ 3,232,893	\$ (1,377,184)	\$ 690	\$ 2,575,038	\$ 2,688	\$ 2,577,726	\$

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS****(in thousands)**

	<b>For The Year Ended December 31,</b>		
	<b>2010</b>	<b>2009</b>	<b>2008</b>
<b>Cash Flows from Operating Activities:</b>			
Net income (loss)	\$ (1,015,892)	\$ 34,181	\$ (21,601)
Income (loss) from discontinued operations, net of tax	11,397	1,934	(1,048)
Income (loss) from continuing operations	(1,027,289)	32,247	(20,553)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:			
Non-cash interest expense including amortization of original issue discounts and write-off of deferred financing costs	13,758	10,423	5,930
Depreciation and amortization	372,790	312,435	265,654
Non-cash stock-based compensation expense	29,879	28,220	26,405
Impairment of inventory	848	1,467	4,193
Impairment of long-lived assets	1,411	6,983	20,031
Impairment of goodwill	1,006,357		
Loss on sale of fixed assets	998	1,205	777
Gain on sale of marketable securities	(4,504)		
Equity earnings of unconsolidated entities, net of tax	(10,566)	(7,626)	(1,050)
Deferred income taxes	(74,418)	(9,124)	(41,714)
Other non-cash items	3,802	3,264	4,378
Changes in assets and liabilities, net of acquisitions:			
Accounts receivable, net	(9,360)	(36,455)	(39,546)
Inventories, net	(22,845)	(16,425)	(41,945)
Prepaid expenses and other current assets	8,310	9,081	(7,386)
Accounts payable	(9,088)	2,117	7,193
Accrued expenses and other current liabilities	22,202	(45,445)	(29,091)
Other non-current liabilities	(27,452)	(2,709)	3,400
Net cash provided by continuing operations	274,833	289,658	156,676
Net cash provided by (used in) by discontinued operations	591	(2,127)	(8,832)
<b>Net cash provided by operating activities</b>	<b>275,424</b>	<b>287,531</b>	<b>147,844</b>
<b>Cash Flows from Investing Activities:</b>			
Purchases of property, plant and equipment	(96,241)	(100,606)	(65,699)
Proceeds from sale of property, plant and equipment	795	803	1,070
Cash paid for acquisitions and transaction costs, net of cash acquired	(523,507)	(468,527)	(649,899)
Decrease in marketable securities	3,182		
Net cash received from equity method investments	12,354	12,560	12,133

Edgar Filing: ALERE INC. - Form 10-K/A

Increase in other assets	(12,900)	(27,720)	(10,500)
Net cash used in continuing operations	(616,317)	(583,490)	(712,895)
Net cash provided by (used in) discontinued operations	62,596	(237)	(437)
<b>Net cash used in investing activities</b>	<b>(553,721)</b>	<b>(583,727)</b>	<b>(713,332)</b>
<b>Cash Flows from Financing Activities:</b>			
Increase (decrease) in restricted cash	(141)	418	139,204
Issuance costs associated with preferred stock			(350)
Cash paid for financing costs	(13,045)	(17,756)	(1,401)
Proceeds from issuance of common stock, net of issuance costs	19,024	30,015	20,675
Proceeds on long-term debt	400,000	631,177	
Repayment on long-term debt	(9,750)	(11,055)	(13,787)
Net proceeds (repayments) from revolving lines-of-credit	(146,781)	(7,251)	137,242
Excess tax benefit on exercised stock options	1,683	9,269	17,542
Principal payments of capital lease obligations	(1,867)	(798)	(958)
Purchase of non-controlling interest	(52,864)		
Other	(141)	(153)	(56)
Net cash provided by continuing operations	196,118	633,866	298,111
Net cash used in discontinued operations		(12)	(342)
<b>Net cash provided by financing activities</b>	<b>196,118</b>	<b>633,854</b>	<b>297,769</b>
Foreign exchange effect on cash and cash equivalents	(9,288)	13,791	(5,689)
Net increase (decrease) in cash and cash equivalents	(91,467)	351,449	(273,408)
Cash and cash equivalents, beginning of period	492,773	141,324	414,732
<b>Cash and cash equivalents, end of period</b>	<b>\$ 401,306</b>	<b>\$ 492,773</b>	<b>\$ 141,324</b>

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(1) Description of Business and Basis of Presentation**

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere Inc. and subsidiaries enable individuals to take charge of improving their health and quality of life at home under medical supervision. Our global leading products and services, as well as our new product development efforts, focus on cardiology, women's health, infectious disease, oncology and toxicology.

Our business is organized into three primary operating segments: (i) professional diagnostics, (ii) health management and (iii) consumer diagnostics. The professional diagnostics segment includes an array of innovative rapid diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within our areas of focus identified above. The health management segment provides comprehensive, integrated programs and services focused on wellness, disease and condition management, productivity enhancement and informatics, all designed to reduce health-related costs and enhance the health and quality of life of the individuals we serve. The consumer diagnostics segment consists primarily of manufacturing operations related to our role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics, or SPD, our 50/50 joint venture with The Procter & Gamble Company, or P&G. SPD has significant operations in the worldwide over-the-counter pregnancy and fertility/ovulation test market.

On January 15, 2010, we completed the sale of our vitamins and nutritional supplements business (Note 23). The sale included our entire private label and branded nutritionals businesses and represents the complete divestiture of our entire vitamins and nutritional supplements business segment. The results of the vitamins and nutritional supplements business are included in income (loss) from discontinued operations, net of tax, for all periods presented. The assets and liabilities associated with the vitamins and nutritional supplements business have been reclassified to assets held for sale and liabilities related to assets held for sale as of December 31, 2009 on our accompanying consolidated balance sheet.

Acquisitions are an important part of our growth strategy. When we acquire businesses, we seek to complement existing products and services, enhance or expand our product lines and/or expand our customer base. We determine what we are willing to pay for each acquisition partially based on our expectation that we can cost effectively integrate the products and services of the acquired companies into our existing infrastructure. In addition, we utilize existing infrastructure of the acquired companies to cost effectively introduce our products to new geographic areas. All of these factors contributed to the acquisition prices of acquired businesses that were in excess of the fair value of net assets acquired and the resultant goodwill (Note 4).

Following the completion of our 50/50 joint venture with P&G on May 17, 2007, we ceased to consolidate the operating results of our consumer diagnostics business, and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. In our capacity as the manufacturer of products for the joint venture, we supply product to the joint venture and record revenue on those sales. No gain on the proceeds that we received from P&G through the formation of our joint venture will be recognized in our financial statements until P&G's option to require us to purchase its interest in the joint venture at market value expires after the fourth anniversary of the closing.

The consolidated financial statements include the accounts of Alere Inc. and its subsidiaries. Intercompany transactions and balances are eliminated and net earnings are reduced by the portion of the net earnings of subsidiaries applicable to non-controlling interests. Equity investments in which we exercise significant influence but do not

control and are not the primary beneficiary are accounted for using the equity method. Investments in which we are not able to exercise significant influence over the investee and which do not have readily determinable fair values are accounted for under the cost method.

Certain amounts for prior periods have been reclassified to conform to the current period classification.

F-10

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies**

*(a) Use of Estimates*

To prepare our financial statements in conformity with accounting principles generally accepted in the United States of America, our management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from such estimates.

*(b) Foreign Currencies*

In general, the functional currencies of our foreign subsidiaries are the local currencies. For purpose of consolidating the financial statements of our foreign subsidiaries, all assets and liabilities of the foreign subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date while the stockholders' equity accounts are translated at historical exchange rates. Translation gains and losses that result from the conversion of the balance sheets of the foreign subsidiaries into U.S. dollars are recorded to cumulative translation adjustment which is a component of accumulated other comprehensive income within stockholders' equity (Note 15). The revenue and expenses of our foreign subsidiaries are translated using the average rates of exchange in effect during each fiscal month during the year.

Net realized and unrealized foreign currency exchange transaction gains of \$9.8 million during 2010, \$1.3 million during 2009 and losses of \$0.5 million during 2008, are included as a component of other income (expense), net in the accompanying consolidated statements of operations.

*(c) Cash and Cash Equivalents*

We consider all highly-liquid investments purchased with original maturities of three months or less at the date of acquisition to be cash equivalents. Cash equivalents consisted of money market funds at December 31, 2010 and 2009.

*(d) Restricted Cash*

We had restricted cash of \$2.6 million and \$2.4 million as of December 31, 2010 and 2009, respectively.

*(e) Marketable Securities*

Securities classified as available-for-sale or trading are carried at estimated fair value, as determined by quoted market prices at the balance sheet date. Realized gains and losses on securities are included in earnings and are determined using the specific identification method. Unrealized holding gains and losses (except for other than temporary impairments) on securities classified as available for sale, are excluded from earnings and are reported in accumulated other comprehensive income, net of related tax effects. Unrealized gains and losses on actively-traded securities are included in earnings. Marketable securities that are held indefinitely are classified in our accompanying consolidated balance sheets as long-term marketable securities.



*(f) Inventories*

Inventories are stated at the lower of cost (first-in, first-out) or market and made up of raw material, work-in-process and finished goods. The cost elements of work-in-process and finished goods inventory consist of raw material, direct labor and manufacturing overhead. Where finished goods inventory is purchased from third-party manufacturers, the costs of such finished goods inventory represent the costs to acquire such inventory.

*(g) Property, Plant and Equipment*

We record property, plant and equipment at historical cost or, in the case of a business combination, at fair value on the date of the business combination. Depreciation is computed using the straight-line method

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

based on the following estimated useful lives of the related assets: machinery, laboratory equipment and tooling, 2-25 years; buildings, 7-55 years; leasehold improvements, lesser of remaining term of lease or estimated useful life of asset; computer software and equipment, 1-25 years and furniture and fixtures, 2-25 years. Land is not depreciated. Depreciation expense related to property, plant and equipment amounted to \$67.7 million, \$54.3 million and \$49.7 million in 2010, 2009 and 2008, respectively. Expenditures for repairs and maintenance are expensed as incurred.

*(h) Goodwill and Other Intangible Assets with Indefinite Lives*

In accordance with Accounting Standards Codification, or ASC 350 *Intangibles – Goodwill and Other*, or ASC 350, we test goodwill and other intangible assets with indefinite lives at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator.

In performing the impairment test, we utilize the two-step approach prescribed under ASC 350. The first step requires a comparison of the carrying value of each reporting unit to its estimated fair value. To estimate the fair value of our reporting units for Step 1, we use a combination of the income approach and the market approach. The income approach is based on a discounted cash flow analysis, or DCF, and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value, using a risk-adjusted discount rate. Assumptions used in the DCF require the exercise of significant judgment, including judgment about appropriate discount rates and terminal values, growth rates and the amount and timing of expected future cash flows. The forecasted cash flows are based on our most recent budget and for years beyond the budget, our estimates are based on assumed growth rates. We believe our assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates, which are intended to reflect the risks inherent in future cash flow projections, used in the DCF are based on estimates of the weighted-average cost of capital, or WACC, of market participants relative to each respective reporting unit. The market approach considers comparable market data based on multiples of revenue or earnings before taxes, depreciation and amortization, or EBITDA.

If the carrying value of a reporting unit exceeds its estimated fair value, we are required to perform the second step of the goodwill impairment test to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of a reporting unit's goodwill to its carrying value. The implied fair value of goodwill is derived by performing a hypothetical purchase price allocation for the reporting unit as of the measurement date, allocating the reporting unit's estimated fair value to its assets and liabilities. The residual amount from performing this allocation represents the implied fair value of goodwill. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded.

We conducted our annual impairment test for our reporting units during the fourth quarter of 2010. Key assumptions (which vary by reporting unit) used in determining fair value under the discounted cash flow approach included discount rates ranging from 12.5% to 13.0%, projected compound average revenue growth rates of 6.0% to 10.0% and terminal value growth rates of 4.0%. In determining the appropriate discount rate, we considered the weighted-average

cost of capital for each reporting unit, which among other factors considers the cost of common equity capital and the marginal cost of debt of market participants. Key assumptions (which again vary by reporting unit) used in determining fair value under the market approach were based on observed market multiples of enterprise value to revenue and EBITDA for both comparable

F-12

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

publicly-traded companies and recent merger and acquisition transactions involving similar companies to estimate appropriate controlling basis multiples to apply to each of the reporting units. Based on the multiples implied by this market data, we selected multiples of revenue of 1.0 to 2.8 times and multiples of EBITDA of 7.5 to 10.0 times. In assessing the reasonableness of our estimated fair values of the reporting units, management compared the results of the valuation analyses against our then-current market capitalization to imply a control premium. Based on this analysis, the implied control premium was within the range of comparable industry transactions.

The Step 1 impairment analysis indicated that the carrying value of the net assets of our Health Management reporting unit exceeded the estimated fair value of the reporting unit. As a result, we were required to perform Step 2 of the goodwill impairment test to determine the amount, if any, of goodwill impairment charges for the Health Management reporting unit. We completed Step 2, consistent with the procedures described above, and determined that a goodwill impairment charge in the amount of approximately \$1.0 billion was required. The resulting goodwill impairment charge is reflected in operating income (loss) in our accompanying consolidated statements of operations.

The estimate of fair value requires significant judgment. We based our fair value estimates on assumptions that we believe to be reasonable but that are unpredictable and inherently uncertain, including estimates of future growth rates and operating margins and assumptions about the overall economic climate and the competitive environment for our business units. There can be no assurance that our estimates and assumptions made for purposes of our goodwill and identifiable intangible asset testing as of the time of testing will prove to be accurate predictions of the future. If our assumptions regarding business plans, competitive environments or anticipated growth rates are not correct, we may be required to record goodwill and/or intangible asset impairment charges in future periods, whether in connection with our next annual impairment testing or earlier, if an indicator of an impairment is present before our next annual evaluation.

Impairment charges related to goodwill have no impact on our cash balances or compliance with financial covenants under our Amended and Restated Credit Agreement.

*(i) Impairment of Other Long-Lived Tangible and Intangible Assets*

We evaluate long-lived tangible and intangible assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment are present with respect to long-lived tangible and intangible assets used in operations and undiscounted future cash flows are not expected to be sufficient to recover the assets' carrying amount, additional analysis is performed as appropriate and the carrying value of the long-lived asset is reduced to the estimated fair value, if this is lower, and an impairment loss would be charged to expense in the period the impairment is identified.

We conducted our annual goodwill impairment test for our reporting units during the fourth quarter of 2010. The impairment test indicated there was an impairment of goodwill associated with our health management reporting unit, and thus, a potential impairment of our long-lived tangible and intangible assets associated with the same reporting unit. We conducted an analysis as prescribed under ASC 360 *Property, Plant and Equipment*, utilizing an undiscounted cash flow model at the lowest level of independent cash flows. The analysis indicated there was no impairment of the long-lived tangible or intangible assets associated with our health management reporting unit. Although we believe that the carrying value of our long-lived tangible and intangible assets was realizable as of

December 31, 2010, future events could cause us to conclude otherwise.

*(j) Business Acquisitions*

On January 1, 2009, we adopted a new accounting standard issued by the Financial Accounting Standards Board, or FASB, related to accounting for business combinations using the acquisition method of accounting

F-13

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

(previously referred to as the purchase method). Among the significant changes, this standard requires a redefining of the measurement date of a business combination, expensing direct transaction costs as incurred, capitalizing in-process research and development costs as an intangible asset and recording a liability for contingent consideration at the measurement date with subsequent re-measurements recorded as general and administrative expense. This standard also requires costs for business restructuring and exit activities related to the acquired company to be included in the post-combination financial results of operations and also provides new guidance for the recognition and measurement of contingent assets and liabilities in a business combination. Acquisitions consummated prior to January 1, 2009 were accounted for in accordance with the previously applicable guidance. During 2010 and 2009, we incurred \$8.2 million and \$15.9 million of acquisition-related costs. Included in the \$15.9 million of expense incurred during 2009, was \$3.8 million of costs associated with acquisition-related activity for transactions not consummated prior to January 1, 2009.

Our business acquisitions have historically been made at prices above the fair value of the acquired net assets, resulting in goodwill, based on our expectations of synergies of combining the businesses. These synergies include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the acquired businesses' products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand product sales.

Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain.

We generally employ the income method to estimate the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product life cycles, economic barriers to entry, a brand's relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.

Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation. We are not aware of any information that indicates the final purchase price allocations will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets on patterns in which the economic benefits are expected to be realized.

*(k) Income Taxes*

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax

assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future (Note 16).

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

*(l) Revenue Recognition*

We primarily recognize revenue when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed or determinable and (4) collection is reasonably assured.

The majority of our revenue is derived from product sales. We recognize revenue upon title transfer of the products to third-party customers, less a reserve for estimated product returns and allowances. Determination of the reserve for estimated product returns and allowances is based on our management's analyses and judgments regarding certain conditions. Should future changes in conditions prove management's conclusions and judgments on previous analyses to be incorrect, revenue recognized for any reporting period could be adversely affected.

Additionally, we generate services revenue in connection with contracts with health plans (both commercial and governmental) and self-insured employers, whereby we provide clinical expertise through fee-based arrangements. Revenue for fee-based arrangements is recognized over the period in which the services are provided. Some contracts provide that a portion of our fees are at risk if our customers do not achieve certain financial cost savings or we do not achieve certain other clinical and operational metrics, over a period of time, typically one year. Revenue subject to refund is not recognized if (i) sufficient information is not available to calculate performance measurements or (ii) interim performance measurements indicate that we are not meeting performance targets. If either of these two conditions exists, we record the amounts as other current liabilities in the consolidated balance sheet, deferring recognition of the revenue until we establish that we have met the performance criteria. If we do not meet the performance targets at the end of the contractual period we are obligated under the contract to refund some or all of the at risk fees.

We also receive license and royalty revenue from agreements with third-party licensees. Revenue from fixed-fee license and royalty agreements is recognized on a straight-line basis over the obligation period of the related license agreements. License and royalty fees that the licensees calculate based on their sales, which we have the right to audit under most of our agreements, are generally recognized upon receipt of the license or royalty payments unless we are able to reasonably estimate the fees as they are earned. License and royalty fees that are determinable prior to the receipt thereof are recognized in the period they are earned.

*(m) Employee Stock-Based Compensation Arrangements*

We account for share-based payments in accordance with ASC 718 *Compensation - Stock Compensation*. Compensation cost associated with stock options includes: (i) amortization related to the remaining unvested portion of all stock option awards granted prior to January 1, 2006, based on the grant-date fair value estimated in accordance with the original provisions of Statement of Financial Accounting Standards No. 123, and (ii) amortization related to all stock option awards granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 718. In addition, we record expense over the offering period in connection with shares issued under our employee stock purchase plan. Compensation expense for stock-based compensation awards includes an estimate for forfeitures and is recognized over the expected term of the options using the straight-line method. It is our policy to recognize, through additional paid in capital, the excess or windfall tax benefits on stock option deductions, as those deductions are recognized on tax returns.



Our stock option plans provide for grants of options to employees to purchase common stock at or above the fair market value of such shares on the grant date of the award. The options generally vest over a four-year period, beginning on the date of grant, with a graded vesting schedule of 25% at the end of each of the four years. The fair value of each option grant is estimated on the date of grant primarily using a Black-Scholes option-pricing method. We use historical data to estimate the expected price volatility and the

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

expected forfeiture rate. The contractual term of our stock option awards is ten years. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant with a remaining term equal to the expected term of the option. We have not made any dividend payments nor do we have plans to pay dividends in the foreseeable future.

*(n) Net Income (Loss) per Common Share*

Net income (loss) per common share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year (Note 12).

*(o) Other Operating Expenses*

We expense advertising costs as incurred. In 2010, 2009 and 2008, advertising costs amounted to \$14.4 million, \$15.4 million and \$15.7 million, respectively, and are included in sales and marketing expenses in the accompanying consolidated statements of operations.

Shipping and handling costs are included in cost of net revenue in the accompanying consolidated statements of operations. Additionally, to the extent that we charge our customers for shipping and handling costs, these costs are recorded as product revenues.

*(p) Concentration of Credit Risk, Off-Balance Sheet Risks and Other Risks and Uncertainties*

Financial instruments that potentially subject us to concentration of credit risk primarily consist of cash and cash equivalents and accounts receivable. We invest our excess cash primarily in high quality securities and limit the amount of our credit exposure to any one financial institution. We do not require collateral or other securities to support customer receivables; however, we perform on-going credit evaluations of our customers and maintain allowances for potential credit losses.

At December 31, 2010 and 2009, no individual customer's accounts receivable balance was in excess of 10%. During 2010, no one customer represented greater than 10% of our net revenue. During 2009 and 2008, we had one customer that represented 15% and 23% of our net revenue, respectively, and purchased our professional diagnostics products.

We rely on a number of third parties to manufacture certain of our products. If any of our third-party manufacturers cannot, or will not, manufacture our products in the required volumes, on a cost-effective basis, in a timely manner, or at all, we will have to secure additional manufacturing capacity. Any interruption or delay in manufacturing could have a material adverse effect on our business and operating results.

*(q) Financial Instruments and Fair Value of Financial Instruments*

Our primary financial instruments at December 31, 2010 and 2009 consisted of cash equivalents, restricted cash, marketable securities, accounts receivable, accounts payable, debt and our interest rate swap contract. We apply fair value measurement accounting to value our financial assets and liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous

market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The estimated fair value of these financial instruments approximates their carrying values at December 31, 2010 and 2009.

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(2) Summary of Significant Accounting Policies (Continued)**

*(r) Recent Accounting Pronouncements*

Recently Issued Standards

In April 2010, the FASB issued Accounting Standards Update, or, ASU, No. 2010-17, *Revenue Recognition Milestone Method (Topic 605): Milestone Method of Revenue Recognition*, or ASU 2010-17. ASU 2010-17 allows the milestone method as an acceptable revenue recognition methodology when an arrangement includes substantive milestones. ASU 2010-17 provides a definition of substantive milestone and should be applied regardless of whether the arrangement includes single or multiple deliverables or units of accounting. ASU 2010-17 is limited to transactions involving milestones relating to research and development deliverables. ASU 2010-17 also includes enhanced disclosure requirements about each arrangement, individual milestones and related contingent consideration, information about substantive milestones and factors considered in the determination. ASU 2010-17 is effective on a prospective basis for milestones achieved in fiscal years, and interim periods within those years, beginning on or after June 15, 2010, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or cash flows.

In October 2009, the FASB issued ASU No. 2009-14, *Software (Topic 985): Certain Revenue Arrangements That Include Software Elements a consensus of the FASB EITF*, or ASU 2009-14. ASU 2009-14 changes the accounting model for revenue arrangements that include tangible products and software elements. The amendments of this update provide additional guidance on how to determine which software, if any, relating to the tangible product also would be excluded from the scope of the software revenue recognition guidance. The amendments in this update also provide guidance on how a vendor should allocate arrangement consideration to deliverables in an arrangement that includes both tangible products and software, as well as arrangements that have deliverables both included and excluded from the scope of software revenue recognition guidance. This standard is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or cash flows.

In October 2009, the FASB issued ASU No. 2009-13, *Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements a consensus of the FASB EITF*, or ASU 2009-13. ASU 2009-13 will separate multiple-deliverable revenue arrangements. This update establishes a selling price hierarchy for determining the selling price of a deliverable. The amendments of this update will replace the term fair value in the revenue allocation guidance with selling price to clarify that the allocation of revenue is based on entity-specific assumptions rather than assumptions of a marketplace participant. The amendments of this update will eliminate the residual method of allocation and require that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. The amendments in this update will require that a vendor determine its best estimated selling price in a manner consistent with that used to determine the price to sell the deliverable on a standalone basis. This standard is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The adoption of this standard is not expected to have a material impact on our financial position, results of operations or cash flows.

Recently Adopted Standards

Effective January 1, 2010, we adopted ASU No. 2010-06, *Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair Value Measurements*, or ASU 2010-06. A reporting entity should provide additional disclosures about the different classes of assets and liabilities measured at fair value, the valuation techniques and inputs used, the activity in Level 3 fair value measurements, and the transfers between Levels 1, 2, and 3 fair value measurements. The adoption of the additional disclosures for Level 1

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(2) Summary of Significant Accounting Policies (Continued)**

and Level 2 fair value measurements did not have an impact on our financial position, results of operations or cash flows. The disclosures regarding Level 3 fair value measurements do not become effective until January 1, 2011 and, given such, we are currently evaluating the potential impact of this part of the update.

Effective January 1, 2010, we adopted ASU No. 2009-17, *Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities*, or ASU 2009-17. The amendments in this update replace the quantitative-based risks and rewards calculation for determining which reporting entity, if any, has a controlling financial interest in a variable interest entity with an approach focused on identifying which reporting entity has the power to direct the activities of a variable interest entity that most significantly impact the entity's economic performance and (1) the obligation to absorb losses of the entity or (2) the right to receive benefits from the entity. An approach that is expected to be primarily qualitative will be more effective for identifying which reporting entity has a controlling financial interest in a variable interest entity. The amendments in this update also require additional disclosures about a reporting entity's involvement in variable interest entities, which will enhance the information provided to users of financial statements. We evaluated our business relationships to identify potential variable interest entities and have concluded that consolidation of such entities is not required for the periods presented. On a quarterly basis, we will continue to reassess our involvement with variable interest entities.

**(3) Other Balance Sheet Information**

Components of selected captions in the consolidated balance sheets consist of (in thousands):

	<b>December 31,</b>	
	<b>2010</b>	<b>2009</b>
<b>Inventories, net:</b>		
Raw materials	\$ 81,640	\$ 62,397
Work-in-process	61,849	56,338
Finished goods	114,231	102,804
	<b>\$ 257,720</b>	<b>\$ 221,539</b>
<b>Property, plant and equipment, net:</b>		
Machinery, laboratory equipment and tooling	\$ 252,581	\$ 183,490
Land and buildings	158,109	135,644
Leasehold improvements	24,552	22,841
Computer software and equipment	129,794	96,950
Furniture and fixtures	22,773	19,340
	587,809	458,265
Less: Accumulated depreciation and amortization	(197,299)	(133,877)
	<b>\$ 390,510</b>	<b>\$ 324,388</b>

**Accrued expenses and other current liabilities:**

Compensation and compensation-related	\$ 65,839	\$ 76,360
Advertising and marketing	3,228	6,155
Professional fees	8,507	9,743
Interest payable	25,283	16,661
Royalty obligations	22,014	17,451
Deferred revenue	24,924	23,095
Taxes payable	46,944	33,511
Acquisition-related obligations	72,102	55,496
Other	76,991	41,260
	\$ 345,832	\$ 279,732

F-18

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations**

*(a) Acquisitions in 2010*

(i) Immunalysis

On August 16, 2010, we acquired Diagnostixx of California, Corp. (d/b/a Immunalysis Corporation), or Immunalysis, located in Pomona, California, a privately-owned manufacturer and marketer of abused and prescription drug screening solutions used by clinical reference and forensic/crime laboratories. The preliminary aggregate purchase price was \$56.2 million, which consisted of an initial cash payment totaling \$55.0 million and a contingent consideration obligation of up to \$5.0 million with an acquisition date fair value of \$1.2 million. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately \$7.9 million related to this acquired business. The operating results of this acquired operation are included in our professional diagnostics reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes.

(ii) A privately-owned U.K. research and development operation

On March 11, 2010, we acquired a privately-owned U.K. research and development operation. The preliminary aggregate purchase price was \$70.8 million, which consisted of an initial cash payment totaling \$35.2 million and a contingent consideration obligation of up to \$125.0 million with an acquisition date fair value of \$35.6 million. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately \$0.2 million related to this acquired business. The operating results of this acquired operation are included in our professional diagnostics reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes.

(iii) Alere Toxicology

On February 17, 2010, we acquired Kroll Laboratory Specialists, Inc., headquartered in Gretna, Louisiana, which provides forensic quality substance abuse testing products and services across the United States. The preliminary aggregate purchase price was \$109.5 million, which was paid in cash. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately \$31.3 million related to the acquired business, which we have subsequently renamed Alere Toxicology Services, or Alere Toxicology. The operating results of Alere Toxicology are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(iv) Standard Diagnostics

On February 8, 2010, we acquired a 61.92% ownership interest in Standard Diagnostics via a tender offer for approximately \$162.1 million. On March 22, 2010, we acquired an incremental 13.37% ownership interest in Standard Diagnostics via a follow-on tender offer for approximately \$36.2 million. In June 2010, we acquired an incremental 2.84% ownership interest for approximately \$7.3 million, bringing our acquisition-related aggregate ownership interest in Standard Diagnostics to approximately 78.13%. Standard Diagnostics specializes in the medical diagnostics industry. Its main product lines relate to diagnostic reagents and devices for hepatitis, infectious diseases, tumor markers, fertility, drugs of abuse, urine strips and protein strips. The preliminary aggregate purchase price was



\$205.6 million in cash. Included in our consolidated statement of operations for the year ended December 31, 2010 is revenue totaling approximately \$78.9 million related to Standard Diagnostics. The operating results of Standard Diagnostics are included in our professional diagnostics reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes. During the fourth quarter of 2010, we acquired the remaining outstanding minority interests in Standard Diagnostics bringing our aggregate ownership interest to approximately 100%

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations (Continued)**

as of December 31, 2010. In connection with our purchase of shares from a certain minority shareholder, we incurred a compensation charge of \$60.1 million, as a result of the transition of the day-to-day management control of the business to us.

(v) Other acquisitions in 2010

During 2010, we acquired the following businesses for a preliminary aggregate purchase price of \$160.1 million, which consisted of initial cash payments totaling \$106.5 million, contingent consideration obligations with an acquisition date fair value of \$52.9 million and deferred purchase price consideration with an acquisition date present value of \$0.7 million.

RMD Networks, Inc., or RMD, located in Denver, Colorado, a provider of clinical groupware software and services designed to improve communication and coordination of care among providers, patients, and payers in the healthcare environment (Acquired January 2010)

certain assets of Streck, Inc., or Streck, located in Nebraska, a manufacturer of hematology, chemistry and immunology products for the clinical laboratory (Acquired January 2010)

assets of the diagnostics division of Micropharm Ltd., or Micropharm, located in Wales, United Kingdom, an expert in high quality antibody production in sheep for both diagnostic and therapeutic purposes, providing antisera on a contract basis for U.K. and overseas companies and academic institutions, mainly for research, therapeutic and diagnostic uses (Acquired March 2010)

Quantum Diagnostics Group Limited, or Quantum, headquartered in Essex, England, an independent provider of drug testing products and services to healthcare professionals across the U.K. and Europe (Acquired April 2010)

assets of the workplace health division of Good Health Solutions Pty Ltd., or GHS, located in East Sydney, Australia, an important player in the Australian health and wellness market, focusing on health screenings, health related consulting services, health coaching and fitness instruction (Acquired April 2010)

certain assets of Unotech Diagnostics, Inc., or Unotech, located in California, a privately-owned company engaged in the development, formulation, manufacture, packaging, supply and distribution of our BladderCheck NMP22 lateral flow test and related lateral flow products (Acquired June 2010)

Scipac Holdings Limited, or Scipac, headquartered in Kent, England, a diagnostic reagent company with an extensive product portfolio supplying purified human antigens, recombinant proteins and disease state plasma to a global customer base (Acquired June 2010)

a privately-owned research and development operation, located in San Diego, California (Acquired July 2010)

AdnaGen AG, or AdnaGen, located in Langenhagen, Germany, a company that focuses on the development of innovative tumor diagnostics for the detection of rare cells (Acquired November 2010)

Medlab Produtos Medicos Hospitalares Ltda, or Medlab, located in San Paulo, Brazil, a distributor of medical instruments and reagents to public and private laboratories throughout Brazil and Uruguay (Acquired December 2010)

Capital Toxicology, LLC, or Capital Toxicology, located in Austin, Texas, a privately-held toxicology business specializing in pain management services (Acquired December 2010)

F-20

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

The operating results of the acquired businesses mentioned above, except for RMD and GHS, are included in our professional diagnostics reporting unit and business segment. The operating results of RMD and GHS are included in our health management reporting unit and business segment. Our consolidated statement of operations for the year ended December 31, 2010 included revenue totaling approximately \$12.6 million related to these businesses. Goodwill has been recognized in all of the acquisitions, with the exception of Unotech, and amounted to approximately \$114.0 million. Goodwill related to the acquisition of Capitol Toxicology, which totaled \$11.0 million, is expected to be deductible for tax purposes.

A summary of the preliminary aggregate purchase price allocation for the acquisitions consummated in 2010 is as follows (in thousands):

	<b>Privately- Owned U.K. Research and Development</b>		<b>Standard</b>				
	<b>Immunalysis</b>	<b>Operation</b>	<b>Alere Toxicology</b>	<b>Diagnostics</b>	<b>Other</b>	<b>Total</b>	
Current assets	\$ 6,953	\$ 374	\$ 6,044	\$ 50,687	\$ 19,863	\$ 83,921	
Property, plant and equipment	1,092	152	3,300	18,580	14,039	37,163	
Goodwill	18,197	61,463	53,435	37,234	114,018	284,347	
Intangible assets	30,600	15,700	48,400	131,179	59,513	285,392	
Other non-current assets				13,341	317	13,658	
<b>Total assets acquired</b>	<b>56,842</b>	<b>77,689</b>	<b>111,179</b>	<b>251,021</b>	<b>207,750</b>	<b>704,481</b>	
Current liabilities	568	751	1,640	13,371	13,999	30,329	
Non-current liabilities	50	6,107		32,088	33,655	71,900	
<b>Total liabilities assumed</b>	<b>618</b>	<b>6,858</b>	<b>1,640</b>	<b>45,459</b>	<b>47,654</b>	<b>102,229</b>	
<b>Net assets acquired</b>	<b>56,224</b>	<b>70,831</b>	<b>109,539</b>	<b>205,562</b>	<b>160,096</b>	<b>602,252</b>	
Less:							
Contingent consideration	1,200	35,600			52,908	89,708	
Present value of deferred purchase price consideration					688	688	
<b>Cash paid</b>	<b>\$ 55,024</b>	<b>\$ 35,231</b>	<b>\$ 109,539</b>	<b>\$ 205,562</b>	<b>\$ 106,500</b>	<b>\$ 511,856</b>	



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

	Privately-owned U.K. Research and Development		Standard Alere		Other	Total	Weighted Average Useful Life
	Immunoanalysis operation	Toxicology	Diagnosics				
Core technology and patents	\$ 8,800	\$ 8,600	\$ 13,300	\$ 62,135	\$ 14,050	\$ 106,885	12.38 years
Quality systems Database					153	153	5 years
Trademarks and trade names	800			9,350	3,041	13,191	8.51 years
License agreements					459	459	10 years
Customer relationships	19,900	35,100	45,754	24,578		125,332	14.32 years
Non-compete agreements	300		255	2,095		2,650	4.18 years
Software					5,000	5,000	7 years
Distribution agreement	800					800	14 years
Manufacturing know-how					3,683	3,683	10.46 years
In-process research and development		7,100		13,685	5,800	26,585	N/A
Total intangible assets	\$ 30,600	\$ 15,700	\$ 48,400	\$ 131,179	\$ 59,513	\$ 285,392	

*(b) Acquisitions in 2009**(i) Acquisition of Tapestry Medical*

On November 6, 2009, we acquired Tapestry Medical, Inc., or Tapestry, located in Livermore, California, a privately-owned company that is a provider of products and related services designed to support anti-coagulation disease management for patients at risk for stroke and other clotting disorders. The aggregate purchase price was \$61.1 million, which consisted of an initial cash payment totaling \$45.1 million and a contingent consideration obligation with a fair value of \$16.0 million payable in shares of our common stock, except in the case of the 2010 earn-out which will be paid in cash. Included in our consolidated statements of operations for the year ended December 31, 2010 and 2009 is revenue totaling approximately \$54.1 million and \$1.8 million, respectively, related to Tapestry. The operating results of Tapestry are included in our health management reporting unit and business segment. The amount allocated to goodwill from this acquisition is deductible for tax purposes.

(ii) Acquisition of Free & Clear

On September 28, 2009, we acquired Free & Clear, Inc., or Free & Clear, located in Seattle, Washington, a privately-owned company that specializes in behavioral coaching to help employers, health plans and government agencies improve the overall health and productivity of their covered populations. The aggregate purchase price was \$121.5 million, which consisted of an initial cash payment totaling \$107.3 million and a contingent consideration obligation with a fair value of \$14.2 million. Included in our consolidated statements of operations for the year ended December 31, 2010 and 2009 is revenue totaling approximately \$75.3 million and \$14.3 million, respectively, related to Free & Clear. The operating results of Free & Clear are included in our health management reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes.

F-22

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations (Continued)**

(iii) Acquisition of Concateno

On August 11, 2009, we acquired Concateno plc, or Concateno, a publicly-traded company headquartered in the United Kingdom that specializes in the manufacture and distribution of rapid drugs of abuse diagnostic products used in health care, criminal justice, workplace and other testing markets. The aggregate purchase price was \$251.9 million, which consisted of \$178.8 million in cash, including \$0.5 million of cash paid for shares of Concateno common stock which we acquired prior to the acquisition date, 2,091,080 shares of our common stock with an aggregate fair value of \$70.2 million and \$2.9 million of fair value associated with Concateno employee stock options exchanged as part of the transaction. Our consolidated statements of operations for the year ended December 31, 2010 and 2009 included revenue totaling approximately \$78.8 million and \$33.3 million, respectively, related to Concateno. The operating results of Concateno are included in our professional diagnostics reporting unit and business segment. We do not expect the amount allocated to goodwill to be deductible for tax purposes.

(iv) Acquisition of ACON's Second Territory Business

On April 30, 2009, we completed our acquisition of the assets of ACON Laboratories, Inc.'s and certain related entities (collectively, ACON) business of researching, developing, manufacturing, distributing, marketing and selling lateral flow immunoassay and directly-related products (the Business) for the remainder of the world outside of the First Territory (as defined below), including China, Asia Pacific, Latin America, South America, the Middle East, Africa, India, Pakistan, Russia and Eastern Europe (the Second Territory Business). We acquired ACON's Business in the United States, Canada, Western Europe (excluding Russia, the former Soviet Republics that are not part of the European Union and Turkey), Israel, Australia, Japan and New Zealand (the First Territory) in March 2006. The aggregate purchase price for the Second Territory Business was approximately \$191.0 million (\$188.9 million present value), which consisted of cash payments totaling \$104.7 million, 1,202,691 shares of our common stock with an aggregate fair value of \$42.1 million and deferred purchase price consideration payable in cash and common stock with an aggregate fair value of \$42.1 million. Our consolidated statements of operations for the year ended December 31, 2010 and 2009 included revenue totaling approximately \$50.9 million and \$38.0 million, respectively related to the Second Territory Business. The operating results of the Second Territory Business are included in our professional diagnostics reporting unit and business segment. Goodwill resulting from this acquisition is generally not expected to be deductible for tax purposes depending on the tax jurisdiction.

(v) Other acquisitions in 2009

During 2009, we acquired the following assets and businesses for an aggregate purchase price of \$85.8 million (\$83.9 million present value), which consisted of \$45.4 million in cash, 128,513 shares of our common stock with an aggregate fair value of \$5.1 million, notes payable totaling \$7.9 million, deferred purchase price consideration payable in cash with an aggregate fair value of \$15.8 million, warrants with a fair value of \$0.1 million and contingent consideration obligations with an aggregate fair value of \$9.6 million which is recorded as a liability of which \$5.4 million is payable in shares of our common stock.

GeneCare Medical Genetics Center, Inc., or GeneCare, located in Chapel Hill, North Carolina, a medical genetics testing and counseling business (Acquired July 2009)



Edgar Filing: ALERE INC. - Form 10-K/A

Certain assets from CVS Caremark's Accordant Common disease management programs, or Accordant, whereby chronically-ill patients served by Accordant Common disease management programs will be managed and have access to expanded offerings provided by Alere (Acquired August 2009)

ZyCare, Inc., or ZyCare, located in Chapel Hill, North Carolina, a provider of technology and services used to help manage many chronic illnesses (Acquired August 2009)

F-23

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations (Continued)**

Medim Schweiz GmbH., or Medim, located in Zug, Switzerland, a distributor of point-of-care diagnostics testing products primarily to the Swiss marketplace (Acquired September 2009)

Biosyn Diagnostics Limited, or Biosyn, located in Belfast, Ireland, a distributor of point-of-care diagnostics testing products primarily to the Irish marketplace (Acquired October 2009)

Mologic Limited, or Mologic, located in Sharnbrook, United Kingdom, a research and development entity having extensive experience in applied immunoassay technology, as well as a broad understanding of medical diagnostic devices and antibody development (Acquired October 2009)

Jinsung Meditech, Inc., or JSM, located in Seoul, South Korea, a distributor of point-of-care diagnostics testing products primarily to the South Korean marketplace (Acquired December 2009)

Biolinker S.A., or Biolinker, located in Buenos Aires, Argentina, a distributor of point-of-care diagnostics testing products primarily to the Argentinean marketplace (Acquired December 2009)

51.0% share in Long Chain International Corp., or Long Chain, located in Taipei, Taiwan, a distributor of point-of-care diagnostics testing products primarily to the Taiwanese marketplace (Acquired December 2009). In January 2010, we acquired the remaining 49.0% interest in Long Chain.

The operating results of Medim, Biosyn, Mologic, JSM, Biolinker and Long Chain are included in our professional diagnostics reporting unit and business segment. The operating results of GeneCare, Accordant and Zycare are included in our health management reporting unit and business segment. Our consolidated statements of operations for the years ended December 31, 2010 and 2009 included revenue totaling approximately \$61.6 million and \$19.6 million, respectively, related to these businesses. Goodwill has been recognized in all transactions and amounted to approximately \$35.6 million. Goodwill related to the acquisitions of GeneCare and Accordant, which totaled \$12.8 million, is expected to be deductible for tax purposes. Goodwill related to all other acquisitions is not deductible for tax purposes.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

A summary of the aggregate purchase price allocation for the acquisitions consummated in 2009 is as follows (in thousands):

				<b>Second Territory</b>		
	<b>Tapestry</b>	<b>Free &amp; Clear</b>	<b>Concateno</b>	<b>Business</b>	<b>Other</b>	<b>Total</b>
Current assets	\$ 2,682	\$ 18,723	\$ 38,292	\$ 4,156	\$ 23,130	\$ 86,983
Property, plant and equipment	5,026	1,224	5,192	305	1,272	13,019
Goodwill	45,134	80,293	156,563	83,976	35,563	401,529
Intangible assets	10,680	44,100	102,735	100,600	40,861	298,976
Other non-current assets	25	1,786	2,405		631	4,847
<b>Total assets acquired</b>	<b>63,547</b>	<b>146,126</b>	<b>305,187</b>	<b>189,037</b>	<b>101,457</b>	<b>805,354</b>
Current liabilities	2,413	6,948	20,589	117	11,027	41,094
Non-current liabilities	13	17,640	32,707		6,531	56,891
<b>Total liabilities assumed</b>	<b>2,426</b>	<b>24,588</b>	<b>53,296</b>	<b>117</b>	<b>17,558</b>	<b>97,985</b>
Net assets acquired	61,121	121,538	251,891	188,920	83,899	707,369
Less:						
Contingent consideration	16,000	14,208			9,606	39,814
Notes payable					7,912	7,912
Fair value of common stock issued and options exchanged			73,099	42,142	5,172	120,413
Present value of deferred purchase price consideration				42,089	15,764	57,853
Cash paid	\$ 45,121	\$ 107,330	\$ 178,792	\$ 104,689	\$ 45,445	\$ 481,377

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

				<b>Second Territory</b>			<b>Weighted Average</b>
	<b>Tapestry</b>	<b>Free &amp; Clear</b>	<b>Concateno</b>	<b>Business</b>	<b>Other</b>	<b>Total</b>	<b>Useful Life</b>
	\$	\$ 4,600	\$ 500	\$ 3,000	\$ 5,220	\$ 13,320	6.46 years

Edgar Filing: ALERE INC. - Form 10-K/A

Core technology and patents							
Supply arrangements					1,581	1,581	8 years
Trademarks and trade names	3,000	3,400	25,184	1,900	270	33,754	14.14 years
Customer relationships	6,500	36,100	77,051	94,200	31,074	244,925	14.93 years
Non-compete agreements	1,180			1,500	1,600	4,280	2.91 years
In-process research and development					1,116	1,116	N/A
Total intangible assets	\$ 10,680	\$ 44,100	\$ 102,735	\$ 100,600	\$ 40,861	\$ 298,976	

F-25

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations (Continued)**

*(c) Acquisitions in 2008*

(i) Acquisition of Matria

On May 9, 2008, we acquired Matria Healthcare Inc., or Matria, a national provider of health improvement, disease management and high-risk pregnancy management programs and services. The aggregate purchase price was \$1.1 billion, which consisted of \$420.6 million in cash, Series B convertible preferred stock with a fair value of approximately \$657.9 million, \$17.3 million of fair value associated with Matria employee stock options exchanged as part of the transaction and \$18.0 million for direct acquisition costs. The operating results of Matria are included in our health management reporting unit and business segment. We expect that all of the amount allocated to goodwill will not be deductible for tax purposes.

(ii) Acquisition of BBI

On February 12, 2008, we acquired BBI Holdings Plc, or BBI, a publicly-traded company headquartered in the United Kingdom that specializes in the development and manufacture of non-invasive lateral flow tests and gold reagents. The aggregate purchase price was \$163.2 million, which consisted of \$138.6 million in cash, including \$14.7 million of cash paid for shares of BBI common stock which we owned prior to the acquisition date, common stock with an aggregate fair value of \$14.4 million, \$6.6 million for direct acquisition costs and \$3.6 million of fair value associated with BBI employee stock options exchanged as part of the transaction. The operating results of BBI are included in our professional and consumer diagnostics reporting units and business segments. We expect that all of the amount allocated to goodwill will not be deductible for tax purposes.

(iii) Other acquisitions in 2008

During 2008, we acquired the following assets and businesses for an aggregate purchase price of \$120.0 million, in which we paid \$86.0 million in cash, \$2.3 million in direct acquisition costs, and accrued contingent consideration and milestone payments totaling \$31.9 million. Upon settlement of certain milestones, we recognized a \$0.2 million foreign currency exchange loss which was included in the aggregate purchase price.

Panbio Limited, or Panbio, headquartered in Brisbane, Australia, an Australian publicly-traded company that develops and manufactures diagnostic tests for use in the diagnosis of a broad range of infectious diseases (Acquired January 2008)

Certain assets from Mochida Pharmaceutical Co., Ltd, or Mochida. As part of the acquisition of certain assets, Mochida transferred the exclusive distribution rights in Japan for certain Osteomark products (Acquired April 2008)

Privately-owned provider of care and health management services (Acquired July 2008)

Vision Biotech Pty Ltd, or Vision, located in Cape Town, South Africa, a privately-owned distributor of rapid diagnostic products predominantly to the South African marketplace (Acquired September 2008)

Edgar Filing: ALERE INC. - Form 10-K/A

Global Diagnostics CC, or Global, located in Johannesburg, South Africa, a privately-owned contract manufacturer and distributor of high quality rapid diagnostic tests predominantly to the South African marketplace (Acquired September 2008)

DiaTeam Diagnostika und Arzneimittel Großhandel GmbH, or DiaTeam, located in Linz, Austria, a privately-owned distributor of high quality rapid diagnostic tests predominantly to the Austrian marketplace (Acquired September 2008)

F-26

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

Prodimol Biotecnologia S.A., or Prodimol, located in Brazil, a privately-owned distributor of high quality rapid diagnostic tests predominantly to the Brazilian marketplace (Acquired October 2008)

Ameditech, Inc., or Ameditech, located in San Diego, California, a manufacturer of high quality drugs of abuse diagnostic tests (Acquired December 2008)

A summary of the aggregate purchase price allocation for the acquisitions consummated in 2008 is as follows (in thousands):

	<b>Matria</b>	<b>BBI</b>	<b>Other</b>	<b>Total</b>
Current assets	\$ 121,399	\$ 22,421	\$ 23,795	\$ 167,615
Property, plant and equipment	23,659	7,603	2,850	34,112
Goodwill	844,301	89,626	62,478	996,405
Intangible assets	325,385	90,201	54,802	470,388
Other non-current assets	35,063	3,001	314	38,378
<b>Total assets acquired</b>	<b>1,349,807</b>	<b>212,852</b>	<b>144,239</b>	<b>1,706,898</b>
Current liabilities	98,669	15,668	9,357	123,694
Non-current liabilities	137,346	33,953	14,843	186,142
<b>Total liabilities assumed</b>	<b>236,015</b>	<b>49,621</b>	<b>24,200</b>	<b>309,836</b>
<b>Net assets acquired</b>	<b>1,113,792</b>	<b>163,231</b>	<b>120,039</b>	<b>1,397,062</b>
Less:				
Acquisition costs paid	17,956	6,601	2,333	26,890
Contingent consideration			31,891	31,891
Realized foreign currency exchange loss			(179)	(179)
Fair value of common/preferred stock issued and options exchanged	675,257	18,036		693,293
<b>Cash paid</b>	<b>\$ 420,579</b>	<b>\$ 138,594</b>	<b>\$ 85,994</b>	<b>\$ 645,167</b>

The following are the intangible assets acquired and their respective amortizable lives (dollars in thousands):

	<b>Matria</b>	<b>BBI</b>	<b>Other</b>	<b>Total</b>	<b>Weighted Average Useful Life</b>
--	---------------	------------	--------------	--------------	-------------------------------------

Edgar Filing: ALERE INC. - Form 10-K/A

Core technology and patents	\$ 31,000	\$ 28,043	\$ 7,220	\$ 66,263	9.94 years
Database	25,000			25,000	10 years
Trademarks and trade names and other intangibles	1,185	16,180	5,072	22,437	14.76 years
Customer relationships	253,000	45,978	40,605	339,583	13.73 years
Non-compete agreements	15,200		1,063	16,263	2 years
Manufacturing know-how			842	842	5 years
Total intangible assets	\$ 325,385	\$ 90,201	\$ 54,802	\$ 470,388	

Panbio, Mochida, Vision, Global, DiaTeam, Prodimol and Ameditech are included in our professional diagnostics reporting unit and business segment; and our privately-owned health management acquisition is included in our health management reporting unit and business segment. Goodwill has been recognized in the

F-27

---



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

Panbio, Vision, Global, DiaTeam, Prodimol, Ameditech and our privately-owned health management business transactions and amounted to approximately \$62.5 million. Goodwill related to these acquisitions, excluding Ameditech and the privately-owned health management acquisition, is not deductible for tax purposes.

*(d) Restructuring Plans Related to Business Combinations*

In connection with several of our acquisitions consummated during 2008 and prior, we initiated integration plans to consolidate and restructure certain functions and operations, including the relocation and termination of certain personnel of these acquired entities and the closure of certain of the acquired entities' leased facilities. These costs have been recognized as liabilities assumed, in connection with the acquisition of these entities and are subject to potential adjustments as certain exit activities are confirmed or refined. The following table summarizes the liabilities established for exit activities related to these acquisitions (in thousands):

	<b>Severance Related</b>	<b>Facility And Other</b>	<b>Total Exit Activities</b>
Balance at December 31, 2007	\$ 14,579	\$ 1,898	\$ 16,477
Restructuring plan accruals and adjustments	19,561	3,897	23,458
Payments	(23,407)	(854)	(24,261)
Currency adjustments	(385)	(15)	(400)
Balance at December 31, 2008	10,348	4,926	15,274
Restructuring plan accruals and adjustments	203	5,317	5,520
Payments	(5,182)	(3,243)	(8,425)
Currency adjustments		2	2
Balance at December 31, 2009	5,369	7,002	12,371
Restructuring plan accruals and adjustments	(2,167)	(281)	(2,448)
Payments	(2,863)	(3,701)	(6,564)
Balance at December 31, 2010	\$ 339	\$ 3,020	\$ 3,359

**(i) 2008 Acquisitions**

In connection with our acquisition of Matria, we implemented an integration plan to improve operating efficiencies and eliminate redundant costs resulting from the acquisition. The restructuring plan impacted all cost centers within the Matria organization, as activities were combined with our existing business operations. We recorded \$18.5 million in exit costs, of which \$13.8 million relates to change of control and severance costs to involuntarily terminate employees and \$4.7 million related to facility exit costs. During 2010, we determined that \$1.5 million in change of control costs and \$0.2 million in facility exit costs would not be incurred, thereby reducing the assumed liability and goodwill related to the Matria acquisition by \$1.7 million. As of December 31, 2010, \$1.2 million in exit costs remain

unpaid. See Note 20 for additional restructuring charges related to the Matria facility exit costs, within the health management reporting unit.

In conjunction with our acquisition of Panbio, we formulated a restructuring plan to realize efficiencies and cost savings. In February 2008, we agreed upon a plan to close Panbio's facility located in Columbia, Maryland. The manufacturing operation at the Maryland-based facility was transferred to a third-party manufacturer, the sales of the products at this facility were transferred to our shared services center in Orlando, Florida and the distribution operations were transferred to our distribution facility in Freehold, New Jersey. We recorded \$1.0 million in exit costs, including \$0.8 million related to facility and other exit

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(4) Business Combinations (Continued)**

costs and \$0.2 million related to severance costs to involuntarily terminated employees. As of December 31, 2010, \$0.3 million in facility exit costs remain unpaid. See Note 20 for additional restructuring charges related to the Panbio facility closure and integration.

Although we believe our plan and estimated exit costs for our 2008 acquisitions are reasonable, actual spending for exit activities may differ from current estimated exit costs.

*(ii) 2007 Acquisitions*

During 2007, we formulated restructuring plans in connection with our acquisition of Cholestech Corporation, or Cholestech, consistent with our acquisition strategy to realize operating efficiencies and cost savings. Additionally, in March 2008, we announced plans to close the Cholestech facility in Hayward, California. We have transitioned the manufacturing of the related products to our facility in San Diego, California and have transitioned the sales and distribution of the products to our shared services center in Orlando, Florida. Since inception of the plans, we recorded \$8.6 million in exit costs, of which \$5.9 million relates to executive change of control agreements and severance costs to involuntarily terminate employees and \$2.7 million relates to facility exit costs. During the third quarter of 2010, we determined that \$0.6 million in change of control and severance costs would not be incurred, thereby reducing the assumed liability and goodwill related to the Cholestech acquisition. As of December 31, 2010, \$1.9 million in exit costs remain unpaid. Although we believe our plans and estimated exit costs are reasonable, actual spending for exit activities may differ from current estimated exit costs.

In conjunction with our acquisitions of Biosite Incorporated, or Biosite, HemoSense, Inc., or HemoSense, Alere Medical, Inc., or Alere Medical, ParadigmHealth, Inc., or ParadigmHealth, and Matritech, Inc., or Matritech, we implemented integration plans to improve efficiencies and eliminate redundant costs resulting from the acquisitions. Since inception of the plans, we recorded \$20.6 million in exit costs, including \$18.6 million in change in control and severance costs to involuntarily terminated employees and \$2.0 million in facility and other exit costs primarily related to the closure of the Matritech and HemoSense facilities. As of December 31, 2010, substantially all exit costs have been paid.

See Note 20 for additional restructuring charges related to the Cholestech and HemoSense facility closures and integrations.

*(e) Pro Forma Financial Information*

The following table presents selected unaudited financial information, including the assets of the ACON Second Territory Business and Standard Diagnostics, as if the acquisition of these entities had occurred on January 1, 2009. Pro forma results exclude adjustments for various other less significant acquisitions completed since January 1, 2009, as these acquisitions did not materially affect our results of operations.

The pro forma results are derived from the historical financial results of the acquired businesses for the periods presented and are not necessarily indicative of the results that would have occurred had the acquisitions been consummated on January 1, 2009 (in thousands, except per share amount).



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(4) Business Combinations (Continued)**

	<b>2010</b>	<b>2009</b>
Pro forma net revenue	\$ 2,161,500	\$ 1,994,771
Pro forma net income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	\$ (1,048,463)	\$ 11,403
Pro forma net income (loss) available to common stockholders	\$ (1,037,066)	\$ 13,336
Pro forma net income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries per common share basic(1)	\$ (12.42)	\$ 0.14
Pro forma net income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries per common share diluted(1)	\$ (12.42)	\$ 0.14
Pro forma net income (loss) available to common stockholders basic(1)	\$ (12.28)	\$ 0.16
Pro forma net income (loss) available to common stockholders diluted(1)	\$ (12.28)	\$ 0.16

(1) Net income (loss) per common share amounts are computed as described in Note 12.

F-30

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(5) Goodwill and Other Intangible Assets**

The following is a summary of goodwill and other intangible assets as of December 31, 2010 (in thousands, except useful life):

	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization and Impairment Losses</b>	<b>Net Carrying Value</b>	<b>Weighted Average Useful Life</b>
<b>Amortized intangible assets:</b>				
Core technology and patents	\$ 660,245	\$ 195,559	\$ 464,686	13.45 years
Other intangible assets:				
Supplier relationships	18,775	13,255	5,520	9.19 years
Trademarks and trade names	226,290	60,814	165,476	9.65 years
License agreements	11,325	10,292	1,033	7.04 years
Customer relationships	1,525,842	532,799	993,043	16.11 years
Manufacturing know-how	11,215	5,071	6,144	12.62 years
Other	136,154	64,475	71,679	7.36 years
Total other intangible assets	1,929,601	686,706	1,242,895	
Total intangible assets with finite lives	\$ 2,589,846	\$ 882,265	\$ 1,707,581	
<b>Intangible assets with indefinite lives:</b>				
Goodwill	\$ 3,837,657	\$ 1,006,357	\$ 2,831,300	
Other intangible assets(1)	28,183		28,183	
Total intangible assets with indefinite lives	\$ 3,865,840	\$ 1,006,357	\$ 2,859,483	

(1) Primarily includes in-process research and development recorded in connection with certain acquisitions completed during 2009 and 2010.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(5) Goodwill and Other Intangible Assets (Continued)**

The following is a summary of goodwill and other intangible assets as of December 31, 2009 (in thousands, except useful life):

	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Net Carrying Value</b>	<b>Weighted Average Useful Life</b>
<b>Amortized intangible assets:</b>				
Core technology and patents	\$ 558,036	\$ 136,317	\$ 421,719	13.92 years
Other intangible assets:				
Supplier relationships	18,939	11,781	7,158	9.21 years
Trademarks and trade names	174,856	37,720	137,136	10.95 years
License agreements	10,825	9,881	944	6.91 years
Customer relationships	1,395,786	343,728	1,052,058	16.31 years
Manufacturing know-how	7,259	4,190	3,069	13.77 years
Other	103,642	39,299	64,343	6.02 years
Total other intangible assets	1,711,307	446,599	1,264,708	
Total intangible assets with finite lives	\$ 2,269,343	\$ 582,916	\$ 1,686,427	
<b>Intangible assets with indefinite lives:</b>				
Goodwill	\$ 3,463,358	\$	\$ 3,463,358	
Other intangible assets(1)	43,644		43,644	
Total intangible assets with indefinite lives	\$ 3,507,002	\$	\$ 3,507,002	

(1) Primarily includes trademarks and trade names. During 2010, we began the process of rebranding our company and key products under the name Alere. In connection with the rebranding initiative, we assigned economic useful lives to certain intangible assets previously classified as other intangible assets with indefinite lives. Of the \$43.6 million recorded as other intangible assets with indefinite lives as of December 31, 2009, we reclassified \$42.9 million to other intangible assets with finite lives during 2010.

The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets on patterns in which the economic benefits are expected to be realized. Amortization expense of intangible assets, which in the

aggregate amounted to \$298.1 million, \$255.4 million and \$213.8 million in 2010, 2009 and 2008, respectively, is included in cost of net revenue, research and development, sales and marketing and general and administrative in the accompanying consolidated statements of operations. The allocation of amortization expense to the expense categories is based on the intended usage and the expected benefits of the intangible assets in relation to the expense categories.



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(5) Goodwill and Other Intangible Assets (Continued)**

The following is a summary of estimated aggregate amortization expense of intangible assets for each of the five succeeding fiscal years as of December 31, 2010 (in thousands):

2011	\$ 282,349
2012	\$ 235,824
2013	\$ 202,054
2014	\$ 178,391
2015	\$ 156,042

During the fourth quarter, we perform our annual impairment tests of the carrying value of our goodwill by reporting unit. Our annual impairment review conducted during the fourth quarter of 2010 indicated that a goodwill impairment charge was required in our health management business segment and reporting unit. For further discussion see Note 2(h).

We allocate goodwill by reporting unit based on the relative percentage of estimated future revenues generated for the respective reporting unit as of the acquisition date. Goodwill amounts allocated to our professional diagnostics, health management and consumer diagnostics reporting units are summarized as follows (in thousands):

	<b>Professional Diagnostics</b>	<b>Health Management</b>	<b>Consumer Diagnostics</b>	<b>Total</b>
Goodwill at December 31, 2008	\$ 1,713,223	\$ 1,280,179	\$ 52,481	\$ 3,045,883
Acquisitions(1)	262,567	141,964		404,531
Other(2)	13,133	62	(251)	12,944
Goodwill at December 31, 2009	\$ 1,988,923	\$ 1,422,205	\$ 52,230	\$ 3,463,358
Acquisitions(1)	327,467	36,948		364,415
Goodwill impairment charge(3)		(1,006,357)		(1,006,357)
Other(2)	9,724	166	(6)	9,884
Goodwill at December 31, 2010	\$ 2,326,114	\$ 452,962	\$ 52,224	\$ 2,831,300

(1) Includes initial purchase price allocation, purchase accounting adjustments recorded to the acquired entities opening balance sheet and additional payments made for earn-outs and milestones achieved.

(2) These amounts relate primarily to adjustments resulting from fluctuations in foreign currency exchange rates.

(3) We recorded a goodwill impairment charge of approximately \$1.0 billion related to our health management business segment and reporting unit. Any further reduction or impairment of the value of goodwill or other

intangible assets will result in additional charges against earnings, which could materially reduce our reported results of operations in future periods.

We generally expense costs incurred to internally-develop intangible assets, except for costs that are incurred to establish patents and trademarks, such as legal fees for initiating, filing and obtaining the patents and trademarks. As of December 31, 2010, we had approximately \$8.9 million of costs capitalized, net of amortization, in connection with establishing patents and trademarks which are included in other intangible assets, net, in the accompanying consolidated balance sheets. Upon the initial filing of the patents and trademarks, we commence amortization of such intangible assets over their estimated useful lives. Costs incurred to maintain the patents and trademarks are expensed as incurred.

F-33

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(6) Long-term Debt**

We had the following long-term debt balances outstanding (in thousands):

	<b>December 31,</b>	
	<b>2010</b>	<b>2009</b>
First Lien Credit Agreement Term loans	\$ 941,250	\$ 951,000
First Lien Credit Agreement Revolving line-of-credit		142,000
Second Lien Credit Agreement	250,000	250,000
3% Senior subordinated convertible notes	150,000	150,000
9% Senior subordinated notes	389,686	388,278
7.875% Senior notes	244,756	243,959
8.625% Senior subordinated notes	400,000	
Lines-of-credit	4,405	2,902
Other	15,360	19,346
	2,395,457	2,147,485
Less: Current portion	(16,891)	(18,970)
	\$ 2,378,566	\$ 2,128,515

The following describes each of the above listed debt instruments:

*(a) First Lien Credit Agreement and Second Lien Credit Agreement*

On June 26, 2007, in conjunction with our acquisition of Biosite, we entered into a First Lien Credit Agreement, or senior secured credit facility, and a Second Lien Credit Agreement, or junior secured credit facility, collectively, secured credit facility, with certain lenders, General Electric Capital Corporation as administrative agent and collateral agent, and certain other agents and arrangers, and certain related guaranty and security agreements. The senior secured credit facility initially provided for term loans in the aggregate amount of \$900.0 million and, subject to our continued compliance with the senior secured credit facility, a \$150.0 million revolving line-of-credit. The junior secured credit facility provides for term loans in the aggregate amount of \$250.0 million. We may repay any future borrowings under the senior secured credit facility revolving line-of-credit at any time, but in no event later than June 26, 2013. We must repay the entire junior facility term loan on June 26, 2015. As of December 31, 2010, the term loans and the revolving line-of-credit under the senior secured credit facility bore interest at 2.26% and 4.25%, respectively. The term loan under the junior secured credit facility bore interest at 4.51%.

On November 15, 2007, we amended the senior secured credit facility, increasing the total amount of credit available to us to \$1,125,000,000 resulting from the increase in the term loans to the aggregate amount of \$975.0 million. Additionally, under the amendment, we must repay the senior secured credit facility term loans as follows: (a) in two initial installments in the amount of \$2,250,000 each on September 30, 2007 and December 31, 2007 (each of which installment payment has been made), (b) in twenty-five consecutive quarterly installments, beginning on March 31,

2008 and continuing through March 31, 2014, in the amount of \$2,437,500 each and (c) in a final installment on June 26, 2014 in an amount equal to the then outstanding principal balance of the senior secured credit facility term loans.

As of December 31, 2010, aggregate borrowings amounted to \$1.2 billion under the term loans. Interest expense related to the secured credit facility for the year ended December 31, 2010, including amortized deferred financing costs, was \$60.6 million. As of December 31, 2010, accrued interest related to the secured credit facility amounted to \$0.9 million. As of December 31, 2010, we were in compliance with all debt

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(6) Long-term Debt (Continued)**

covenants related to the above debt, which consisted principally of maximum consolidated leverage and minimum interest coverage requirements.

In August 2007, we entered into interest rate swap contracts, with an effective date of September 28, 2007, that have a total notional value of \$350.0 million and had an original maturity date of September 28, 2010. These interest rate swap contracts paid us variable interest at the three-month LIBOR rate, and we paid the counterparties a fixed rate of 4.85%. In March 2009, we extended our August 2007 interest rate hedge for an additional two-year period commencing in September 2010 at a one-month LIBOR rate of 2.54%. These interest rate swap contracts were entered into to convert \$350.0 million of the \$1.2 billion variable rate term loans under the secured credit facilities into fixed rate debt.

In January 2009, we entered into interest rate swap contracts, with an effective date of January 14, 2009, that had a total notional value of \$500.0 million and a maturity date of January 5, 2011. These interest rate swap contracts paid us variable interest at the one-month LIBOR rate, and we paid the counterparties a fixed rate of 1.195%. These interest rate swap contracts were entered into to convert \$500.0 million of the \$1.2 billion variable rate term loan under the secured credit facility into fixed rate debt. We did not extend the terms of this interest rate swap after January 5, 2011.

*(b) 3% Senior Subordinated Convertible Notes, Principal Amount \$150.0 million*

On May 14, 2007, we sold \$150.0 million principal amount of 3% senior subordinated convertible notes due 2016, or the Convertible Notes, in a private placement to qualified institutional buyers. At the initial conversion price of \$52.30, the Convertible Notes were convertible into an aggregate 2,868,120 shares of our common stock. The conversion price was subject to adjustment one year from the date of sale. Based upon the daily volume-weighted price per share of our common stock for the thirty consecutive trading days ending May 9, 2008, the conversion price decreased from \$52.30 to \$43.98 in May 2008. The decrease in conversion price resulted in additional shares of our common stock becoming issuable upon conversion of our senior subordinated convertible notes. The senior subordinated convertible notes are now convertible into 3.4 million shares of our common stock at a conversion price of \$43.98. Interest accrues at 3% per annum, compounded daily, on the outstanding principal amount and is payable in arrears on May 15th and November 15th, which started on November 15, 2007. Interest expense for the year ended December 31, 2010 and 2009, including amortized deferred costs, was \$5.0 million and \$5.1 million, respectively.

*(c) 9% Senior Subordinated Notes*

On May 12, 2009, we completed the sale of \$400.0 million aggregate principal amount of 9% senior subordinated notes due 2016, or the 9% subordinated notes, in a public offering. Net proceeds from this offering amounted to \$379.5 million, which was net of underwriters' commissions totaling \$8.0 million and original issue discount totaling \$12.5 million. The net proceeds are intended to be used for general corporate purposes. At December 31, 2010, we had \$389.7 million in indebtedness under our 9% subordinated notes.

The 9% subordinated notes, which were issued under an Indenture dated May 12, 2009, as amended or supplemented, the 9% Indenture, accrue interest from the date of their issuance, or May 12, 2009, at the rate of 9% per year. Interest on the notes are payable semi-annually on May 15 and November 15, commencing on November 15, 2009. The notes mature on May 15, 2016, unless earlier redeemed.

We may redeem the 9% subordinated notes, in whole or part, at any time on or after May 15, 2013, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to, but excluding, the redemption date. The premium declines from 4.50% during the twelve months after May 15, 2013 to 2.25% during the twelve months after May 15, 2014 to zero on and after May 15, 2015. At any time prior to May 15, 2012, we may redeem up to 35% of the aggregate principal amount of the

F-35

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(6) Long-term Debt (Continued)**

9% subordinated notes with money that we raise in certain equity offerings so long as (i) we pay 109% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 9% subordinated notes remains outstanding afterwards. In addition, at any time prior to May 15, 2013, we may redeem some or all of the 9% subordinated notes by paying the principal amount of the notes being redeemed plus the payment of a make-whole premium, plus accrued and unpaid interest to, but excluding, the redemption date.

If a change of control occurs, subject to specified conditions, we must give holders of the 9% subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to, but excluding, the date of the purchase.

If we, or our, subsidiaries engage in asset sales, we, or they, generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, prepay senior debt or make an offer to purchase a principal amount of the 9% subordinated notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the notes will be 100% of their principal amount, plus accrued and unpaid interest.

The 9% subordinated notes are unsecured and are subordinated in right of payment to all of our existing and future senior debt, including our borrowing under our secured credit facilities. Our obligations under the 9% subordinated notes and the 9% Indenture are fully and unconditionally guaranteed, jointly and severally, on an unsecured senior subordinated basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt. See Note 25 for guarantor financial information.

The 9% Indenture contains covenants that will limit our ability, and the ability of our subsidiaries, to, among other things, incur additional debt; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated debt; make certain investments; create liens on assets; transfer or sell assets; engage in transactions with affiliates; create restrictions on our or their ability pay dividends or make loans, asset transfers or other payments to us or them; issue capital stock; engage in any business, other than our or their existing businesses and related businesses; enter into sale and leaseback transactions; incur layered indebtedness and consolidate, merge or transfer all or substantially all of our, or their, assets, taken as a whole. These covenants are subject to certain exceptions and qualifications.

Interest expense related to our 9% subordinated notes for the year ended December 31, 2010, including amortization of deferred financing costs and original issue discounts, was \$38.3 million. As of December 31, 2010, accrued interest related to the senior subordinated notes amounted to \$4.5 million.

*(d) 7.875% Senior Notes*

During the third quarter of 2009, we sold a total of \$250.0 million aggregate principal amount of 7.875% senior notes due 2016, or the 7.875% senior notes, in two separate transactions. On August 11, 2009, we sold \$150.0 million aggregate principal amount of 7.875% senior notes in a public offering. Net proceeds from this offering amounted to approximately \$145.0 million, which was net of underwriters' commissions totaling \$2.2 million and original issue discount totaling \$2.8 million. The net proceeds were used to fund our acquisition of Concateno. At December 31,

2010, we had \$147.7 million in indebtedness under this issuance of our 7.875% senior notes.

On September 28, 2009, we sold \$100.0 million aggregate principal amount of 7.875% senior notes in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers. We also agreed to file a registration statement with the SEC so that the holders of these notes could exchange



**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(6) Long-term Debt (Continued)**

the notes for registered notes that have substantially identical terms as the original notes. We filed this registration statement with the SEC on February 12, 2010 and the exchange offer was completed on June 11, 2010. Net proceeds from this offering amounted to approximately \$95.0 million, which was net of the initial purchasers' original issue discount totaling \$3.5 million and offering expenses totaling approximately \$1.5 million. The net proceeds were used to partially fund our acquisition of Free & Clear. At December 31, 2010, we had \$97.1 million in indebtedness under this issuance of our 7.875% senior notes.

The 7.875% senior notes were issued under an Indenture dated August 11, 2009, as amended or supplemented, the 7.875% Indenture. The 7.875% senior notes accrue interest from the dates of their respective issuances at the rate of 7.875% per year. Interest on the notes are payable semi-annually on February 1 and August 1, commencing on February 1, 2010. The notes mature on February 1, 2016, unless earlier redeemed.

We may redeem the 7.875% senior notes, in whole or part, at any time on or after February 1, 2013, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to, but excluding, the redemption date. The premium declines from 3.938% during the twelve months on and after February 1, 2013 to 1.969% during the twelve months on and after February 1, 2014 to zero on and after February 1, 2015. At any time prior to August 1, 2012, we may redeem up to 35% of the aggregate principal amount of the 7.875% senior notes with money that we raise in certain equity offerings, so long as (i) we pay 107.875% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date; (ii) we redeem the notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 7.875% senior notes remains outstanding afterwards. In addition, at any time prior to February 1, 2013, we may redeem some or all of the 7.875% senior notes by paying the principal amount of the notes being redeemed plus the payment of a make-whole premium, plus accrued and unpaid interest to, but excluding, the redemption date.

If a change of control occurs, subject to specified conditions, we must give holders of the 7.875% senior notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to, but excluding, the date of the purchase.

If we, or our, subsidiaries engage in asset sales, we, or they, generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, prepay certain indebtedness or make an offer to purchase a principal amount of the 7.875% senior notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the notes will be 100% of their principal amount, plus accrued and unpaid interest.

The 7.875% senior notes are unsecured and are equal in right of payment to all of our existing and future senior debt, including our borrowing under our secured credit facilities. Our obligations under the 7.875% senior notes and the 7.875% Indenture are fully and unconditionally guaranteed, jointly and severally, on an unsecured senior basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are equal in right of payment to all of their existing and future senior debt. See Note 25 for guarantor financial information.

The 7.875% Indenture contains covenants that will limit our ability, and the ability of our subsidiaries, to, among other things, incur additional debt; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated debt; make certain investments; create liens on assets; transfer or sell assets; engage in transactions with

affiliates; create restrictions on our or their ability pay dividends or make loans, asset transfers or other payments to us or them; issue capital stock; engage in any business, other than our or their existing businesses and related businesses; enter into sale and leaseback transactions; incur layered indebtedness and consolidate, merge or transfer all or substantially all of our, or their, assets, taken as a whole. These covenants are subject to certain exceptions and qualifications. Interest expense related to our

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(6) Long-term Debt (Continued)**

7.875% senior notes for the year ended December 31, 2010, including amortization of deferred financing costs and original issue discounts, was \$21.3 million. As of December 31, 2010, accrued interest related to the senior notes amounted to \$8.2 million.

*(e) 8.625% Senior Subordinated Notes*

On September 21, 2010, we completed the sale of \$400.0 million aggregate principal amount of the 8.625% senior subordinated notes due 2018, or the 8.625% subordinated notes, in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States. The proceeds are intended to be used for working capital and other general corporate purposes. At December 31, 2010, we had \$400.0 million in indebtedness under our 8.625% subordinated notes.

The 8.625% subordinated notes, which were issued under a supplemental indenture dated September 21, 2010, as amended or supplemented, the 8.625% Indenture, accrue interest from the date of their issuance, at the rate of 8.625% per year. Interest on the notes is payable semi-annually on April 1 and October 1, commencing on April 1, 2011. The notes mature on October 1, 2018, unless earlier redeemed.

We may redeem the 8.625% subordinated notes, in whole or part, at any time (which may be more than once) on or after October 1, 2014, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to, but excluding, the redemption date. The premium declines from 4.313% during the twelve months on and after October 1, 2014 to 2.156% during the twelve months on and after October 1, 2015 to zero on and after October 1, 2016. Prior to October 1, 2013, we may redeem, in whole or part, at any time (which may be more than once), up to 35% of the aggregate principal amount of the 8.625% subordinated notes with money that we raise in certain equity offerings so long as (i) we pay 108.625% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 8.625% subordinated notes, including any 8.625% subordinated notes issued after September 21, 2010, remains outstanding afterwards. In addition, at any time prior to October 1, 2014, we may redeem some or all of the 8.625% subordinated notes by paying the principal amount of the notes being redeemed plus the payment of a make-whole premium, plus accrued and unpaid interest to, but excluding, the redemption date.

If a change of control occurs, subject to specified conditions, we must give holders of the 8.625% subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to, but excluding, the date of the purchase.

If we or our subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 8.625% subordinated notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the notes will be 100% of their principal amount, plus accrued and unpaid interest.

The 8.625% subordinated notes are unsecured and are subordinated in right of payment to all of our existing and future senior debt, including our borrowing under our secured credit facilities. Our obligations under the 8.625% subordinated notes and the 8.625% Indenture are fully and unconditionally guaranteed, jointly and severally,

on an unsecured senior subordinated basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt. See Note 25 for guarantor financial information.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(6) Long-term Debt (Continued)**

The 8.625% Indenture contains covenants that will limit our ability and the ability of our subsidiaries to, among other things, incur additional debt; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated debt; make certain investments; create liens on assets; transfer or sell assets; engage in transactions with affiliates; create restrictions on our or their ability to pay dividends or make loans, asset transfers or other payments to us or them; issue capital stock of our or their subsidiaries; engage in any business, other than our or their existing businesses and related businesses; enter into sale and leaseback transactions; incur layered indebtedness; and consolidate, merge or transfer all or substantially all of our or their assets, taken as a whole. These covenants are subject to certain exceptions and qualifications. Interest expense related to our 8.625% subordinated notes for the year ended December 31, 2010, including amortization of deferred financing costs, was \$9.9 million. As of December 31, 2010, accrued interest related to the subordinated notes amounted to \$9.6 million.

*(f) Lines of credit*

Some of our subsidiaries maintain local lines of credit for short-term advances. Total available credit under the local lines of credit is approximately \$5.4 million, of which \$4.4 million was borrowed and outstanding as of December 31, 2010.

*(g) Other Debt*

Included in other debt above, for the year ended December 31, 2010, are borrowings by certain of our subsidiaries from various financial institutions. The borrowed funds are used to fund capital expenditure and working capital requirements. Interest expense on these borrowings was \$1.1 million for the year ended December 31, 2010.

*(i) Maturities of Long-term Debt*

The following is a summary of the maturities of long-term debt outstanding on December 31, 2010 (in thousands):

2011	\$	16,891
2012		12,125
2013		9,922
2014		912,174
2015		250,155
Thereafter		1,209,748
		2,411,015
Less: Original issue discounts		(15,558)
	\$	2,395,457

**(7) Fair Value Measurements**

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(7) Fair Value Measurements (Continued)**

measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

Described below are the three levels of inputs that may be used to measure fair value:

*Level 1* Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets and liabilities include investments in marketable securities.

*Level 2* Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 liabilities include interest rate swap contracts.

*Level 3* Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of the contingent consideration obligations related to our acquisitions completed after January 1, 2009 are valued using Level 3 inputs.

The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2010 and 2009, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

Description	December 31, 2010	Quoted Prices in		
		Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
Assets:				
Marketable securities	\$ 11,948	\$ 11,948	\$	\$
Total assets	\$ 11,948	\$ 11,948	\$	\$
Liabilities:				
Interest rate swap liability(1)	\$ 11,980	\$	\$ 11,980	\$
Contingent consideration obligations(2)	132,879			132,879
Total liabilities	\$ 144,859	\$	\$ 11,980	\$ 132,879





**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(7) Fair Value Measurements (Continued)**

<b>Description</b>	<b>December 31, 2009</b>	<b>Quoted Prices in Active Markets (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Unobservable Inputs (Level 3)</b>
<b>Assets:</b>				
Marketable securities	\$ 2,450	\$ 2,450	\$	\$
Total assets	\$ 2,450	\$ 2,450	\$	\$
<b>Liabilities:</b>				
Interest rate swap liability(1)	\$ 15,945	\$	\$ 15,945	\$
Contingent consideration obligations(2)	43,178			43,178
Total liabilities	\$ 59,123	\$	\$ 15,945	\$ 43,178

(1) The fair value of our interest rate swaps is based on the application of standard discounted cash flow models using market interest rate data.

(2) The fair value measurements for our contingent consideration obligations related to the acquisitions completed after January 1, 2009 are valued using Level 3 inputs. We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Changes in the value of these contingent consideration obligations are recorded as income or expense, a component of operating income in our consolidated statement of operations. See Note 11 for additional information on the valuation of our contingent consideration obligations.

Changes in the fair value of our Level 3 contingent consideration obligations during the year ended December 31, 2010 were as follows (in thousands):

Fair value of contingent consideration obligations, January 1, 2010	\$ 43,178
Acquisition date fair value of contingent consideration obligations recorded	88,400
Payments	(500)
Adjustments, net (income) expense	1,801
Fair value of contingent consideration obligations, December 31, 2010	\$ 132,879

At December 31, 2010 and 2009, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

Both the carrying amounts and estimated fair values of our long-term debt were \$2.4 billion and \$2.1 billion at December 31, 2010 and 2009, respectively. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information and may not be representative of actual values that could have been or will be realized in the future.

F-41

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(8) Capital Leases**

The following is a schedule of the future minimum lease payments under the capital leases, together with the present value of such payments as of December 31, 2010 (in thousands):

2011	\$ 2,126
2012	773
2013	527
2014	80
2015	24
Total future minimum lease payments	3,530
Less: Imputed interest	(2)
Present value of future minimum lease payments	3,528
Less: Current portion	(2,126)
	\$ 1,402

At December 31, 2010, the capitalized amounts of the building, machinery and equipment and computer equipment under capital leases were as follows (in thousands):

Machinery, laboratory equipment and tooling	\$ 5,916
Computer equipment	18
Furniture and fixtures	179
Leasehold improvements	72
	6,185
Less: Accumulated amortization	(2,039)
	\$ 4,146

The amortization expense of assets recorded under capital leases is included in depreciation and amortization expense of property, plant and equipment.

**(9) Postretirement Benefit Plans***(a) Employee Savings Plans*

Our company and several of our U.S.-based subsidiaries sponsor various 401(k) savings plans, to which eligible domestic employees may voluntarily contribute a portion of their income, subject to statutory limitations. In addition

to the participants' own contributions to these 401(k) savings plans, we match such contributions up to a designated level. Total matching contributions related to employee savings plans were \$6.9 million, \$6.4 million and \$4.6 million in 2010, 2009 and 2008, respectively.

F-42

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(9) Postretirement Benefit Plans (Continued)***(b) U.K. Pension Plans*

Changes in benefit obligations, plan assets, funded status and amounts recognized on the accompanying balance sheet as of and for the years ended December 31, 2010 and 2009, for our Defined Benefit Plan, were as follows (in thousands):

	<b>2010</b>	<b>2009</b>
<b>Change in projected benefit obligation</b>		
Benefit obligation at beginning of year	\$ 12,909	\$ 9,078
Interest cost	717	596
Actuarial loss	1,195	1,990
Benefits paid	(167)	(127)
Curtailment loss (gain)		313
Foreign exchange impact	(263)	1,059
Benefit obligation at end of year	\$ 14,391	\$ 12,909
<b>Change in plan assets</b>		
Fair value of plan assets at beginning of year	\$ 8,833	\$ 5,928
Actual return on plan assets	1,462	1,477
Employer contribution	894	854
Benefits paid	(167)	(127)
Foreign exchange impact	(167)	701
Fair value of plan assets at end of year	\$ 10,855	\$ 8,833
<b>Funded status at end of year for projected benefit obligation</b>	\$ (3,536)	\$ (4,076)
<b>Funded status at end of year for accumulated benefit obligation</b>	\$ (812)	\$ (1,290)

The net amounts recognized in the accompanying consolidated balance sheets are shown in current liabilities and were \$3.5 million and \$4.1 million for the years ended December 31, 2010 and 2009, respectively.

Amounts recognized in accumulated other comprehensive income (loss) for the years ending December 31, 2010 and 2009, are as follows:

	<b>2010</b>	<b>2009</b>
Net actuarial loss	\$ 1,824	\$ 1,545

Prior service costs	5,413	5,535
Net amount recognized	\$ 7,237	\$ 7,080

The measurement date used to determine plan assets and benefit obligations for the Defined Benefit Plan was December 31, 2010 and 2009.

F-43

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(9) Postretirement Benefit Plans (Continued)**

The following table provides the weighted-average actuarial assumptions:

	2010	2009
<b>Assumptions used to determine benefit obligations(1):</b>		
Discount rate	5.30%	5.70%
Rate of compensation increase	4.15%	4.25%
<b>Assumptions used to determine net periodic benefit cost(2):</b>		
Discount rate	5.70%	6.10%
Expected return on plan assets	6.70%	6.55%
Rate of compensation increase	4.25%	3.85%

(1) The actuarial assumptions used to compute the unfunded status for the plan are based upon information available as of December 31, 2010 and 2009.

(2) The actuarial assumptions used to compute the net periodic pension benefit cost are based upon the information available as of the beginning of the year.

The actuarial assumptions are reviewed on an annual basis. The overall expected long-term rate of return on plan assets assumption was determined based on historical investment return rates on portfolios with a high proportion of equity securities.

The annual cost of the Defined Benefit Plan is as follows (in thousands):

	2010	2009	2008
Interest cost	\$ 717	\$ 596	\$ 677
Expected return on plan assets	(597)	(444)	(634)
Amortization of net loss (gain)	20		(80)
Curtailement loss (gain)		313	(1,113)
Net periodic benefit cost (benefit)	\$ 140	\$ 465	\$ (1,150)

The plan assets of the Defined Benefit Plan comprise of a mix of stocks and fixed income securities and other investments. At December 31, 2010, these stocks and fixed income securities represented 70% and 30%, respectively, of the market value of the pension assets. We expect to contribute approximately 0.6 million British Pounds Sterling (or \$0.9 million at December 31, 2010) to the Defined Benefit Plan in 2011. We expect benefits to be paid to plan participants of approximately \$0.3 million per year for each of the next five years and for benefits totaling \$0.4 million to be paid annually for the five years thereafter.

Our overall investment strategy is to ensure the investments are spread across a range of investments varying by both investment class and geographical location which is achieved by investing largely in equity and fixed income funds. Spreading the investments in this manner reduces the risk of a decline in a particular market having a substantial impact on the whole fund. The target allocation for the plan assets is a 70% holding in equities (both in the U.K. and overseas), with the remaining assets invested in investment grade corporate bonds.

F-44

---



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(9) Postretirement Benefit Plans (Continued)**

The fair values of our pension plan assets at December 31, 2010 and 2009 by asset category are presented in the following table (Level 2 in the fair value hierarchy).

Asset Category	Plan Assets at December 31,	
	2010	2009
Equity securities:		
U.K. equities	\$ 3,758	\$ 2,997
Overseas equities	3,828	3,037
Debt securities – corporate bonds	3,067	2,581
Other – cash	202	218
Total plan assets	\$ 10,855	\$ 8,833

The table above presents the fair value of our plan's assets in accordance with the fair value hierarchy. The pension plan assets are measured using net asset value per share (or its equivalent) and are reported as a Level 2 investment above due to our ability to redeem the investment either at the balance sheet date or within limited time restrictions.

Unipath Limited, or Unipath, contributed \$0.4 million in 2010, \$0.8 million in 2009 and \$1.0 million in 2008 to a Defined Contribution Plan, which was recognized as an expense in the accompanying consolidated statement of operations.

**(10) Derivative Financial Instruments**

We use derivative financial instruments (interest rate swap contracts) in the management of our interest rate exposure related to our secured credit facilities. We do not hold or issue derivative financial instruments for speculative purposes.

The following tables summarize the fair value of our derivative instruments and the effect of derivative instruments on/in our accompanying consolidated balance sheets and consolidated statements of operations and in accumulated other comprehensive income (loss) (in thousands):

Derivative Instruments	Balance Sheet Caption	Fair Value at December 31, 2010	Fair Value at December 31, 2009
Interest rate swap contracts(1)	Accrued expenses and other current liabilities	\$ 26	\$

Interest rate swap contracts(1)	Other long-term liabilities	\$	11,954	\$	15,945
---------------------------------	-----------------------------	----	--------	----	--------

<b>Derivative Instruments</b>	<b>Location of Gain (Loss) Recognized in Income</b>		<b>Amount of Gain Recognized During the Year Ended December 31, 2010</b>		<b>Amount of Gain Recognized During the Year Ended December 31, 2009</b>
Interest rate swap contracts(1)	Other comprehensive income (loss)	\$	3,965	\$	5,187

(1) See Note 6(a) regarding our interest rate swaps which qualify as cash flow hedges.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(11) Commitments and Contingencies***(a) Operating Leases*

We have operating lease commitments for certain of our facilities and equipment that expire on various dates through 2020. The following schedule outlines future minimum annual rental payments under these leases at December 31, 2010 (in thousands):

2011	\$ 33,772
2012	30,155
2013	27,615
2014	21,737
2015	19,748
Thereafter	52,088
	\$ 185,115

Rent expense relating to operating leases was approximately \$39.0 million, \$37.3 million and \$34.2 million during 2010, 2009 and 2008, respectively.

*(b) Contingent Consideration Obligations*

Effective January 1, 2009, we adopted changes issued by the FASB to accounting for business combinations. These changes apply to all assets acquired and liabilities assumed in a business combination that arise from certain contingencies and require: (i) an acquirer to recognize at fair value, at the acquisition date, an asset acquired or liability assumed in a business combination that arises from a contingency if the acquisition-date fair value of that asset or liability can be determined during the measurement period; otherwise, the asset or liability should be recognized at the acquisition date if certain defined criteria are met and (ii) contingent consideration arrangements of an acquiree assumed by the acquirer in a business combination to be recognized initially at fair value.

We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving the targets before the corresponding delivery dates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted milestone payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations.

Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.

The adoption of this guidance was done on a prospective basis. For acquisitions completed prior to January 1, 2009, contingent consideration will be accounted for as an increase in the aggregate purchase price and goodwill, if and when the contingencies occur.

We have contractual contingent consideration obligations related to our acquisitions of Accordant, AdnaGen, Capital Toxicology, Free & Clear, Immunalysis, a privately-owned research and development operation, JSM, Medlab, Mologic, Tapestry, a privately-owned U.K. research and development operation, a privately-owned health management business acquired in 2008, and certain other small businesses.

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(11) Commitments and Contingencies (Continued)**

(i) Acquisitions Completed prior to January 1, 2009

Privately-owned health management business

With respect to a privately-owned health management business which we acquired in 2008, the terms of the acquisition agreement provide for contingent consideration payable upon successfully meeting certain revenue and EBITDA targets. The final earn-out was achieved during the fourth quarter of 2010, resulting in an accrual of approximately \$31.8 million. Payment is expected to be made during the first quarter of 2011. The achievement of this milestone was accounted for as an increase in the aggregate purchase price and goodwill during the fourth quarter of 2010.

(ii) Acquisitions Completed on or after January 1, 2009

Accordant

With respect to Accordant, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and cash collection targets starting after the second anniversary of the acquisition date and completed prior to the third anniversary date of the acquisition. The maximum amount of the earn-out payment is \$6.0 million and, if earned, payment is expected to be made during 2012 and 2013. We recorded expense of approximately \$0.5 million and \$0.2 million within general and administrative expense in our consolidated statements of operations during the years ended December 31, 2010 and 2009, respectively, as a net result of a decrease in the discount period and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$3.9 million.

AdnaGen

With respect to AdnaGen, the terms of the acquisition agreement require us to pay earn-outs upon successfully (i) meeting certain financial targets during the two years following the acquisition; (ii) achieving multiple product development milestones during the three years following the acquisition and (iii) creating pharmaceutical alliances during the six years following the acquisition. The maximum amount of the earn-out payments is approximately \$63.0 million. We recorded expense of approximately \$0.1 million within general and administrative expense in our consolidated statement of operations during the year ended December 31, 2010 as a net result of a decrease in the discount period and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$20.6 million.

Capital Toxicology

With respect to Capital Toxicology, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain operating income targets during each of the calendar years 2011 and 2012. The maximum amount of the earn-out payments is approximately \$16.0 million. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$2.9 million.

Free & Clear

With respect to Free & Clear, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and EBITDA targets during fiscal year 2010. We recorded income of approximately \$3.7 million and expense of \$0.5 million within general and administrative expense in our consolidated statements of operations during the years ended December 31, 2010 and 2009, respectively, as a net result of changes to revenue and EBITDA estimates, changes in probability assumptions, a decrease in the discount period and fluctuations in the discount rate since the acquisition date. The earn-out was achieved as

F-47

---

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(11) Commitments and Contingencies (Continued)**

of December 31, 2010, resulting in an accrual of approximately \$11.0 million. Payment is expected to be made during the second quarter of 2011.

**Immunoanalysis**

With respect to Immunoanalysis, the terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain gross profit targets during each of the calendar years 2010 through 2012. The maximum amount of the earn-out payments is \$5.0 million. We recorded income of approximately \$0.1 million within general and administrative expense in our consolidated statement of operations during the year ended December 31, 2010 as a net result of a decrease in the discount period, changes in probability assumptions and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$1.1 million.

Additionally, we have a contractual contingent obligation to pay up to a total of \$3.0 million in compensation to certain executives of Immunoanalysis in accordance with the acquisition agreement that, if earned, will be paid out in connection with the contingent consideration payable to the former shareholders of Immunoanalysis, in each of the calendar years 2010, 2011 and 2012. As of December 31, 2010, approximately \$0.3 million of compensation was earned. Payment is expected to be made during the first quarter of 2011.

In no case will the aggregate total of the two contingent obligations noted above exceed \$6.0 million.

**JSM**

With respect to JSM, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and operating income targets during each of the calendar years 2010 through 2012. We recorded expense of approximately \$0.2 million within general and administrative expense in our consolidated statement of operations during the year ended December 31, 2010 as a net result of a decrease in the discount period, changes in probability assumptions and fluctuations in the discount rate since the acquisition date. The 2010 portion of the earn-out totaling approximately \$0.6 million was earned as of December 31, 2010. Payment of the 2010 earn-out is expected to be made during the second quarter of 2011. As of December 31, 2010, the fair value of the contingent consideration obligation, including the \$0.6 million earned in 2010, was approximately \$1.2 million. The maximum remaining amount of the earn-out payments is approximately \$2.4 million.

**Medlab**

With respect to Medlab, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and operating income targets during each of the calendar years 2011 through 2016. The maximum amount of the earn-out payments is approximately \$10.0 million. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$4.3 million.

**Mologic**

With respect to Mologic, the terms of the acquisition agreement require us to pay earn-outs upon successfully meeting four R&D project milestones during the four years following the acquisition. We recorded expense of approximately \$5.0 million and \$0.4 million within general and administrative expense in our consolidated statements of operations during the year ended December 31, 2010 and 2009, respectively, as a net result of a decrease in the discount period, adjustments to certain probability factors and fluctuations in the discount rate since the acquisition date. A portion of the earn-out was achieved during the fourth quarter of 2010, resulting in an accrual of approximately \$3.9 million as of December 31, 2010. Payment of this portion of the earn-out is expected to be made during the first quarter of 2011. As of December 31, 2010, the fair value of the contingent consideration obligation, including the \$3.9 million earned during 2010, was

F-48

---



**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(11) Commitments and Contingencies (Continued)**

approximately \$10.8 million. The maximum remaining amount of the earn-out payments is \$15.0 million, which will be paid in shares of our common stock.

Privately-owned research and development operation

With respect to our acquisition of a privately-owned research and development operation, the terms of the acquisition agreement require us to pay earn-outs upon successfully meeting multiple product development milestones during the five years following the acquisition. The maximum amount of the earn-out payments is \$57.5 million. We recorded expense of approximately \$0.3 million within general and administrative expense in our consolidated statement of operations during the year ended December 31, 2010 as a net result of a decrease in the discount period and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$24.8 million.

Privately-owned U.K. research and development operation

With respect to our acquisition of a privately-owned U.K. research and development operation, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets. The maximum amount of the earn-out payments is \$125.0 million and, if earned, payments are expected to be made during the eight-year period following the acquisition date, but could extend thereafter. We recorded expense of approximately \$2.2 million within general and administrative expense in our consolidated statement of operations during the year ended December 31, 2010 as a net result of a decrease in the discount period and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the fair value of the contingent consideration obligation was approximately \$37.8 million.

Tapestry

With respect to Tapestry, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and EBITDA targets during each of the calendar years 2010 and 2011. The maximum amount of the earn-out payments is \$25.0 million which, if earned, will be paid in shares of our common stock, except that the 2010 earn-out under the amended agreement and plan of merger will be paid in cash. We recorded income of approximately \$2.7 million and expense of \$0.7 million within general and administrative expense in our consolidated statements of operations during the year ended December 31, 2010 and 2009, respectively, as a net result of a decrease in the discount period, adjustments to certain probability factors and fluctuations in the discount rate since the acquisition date. As of December 31, 2010, the 2010 financial targets were achieved resulting in an accrual of approximately \$10.7 million. Cash payment is expected to be made during the first quarter of 2011. As of December 31, 2010, the fair value of the contingent consideration obligation, which includes the \$10.7 million earned during 2010, was approximately \$14.0 million.

*(c) Contingent Obligations*

Agreements with Epocal

In November 2009, we entered into a distribution agreement with Epocal, Inc., or Epocal, to distribute the epoc<sup>®</sup> Blood Analysis System for blood gas and electrolyte testing for \$20.0 million, which is recorded on our accompanying consolidated balance sheet in other intangible assets, net. We also entered into a definitive agreement to acquire all of the issued and outstanding equity securities of Epocal for a total potential purchase price of up to \$255.0 million, including a base purchase price of up to \$172.5 million if Epocal achieves certain gross margin and other financial milestones on or prior to October 31, 2014, plus additional payments of up to \$82.5 million if Epocal achieves certain other milestones relating to its gross margin and product development efforts on or prior to this date. We also agreed that, if the acquisition is consummated, we will provide \$12.5 million in management incentive arrangements, 25% of which will vest over three years and

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(11) Commitments and Contingencies (Continued)**

75% of which will be payable only upon the achievement of certain milestones. The acquisition will also be subject to other closing conditions, including the receipt of any required antitrust or other approvals.

Option agreement with P&G

In connection with the formation of SPD in May 2007, we entered into an option agreement with P&G, pursuant to which P&G has the right, for a period of 60 days commencing on May 17, 2011, to require us to acquire all of P&G's interest in SPD at fair market value, and P&G has the right, upon certain material breaches by us of our obligations to SPD, to acquire all of our interest in SPD at fair market value. No gain on the proceeds that we received from P&G through the formation of SPD will be recognized in our financial statements until P&G's option to require us to purchase its interest in SPD expires. If P&G chooses to exercise its option, the deferred gain carried on our books would be reversed in connection with the repurchase transaction. As of December 31, 2010, the deferred gain of \$288.4 million is presented as a current liability on our accompanying consolidated balance sheet. As of December 31, 2009, the deferred gain of \$288.8 million is presented as a long-term liability.

*(d) Legal Proceedings*

We are not a party to any pending legal proceedings that we currently believe could have a material adverse impact on our sales, operations or financial performance. However, because of the nature of our business, we may be subject at any particular time to lawsuits or other claims arising in the ordinary course of our business, and we expect that this will continue to be the case in the future.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(12) Net Income (Loss) Per Common Share**

The following tables set forth the computation of basic and diluted income (loss) per common share (in thousands, except per share amounts):

	<b>2010</b>	<b>2009</b>	<b>2008</b>
<b>Income (loss) per common share basic:</b>			
<b><u>Numerator continuing operations:</u></b>			
Income (loss) from continuing operations	\$ (1,028,707)	\$ 31,782	\$ (20,720)
Less: Preferred stock dividends	(24,235)	(22,972)	(13,989)
Income (loss) available to common stockholders from continuing operations	\$ (1,052,942)	\$ 8,810	\$ (34,709)
<b><u>Numerator discontinued operations:</u></b>			
Income (loss) from discontinued operations	11,397	1,934	(1,048)
<b><u>Numerator net income (loss):</u></b>			
Income (loss) from continuing operations	\$ (1,028,707)	\$ 31,782	\$ (20,720)
Income (loss) from discontinued operations	11,397	1,934	(1,048)
Net income (loss)	(1,017,310)	33,716	(21,768)
Less: Preferred stock dividends	(24,235)	(22,972)	(13,989)
Net income (loss) available to common stockholders	\$ (1,041,545)	\$ 10,744	\$ (35,757)
<b><u>Denominator:</u></b>			
Weighted average shares outstanding	84,445	80,572	77,778
Income (loss) per common share from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)
Income (loss) per common share from discontinued operations	\$ 0.14	\$ 0.02	\$ (0.01)
Net income (loss) per common share	\$ (12.33)	\$ 0.13	\$ (0.46)

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(12) Net Income (Loss) Per Common Share (Continued)**

	<b>2010</b>	<b>2009</b>	<b>2008</b>
<b>Income (loss) per common share diluted:</b>			
<b><u>Numerator continuing operations:</u></b>			
Income (loss) from continuing operations	\$ (1,028,707)	\$ 31,782	\$ (20,720)
Less: Preferred stock dividends	(24,235)	(22,972)	(13,989)
Income (loss) available to common stockholders from continuing operations	\$ (1,052,942)	\$ 8,810	\$ (34,709)
<b><u>Numerator discontinued operations:</u></b>			
Income (loss) from discontinued operations	11,397	\$ 1,934	\$ (1,048)
<b><u>Numerator net income (loss):</u></b>			
Income (loss) from continuing operations	\$ (1,028,707)	\$ 31,782	\$ (20,720)
Income (loss) from discontinued operations	11,397	1,934	(1,048)
Net income (loss)	(1,017,310)	\$ 33,716	\$ (21,768)
Less: Preferred stock dividends	(24,235)	(22,972)	(13,989)
Net income (loss) available to common stockholders	\$ (1,041,545)	\$ 10,744	\$ (35,757)
<b><u>Denominator:</u></b>			
Weighted average shares outstanding	84,445	80,572	77,778
Stock options		1,228	
Warrants		167	
Total shares	84,445	81,967	77,778
Income (loss) per common share from continuing operations	\$ (12.47)	\$ 0.11	\$ (0.45)
Income (loss) per common share from discontinued operations	\$ 0.14	\$ 0.02	\$ (0.01)
Net income (loss) per common share	\$ (12.33)	\$ 0.13	\$ (0.46)

We had the following potential dilutive securities outstanding on December 31, 2010: (a) options to purchase an aggregate of 10.148 million shares of our common stock at a weighted average exercise price of \$35.61 per share; (b) warrants to purchase 0.24 million shares at a weighted average exercise price of \$16.00 per share; (c) 3.4 million shares issuable upon conversion of our \$150.0 million, 3% senior subordinated convertible notes, convertible at \$43.98 per share; (d) \$1.7 million of subordinated convertible promissory notes, convertible at \$61.49 per share; and (e) 2.1 million shares of our Series B convertible preferred stock, with an aggregate liquidation preference of

approximately \$836.2 million, convertible under certain circumstances at \$69.32 per share into 12.1 million shares of our common stock. In addition, at December 31, 2010, we had 0.3 million common stock equivalents from the potential settlement of a portion of the deferred purchase price consideration related to the ACON Second Territory Business and 0.03 million common stock equivalents from the potential settlement of a contingent consideration obligation. These potential dilutive securities were not included in the computation of diluted net earnings per common share in 2010 because the inclusion thereof would be antidilutive.

F-52

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(12) Net Income (Loss) Per Common Share (Continued)**

We had dilutive securities outstanding on December 31, 2009 consisting of options and warrants to purchase an aggregate of 10.3 million shares of our common stock at a weighted average exercise price of \$34.11 per share. We had the following potential dilutive securities outstanding on December 31, 2009: (a) 3.4 million shares issuable upon conversion of our \$150.0 million, 3% senior subordinated convertible notes, convertible at \$43.98 per share; (b) \$1.7 million of subordinated convertible promissory notes, convertible at \$61.49 per share; and (c) 2.0 million shares of our Series B convertible preferred stock, with an aggregate liquidation preference of approximately \$793.7 million, convertible under certain circumstances at \$69.32 per share into 11.4 million shares of our common stock. In addition, at December 31, 2009, we had 0.4 million common stock equivalents from the potential settlement of a portion of the deferred purchase price consideration related to the ACON Second Territory Business. These potential dilutive securities were not included in the computation of diluted net earnings per common share in 2009 because the inclusion thereof would be antidilutive.

We had the following potential dilutive securities outstanding on December 31, 2008: (a) options and warrants to purchase an aggregate of 10.6 million shares of our common stock at a weighted average exercise price of \$32.15 per share, (b) 3.4 million shares issuable upon conversion of our \$150.0 million, 3% senior subordinated convertible notes and (c) 1.9 million shares of our Series B convertible preferred stock, convertible under certain circumstances at \$69.32 per share into 10.8 million shares of our common stock. Potential dilutive securities were not included in the computation of diluted net loss per common share in 2008 because the inclusion thereof would be antidilutive.

**(13) Stockholders Equity***(a) Common Stock*

As of December 31, 2010, we had 200.0 million shares of common stock, \$0.001 par value, authorized, of which approximately 84.9 million shares were issued and outstanding, 11.1 million shares were reserved for issuance upon grant and exercise of equity awards under current equity compensation plans, 0.8 million shares were reserved for issuance under our employee stock purchase plan and 0.2 million shares were reserved for issuance upon exercise of outstanding warrants. We had the following potential dilutive securities outstanding on December 31, 2010: \$150.0 million, 3% senior subordinated convertible notes, convertible at \$43.98 per share into 3.4 million shares of our common stock which are reserved; \$1.7 million of subordinated convertible promissory notes, convertible at \$61.49 per share into 27,647 shares of our common stock which are reserved and 2.1 million shares of our Series B convertible preferred stock, with an aggregate liquidation preference of approximately \$836.2 million, convertible under certain circumstances at \$69.32 per share into 12.1 million shares of our common stock which are reserved.

*(b) Preferred Stock*

As of December 31, 2010, we had 5.0 million shares of preferred stock, \$0.001 par value, authorized, of which 2.3 million shares were designated as Series B Convertible Perpetual Preferred Stock, or Series B preferred stock. In connection with our acquisition of Matria, we issued shares of the Series B preferred stock and through December 31, 2010 paid all dividends on outstanding shares of series B preferred stock in additional shares of Series B preferred stock. At December 31, 2010, there were 2.1 million shares of Series B preferred stock outstanding with a fair value of approximately \$521.5 million (Note 4(c)(i)).

Each share of Series B preferred stock, which has a liquidation preference of \$400.00 per share, is convertible, at the option of the holder and only upon certain circumstances, into 5.7703 shares of our common stock, plus cash in lieu of fractional shares. The initial conversion price is \$69.32 per share, subject to adjustment upon the occurrence of certain events, but will not be adjusted for accumulated and unpaid

F-53

---



**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(13) Stockholders Equity (Continued)**

dividends. Upon a conversion of shares of the Series B preferred stock, we may, at our option, satisfy the entire conversion obligation in cash or through a combination of cash and common stock. Series B preferred stock outstanding at December 31, 2010 would convert into 12.1 million shares of our common stock which are reserved. There were no conversions as of December 31, 2010.

Generally, the shares of Series B preferred stock are convertible, at the option of the holder, if during any calendar quarter beginning with the second calendar quarter after the issuance date of the Series B preferred stock, if the closing sale price of our common stock for each of 20 or more trading days within any period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price per share of common stock in effect on the last trading day of the immediately preceding calendar quarter. In addition, the shares of Series B preferred stock are convertible, at the option of the holder, in certain other circumstances, including those relating to the trading price of the Series B preferred stock and upon the occurrence of certain fundamental changes or major corporate transactions. We also have the right, under certain circumstances relating to the trading price of our common stock, to force conversion of the Series B preferred stock. Depending on the timing of any such forced conversion, we may have to make certain payments relating to foregone dividends, which payments we can make, at our option, in the form of cash, shares of our common stock, or a combination of cash and shares of our common stock.

Each share of Series B preferred stock accrues dividends at \$12.00, or 3%, per annum, payable quarterly on January 15, April 15, July 15 and October 15 of each year, commencing following the first full calendar quarter after the issuance date. Dividends on the Series B preferred stock are cumulative from the date of issuance. For the year ended December 31, 2010, Series B preferred stock dividends amounted to \$24.2 million, which reduced earnings available to common stockholders for purposes of calculating net income per common share in 2010 (Note 12). Accrued dividends are payable only if declared by our board of directors and, upon conversion by the Series B preferred stockholder, holders will not receive any cash payment representing accumulated dividends. If our board of directors declares a dividend payable, we have the right to pay the dividends in cash, shares of common stock, additional shares of Series B preferred stock or a similar convertible preferred stock or any combination thereof.

The holders of Series B preferred stock have liquidation preferences over the holders of our common stock and other classes of stock, if any, outstanding at the time of liquidation. Upon liquidation, the holders of outstanding Series B preferred stock would receive an amount equal to \$400.00 per share of Series B preferred stock, plus any accumulated and unpaid dividends. As of December 31, 2010, the liquidation preference of the outstanding Series B preferred stock was \$836.2 million. The holders of the Series B preferred stock have no voting rights, except with respect to matters affecting the Series B preferred stock (including the creation of a senior preferred stock).

We evaluated the terms and provisions of our Series B preferred stock to determine if it qualified for derivative accounting treatment. Based on our evaluation, these securities do not qualify for derivative accounting.

*(c) Stock Options and Awards*

In 2010, we adopted the Alere Inc. 2010 Stock Option and Incentive Plan, or the 2010 Plan, which replaced our 2001 Stock Option and Incentive Plan, or the 2001 Plan. The 2010 Plan currently allows for the issuance of up to 1.7 million shares of common stock and other awards. The 2010 Plan is administered by the Compensation Committee

of the Board of Directors, which selects the individuals eligible to receive awards, determines or modifies the terms and conditions of the awards granted, accelerates the vesting schedule of any award and generally administers and interprets the 2010 Plan. The 2010 Plan permits the granting of incentive and nonqualified stock options with terms of up to ten years and the granting of stock appreciation rights,

F-54

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(13) Stockholders Equity (Continued)**

restricted stock awards, unrestricted stock awards, performance share awards and dividend equivalent rights. The 2010 Plan also provides for option grants to non-employee directors and automatic vesting acceleration of all options and stock appreciation rights upon a change in control, as defined by the 2010 Plan. As of December 31, 2010, there were 0.9 million shares available for future grant under the 2010 Plan. As of December 31, 2009, there were 1.1 million shares available for future grant under the 2001 Plan.

The following summarizes all stock option activity during the year ended December 31 (in thousands, except exercise price):

	2010		2009		2008	
	Options	Weighted Average Exercise Price	Options	Weighted Average Exercise Price	Options	Weighted Average Exercise Price
Outstanding at January 1	9,838	\$ 34.72	10,155	\$ 32.65	7,836	\$ 31.42
Exchanged		N/A	315	\$ 29.78	1,820	\$ 30.52
Granted	1,542	\$ 40.33	1,243	\$ 36.28	1,787	\$ 34.13
Exercised	(484)	\$ 23.39	(1,319)	\$ 17.83	(836)	\$ 16.84
Canceled/expired/forfeited	(748)	\$ 41.18	(556)	\$ 39.21	(452)	\$ 37.75
Outstanding at December 31	10,148	\$ 35.61	9,838	\$ 34.72	10,155	\$ 32.65
Exercisable at December 31	6,646	\$ 33.57	5,902	\$ 31.71	5,866	\$ 27.08

The aggregate intrinsic value of the options outstanding at December 31, 2010 was \$61.5 million. The aggregate intrinsic value of the options exercisable at December 31, 2010 was \$50.8 million. The aggregate intrinsic value of stock options exercised during 2010, 2009 and 2008 was \$6.9 million, \$25.7 million, and \$18.2 million, respectively. Based on equity awards outstanding as of December 31, 2010, there was \$40.1 million of unrecognized compensation costs related to unvested share-based compensation arrangements that are expected to vest. Such costs are expected to be recognized over a weighted average period of 1.5 years.

*(d) Warrants*

The following is a summary of all warrant activity during the three years ended December 31:

	Number of Shares (in thousands)	Exercise Price	Weighted Average Exercise Price
--	------------------------------------	----------------	---------------------------------

Edgar Filing: ALERE INC. - Form 10-K/A

Warrants outstanding and exercisable, December 31, 2007	469	\$	3.81 - \$29.78	\$	20.80
Exercised	(12)	\$	13.54 - \$20.06	\$	19.64
Warrants outstanding and exercisable, December 31, 2008	457	\$	3.81 - \$29.78	\$	20.83
Issued	4	\$	50.00	\$	50.00
Warrants outstanding and exercisable, December 31, 2009	461	\$	3.81 - \$50.00	\$	21.09
Exercised	(105)	\$	3.81 - \$29.78	\$	23.66
Cancelled	(113)	\$	20.06 - \$29.78	\$	29.62
Warrants outstanding and exercisable, December 31, 2010	243	\$	13.54 - \$50.00	\$	16.00

F-55

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(13) Stockholders Equity (Continued)**

The following table presents additional information related to warrants outstanding and exercisable at December 31, 2010:

Exercise Price	Number of Shares	Outstanding and Exercisable	
		Weighted Average Remaining Contract Life	Weighted Average Exercise Price
\$13.54 \$18.12	214	0.97 - 1.72	\$ 14.43
\$24.00	25	4.25	\$ 24.00
\$50.00	4	5.50	\$ 50.00
	243	1.92	\$ 16.00

The majority of the warrants included in the table above were issued in connection with debt and equity financings, or amendments thereto, of which warrants to purchase an aggregate of 0.04 million shares of our common stock were issued to officers and directors of our company or entities controlled by these officers and directors and were outstanding at December 31, 2010. All outstanding warrants have been classified in equity.

*(e) Employee Stock Purchase Plan*

In 2001, we adopted the 2001 Employee Stock Purchase Plan, under which eligible employees are allowed to purchase shares of our common stock at a discount through periodic payroll deductions. Purchases may occur at the end of every six month offering period at a purchase price equal to 85% of the market value of our common stock at either the beginning or end of the offering period, whichever is lower. We may issue up to 2.0 million shares of common stock under this plan. At December 31, 2010, 1.2 million shares had been issued under this plan.

**(14) Stock-based Compensation**

We recorded stock-based compensation expense in our consolidated statements of operations for the year ended December 31, 2010, 2009 and 2008, respectively, as follows (in thousands):

	2010	2009	2008
Cost of net revenue	\$ 1,904	\$ 2,011	\$ 1,504
Research and development	7,087	5,246	4,627
Sales and marketing	4,161	4,236	4,264
General and administrative	16,727	16,727	16,010

	29,879	28,220	26,405
Benefit for income taxes	(6,203)	(5,577)	(5,707)
Stock-based compensation, net of tax	\$ 23,676	\$ 22,643	\$ 20,698

Included in the amount above for general and administrative expense for the year ended December 31, 2009, is \$1.0 million related to our assumption of certain Concateno options. The expense relates to the acceleration of certain unvested Concateno employee options. See Note 4(b)(iii) regarding our acquisition of Concateno.

For the year ended December 31, 2010, 2009 and 2008, the presentation of our cash flows reports the excess tax benefits from the exercise of stock options as financing cash flows. For the year ended December 31, 2010, 2009 and 2008, excess tax benefits generated from option exercises amounted to \$1.7 million, \$9.3 million and \$17.5 million, respectively.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(14) Stock-based Compensation (Continued)**

The following assumptions were used to estimate the fair value of options granted during the year ended December 31, 2010, 2009 and 2008, using a Black-Scholes option-pricing model:

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Risk-free interest rate	2.03%	2.26%	2.89%
Expected dividend yield			
Expected life	5.34 years	5.20 years	5.19 years
Expected volatility	41.91%	44.02%	39.55%

The weighted average fair value under a Black-Scholes option pricing model of options granted to employees during 2010, 2009 and 2008 was \$13.54, \$15.11 and \$10.66 per share, respectively. All options granted during these periods were granted at or above the fair market value on the date of grant.

For the year ended December 31, 2010, we recorded compensation expense of \$2.7 million related to our Employee Stock Purchase Plan. The fair value of the option component of the Employee Stock Purchase Plan shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 39% and 45%, a risk-free interest rate of 0.18% and 0.22% and an expected life of 181 days and 184 days, for each of the two respective offering periods. The charge is included in general and administrative expense in the table above.

For the year ended December 31, 2009, we recorded compensation expense of \$2.7 million related to our Employee Stock Purchase Plan. The fair value of the option component of the Employee Stock Purchase Plan shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 72% and 43%, a risk-free interest rate of 0.28% and 0.33% and an expected life of 181 days and 184 days, for each of the two respective offering periods. The charge is included in general and administrative expense in the table above.

For the year ended December 31, 2008, we recorded compensation expense of \$2.8 million related to our Employee Stock Purchase Plan. The fair value of the option component of the Employee Stock Purchase Plan shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 43% and 54%, a risk-free interest rate of 3.32% and 2.13%, and an expected life of 181 days and 184 days, for each of the two respective offering periods. The charge is included in general and administrative expense in the table above.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(15) Comprehensive Income**

In general, comprehensive income combines net income and other changes in equity during the year from non-owner sources. Accumulated other comprehensive income is recorded as a component of stockholders' equity. The following is a summary of the components of and changes in accumulated other comprehensive income as of December 31, 2010 and in each of the three years then ended (in thousands):

	<b>Cumulative Translation Adjustment</b>	<b>Pension Liability Adjustment</b>	<b>Other(1)</b>	<b>Accumulated Other Comprehensive Income (Loss)(2)</b>
	<b>(Note 2(b))</b>	<b>(Note 9(b))</b>		
Balance at December 31, 2007	\$ 30,633	\$ (3,397)	\$ (5,967)	\$ 21,269
Period change	(32,889)	(562)	(16,663)	(50,114)
Balance at December 31, 2008	(2,256)	(3,959)	(22,630)	(28,845)
Period change	15,171	(1,137)	12,357	26,391
Balance at December 31, 2009	12,915	(5,096)	(10,273)	(2,454)
Period change	(210)	(113)	3,467	3,144
Balance at December 31, 2010	\$ 12,705	\$ (5,209)	\$ (6,806)	\$ 690

(1) Other represents (realization of) unrealized gains on available-for-sale securities and interest rate swaps.

(2) All of the components of accumulated other comprehensive income relate to our foreign subsidiaries, except item (1) above. No adjustments for income taxes were recorded against other comprehensive income of our foreign subsidiaries, as we intend to permanently invest in our foreign subsidiaries in the foreseeable future.

**(16) Income Taxes**

Our income tax provision (benefit) in 2010, 2009 and 2008 mainly represents those recorded by us and certain of our U.S. subsidiaries and by our foreign subsidiaries located in Australia, the United Kingdom, France, Italy, Israel, Japan, China and Switzerland. Income (loss) before provision (benefit) for income taxes consists of the following (in thousands):

**Continuing Operations:**

**2010                      2009                      2008**



Edgar Filing: ALERE INC. - Form 10-K/A

United States	\$ (1,078,981)	\$ (14,032)	\$ (52,805)
Foreign	11,195	54,280	14,558
	\$ (1,067,786)	\$ 40,248	\$ (38,247)

**Discontinued Operations:**

	<b>2010</b>	<b>2009</b>	<b>2008</b>
United States	\$ 16,973	\$ 2,069	\$ (107)
Foreign	1,514	33	(983)
	\$ 18,487	\$ 2,102	\$ (1,090)

Our primary temporary differences that give rise to the deferred tax asset and liability are net operating loss, or NOL, carryforwards, nondeductible reserves, accruals and differences in bases of the tangible and

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(16) Income Taxes (Continued)**

intangible assets, and the gain on the joint venture transaction. The income tax effects of these temporary differences are as follows (in thousands):

	<b>2010</b>	<b>2009</b>
NOL and capital loss carryforwards	\$ 99,540	\$ 96,355
Tax credit carryforwards	29,862	26,316
Nondeductible reserves	15,381	16,151
Nondeductible accruals	30,269	39,505
Difference between book and tax bases of tangible assets	3,654	13,662
Difference between book and tax bases of intangible assets	31,287	38,956
Gain on joint venture	33,376	33,709
All other	30,059	30,476
Gross deferred tax asset	273,428	295,130
Less: Valuation allowance	(42,518)	(37,524)
Total deferred tax assets	230,910	257,606
Deferred tax liabilities:		
Difference between book and tax bases of tangible assets	36,468	32,248
Difference between book and tax bases of intangible assets	523,316	571,611
Other	8,999	8,317
Total deferred tax liability	568,783	612,176
Net deferred tax liability	\$ 337,873	\$ 354,570
Reported as:		
Deferred tax assets, current portion	\$ 57,111	\$ 66,492
Deferred tax assets, long-term	25,182	20,987
Deferred tax liabilities, long-term	(420,166)	(442,049)
Net deferred tax liability	\$ (337,873)	\$ (354,570)

As of December 31, 2010, we had approximately \$156.1 million of domestic NOL and domestic capital loss carryforwards and \$60.3 million of foreign NOL and foreign capital loss carryforwards, which either expire on various dates through 2030 or can be carried forward indefinitely. As of December 31, 2010, we had approximately \$26.5 million of domestic R&D, foreign tax and AMT credits which either expire on various dates through 2030 or can be carried forward indefinitely. These loss carryforwards and tax credits are available to reduce future federal, state and foreign taxable income, if any. These loss carryforwards and tax credits are subject to review and possible

adjustment by the appropriate tax authorities. The domestic NOL carryforwards include approximately \$102.2 million of pre-acquisition losses. Our domestic NOLs and tax credits are subject to the Internal Revenue Service, or IRS, Code Section 382 limitation. Section 382 imposes an annual limitation on the use of these losses to an amount equal to the value of the company at the time of the ownership change multiplied by the long-term tax exempt rate. The acquired Section 382 limited amount for 2011 is approximately \$74.8 million. In addition, the total NOL available for use in 2011 is approximately \$132.8 million.

We have recorded a valuation allowance of \$42.5 million as of December 31, 2010 due to uncertainties related to the future benefits, if any, from our deferred tax assets related primarily to our foreign businesses

**Table of Contents**

**ALERE INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(16) Income Taxes (Continued)**

and certain U.S. net operating losses and tax credits. This is an increase of \$5.0 million from the valuation allowance of \$37.5 million as of December 31, 2009. The increase is primarily related to foreign NOLs and domestic state credits. The valuation allowance is based on our estimates of taxable income by jurisdiction in which we operate and the period over which our deferred tax assets will be recoverable. In the event that actual results differ from these estimates or we adjust these estimates in future periods, we may need to establish an additional valuation allowance or reduce our current valuation allowance, which could materially impact our tax provision.

The accounting for the tax benefits of acquired deductible temporary differences and NOL carryforwards, which are not recognized at the acquisition date because a valuation allowance is established and which are recognized subsequent to the relevant acquisition, will be applied to reduce our income tax expense as required under a new accounting standard for business combinations, adopted January 1, 2009. As of December 31, 2010, \$13.1 million of deferred tax assets with a valuation allowance pertains to acquired companies.

Our two China-based manufacturing subsidiaries qualify for a reduced income tax rate in 2010 and 2009. The general income tax rate is 25%. The income tax rate for one of the subsidiaries is 12.5% for 2009 and 2010, and for the other is 10% for 2009 and 11% for 2010. The reduced rates for 2009 and 2010 are grandfathered in the China Tax Reform Act. A tax rate of 15% or 25% will apply to 2011 and future years. The tax rate of 15% applies to companies with high technology status. Both subsidiaries are approved for high technology status. Therefore, a 15% tax rate will apply to both companies in 2011. The reduced tax rate produced a tax expense of approximately \$1.3 million in 2010. In the absence of the reduced tax rate for 2010 a tax rate of 25% would have applied and would have resulted in a tax expense of approximately \$2.9 million in 2010. The earnings per common share effect of the reduced tax rate is \$0.02 for 2009. The reduced tax rate produced a tax expense of approximately \$1.6 million in 2009. In the absence of the reduced tax rate for 2009 a tax rate of 25% would have applied and would have resulted in a tax expense of approximately \$3.4 million in 2009. The earnings per common share effect of the reduced tax rate was \$0.02 for 2009.

The estimated amount of undistributed earnings of our foreign subsidiaries is \$231.6 million at December 31, 2010. No amount for U.S. income tax has been provided on undistributed earnings of our foreign subsidiaries because we consider such earnings to be indefinitely reinvested. In the event of distribution of those earnings in the form of dividends or otherwise, we would be subject to both U.S. income taxes, subject to an adjustment, if any, for foreign tax credits, and foreign withholding taxes payable to certain foreign tax authorities. Determination of the amount of U.S. income tax liability that would be incurred is not practicable because of the complexities associated with this hypothetical calculation, however, unrecognized foreign tax credit carryforwards may be available to reduce some portion of the U.S. tax liability, if any.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(16) Income Taxes (Continued)**

The following table presents the components of our provision (benefit) for income taxes (in thousands) for continuing operations:

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Current:			
Federal	\$ (2,350)	\$ (1,409)	\$ 7,433
State	5,285	2,435	7,250
Foreign	41,552	23,725	10,387
	44,487	24,751	25,070
Deferred:			
Federal	(40,154)	8,170	(5,859)
State	(12,695)	(3,017)	(4,233)
Foreign	(21,569)	(14,277)	(31,622)
	(74,418)	(9,124)	(41,714)
Total provision (benefit) for income taxes	\$ (29,931)	\$ 15,627	\$ (16,644)

The following table presents the components of our provision (benefit) for income taxes (in thousands) for discontinued operations:

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Current:			
Federal	\$	\$	\$
State	(73)		
Foreign	(73)		
Deferred:			
Federal	5,644	738	(38)
State	1,095	(269)	(4)
Foreign	424	(301)	
	7,163	168	(42)

Total provision (benefit) for income taxes	\$ 7,090	\$ 168	\$ (42)
--	----------	--------	---------

F-61

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(16) Income Taxes (Continued)**

The following table presents a reconciliation from the U.S. statutory tax rate to our effective tax rate:

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Statutory rate	35%	35%	35%
Effect of goodwill impairment charge	(31)		
Stock-based compensation		10	(10)
Rate differential on foreign earnings		(8)	3
Research and development benefit		(4)	6
State income taxes, net of federal benefit	1		2
Acquisition costs	(2)	6	
Other permanent items		3	(4)
Change in valuation allowance		(3)	11
Effective tax rate	3%	39%	43%

The goodwill impairment charge created a deferred tax impact due to the existence of goodwill deductible for tax purposes. The deferred tax is calculated based on a methodology which allocates the goodwill impairment loss proportionally to the goodwill deductible for tax purposes compared to total goodwill. The goodwill impairment allocated to goodwill deductible for tax purposes created a deferred tax asset of \$25.9 million as of December 31, 2010.

During the year ended December 31, 2010, we increased the liability for income taxes associated with uncertain tax positions by \$1.3 million to a total of \$6.2 million at December 31, 2010. The primary reasons for the increase is due to our acquisition of a German company, which increased the liability for income taxes associated with uncertain tax positions by \$1.9 million. We classify \$6.2 million of income tax liabilities as non-current income tax liabilities because a payment of cash is not anticipated within one year of the balance sheet date. These non-current income tax liabilities are recorded in other long-term liabilities in our consolidated balance sheet at December 31, 2010. We anticipate an increase every quarter to the total amount of unrecognized tax benefits. We do not anticipate a significant increase or decrease of the total amount of unrecognized tax benefits within twelve months of the reporting date.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(16) Income Taxes (Continued)**

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):

	<b>Amount</b>
Balances as of January 1, 2008	\$ 8,765
Additions for tax positions taken during prior years	63
Additions for tax positions in current and prior year acquisitions	2,296
Additions for tax positions taken during current year	143
Expiration of statutes of limitations or closure of tax audits	(134)
Balances as of December 31, 2008	11,133
Reductions for tax positions taken during prior years	(728)
Reductions for tax positions in current and prior year acquisitions	(3,535)
Additions for tax positions taken during current year	360
Expiration of statutes of limitations or closure of tax audits	(2,325)
Balances as of December 31, 2009	4,905
Additions for tax positions in current and prior year acquisitions	2,070
Additions for tax positions taken during current year	263
Expiration of statutes of limitations or closure of tax audits	(1,078)
Balance as of December 31, 2010	\$ 6,160

Interest and penalties related to income tax liabilities are included in income tax expense. The interest and penalties recorded in 2010 amounted to \$0.2 million. The balance of accrued interest and penalties recorded on the consolidated balance sheet at December 31, 2010 was \$0.7 million.

With limited exceptions, we are subject to U.S. federal, state and local or non-U.S. income tax audits by tax authorities for 2004 through 2009. We are currently under income tax examination by the IRS and a number of state and foreign tax authorities and anticipate these audits will be completed by the end of 2011. We cannot currently estimate the impact of these audits due to the uncertainties associated with tax examinations.

**(17) Financial Information by Segment**

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are Professional Diagnostics, Health Management, Consumer Diagnostics and Corporate and Other. Our operating results include license and royalty revenue which are allocated to Professional Diagnostics and Consumer Diagnostics on the basis of the original license or royalty agreement.



On January 15, 2010, we completed the sale of our vitamins and nutritional supplements business (Note 23). The sale included all of our private label and branded nutritional businesses and represents the complete divestiture of our entire vitamins and nutritional supplements business segment. The results of the vitamins and nutritional supplements business, which represents our entire vitamins and nutritional supplements business segment, are included in income (loss) from discontinued operations, net of tax, for all periods presented. The net assets and net liabilities associated with the vitamins and nutritional supplements business have been reclassified to assets held for sale and liabilities related to assets held for sale within

F-63

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(17) Financial Information by Segment (Continued)**

current assets and current liabilities, respectively, and have been presented in Corporate and Other as of December 31, 2009.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies. We evaluate performance of our operating segments based on revenue and operating income (loss). Revenues are attributed to geographic areas based on where the customer is located. Segment information for 2010, 2009 and 2008 are as follows (in thousands):

<b>2010</b>	<b>Professional Diagnostics</b>	<b>Health Management</b>	<b>Consumer Diagnostics</b>	<b>Corporate and Other</b>	<b>Total</b>
Net revenue to external customers	\$ 1,459,492	\$ 598,819	\$ 97,036	\$	\$ 2,155,347
Operating income (loss)	\$ 134,687	\$ (1,024,809)	\$ 11,310	\$ (72,277)	\$ (951,089)
Goodwill impairment charge	\$	\$ 1,006,357	\$	\$	\$ 1,006,357
Depreciation and amortization	\$ 246,080	\$ 120,617	\$ 5,439	\$ 654	\$ 372,790
Restructuring charge	\$ 7,941	\$ 7,249	\$ 77	\$	\$ 15,267
Stock-based compensation	\$	\$	\$	\$ 29,879	\$ 29,879
Assets	\$ 4,913,491	\$ 1,011,183	\$ 207,795	\$ 197,905	\$ 6,330,374
Expenditures for property, plant and equipment	\$ 43,364	\$ 48,410	\$ 4,314	\$ 153	\$ 96,241

<b>2009</b>	<b>Professional Diagnostics</b>	<b>Health Management</b>	<b>Consumer Diagnostics</b>	<b>Corporate and Other</b>	<b>Total</b>
Net revenue to external customers	\$ 1,263,511	\$ 521,947	\$ 137,183	\$	\$ 1,922,641
Operating income (loss)	\$ 235,412	\$ (6,829)	\$ (2,008)	\$ (80,525)	\$ 146,050
Depreciation and amortization	\$ 187,907	\$ 116,800	\$ 6,637	\$ 1,091	\$ 312,435
Restructuring charge	\$ 14,537	\$ 2,292	\$ 563	\$	\$ 17,392
Stock-based compensation	\$	\$	\$	\$ 28,220	\$ 28,220
Assets	\$ 4,261,716	\$ 2,031,260	\$ 219,647	\$ 431,369	\$ 6,943,992
Expenditures for property, plant and equipment	\$ 45,588	\$ 50,871	\$ 3,536	\$ 611	\$ 100,606

<b>2008</b>	<b>Professional Diagnostics</b>	<b>Health Management</b>	<b>Consumer Diagnostics</b>	<b>Corporate and Other</b>	<b>Total</b>
Net revenue to external customers	\$ 1,051,301	\$ 392,399	\$ 138,853	\$	\$ 1,582,553

Edgar Filing: ALERE INC. - Form 10-K/A

Operating income (loss)	\$ 97,994	\$ 11,241	\$ 9,505	\$ (54,048)	\$ 64,692
Depreciation and amortization	\$ 171,980	\$ 85,990	\$ 6,821	\$ 863	\$ 265,654
Restructuring charge	\$ 36,196	\$	\$ 238	\$	\$ 36,434
Stock-based compensation	\$	\$	\$	\$ 26,405	\$ 26,405
Expenditures for property, plant and equipment	\$ 46,859	\$ 7,935	\$ 1,917	\$ 8,988	\$ 65,699

F-64

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(17) Financial Information by Segment (Continued)**

	<b>2010</b>	<b>2009</b>	<b>2008</b>
<b>Revenue by Geographic Area:</b>			
United States	\$ 1,380,314	\$ 1,329,747	\$ 1,121,477
Europe	361,810	316,623	285,696
Elsewhere	413,223	276,271	175,380
	\$ 2,155,347	\$ 1,922,641	\$ 1,582,553

	<b>December 31,</b>	
	<b>2010</b>	<b>2009</b>
<b>Long-lived Tangible Assets by Geographic Area:</b>		
United States	\$ 255,572	\$ 238,475
United Kingdom	19,864	15,807
China	26,164	22,112
Elsewhere	88,910	47,994
	\$ 390,510	\$ 324,388

**(18) Related Party Transactions**

In November 2008, the Zwanziger Family Trust, a trust established for the benefit of the children of Ron Zwanziger, our Chairman, Chief Executive Officer and President, and the trustee of which is Mr. Zwanziger's sister, purchased certain of our securities from third parties in market transactions. The purchase consisted of approximately \$1.0 million of each of the following securities: our common stock, our Series B Preferred Stock, our Convertible Notes, interests in our First Lien Credit Agreement and interests in our Second Lien Credit Agreement. To the extent we make principal and interest payments under the Convertible Notes and the credit facilities in accordance with their terms, the Zwanziger Family Trust, as a holder of Convertible Notes and as a lender under the credit facilities, will receive its proportionate share. In connection with its purchases of interests under our First Lien Credit Agreement and Second Lien Credit Agreement, the Trust agreed that, whenever the consent or vote of the lenders is required under the credit facilities, it will vote the outstanding principal amount of its holdings in the same proportion as the votes cast by the other lenders under these credit facilities.

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

At December 31, 2010 and 2009, we had a net payable to the joint venture of \$2.8 million and \$0.5 million, respectively. Additionally, customer receivables associated with revenue earned after the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying consolidated balance sheets in the amount of \$7.8 million and \$12.3 million as of December 31, 2010 and 2009, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled \$68.1 million, \$103.1 million and \$103.0 million during the years ended December 31, 2010, 2009 and 2008, respectively. Additionally, services revenue generated pursuant to the long-term services

F-65

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(18) Related Party Transactions (Continued)**

agreement with the joint venture totaled \$1.2 million, \$1.8 million and \$2.4 million during the years ended December 31, 2010, 2009 and 2008, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations.

Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in the U.K. and China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded \$7.0 million and \$14.5 million of trade receivables which are included in accounts receivable on our accompanying consolidated balance sheets as of December 31, 2010 and 2009, respectively, and \$20.5 million and \$23.2 million of trade accounts payable which are included in accounts payable on our accompanying consolidated balance sheets as of December 31, 2010 and 2009, respectively. During 2010 and 2009, we received \$8.8 million and \$10.0 million, respectively, in cash from SPD as a return of capital.

In July 2009, we sold one of our consumer-related Australian subsidiaries to SPD for approximately \$0.2 million in connection with the original terms of the joint venture agreement to transition the distribution responsibilities of certain consumer diagnostic products to SPD. The sale of the subsidiary was completed at net book value resulting in no gain or loss on the transaction.

**(19) Valuation and Qualifying Accounts**

We have established reserves against accounts receivable for doubtful accounts, product returns, discounts and other allowances. The activity in the table below includes all accounts receivable reserves. Provisions for doubtful accounts are recorded as a component of general and administrative expenses. Provisions for returns, discounts and other allowances are charged against net product sales. The following table sets forth activities in our accounts receivable reserve accounts (in thousands):

	<b>Balance at Beginning of Period</b>	<b>Provision</b>	<b>Amounts Charged Against Reserves</b>	<b>Balance at End of Period</b>
Year ended December 31, 2008	\$ 6,847	\$ 9,328	\$ (6,214)	\$ 9,961
Year ended December 31, 2009	\$ 9,961	\$ 9,314	\$ (6,813)	\$ 12,462
Year ended December 31, 2010	\$ 12,462	\$ 14,021	\$ (6,102)	\$ 20,381

We have established reserves against obsolete and slow-moving inventories. The activity in the table below includes all inventory reserves. Provisions for obsolete and slow-moving inventories are recorded as a component of cost of net product sales. The following table sets forth activities in our inventory reserve accounts (in thousands):

**Amounts**

	<b>Balance at Beginning of Period</b>	<b>Provision</b>	<b>Charged Against Reserves</b>	<b>Balance at End of Period</b>
Year ended December 31, 2008	\$ 6,637	\$ 8,023	\$ (5,042)	\$ 9,618
Year ended December 31, 2009	\$ 9,618	\$ 6,954	\$ (3,940)	\$ 12,632
Year ended December 31, 2010	\$ 12,632	\$ 6,269	\$ (6,593)	\$ 12,308

F-66

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(20) Restructuring Activities**

The following table sets forth the aggregate charges associated with restructuring plans recorded in operating income (loss) for the years ended December 31, (in thousands):

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Cost of net revenue	\$ 3,896	\$ 9,451	\$ 17,894
Research and development	488	1,076	7,230
Sales and marketing	1,539	1,856	4,219
General and administrative	9,344	5,009	7,091
	<b>\$ 15,267</b>	<b>\$ 17,392</b>	<b>\$ 36,434</b>

*(a) 2010 Restructuring Plans*

In 2010, management developed additional plans to reduce costs and improve efficiencies in our health management business segment. As a result of these plans, we recorded \$7.4 million in charges during the year ended December 31, 2010, which included \$4.6 million in severance costs, \$2.4 million in costs associated with facility exit costs, \$0.2 million in fixed asset impairments and \$0.2 million in present value accretion on facility exit costs, which was included in interest expense. As of December 31, 2010, \$3.0 million in costs remains unpaid. We anticipate incurring \$0.2 million in additional restructuring costs associated with the present value accretion on facility exit costs under these plans, as well as minimal severance charges.

During 2010, management also developed several plans to reduce costs and improve efficiencies in our professional diagnostics business segment. As a result of these plans, we recorded \$3.4 million in charges during the year ended December 31, 2010, which included \$2.4 million in severance-related costs, \$0.8 million in facility and other exit costs and \$0.2 million in fixed asset impairments. As of September 30, 2010, \$0.3 million of these costs remains unpaid. We anticipate incurring additional severance and facility exit costs of \$0.2 million under these plans.

*(b) 2009 Restructuring Plans*

In 2009, management developed plans to reduce costs and improve efficiencies in our health management reporting unit and business segment, as well as reduce costs and consolidate operating activities among several of our professional diagnostics related German subsidiaries. As a result of these plans, we recorded \$0.4 million in severance-related restructuring charges in our professional diagnostics business segment during the year ended December 31, 2010. We recorded \$3.2 million in restructuring charges during the year ended December 31, 2009, which included \$2.5 million in severance costs, \$0.5 million in contract cancellation costs, \$0.1 million in present value accretion on facility exit costs and \$0.1 million in fixed asset impairment costs. Of the \$3.1 million included in operating income for the year ended December 31, 2009, \$2.3 million and \$0.8 million was included in our health management and professional diagnostics business segments, respectively. We also recorded \$0.1 million in present value accretion related to Matria's facility exit costs to interest expense during the year ended December 31, 2009. We have incurred a total of \$3.6 million under this plan and we do not expect to incur any additional costs. As of



December 31, 2010, all costs have been paid.

*(c) 2008 Restructuring Plans*

In May 2008, we decided to close our facility located in Bedford, England and initiated steps to cease operations at this facility and transition the manufacturing operations principally to our manufacturing facilities in Shanghai and Hangzhou, China. Based upon this decision, during the year ended December 31, 2010, we recorded net recoveries of \$1.2 million in restructuring charges, of which \$0.2 million related to

F-67

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(20) Restructuring Activities (Continued)**

severance-related costs, \$1.6 million related to transition costs, \$0.4 million related to fixed asset and inventory write-offs and \$3.4 million net recovery related to facility restoration and other facility exit costs. During the year ended December 31, 2009, we recorded \$5.5 million in restructuring charges, of which \$2.8 million related primarily to severance-related costs, \$1.3 million related to transition costs, \$0.7 million related to fixed asset and inventory write-offs, \$0.3 million related to a pension plan curtailment charge and \$0.4 million related to the acceleration of facility restoration costs. During the year ended December 31, 2008, we recorded \$12.6 million in restructuring charges, including \$6.9 million related to the acceleration of facility restoration costs, \$4.8 million of fixed asset impairments, \$1.1 million in severance costs, \$0.7 million in early termination lease penalties and \$0.9 million related to a pension plan curtailment gain associated with the Bedford employees being terminated. Of the \$2.2 million charge included in operating income for the year ended December 31, 2010, substantially all was charged to our professional diagnostics business segment. Of the \$5.1 million included in operating income for the year ended December 31, 2009, \$0.6 million and \$4.5 million was charged to our consumer diagnostics and professional diagnostics business segments, respectively. The \$5.7 million included in operating income for the year ended December 31, 2008 was charged to our professional diagnostics business segment. Included in interest expense during the years ended December 31, 2010, 2009 and 2008 were charges of \$0.1 million, \$0.4 million and \$6.9 million, respectively, related to the accelerated present value accretion of our lease restoration costs due to the early termination of our facility lease. We also recorded a net recovery of \$3.5 million related to the facility lease obligation settlement during the year ended December 31, 2010, to other income (expense), net.

In addition to the restructuring charges discussed above, \$6.0 million, \$10.4 million and \$14.5 million of charges associated with the Bedford facility closure was borne by SPD during the years ended December 31, 2010, 2009 and 2008, respectively. Included in the \$6.0 million charges for the year ended December 31, 2010, was \$4.7 million in facility and transition costs, \$1.5 million in severance and retention costs, \$0.1 million in inventory write-offs, \$0.3 million in acceleration of facility exit costs and a net recovery of \$0.6 million in fixed asset impairments due to unanticipated asset sales. Included in the \$10.4 million charges for the year ended December 31, 2009, was \$7.3 million in severance and retention costs, \$1.2 million of fixed asset and inventory impairments, \$1.7 million in transition costs and \$0.2 million in acceleration of facility exit costs. Included in the \$14.5 million charges for the year ended December 31, 2008, was \$8.4 million of fixed asset impairments, \$3.2 million in early termination lease penalties, \$2.6 million in severance and retention costs, \$0.2 million facility exit costs and \$0.1 million related to the acceleration of facility restoration costs. Of these restructuring charges, 50%, or \$3.0 million, \$5.2 million and \$7.2 million, has been included in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations for the years ended December 31, 2010, 2009 and 2008, respectively. Of the total exit costs incurred jointly with SPD under this plan, including severance-related costs, lease penalties and restoration costs, \$5.8 million remains unpaid as of December 31, 2010.

Since inception of the plan, we recorded \$16.9 million in restructuring charges, including \$5.9 million of fixed asset and inventory impairments, \$4.6 million related to the acceleration of facility restoration costs and early termination lease penalties, \$4.1 million in severance costs, \$2.9 million in transition costs and \$0.6 million related to a pension plan curtailment gain associated with the Bedford employees being terminated. SPD has been allocated \$30.9 million in restructuring charges since the inception of the plan, including \$9.1 million of fixed asset and inventory impairments, \$11.4 million in severance and retention costs, \$2.9 million in early termination lease penalties, \$6.9 million in facility exit costs and \$0.6 million related to the acceleration of facility exit costs. We anticipate incurring additional costs of approximately \$1.0 million related to the closure of this facility, primarily related to

severance and transition costs through the end of 2011. Of these additional anticipated costs, approximately \$0.8 million will be borne by SPD and \$0.2 million will be borne by us and included primarily in our professional diagnostics business segment.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(20) Restructuring Activities (Continued)**

On March 18, 2008, we announced our plans to close our BioStar, Inc., or BioStar, facility in Louisville, Colorado and exit production of the BioStar OIA product line, along with our plans to close two of our newly-acquired facilities in the San Francisco, California area, relating to Cholestech and HemoSense and our newly-acquired facility in Columbia, Maryland, relating to Panbio. The Cholestech operation, which was acquired in September 2007 and manufactures and distributes the Cholestech LDX system, a point-of-care monitor of blood cholesterol and related lipids used to test patients at risk of, or suffering from, heart disease and related conditions, has moved to our Biosite facility in San Diego, California. The HemoSense operation, which was acquired in November 2007 and manufactures and distributes the INRatio System, an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly-prescribed medication used to prevent blood clots, has moved to our Biosite facility. The operations of the Panbio distribution facility, which was acquired in January 2008, have transferred to our distribution center in Freehold, New Jersey.

BioStar manufacturing ceased at the end of June 2008, with BioStar OIA products available for purchase through the end of the first quarter of 2009. During the year ended December 31, 2009, we incurred \$0.1 million in severance-related restructuring charges. During the year ended December 31, 2008, we incurred \$10.6 million in restructuring charges related to this plan, which consisted of \$5.1 million of intangible asset impairments, \$1.4 million in severance-related costs, \$0.6 million in fixed asset impairments, \$1.2 million in facility exit costs and \$2.3 million related to the write-off of inventory. Since the inception of the plan, we incurred \$10.7 million in restructuring charges related to this plan, which consisted of \$5.1 million of intangible assets impairment, \$1.5 million in severance-related costs, \$0.6 million in fixed asset impairments, \$1.2 million in facility exit costs and \$2.3 million related to the write-off of inventory. All costs related to this plan have been included in our professional diagnostics business segment. We do not expect to incur additional charges under this plan. As of December 31, 2009, all costs have been paid.

As a result of our plans to transition the businesses of Cholestech and HemoSense to Biosite and Panbio to Orlando, Florida and close these facilities, we incurred \$2.5 million in restructuring charges during the year ended December 31, 2010, of which \$0.2 million relates to severance and retention costs, \$1.3 million in facility closure and transition costs, \$0.9 million in fixed asset and inventory write-offs and \$0.1 million in present value accretion of facility lease costs. We incurred \$8.2 million in restructuring charges during the year ended December 31, 2009, of which \$2.4 million relates to fixed asset impairments, \$1.7 million relates to severance and retention costs, \$2.6 million in transition costs, \$1.3 million in inventory write-offs and \$0.2 million in present value accretion of facility lease costs. We incurred \$3.8 million in restructuring charges during the year ended December 31, 2008, of which \$2.7 million relates to severance and retention costs, \$0.4 million in fixed asset impairments, \$0.5 million in transition costs and \$0.2 million in present value accretion of facility lease costs related to these plans. During the years ended December 31, 2010, 2009 and 2008, respectively, \$2.4 million, \$8.0 million and \$3.6 million in charges were included in operating income of our professional diagnostics business segment. We charged \$0.1 million, \$0.2 million and \$0.2 million related to the present value accretion of facility lease costs, to interest expense for the years ended December 31, 2010, 2009 and 2008, respectively. Since the inception of the plan, we incurred \$14.5 million in restructuring charges, of which \$4.6 million relates to severance and retention costs, \$3.4 million in fixed asset impairments, \$4.4 million in transition costs, \$1.6 million in inventory write-offs and \$0.5 million in present value accretion of facility lease costs related to these plans. Of the \$9.5 million in severance and exit costs, \$0.6 million remains unpaid as of December 31, 2010. We do not anticipate incurring significant additional restructuring charges under these plans. See Note 4(d) for further information and costs related to these plans.

In addition to transitioning the businesses of Cholestech and HemoSense to Biosite, we also made the decision to close our Innovacon facility in San Diego, California and move the operating activities to Biosite;

F-69

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(20) Restructuring Activities (Continued)**

the Innovacon business is the rapid diagnostics business that we acquired from ACON in March 2006. During the year ended December 31, 2008 and since inception, we recorded \$0.6 million in restructuring charges, of which \$0.5 million related to facility lease and exit costs and \$0.1 million related to impairment of fixed assets. These charges are included in our professional diagnostics business segment. As of December 31, 2009, all costs have been paid. We vacated the facility in August 2008 and do not anticipate incurring additional costs under this plan.

In February 2008, we decided to cease research and development activities for one of the products in development at our Bedford, England facility, based upon comparison of the product under development with existing products acquired in the HemoSense acquisition. During the year ended December 31, 2008 and since inception of the plan, we recorded restructuring charges of \$9.4 million, of which \$6.8 million related to the impairment of fixed assets, \$1.9 million related to the write-off of inventory, \$0.5 million related to contractual obligations with suppliers and \$0.2 million related to severance costs to involuntarily terminate employees working on the development of this product. The \$9.4 million was included in our professional diagnostics business segment. Of the \$0.7 million in contractual obligations and severance costs, all has been paid as of December 31, 2008. We do not expect to incur additional charges under this plan.

In April 2008, we initiated cost reduction efforts at our facilities in Stirling, Scotland, consolidating our business activities into one facility and with our Biosite operations. As a result of these efforts, we recorded \$3.3 million in restructuring charges for the year ended December 31, 2008 and since inception of the plan, consisting of \$2.0 million in fixed asset impairments, \$1.0 million in severance costs and \$0.3 million in facility exit costs. All costs related to this plan are included in our professional diagnostics business segment. Of the \$1.3 million in severance and facility exit costs, substantially all has been paid as of December 31, 2010. We do not expect to incur additional charges under this plan.

*(d) 2007 Restructuring Plans*

During 2007, we committed to several plans to restructure and integrate our worldwide sales, marketing, order management and fulfillment operations, as well as to evaluate certain research and development projects. The objectives of the plans were to eliminate redundant costs, improve customer responsiveness and improve operational efficiencies. As a result of these restructuring plans, we recorded a recovery of \$0.3 million in restructuring charges during the year ended December 31, 2010, related to severance charges. We recorded \$1.1 million in restructuring charges during the year ended December 31, 2009, primarily related to severance charges and outplacement services. We recorded \$3.0 million in restructuring charges during the year ended December 31, 2008, including \$2.6 million related to severance charges and outplacement services and \$0.4 million related to facility exit costs. Since inception of the plans, we have recorded \$9.0 million in restructuring charges, including \$4.6 million related to severance charges and outplacement services, \$0.4 million related to facility exit costs and \$4.0 million related to impairment charges on fixed assets. The restructuring charges related to this plan are included in our professional diagnostics business segment. As of December 31, 2010, all costs have been paid. We do not anticipate incurring additional charges related to this plan.

In addition, we recorded restructuring charges associated with the formation of our joint venture with P&G. In connection with the joint venture, we committed to a plan to close our sales offices in Germany and Sweden, as well as to evaluate redundancies in all departments of the consumer diagnostics business segment that are impacted by the

formation of the joint venture. For the year ended December 31, 2008, we recorded \$0.2 million in severance costs related to this plan. We have recorded \$1.4 million in restructuring charges since inception of the plan, of which \$1.0 million relates to severance costs and \$0.4 million relates to facility and other exit costs. Of the total \$1.4 million in exit costs, all have been paid as of December 31, 2010. We do not anticipate incurring additional charges related to this plan.

F-70

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(20) Restructuring Activities (Continued)***(e) Restructuring Reserves*

The following table summarizes our liabilities related to the restructuring activities associated with the plans discussed above (in thousands):

	<b>Balance at Beginning of Period</b>	<b>Additions to the Reserve</b>	<b>Amounts Paid</b>	<b>Other(1)</b>	<b>Balance at End of Period</b>
Year ended December 31, 2008	\$ 1,123	\$ 25,642	\$ (9,148)	\$ (2,823)	\$ 14,794
Year ended December 31, 2009	\$ 14,794	\$ 22,730	\$ (18,021)	\$ (597)	\$ 18,906
Year ended December 31, 2010	\$ 18,906	\$ 17,036	\$ (25,563)	\$ (676)	\$ 9,703

(1) Represents foreign currency translation adjustment.

**(21) Equity Investments**

We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323 *Investments – Equity Method and Joint Ventures*, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

*(i) SPD*

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form SPD, we ceased to consolidate the operating results of our consumer diagnostics business related to SPD. For the years ended December 31, 2010 and 2009, we recorded earnings of \$8.5 million, and \$5.7 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD's net income for the respective periods. For the year ended December 31, 2008, we recorded a loss of \$0.9 million in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD's net loss for the respective period.

*(ii) TechLab*

In May 2006, we acquired 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic associated diarrhea and parasitology. For the years ended December 31, 2010, 2009 and 2008, we recorded earnings of \$1.9 million, \$1.7 million and \$1.5 million, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab's net income for the respective period.



Summarized financial information for the P&G joint venture and TechLab on a combined basis is as follows (in thousands):

*Combined condensed results of operations:*

	<b>For The Years Ended December 31,</b>		
	<b>2010</b>	<b>2009</b>	<b>2008</b>
Net revenue	\$ 224,193	\$ 203,677	\$ 204,053
Gross profit	\$ 142,159	\$ 127,719	\$ 102,942
Net income after taxes	\$ 20,913	\$ 14,821	\$ 1,209

F-71

---

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(21) Equity Investments (Continued)***Combined condensed balance sheets:*

	<b>As of December 31,</b>	
	<b>2010</b>	<b>2009</b>
Current assets	\$ 93,250	\$ 87,880
Non-current assets	25,965	26,881
<b>Total assets</b>	<b>\$ 119,215</b>	<b>\$ 114,761</b>
Current liabilities	\$ 62,788	\$ 61,959
Non-current liabilities	2,091	1,492
<b>Total liabilities</b>	<b>\$ 64,879</b>	<b>\$ 63,451</b>

**(22) Gain on Disposition**

In September 2009, we disposed of our majority ownership interest in our Diamics operation, which was part of our professional diagnostics reporting unit and business segment. Since the date of acquisition, July 2007, under the principles of consolidation, we consolidated 100% of the operating results of the Diamics operations in our consolidated statement of operations. As a result of disposition, we recorded a gain of \$3.4 million during the year ended December 31, 2009.

**(23) Discontinued Operations**

On January 15, 2010, we completed the sale of our vitamins and nutritional supplements business for a purchase price of approximately \$62.6 million in cash, which is net of the final working capital adjustment. The sale included our entire private label and branded nutritionals businesses and represents the complete divestiture of our entire vitamins and nutritional supplements business segment. We recognized a gain of approximately \$18.7 million (\$11.6 million, net of tax) during 2010. The results of the vitamins and nutritional supplements business, which represents our entire vitamins and nutritional supplements business segment, are included in income (loss) from discontinued operations, net of tax, for all periods presented. The net assets and net liabilities associated with the vitamins and nutritional supplements business were classified as assets held for sale and liabilities related to assets held for sale as of December 31, 2009.

The following assets and liabilities have been segregated and classified as assets held for sale and liabilities related to assets held for sale, as appropriate, in the consolidated balance sheet as of December 31, 2009. The amounts presented below were adjusted to exclude cash, intercompany receivables and payables and certain assets and liabilities between the business held for sale and our company, which were excluded from the transaction (amounts in thousands).



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(23) Discontinued Operations (Continued)**

	<b>December 31, 2009</b>	
<b>Assets</b>		
Accounts receivable, net of allowances of \$2,919 at December 31, 2009	\$	21,100
Inventories, net		21,500
Prepaid expenses and other current assets		160
Property, plant and equipment, net		8,368
Goodwill		200
Other intangible assets with indefinite lives		135
Other intangible assets, net		2,581
Other non-current assets		104
 Total assets held for sale	 \$	 54,148
<b>Liabilities</b>		
Accounts payable	\$	8,299
Accrued expenses and other current liabilities		3,230
Other long-term liabilities		29
 Total liabilities related to assets held for sale	 \$	 11,558

The following summarized financial information related to the vitamins and nutritional supplements businesses have been segregated from continuing operations and reported as discontinued operations (amounts in thousands).

	<b>2010</b>	<b>2009</b>	<b>2008</b>
Net revenue	4,362	99,517	88,873
Income (loss) from discontinued operations before income taxes	18,487	2,102	(1,090)
Provision (benefit) for income taxes	7,090	168	(42)
Net income (loss) from discontinued operations	11,397	1,934	(1,048)

**(24) Supplemental Cash Flow Information***Cash Paid for Interest and Income Taxes:*

During fiscal 2010, 2009 and 2008, we made cash payments for interest totaling \$117.1 million, \$87.3 million and \$88.6 million, respectively.

During fiscal 2010, 2009 and 2008, total net cash paid for income taxes was \$31.1 million, \$49.2 million and \$5.5 million, respectively.



**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(24) Supplemental Cash Flow Information (Continued)***Non-cash Investing Activities:*

During fiscal 2010, 2009 and 2008, we issued shares of our common stock and exchanged employee stock options in connection with several of our acquisitions (dollars in thousands):

Company Acquired	Date of Acquisition	Common Stock Issued		Employee Stock Options/ Restricted Stock Awards Exchanged	
		Number of Shares	Fair Value of Shares	Number of Shares	Fair Value of Shares
Mologic Limited	October 6, 2009	128,513	\$ 5,115		\$
Concateno plc	August 11, 2009	2,091,080	\$ 70,218	315,227	\$ 2,881
GeneCare Medical Genetics Center, Inc.	July 1, 2009	4,000	\$ 57		\$
ACON Second Territory Business(1)	April 30, 2009	1,681,254	\$ 58,708		\$
Matria Healthcare, Inc.	May 9, 2008		\$	1,490,655	\$ 17,334
BBI Holdings Plc	February 12, 2008	251,085	\$ 14,397	355,238	\$ 3,639

(1) Includes 1,210,842 shares of our common stock with a fair value of \$42.4 million, issued during 2009. Includes 470,412 shares of our common stock with a fair value of approximately \$16.3 million, issued during the second quarter of 2010, as settlement of deferred purchase price consideration.

*Non-cash Financing Activities:*

During fiscal 2010, 2009 and 2008, we recorded non-cash income (expense) to accumulated other comprehensive income (expense) of \$2.4 million, \$11.4 million and \$(11.6) million, respectively, representing the change in fair market value of our interest rate swap agreement.

**(25) Guarantor Financial Information**

Our 9% senior subordinated notes due 2016, our 7.875% senior notes due 2016, and our 8.625% subordinated notes due 2018 are guaranteed by certain of our consolidated wholly-owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, audited balance sheets as of December 31, 2010 and 2009 and the related audited statements of operations and cash flows for each of the three years in the period ended December 31, 2010 for the Company, the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of the Company and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification.

F-74

---

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)****CONSOLIDATING STATEMENT OF OPERATIONS  
For the Year Ended December 31, 2010**

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 843,542	\$ 740,371	\$ (111,510)	\$ 1,472,403
Services revenue		608,482	53,703		662,185
Net product sales and services revenue		1,452,024	794,074	(111,510)	2,134,588
License and royalty revenue		10,003	16,167	(5,411)	20,759
<b>Net revenue</b>		<b>1,462,027</b>	<b>810,241</b>	<b>(116,921)</b>	<b>2,155,347</b>
Cost of net product sales	628	395,863	403,098	(111,264)	688,325
Cost of services revenue		304,269	21,017		325,286
Cost of net product sales and services revenue	628	700,132	424,115	(111,264)	1,013,611
Cost of license and royalty revenue		66	12,494	(5,411)	7,149
<b>Cost of net revenue</b>	<b>628</b>	<b>700,198</b>	<b>436,609</b>	<b>(116,675)</b>	<b>1,020,760</b>
<b>Gross profit</b>	<b>(628)</b>	<b>761,829</b>	<b>373,632</b>	<b>(246)</b>	<b>1,134,587</b>
Operating expenses:					
Research and development	20,936	68,862	43,480		133,278
Sales and marketing	3,001	316,884	179,239		499,124
General and administrative	49,222	232,067	165,628		446,917
Goodwill impairment charge		1,006,357			1,006,357
<b>Operating loss</b>	<b>(73,787)</b>	<b>(862,341)</b>	<b>(14,715)</b>	<b>(246)</b>	<b>(951,089)</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(136,772)	(74,718)	(10,431)	82,486	(139,435)
Other income (expense), net	85,600	(5,358)	24,982	(82,486)	22,738
<b>Income (loss) from continuing operations before provision (benefit) for income taxes</b>	<b>(124,959)</b>	<b>(942,417)</b>	<b>(164)</b>	<b>(246)</b>	<b>(1,067,786)</b>



Edgar Filing: ALERE INC. - Form 10-K/A

Provision (benefit) for income taxes	(53,164)	3,631	19,602		(29,931)
<b>Loss from continuing operations before equity earnings of unconsolidated entities, net of tax</b>	(71,795)	(946,048)	(19,766)	(246)	(1,037,855)
Equity in earnings of subsidiaries, net of tax	(946,694)			946,694	
Equity earnings (losses) of unconsolidated entities, net of tax	2,024		8,680	(138)	10,566
Income (loss) from continuing operations	(1,016,465)	(946,048)	(11,086)	946,310	(1,027,289)
Income from discontinued operations, net of tax	573	9,727	1,097		11,397
<b>Net income (loss)</b>	(1,015,892)	(936,321)	(9,989)	946,310	(1,015,892)
Less: Net income attributable to non-controlling interests			1,418		1,418
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	(1,015,892)	(936,321)	(11,407)	946,310	(1,017,310)
Preferred stock dividends	(24,235)				(24,235)
<b>Net income (loss) available to common stockholders</b>	\$ (1,040,127)	\$ (936,321)	\$ (11,407)	\$ 946,310	\$ (1,041,545)

F-75

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)****CONSOLIDATING STATEMENT OF OPERATIONS  
For the Year Ended December 31, 2009**

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 877,135	\$ 597,266	\$ (109,322)	\$ 1,365,079
Services revenue		521,509	6,978		528,487
Net product sales and services revenue		1,398,644	604,244	(109,322)	1,893,566
License and royalty revenue		6,441	26,470	(3,836)	29,075
<b>Net revenue</b>		<b>1,405,085</b>	<b>630,714</b>	<b>(113,158)</b>	<b>1,922,641</b>
Cost of net product sales	380	432,168	334,699	(147,744)	619,503
Cost of services revenue		236,660	3,366		240,026
Cost of net product sales and services revenue	380	668,828	338,065	(147,744)	859,529
Cost of license and royalty revenue		(16)	12,742	(3,836)	8,890
<b>Cost of net revenue</b>	<b>380</b>	<b>668,812</b>	<b>350,807</b>	<b>(151,580)</b>	<b>868,419</b>
<b>Gross profit</b>	<b>(380)</b>	<b>736,273</b>	<b>279,907</b>	<b>38,422</b>	<b>1,054,222</b>
Operating expenses:					
Research and development	21,302	62,115	29,431		112,848
Sales and marketing	1,063	317,235	123,348		441,646
General and administrative	58,598	217,531	80,904		357,033
Gain on dispositions	(2,682)		(673)		(3,355)
<b>Operating income (loss)</b>	<b>(78,661)</b>	<b>139,392</b>	<b>46,897</b>	<b>38,422</b>	<b>146,050</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(102,627)	(50,261)	(11,505)	57,595	(106,798)
Other income (expense), net	55,476	(4,584)	7,699	(57,595)	996
<b>Income (loss) from continuing operations before provision (benefit) for income taxes</b>	<b>(125,812)</b>	<b>84,547</b>	<b>43,091</b>	<b>38,422</b>	<b>40,248</b>
Provision (benefit) for income taxes	(35,006)	39,567	10,875	191	15,627

<b>Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax</b>	(90,806)	44,980	32,216	38,231	24,621
Equity in earnings of subsidiaries, net of tax	124,336			(124,336)	
Equity earnings of unconsolidated entities, net of tax	1,747		5,972	(93)	7,626
Income (loss) from continuing operations	35,277	44,980	38,188	(86,198)	32,247
Income (loss) from discontinued operations, net of tax	(1,096)	2,689	334	7	1,934
<b>Net income (loss)</b>	34,181	47,669	38,522	(86,191)	34,181
Less: Net income attributable to non-controlling interests			465		465
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	34,181	47,669	38,057	(86,191)	33,716
Preferred stock dividends	(22,972)				(22,972)
<b>Net income (loss) available to common stockholders</b>	\$ 11,209	\$ 47,669	\$ 38,057	\$ (86,191)	\$ 10,744

F-76

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)****CONSOLIDATING STATEMENT OF OPERATIONS  
For the Year Ended December 31, 2008**

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 782,085	\$ 485,091	\$ (115,911)	\$ 1,151,265
Services revenue		402,758	2,704		405,462
Net product sales and services revenue		1,184,843	487,795	(115,911)	1,556,727
License and royalty revenue		15,536	10,290		25,826
<b>Net revenue</b>		1,200,379	498,085	(115,911)	1,582,553
Cost of net product sales	358	369,916	286,307	(113,264)	543,317
Cost of services revenue		176,421	677		177,098
Cost of net product sales and services revenue	358	546,337	286,984	(113,264)	720,415
Cost of license and royalty revenue		3,759	6,438	(1,577)	8,620
<b>Cost of net revenue</b>	358	550,096	293,422	(114,841)	729,035
<b>Gross profit</b>	(358)	650,283	204,663	(1,070)	853,518
Operating expenses:					
Research and development	22,693	53,342	35,793		111,828
Sales and marketing	1,693	289,071	91,043	132	381,939
General and administrative	36,447	186,423	72,189		295,059
<b>Operating income (loss)</b>	(61,191)	121,447	5,638	(1,202)	64,692
Interest expense, including amortization of original issue discounts and deferred financing costs	(90,328)	(72,435)	(15,986)	77,617	(101,132)
Other income (expense), net	78,604	(16,281)	13,442	(77,572)	(1,807)
<b>Income (loss) from continuing operations before provision (benefit) for income taxes</b>	(72,915)	32,731	3,094	(1,157)	(38,247)
Provision (benefit) for income taxes	(59,608)	44,690	(1,726)		(16,644)

<b>Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax</b>	(13,307)	(11,959)	4,820	(1,157)	(21,603)
Equity in earnings of subsidiaries, net of tax	(9,816)			9,816	
Equity earnings (losses) of unconsolidated entities, net of tax	1,522	(23)	(379)	(70)	1,050
Income (loss) from continuing operations	(21,601)	(11,982)	4,441	8,589	(20,553)
Loss from discontinued operations, net of tax		(112)	(891)	(45)	(1,048)
<b>Net income (loss)</b>	(21,601)	(12,094)	3,550	8,544	(21,601)
Less: Net income attributable to non-controlling interests			167		167
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	(21,601)	(12,094)	3,383	8,544	(21,768)
Preferred stock dividends	(13,989)				(13,989)
<b>Net income (loss) available to common stockholders</b>	\$ (35,590)	\$ (12,094)	\$ 3,383	\$ 8,544	\$ (35,757)

F-77

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)****CONSOLIDATING BALANCE SHEET**

December 31, 2010

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>ASSETS</b>					
<b>Current assets:</b>					
Cash and cash equivalents	\$ 101,813	\$ 116,758	\$ 182,735	\$	\$ 401,306
Restricted cash		1,739	842		2,581
Marketable securities		914	1,180		2,094
Accounts receivable, net of allowances		202,578	194,570		397,148
Inventories, net		126,374	139,070	(7,724)	257,720
Deferred tax assets	33,483	19,256	4,372		57,111
Income tax receivable		1,383			1,383
Prepaid expenses and other current assets	7,815	22,709	44,390		74,914
Intercompany receivables	836,222	439,521	9,843	(1,285,586)	
<b>Total current assets</b>	<b>979,333</b>	<b>931,232</b>	<b>577,002</b>	<b>(1,293,310)</b>	<b>1,194,257</b>
Property, plant and equipment, net	1,343	253,640	135,660	(133)	390,510
Goodwill		1,944,719	891,599	(5,018)	2,831,300
Other intangible assets with indefinite lives		12,900	15,283		28,183
Finite-lived intangible assets, net	12,698	1,198,979	495,904		1,707,581
Deferred financing costs, net, and other non-current assets	47,884	4,855	28,662		81,401
Investments in unconsolidated entities	3,589,973	1,196	42,700	(3,571,313)	62,556
Marketable securities	2,308		7,096		9,404
Deferred tax assets			25,182		25,182
Intercompany notes receivable	1,320,925	13,128		(1,334,053)	
<b>Total assets</b>	<b>\$ 5,954,464</b>	<b>\$ 4,360,649</b>	<b>\$ 2,219,088</b>	<b>\$ (6,203,827)</b>	<b>\$ 6,330,374</b>
<b>LIABILITIES AND EQUITY</b>					
<b>Current liabilities:</b>					
Current portion of long-term debt	\$ 9,750	\$ 157	\$ 6,984	\$	\$ 16,891
Current portion of capital lease obligations		1,954	172		2,126

## Edgar Filing: ALERE INC. - Form 10-K/A

Accounts payable	6,938	62,562	57,344		126,844
Accrued expenses and other current liabilities	(104,072)	322,019	127,885		345,832
Payable to joint venture, net		(546)	3,333		2,787
Deferred gain on joint venture	16,309		272,069		288,378
Intercompany payables	414,977	294,920	576,058	(1,285,955)	
<b>Total current liabilities</b>	<b>343,902</b>	<b>681,066</b>	<b>1,043,845</b>	<b>(1,285,955)</b>	<b>782,858</b>
<b>Long-term liabilities:</b>					
Long-term debt, net of current portion	2,375,554		3,012		2,378,566
Capital lease obligations, net of current portion		1,267	135		1,402
Deferred tax liabilities	(34,729)	381,228	73,667		420,166
Other long-term liabilities	64,243	18,396	87,017		169,656
Intercompany notes payables	630,456	497,464	200,814	(1,328,734)	
<b>Total long-term liabilities</b>	<b>3,035,524</b>	<b>898,355</b>	<b>364,645</b>	<b>(1,328,734)</b>	<b>2,969,790</b>
Redeemable non-controlling interest					
<b>Stockholders equity</b>	<b>2,575,038</b>	<b>2,781,228</b>	<b>807,910</b>	<b>(3,589,138)</b>	<b>2,575,038</b>
Non-controlling interests			2,688		2,688
<b>Equity</b>	<b>2,575,038</b>	<b>2,781,228</b>	<b>810,598</b>	<b>(3,589,138)</b>	<b>2,577,726</b>
<b>Total liabilities and equity</b>	<b>\$ 5,954,464</b>	<b>\$ 4,360,649</b>	<b>\$ 2,219,088</b>	<b>\$ (6,203,827)</b>	<b>\$ 6,330,374</b>

F-78

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)****CONSOLIDATING BALANCE SHEET****December 31, 2009****(in thousands)**

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>ASSETS</b>					
<b>Current assets:</b>					
Cash and cash equivalents	\$ 294,137	\$ 82,602	\$ 116,034	\$	\$ 492,773
Restricted cash		1,576	848		2,424
Marketable securities		947			947
Accounts receivable, net of allowances		188,355	166,098		354,453
Inventories, net		122,062	106,544	(7,067)	221,539
Deferred tax assets	36,907	27,947	1,638		66,492
Income tax receivable		1,107			1,107
Prepaid expenses and other current assets	8,160	25,077	39,838		73,075
Assets held for sale		53,545	603		54,148
Intercompany receivables	861,596	329,771	12,500	(1,203,867)	
<b>Total current assets</b>	<b>1,200,800</b>	<b>832,989</b>	<b>444,103</b>	<b>(1,210,934)</b>	<b>1,266,958</b>
Property, plant and equipment, net	1,646	241,732	86,034	(5,024)	324,388
Goodwill		2,768,313	700,384	(5,339)	3,463,358
Other intangible assets with indefinite lives		21,120	22,524		43,644
Finite-lived intangible assets, net	20,854	1,267,148	398,425		1,686,427
Deferred financing costs, net, and other non-current assets	43,368	5,640	23,754		72,762
Investments in unconsolidated entities	3,836,524	367	38,443	(3,811,369)	63,965
Marketable securities	1,503				1,503
Deferred tax assets			20,987		20,987
Intercompany notes receivable	1,296,373	83,510		(1,379,883)	
<b>Total assets</b>	<b>\$ 6,401,068</b>	<b>\$ 5,220,819</b>	<b>\$ 1,734,654</b>	<b>\$ (6,412,549)</b>	<b>\$ 6,943,992</b>

**LIABILITIES AND EQUITY****Current liabilities:**



## Edgar Filing: ALERE INC. - Form 10-K/A

Current portion of long-term debt	\$ 9,750	\$ 2,392	\$ 6,828	\$	\$ 18,970
Current portion of capital lease obligations		499	400		899
Accounts payable	2,580	63,204	60,538		126,322
Accrued expenses and other current liabilities	(110,283)	260,293	129,722		279,732
Payable to joint venture, net		(1,242)	1,775		533
Liabilities related to assets held for sale		11,556	2		11,558
Intercompany payables	306,869	275,316	621,683	(1,203,868)	
<b>Total current liabilities</b>	<b>208,916</b>	<b>612,018</b>	<b>820,948</b>	<b>(1,203,868)</b>	<b>438,014</b>
<b>Long-term liabilities:</b>					
Long-term debt, net of current portion	2,125,006		3,509		2,128,515
Capital lease obligations, net of current portion		698	242		940
Deferred tax liabilities	(48,246)	438,492	51,803		442,049
Deferred gain on joint venture	16,309		272,458		288,767
Other long-term liabilities	68,464	16,603	31,751		116,818
Intercompany notes payables	503,064	746,456	127,822	(1,377,342)	
<b>Total long-term liabilities</b>	<b>2,664,597</b>	<b>1,202,249</b>	<b>487,585</b>	<b>(1,377,342)</b>	<b>2,977,089</b>
<b>Stockholders equity</b>	<b>3,527,555</b>	<b>3,406,552</b>	<b>424,787</b>	<b>(3,831,339)</b>	<b>3,527,555</b>
Non-controlling interests			1,334		1,334
<b>Equity</b>	<b>3,527,555</b>	<b>3,406,552</b>	<b>426,121</b>	<b>(3,831,339)</b>	<b>3,528,889</b>
<b>Total liabilities and equity</b>	<b>\$ 6,401,068</b>	<b>\$ 5,220,819</b>	<b>\$ 1,734,654</b>	<b>\$ (6,412,549)</b>	<b>\$ 6,943,992</b>

Table of Contents**ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)**

**CONSOLIDATING STATEMENT OF CASH FLOWS**  
**For the Year Ended December 31, 2010**  
(in thousands)

	Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
<b>Cash Flows from Operating Activities:</b>					
Net income (loss)	\$ (1,015,892)	\$ (936,321)	\$ (9,989)	\$ 946,310	\$ (1,015,892)
Income from discontinued operations, net of tax	573	9,727	1,097		11,397
Income (loss) from continuing operations	(1,016,465)	(946,048)	(11,086)	946,310	(1,027,289)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:					
Equity in earnings of subsidiaries, net of tax	946,694			(946,694)	
Non-cash interest expense including amortization of original issue discounts and write-off of deferred financing costs	12,301	289	1,168		13,758
Depreciation and amortization	1,125	266,013	106,130	(478)	372,790
Non-cash stock-based compensation expense	9,498	9,648	10,733		29,879
Impairment of inventory		261	587		848
Impairment of long-lived assets		1,473	(62)		1,411
Impairment of goodwill		1,006,357			1,006,357
Loss on sale of fixed assets		719	279		998
Gain on sale of marketable securities	(4,190)		(314)		(4,504)
Equity earnings of unconsolidated entities, net of tax	(2,023)		(8,680)	137	(10,566)
Deferred income taxes	3,215	(55,335)	(22,298)		(74,418)
Other non-cash items	1,260	1,368	1,174		3,802
Changes in assets and liabilities, net of acquisitions:					
Accounts receivable, net		(4,300)	(5,060)		(9,360)
Inventories, net		(2,012)	(21,297)	464	(22,845)

Edgar Filing: ALERE INC. - Form 10-K/A

Prepaid expenses and other current assets	303	4,092	3,915		8,310
Accounts payable	4,358	(1,529)	(11,917)		(9,088)
Accrued expenses and other current liabilities	(55,400)	58,379	19,223		22,202
Other non-current liabilities	(5)	120	(27,567)		(27,452)
Intercompany payable (receivable)	(162,963)	(273,166)	436,129		
Net cash provided by (used in) continuing operations	(262,292)	66,329	471,057	(261)	274,833
Net cash provided by (used in) discontinued operations	849	(258)			591
<b>Net cash provided by (used in) operating activities</b>	<b>(261,443)</b>	<b>66,071</b>	<b>471,057</b>	<b>(261)</b>	<b>275,424</b>
<b>Cash Flows from Investing Activities:</b>					
Purchases of property, plant and equipment	(82)	(56,922)	(39,498)	261	(96,241)
Proceeds from sale of property, plant and equipment		73	722		795
Cash paid for acquisitions and transaction costs, net of cash acquired	(184,975)	(32,279)	(306,253)		(523,507)
Decrease (increase) in marketable securities	4,190		(1,008)		3,182
Net cash received from equity method investments	1,317	43	10,994		12,354
Increase in other assets	(5,600)	(695)	(6,605)		(12,900)
Net cash provided by (used in) continuing operations	(185,150)	(89,780)	(341,648)	261	(616,317)
Net cash provided by (used in) discontinued operations	(849)	61,445	2,000		62,596
<b>Net cash provided (used in) by investing activities</b>	<b>(185,999)</b>	<b>(28,335)</b>	<b>(339,648)</b>	<b>261</b>	<b>(553,721)</b>
<b>Cash Flows from Financing Activities:</b>					
Decrease (increase) in restricted cash		(163)	22		(141)
Cash paid for financing costs	(13,045)				(13,045)
Proceeds from issuance of common stock, net of issuance costs	19,024				19,024
Proceeds on long-term debt	400,000				400,000
Repayment on long-term debt	(9,750)				(9,750)
	(142,000)	(2,180)	(2,601)		(146,781)

Net repayments from revolving lines-of-credit				
Excess tax benefit on exercised stock options	1,030	264	389	1,683
Principal payments of capital lease obligations		(1,501)	(366)	(1,867)
Purchase of non-controlling interest			(52,864)	(52,864)
Other	(141)			(141)
Net cash provided by (used in) continuing operations	255,118	(3,580)	(55,420)	196,118
Net cash provided by discontinued operations				
<b>Net cash provided by (used in) financing activities</b>	255,118	(3,580)	(55,420)	196,118
Foreign exchange effect on cash and cash equivalents			(9,288)	(9,288)
Net increase (decrease) in cash and cash equivalents	(192,324)	34,156	66,701	(91,467)
Cash and cash equivalents, beginning of period	294,137	82,602	116,034	492,773
<b>Cash and cash equivalents, end of period</b>	<b>\$ 101,813</b>	<b>\$ 116,758</b>	<b>\$ 182,735</b>	<b>\$ 401,306</b>

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)**

**CONSOLIDATING STATEMENT OF CASH FLOWS**  
**For the Year Ended December 31, 2009**  
(in thousands)

	Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
<b>Cash Flows from Operating Activities:</b>					
Net income (loss)	\$ 34,181	\$ 47,669	\$ 38,522	\$ (86,191)	\$ 34,181
Income (loss) from discontinued operations, net of tax	(1,096)	2,689	334	7	1,934
Income (loss) from continuing operations	35,277	44,980	38,188	(86,198)	32,247
Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:					
Equity in earnings of subsidiaries, net of tax	(124,336)			124,336	
Non-cash interest expense including amortization of original issue discounts and write-off of deferred financing costs	9,710		713		10,423
Depreciation and amortization	1,475	251,388	59,828	(256)	312,435
Non-cash stock-based compensation expense	7,463	10,206	10,551		28,220
Impairment of inventory			1,467		1,467
Impairment of long-lived assets		5,620	1,363		6,983
Loss on sale of fixed assets	4	1,150	51		1,205
Equity earnings of unconsolidated entities, net of tax	(1,747)		(5,972)	93	(7,626)
Deferred income taxes	(5,292)	(29,556)	44,820	(19,096)	(9,124)
Other non-cash items	292	1,835	1,137		3,264
Changes in assets and liabilities, net of acquisitions:					
Accounts receivable, net		(4,785)	(43,950)	12,280	(36,455)
Inventories, net		30,679	(12,666)	(34,438)	(16,425)
Prepaid expenses and other current assets	(4,741)	2,686	11,136		9,081
Accounts payable	(1,979)	844	3,252		2,117

Edgar Filing: ALERE INC. - Form 10-K/A

Accrued expenses and other current liabilities	27,045	7,015	(79,505)		(45,445)
Other non-current liabilities	1,126	4,529	(8,364)		(2,709)
Intercompany payable (receivable)	(66,879)	(252,429)	319,308		
Net cash provided by (used in) continuing operations	(122,582)	74,162	341,357	(3,279)	289,658
Net cash provided by (used in) discontinued operations	(1,096)	(1,097)	59	7	(2,127)
<b>Net cash provided by (used in) operating activities</b>	<b>(123,678)</b>	<b>73,065</b>	<b>341,416</b>	<b>(3,272)</b>	<b>287,531</b>
<b>Cash Flows from Investing Activities:</b>					
Purchases of property, plant and equipment	(610)	(70,674)	(32,594)	3,272	(100,606)
Proceeds from sale of property, plant and equipment		454	349		803
Cash received (paid) for acquisitions and transaction costs, net of cash acquired	(203,460)	15,455	(280,522)		(468,527)
Net cash received from equity method investments	980		11,580		12,560
Increase in other assets	(20,000)	(7,313)	(407)		(27,720)
Net cash provided by (used in) continuing operations	(223,090)	(62,078)	(301,594)	3,272	(583,490)
Net cash used in discontinued operations		(237)			(237)
<b>Net cash provided by (used in) investing activities</b>	<b>(223,090)</b>	<b>(62,315)</b>	<b>(301,594)</b>	<b>3,272</b>	<b>(583,727)</b>
<b>Cash Flows from Financing Activities:</b>					
Decrease (increase) in restricted cash	4	(417)	831		418
Cash paid for financing costs	(17,756)				(17,756)
Proceeds from issuance of common stock, net of issuance costs	30,015				30,015
Proceeds on long-term debt	631,176	312	(311)		631,177
Repayment on long-term debt	(10,325)	(3,054)	2,324		(11,055)
Net repayments from revolving lines-of-credit			(7,251)		(7,251)
Excess tax benefit on exercised stock options	2,758	5,813	698		9,269
Principal payments of capital lease obligations		(584)	(214)		(798)
Other	(153)				(153)
	635,719	2,070	(3,923)		633,866

Net cash provided by (used in) continuing operations				
Net cash used in discontinued operations		(12)		(12)
<b>Net cash provided by (used in) financing activities</b>	635,719	2,058	(3,923)	633,854
Foreign exchange effect on cash and cash equivalents	3,443		10,348	13,791
Net increase in cash and cash equivalents	292,394	12,808	46,247	351,449
Cash and cash equivalents, beginning of period	1,743	69,794	69,787	141,324
<b>Cash and cash equivalents, end of period</b>	<b>\$ 294,137</b>	<b>\$ 82,602</b>	<b>\$ 116,034</b>	<b>\$ 492,773</b>

F-81

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(25) Guarantor Financial Information (Continued)**

**CONSOLIDATING STATEMENT OF CASH FLOWS**  
**For the Year Ended December 31, 2008**  
(in thousands)

	Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
<b>Cash Flows from Operating Activities:</b>					
Net income (loss)	\$ (21,601)	\$ (12,094)	\$ 3,550	\$ 8,544	\$ (21,601)
Loss from discontinued operations, net of tax		(112)	(891)	(45)	(1,048)
Income (loss) from continuing operations	(21,601)	(11,982)	4,441	8,589	(20,553)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:					
Equity in earnings of subsidiaries, net of tax	9,816			(9,816)	
Non-cash interest expense including amortization of original issue discounts and write-off of deferred financing costs	5,930				5,930
Depreciation and amortization	953	221,444	43,257		265,654
Non-cash stock-based compensation expense	7,563	10,661	8,181		26,405
Impairment of inventory		2,300	1,893		4,193
Impairment of long-lived assets		6,117	13,914		20,031
Loss (gain) on sale of fixed assets	(1)	255	523		777
Equity earnings of unconsolidated entities, net of tax	(1,522)	23	379	70	(1,050)
Deferred income taxes	2,587	(27,474)	(16,827)		(41,714)
Other non-cash items	2,714	1,680	(16)		4,378
Changes in assets and liabilities, net of acquisitions:					
Accounts receivable, net		(28,321)	(12,225)	1,000	(39,546)
Inventories, net		(24,331)	(12,677)	(4,937)	(41,945)
Prepaid expenses and other current assets	616	11,645	(24,758)	5,111	(7,386)
Accounts payable	(84)	9,669	(2,392)		7,193



Edgar Filing: ALERE INC. - Form 10-K/A

Accrued expenses and other current liabilities	(137,817)	95,196	15,181	(1,651)	(29,091)
Other non-current liabilities	(1,173)	139	4,434		3,400
Intercompany payable (receivable)	224,817	(282,154)	53,396	3,941	
Net cash provided by continuing operations	92,798	(15,133)	76,704	2,307	156,676
Net cash used in discontinued operations		(7,348)	(1,439)	(45)	(8,832)
<b>Net cash provided by (used in) operating activities</b>	<b>92,798</b>	<b>(22,481)</b>	<b>75,265</b>	<b>2,262</b>	<b>147,844</b>
<b>Cash Flows from Investing Activities:</b>					
Purchases of property, plant and equipment	(1,009)	(42,149)	(24,220)	1,679	(65,699)
Proceeds from sale of property, plant and equipment		96	974		1,070
Cash received (paid) for acquisitions and transaction costs, net of cash acquired	(470,393)	10,185	(189,691)		(649,899)
Net cash received (paid) from equity method investments	1,372	(1,113)	11,874		12,133
Decrease (increase) in other assets	(1,000)	(4,932)	(4,568)		(10,500)
Net cash provided by (used in) continuing operations	(471,030)	(37,913)	(205,631)	1,679	(712,895)
Net cash used in discontinued operations		(437)			(437)
<b>Net cash provided by (used in) investing activities</b>	<b>(471,030)</b>	<b>(38,350)</b>	<b>(205,631)</b>	<b>1,679</b>	<b>(713,332)</b>
<b>Cash Flows from Financing Activities:</b>					
Decrease (increase) in restricted cash		(1,145)	140,349		139,204
Issuance costs associated with preferred stock	(350)				(350)
Cash paid for financing costs	(1,401)				(1,401)
Proceeds from issuance of common stock, net of issuance costs	20,675				20,675
Repayment on long-term debt	(9,750)	(4,037)			(13,787)
Net proceeds (repayments) from revolving lines-of-credit	142,000	(2,320)	(2,438)		137,242
Excess tax benefit on exercised stock options	679	16,568	295		17,542
Principal payments of capital lease obligations		(362)	(596)		(958)
Other	(56)				(56)

Edgar Filing: ALERE INC. - Form 10-K/A

Net cash provided by (used in) continuing operations	151,797	8,704	137,610	298,111
Net cash used in discontinued operations		(342)		(342)
<b>Net cash provided by (used in) financing activities</b>	<b>151,797</b>	<b>8,362</b>	<b>137,610</b>	<b>297,769</b>
Foreign exchange effect on cash and cash equivalents		(866)	(882)	(3,941)
Net increase (decrease) in cash and cash equivalents	(226,435)	(53,335)	6,362	(273,408)
Cash and cash equivalents, beginning of period	228,178	123,129	63,425	414,732
<b>Cash and cash equivalents, end of period</b>	<b>\$ 1,743</b>	<b>\$ 69,794</b>	<b>\$ 69,787</b>	<b>\$ 141,324</b>

F-82